Iodometric JJ 0 0 UNK O
titration NN 0 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
polymer NN 0 1 UNK O
conjugates NNS 1 1 UNK O
was VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
immobilised JJ 0 0 UNK O
cysteine NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
treatment NN 0 1 6 O
of IN 0 0 12 O
depression NN 0 1 6 O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
must MD 0 0 12 O
take VB 0 1 12 O
into IN 0 0 12 O
account NN 0 1 1 O
variations NNS 1 1 1 O
of IN 0 0 12 O
glycemic JJ 0 1 14 O
levels NNS 1 1 1 O
at IN 0 0 12 O
different JJ 0 1 1 O
times NNS 1 1 12 O
and CC 0 0 12 O
a DT 0 0 12 O
comparison NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
available JJ 0 1 1 O
antidepressant JJ 0 1 6 B-Group
agents NNS 1 1 1 I-Group
is VBZ 1 0 12 O
important JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
three CD 0 1 12 O
study NN 0 1 1 O
periods NNS 1 1 1 O
were VBD 1 0 12 O
separated VBN 1 1 3 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
washout IN 0 1 3 O
phase NN 0 1 1 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
its PRP$ 1 0 12 O
nephrotoxicity NN 0 1 UNK O
gentamicin NN 0 1 14 B-Drug
may MD 0 0 1 O
cause VB 0 1 12 O
abnormal JJ 0 1 6 O
renal JJ 0 1 6 O
uptake NN 0 1 14 O
to TO 0 0 12 O
be VB 0 0 12 O
seen VBN 1 1 12 O
on IN 0 0 12 O
9mTc CD 0 0 UNK B-Drug
- : 0 0 2 O
MDP NNP 0 1 UNK I-Drug
bone NN 0 1 6 O
scintigraphy NN 0 1 UNK O
. . 0 0 12 O

METHODS NNP 0 1 UNK O
. . 0 0 12 O

however RB 0 0 12 O
at IN 0 0 12 O
lower JJR 1 1 1 O
concentrations NNS 1 1 13 O
only RB 0 1 12 O
zinc RB 0 1 14 B-Drug
demonstrated VBN 1 0 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

Selective JJ 0 1 7 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitor NN 0 1 14 I-Group
SSRI NNP 0 1 UNK I-Group
antidepressants NNS 1 1 13 I-Group
inhibit VBP 0 1 13 O
isoenzyme JJ 0 1 13 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

A DT 0 0 2 O
review NN 0 1 2 O
. . 0 0 12 O

at IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
decreased VBD 1 1 1 O
FI NNP 0 1 UNK O
and CC 0 0 12 O
FR NNP 0 1 UNK O
responding NN 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
fractional JJ 0 1 1 O
inhibitory NN 0 1 UNK O
concentration NN 0 1 1 O
index NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
evaluated VBN 1 1 1 O
by IN 0 0 12 O
checkerboard NN 0 0 UNK O
analysis NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
which WDT 0 0 12 O
confirmed VBD 1 1 12 O
synergism NN 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
pair NN 0 1 UNK O
. . 0 0 12 O

Taken VBN 0 1 UNK O
together RB 0 1 12 O
these DT 0 0 12 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
site NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
inhibitory JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
RR NNP 0 0 13 B-Drug_n
is VBZ 1 0 12 O
at IN 0 0 12 O
the DT 0 0 12 O
InsP NNP 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
receptor NN 0 1 14 O
or CC 0 0 12 O
its PRP$ 1 0 12 O
closely RB 0 0 1 O
associated VBN 1 1 1 O
proteins NNS 1 1 14 O
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
Bombesin NNP 0 1 UNK B-Drug_n
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
intestinal JJ 0 1 13 O
tumors NNS 1 1 6 O
and CC 0 0 12 O
cancer NN 0 1 6 O
metastasis NN 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
peritoneum NN 0 1 8 O
. . 0 0 12 O

The DT 0 0 2 O
decrease NN 0 1 1 O
in IN 0 0 12 O
temperature NN 0 1 3 O
began VBD 1 1 12 O
within IN 0 0 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
after IN 0 0 12 O
ethanol JJ 0 1 1 B-Drug
administration NN 0 1 1 O
reaching VBG 1 1 12 O
a DT 0 0 12 O
maximal JJ 0 1 1 O
decrease NN 0 1 1 O
between IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
post RB 0 1 12 O
ethanol VBP 0 1 1 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
there EX 0 0 12 O
was VBD 1 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold JJ 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
C NNP 0 0 2 O
( ( 0 0 2 O
max NN 0 0 3 O
) ) 0 0 2 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
panobinostat NN 0 1 UNK B-Drug
respectively RB 0 0 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Moreover RB 0 0 1 O
each DT 0 0 12 O
task NN 0 1 16 O
induced VBD 1 1 6 O
significant JJ 0 1 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
hippocampal JJ 0 1 8 O
adenylate JJ 0 1 UNK O
cyclase NN 0 0 UNK O
activity NN 0 1 1 O
but CC 0 0 12 O
in IN 0 0 12 O
opposite JJ 0 1 UNK O
directions NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
etodolac NN 0 1 13 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
normal JJ 0 1 1 O
volunteers NNS 1 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
extensively RB 0 0 1 O
studied VBN 1 0 1 O
and CC 0 0 12 O
is VBZ 1 0 12 O
well RB 0 1 12 O
described VBN 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
report NN 0 1 1 O
describes VBZ 1 0 1 O
a DT 0 0 12 O
recently RB 0 1 12 O
identified VBN 1 1 1 O
case NN 0 1 12 O
of IN 0 0 12 O
interference NN 0 1 13 O
of IN 0 0 12 O
acetylcysteine NN 0 1 16 B-Drug
with IN 0 0 12 O
the DT 0 0 12 O
urine JJ 0 1 6 O
test NN 0 1 1 O
for IN 0 0 12 O
ketones NNS 1 1 14 O
and CC 0 0 12 O
demonstrates VBZ 1 1 1 O
the DT 0 0 12 O
importance NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
thorough JJ 0 0 1 O
medication NN 0 1 6 O
review NN 0 1 2 O
in IN 0 0 12 O
evaluating VBG 1 1 1 O
abnormal JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
pharmacokinetics NNS 0 1 UNK O
produced VBN 1 0 1 O
by IN 0 0 12 O
amiodarone NN 0 1 0 B-Drug
explain VBP 0 0 12 O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
level NN 0 1 1 O
that WDT 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
when WRB 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
combination NN 0 1 1 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
clinically RB 0 0 6 O
. . 0 0 12 O

Finally RB 0 0 2 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
notable JJ 0 0 12 O
that IN 0 0 12 O
xanthine JJ 0 1 UNK O
- : 0 0 2 O
derived VBN 1 1 UNK O
adenosine JJ 0 1 14 O
antagonists NNS 1 1 13 O
tested VBD 1 1 1 O
here RB 0 0 12 O
commonly RB 0 0 UNK O
showed VBD 1 1 12 O
anxiogenic JJ 0 0 UNK O
effects NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
light JJ 0 1 3 O
/ NNP 0 0 2 O
dark JJ 0 1 3 O
test NN 0 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

only RB 0 1 12 O
ibogaine JJ 0 1 UNK B-Drug_n
enhances NNS 0 1 UNK O
cocaine VBP 0 1 6 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
increases NNS 1 1 1 O
in IN 0 0 12 O
accumbal JJ 0 0 UNK O
dopamine NN 0 1 14 O
. . 0 0 12 O

Dopamine NNP 0 1 7 O
( ( 0 0 2 O
DA NNP 0 1 11 O
) ) 0 0 2 O
levels NNS 1 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
differ VB 0 0 UNK O
significantly RB 0 0 1 O
in IN 0 0 12 O
either CC 0 1 12 O
striatum NN 0 1 13 O
( ( 0 0 2 O
STR NNP 0 0 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
nucleus JJ 0 1 UNK O
accumbens NNS 0 0 UNK O
( ( 0 0 2 O
NAC NNP 0 1 UNK O
) ) 0 0 2 O
for IN 0 0 12 O
the DT 0 0 12 O
cocaine NN 0 1 6 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
animals NNS 1 1 12 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
corresponding JJ 0 0 1 O
saline NN 0 1 14 O
- : 0 0 2 O
treated JJ 0 1 1 O
controls NNS 1 1 UNK O
. . 0 0 12 O

[ RB 0 0 2 O
Hippocampus NNP 0 1 UNK O
as IN 1 0 12 O
interaction NN 0 1 UNK O
sites NNS 1 1 1 O
between IN 0 0 12 O
cerebral JJ 0 0 6 O
memory NN 0 1 1 O
systems NNS 1 1 1 O
] VBP 0 0 2 O
Most JJS 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
current JJ 0 1 1 O
theories NNS 1 1 UNK O
assume VBP 0 0 UNK O
that IN 0 0 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
multiple JJ 0 1 1 O
forms NNS 1 1 1 O
of IN 0 0 12 O
memory NN 0 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
supported VBN 1 1 1 O
by IN 0 0 12 O
separate JJ 0 1 1 O
brain NN 0 1 6 O
systems NNS 1 1 1 O
and CC 0 0 12 O
have VBP 0 0 12 O
different JJ 0 1 1 O
characteristics NNS 1 1 UNK O
. . 0 0 12 O

Recent JJ 0 1 2 O
studies NNS 1 1 1 O
and CC 0 0 12 O
consensus NN 0 1 UNK O
reports NNS 1 1 1 O
have VBP 0 0 12 O
expanded VBN 1 1 1 O
our PRP$ 0 0 12 O
understanding NN 0 1 1 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
efficacy NN 0 1 UNK O
safety NN 0 1 1 O
contraindications NNS 1 1 13 O
and CC 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

aureus NN 0 0 14 O
to TO 0 0 12 O
P NNP 0 1 2 O
. . 0 0 12 O

However RB 0 0 1 O
these DT 0 0 12 O
results NNS 1 1 1 O
provide VBP 0 1 1 O
an DT 0 0 12 O
example NN 0 1 1 O
of IN 0 0 12 O
how WRB 0 0 12 O
small JJ 0 1 12 O
molecule NN 0 1 UNK O
manipulation NN 0 1 1 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
activity NN 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
model NN 0 1 UNK O
can MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
confirm VB 0 1 1 O
metabolism NN 0 1 16 O
- : 0 0 2 O
mediated VBN 1 1 13 O
toxicity NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
initiation NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
or CC 0 0 12 O
nicotine NN 0 1 6 B-Drug
use NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
precipitated VBN 1 1 1 O
by IN 0 0 12 O
similar JJ 0 1 1 O
personality NN 0 1 12 O
characteristics NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
user NN 0 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
impulsivity NN 0 1 UNK O
and CC 0 0 12 O
sensation NN 0 1 3 O
seeking VBG 1 0 12 O
. . 0 0 12 O

The DT 0 0 2 O
anxiogenic JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
were VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
pretreatment NN 0 1 UNK O
with IN 0 0 12 O
CGS NNP 0 1 UNK B-Drug_n
99 CD 0 0 10 I-Drug_n
an DT 0 0 12 O
A9 NNP 0 1 UNK O
- : 0 0 2 O
selective JJ 0 1 13 O
agonist NN 0 1 14 O
but CC 0 0 12 O
not RB 0 1 12 O
by IN 0 0 12 O
N9 NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
cyclopentyladenosine NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
CPA NNP 0 1 19 B-Drug_n
) ) 0 0 2 O
an DT 0 0 12 O
A9 NNP 0 1 UNK O
- : 0 0 2 O
selective JJ 0 1 13 O
agonist NN 0 1 14 O
. . 0 0 12 O

Drug NN 0 1 2 O
interactions NNS 1 1 UNK O
: : 0 0 2 O
How WRB 0 0 UNK O
to TO 0 0 12 O
identify VB 0 0 1 O
them PRP 0 0 12 O
. . 0 0 12 O

the DT 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
naloxone NN 0 1 16 B-Drug
required VBN 1 1 1 O
to TO 0 0 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
were VBD 1 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
higher JJR 1 1 1 O
than IN 0 0 12 O
those DT 0 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

Each DT 0 0 2 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
cases NNS 1 1 UNK O
was VBD 1 0 12 O
matched VBN 1 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
controls NNS 1 1 UNK O
based VBN 1 1 1 O
on IN 0 0 12 O
index NN 0 1 1 O
date NN 0 1 12 O
and CC 0 0 12 O
state NN 0 1 1 O
. . 0 0 12 O

Administration NN 0 1 UNK O
of IN 0 0 12 O
lithium JJ 0 1 16 B-Drug
prophylaxis NN 0 1 6 O
. . 0 0 12 O

Intestinal JJ 0 1 UNK O
absorption NN 0 1 1 O
of IN 0 0 12 O
arsenate NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
the DT 0 0 12 O
chick NN 0 1 UNK O
. . 0 0 12 O

Indomethacin NNP 0 1 0 B-Drug
was VBD 1 0 12 O
also RB 0 0 12 O
ineffective JJ 0 1 UNK O
in IN 0 0 12 O
altering VBG 1 1 1 O
resveratrol NN 0 1 UNK B-Drug_n
activity NN 0 1 1 O
in IN 0 0 12 O
arteries NNS 1 1 6 O
from IN 0 0 12 O
both DT 0 0 12 O
lean JJ 0 0 13 O
and CC 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Both DT 0 0 2 O
ibogaine NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
enhance VB 0 1 UNK O
the DT 0 0 12 O
locomotor NN 0 0 UNK O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
stereotypic JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
stimulants NNS 1 1 13 O
. . 0 0 12 O

We PRP 0 0 12 O
obtained VBD 1 1 1 O
evidence NN 0 1 1 O
that IN 0 0 12 O
increased VBD 1 1 1 O
stability NN 0 1 1 O
of IN 0 0 12 O
nucleophosmin JJ 0 1 UNK O
/ NNP 0 0 2 O
B9 NNP 0 0 UNK O
is VBZ 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
antiapoptotic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
ras NNS 1 1 UNK O
during IN 0 0 12 O
serum JJ 0 1 14 O
deprivation NN 0 1 13 O
. . 0 0 12 O

Indinavir NNP 0 1 UNK B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
light JJ 0 1 3 O
meal NN 0 1 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
didanosine NN 0 1 16 B-Drug
. . 0 0 12 O

Pharmacoeconomic NNP 0 1 UNK O
analyses NNS 1 1 UNK O
indicate VBP 0 0 1 O
that IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
increase VB 0 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
even RB 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
overall JJ 0 1 1 O
direct JJ 0 1 1 O
treatment NN 0 1 6 O
costs NNS 1 1 UNK O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
compared VBN 1 1 1 O
with IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
. . 0 0 12 O

Since IN 0 1 2 O
chronic JJ 0 1 6 O
dosing NN 0 0 14 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
for IN 0 0 12 O
therapeutic JJ 0 1 6 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
antipsychotics NNS 1 1 14 B-Group
future JJ 0 1 12 O
studies NNS 1 1 1 O
should MD 0 0 12 O
focus VB 0 1 1 O
on IN 0 0 12 O
investigation NN 0 1 1 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
dosing VBG 1 0 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
. . 0 0 12 O

When WRB 0 0 12 O
the DT 0 0 12 O
muscle NN 0 1 6 O
was VBD 1 0 12 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
the DT 0 0 12 O
potassium NN 0 1 14 O
- : 0 0 2 O
depleted VBN 1 1 1 O
solution NN 0 1 1 O
the DT 0 0 12 O
first JJ 0 1 12 O
contractile NN 0 1 8 O
response NN 0 1 1 O
to TO 0 0 12 O
PTX NNP 0 1 15 B-Drug_n
was VBD 1 0 12 O
rather RB 0 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

Further RB 0 1 2 O
they PRP 0 0 12 O
bring VBP 0 0 12 O
into IN 0 0 12 O
question NN 0 1 12 O
the DT 0 0 12 O
utility NN 0 1 1 O
of IN 0 0 12 O
using VBG 1 1 1 O
PCP NNP 0 1 13 B-Drug_n
combination NN 0 1 1 O
procedures NNS 1 1 1 O
in IN 0 0 12 O
animals NNS 1 1 12 O
to TO 0 0 12 O
screen VB 0 1 3 O
for IN 0 0 12 O
antipsychotic JJ 0 1 UNK O
potential NN 0 1 1 O
. . 0 0 12 O

changes NNS 1 1 1 O
in IN 0 0 12 O
cervical JJ 0 1 6 O
mucus NN 0 1 6 O
the DT 0 0 12 O
endometrium NN 0 1 8 O
and CC 0 0 12 O
the DT 0 0 12 O
fallopian JJ 0 0 13 O
tubes NN 1 1 3 O
; : 0 0 2 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
dasatinib NN 0 1 13 B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
Src NNP 0 1 UNK O
and CC 0 0 12 O
Abl NNP 0 1 UNK O
kinases NNS 1 1 14 O
on IN 0 0 12 O
paclitaxel JJ 0 1 13 B-Drug
sensitivity NN 0 1 1 O
was VBD 1 0 12 O
measured VBN 1 1 1 O
in IN 0 0 12 O
ovarian JJ 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
and CC 0 0 12 O
HEY NNP 0 0 UNK O
xenografts NNP 1 1 UNK O
. . 0 0 12 O

An DT 0 0 2 O
oral JJ 0 1 6 O
glucose NN 0 1 14 B-Drug
overload NN 0 0 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
ml NN 0 1 16 O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
glucose JJ 0 1 14 B-Drug
solution NN 0 1 1 O
was VBD 1 0 12 O
given VBN 1 1 12 O
to TO 0 0 12 O
rats NNS 1 1 UNK O
and CC 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
was VBD 1 0 12 O
determined VBN 1 1 1 O
after IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
essentially RB 0 0 1 O
completely RB 0 1 12 O
metabolised VBN 1 0 UNK O
therefore RB 0 0 1 O
little JJ 0 1 12 O
is VBZ 1 0 12 O
excreted VBN 1 1 UNK O
unchanged JJ 0 1 1 O
. . 0 0 12 O

Medications NNS 0 1 7 O
can MD 0 0 12 O
cause VB 0 1 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
effects NNS 1 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
or CC 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
analyte NN 0 1 UNK O
is VBZ 1 0 12 O
altered VBN 1 1 1 O
before IN 0 1 12 O
the DT 0 0 12 O
analysis NN 0 1 1 O
and CC 0 0 12 O
therefore RB 0 0 1 O
the DT 0 0 12 O
assay NN 0 1 14 O
result NN 0 1 1 O
is VBZ 1 0 12 O
true JJ 0 1 12 O
and CC 0 0 12 O
accurate NN 0 1 1 O
. . 0 0 12 O

Longitudinal JJ 0 1 UNK O
assessment NN 0 1 1 O
of IN 0 0 12 O
everolimus NN 0 1 13 B-Drug
in IN 0 0 12 O
de FW 0 1 2 O
novo FW 0 0 UNK O
renal JJ 0 1 6 O
transplant NN 0 1 6 O
recipients NNS 1 1 UNK O
over IN 0 1 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
post NN 0 1 12 O
- : 0 0 2 O
transplant JJ 0 1 6 O
year NN 0 1 12 O
: : 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
exposure VBP 0 1 1 O
- : 0 0 2 O
response NN 0 1 1 O
relationships NNS 1 1 13 O
and CC 0 0 12 O
influence NN 0 0 UNK O
on IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
. . 0 0 12 O

Amphetamine NNP 0 1 UNK B-Drug
locomotor NN 0 0 UNK O
sensitization NN 0 1 13 O
and CC 0 0 12 O
conditioned JJ 0 1 UNK O
place NN 0 1 12 O
preference NN 0 1 1 O
in IN 0 0 12 O
adolescent JJ 0 1 13 O
male NN 0 1 12 O
and CC 0 0 12 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
neonatally RB 0 0 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
quinpirole NN 0 1 UNK B-Drug_n
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
first JJ 0 1 12 O
double JJ 0 1 3 O
- : 0 0 2 O
blind NN 0 1 12 O
comparative JJ 0 0 UNK O
study NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
) ) 0 0 2 O
of IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
and CC 0 0 12 O
risperidone NN 0 1 0 B-Drug
olanzapine NN 0 1 16 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
proved VBD 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
significantly RB 0 0 1 O
more RBR 0 1 12 O
effective JJ 0 1 1 O
than IN 0 0 12 O
risperidone RB 0 1 0 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
negative JJ 0 1 1 O
and CC 0 0 12 O
depressive JJ 0 0 13 O
symptoms NNS 1 1 6 O
but CC 0 0 12 O
not RB 0 1 12 O
on IN 0 0 12 O
overall JJ 0 1 1 O
psychopathology NN 0 1 UNK O
symptoms NNS 1 1 6 O
. . 0 0 12 O

PATIENTS NNS 0 1 UNK O
: : 0 0 2 O
Random NNP 0 1 2 O
sample NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
MAC NNP 0 1 UNK O
out IN 0 1 12 O
of IN 0 0 12 O
a DT 0 0 12 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
molecular JJ 0 1 1 O
basis NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
synergism NN 0 1 UNK O
is VBZ 1 0 12 O
that IN 0 0 12 O
the DT 0 0 12 O
signaling NN 0 1 UNK O
pathways NNS 1 1 13 O
that WDT 0 0 12 O
were VBD 1 0 12 O
initially RB 0 1 12 O
activated VBN 1 1 1 O
by IN 0 0 12 O
docetaxel NN 0 1 13 B-Drug
exposure NN 0 1 1 O
were VBD 1 0 12 O
efficiently RB 0 0 UNK O
suppressed VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
subsequent JJ 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
sunitinib VB 0 1 13 B-Drug
. . 0 0 12 O

9C CD 0 0 UNK O
- : 0 0 2 O
cholesterol NN 0 1 6 O
ester RBR 0 1 UNK O
fractional JJ 0 1 1 O
clearance NN 0 1 16 O
rate NN 0 1 1 O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
greater JJR 1 1 1 O
after IN 0 0 12 O
etofibrate NN 0 1 UNK B-Drug
than IN 0 0 12 O
after IN 0 0 12 O
placebo NN 0 1 13 O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
or CC 0 0 12 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
at IN 0 0 12 O
risk NN 0 1 1 O
for IN 0 0 12 O
further JJ 0 1 1 O
kidney NN 0 1 6 O
damage NN 0 1 1 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
complications NNS 1 1 6 O
related VBN 1 1 1 O
to TO 0 0 12 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
herbal JJ 0 1 6 O
remedies NNS 1 0 6 O
with IN 0 0 12 O
complex JJ 0 1 1 O
renal JJ 0 1 6 O
therapy NN 0 1 6 O
regimens NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
nucleophosmin NN 0 1 UNK O
/ NNP 0 0 2 O
B9 NNP 0 0 UNK O
in IN 0 0 12 O
serum NN 0 1 14 O
- : 0 0 2 O
deprived VBN 1 0 UNK O
ras NNS 1 1 UNK O
- : 0 0 2 O
transformed VBN 1 1 UNK O
( ( 0 0 2 O
RAS NNP 0 1 UNK O
- : 0 0 2 O
9T9 CD 0 0 UNK O
) ) 0 0 2 O
cells NNS 1 1 6 O
was VBD 1 0 12 O
as RB 0 0 12 O
stable JJ 0 1 1 O
as IN 1 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
serum NN 0 1 14 O
- : 0 0 2 O
supplemented VBN 1 1 1 O
NIH NNP 0 1 1 O
- : 0 0 2 O
9T9 CD 0 0 UNK O
or CC 0 0 12 O
RAS NNP 0 1 UNK O
- : 0 0 2 O
9T9 CD 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

Conclusions NNS 0 1 7 O
. . 0 0 12 O

Both DT 0 0 2 O
ibogaine NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
ameliorate NN 0 0 6 O
opioid NN 0 1 13 B-Group
withdrawal NN 0 1 1 O
signs NNS 1 1 12 O
. . 0 0 12 O

Combinations NNS 0 1 UNK O
of IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
and CC 0 0 12 O
phencyclidine NN 0 1 UNK B-Drug_n
: : 0 0 2 O
effects NNS 1 1 1 O
on IN 0 0 12 O
drug NN 0 1 1 O
discrimination NN 0 1 13 O
and CC 0 0 12 O
behavioral JJ 0 1 13 O
inhibition NN 0 1 13 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
lines NNS 1 1 3 O
showed VBD 1 1 12 O
variable JJ 0 1 1 O
degrees NNS 1 1 1 O
of IN 0 0 12 O
locomotor NN 0 0 UNK O
activities NNS 1 1 1 O
in IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
cocaine VB 0 1 6 B-Drug
. . 0 0 12 O

Moxifloxacin NNP 0 1 UNK B-Drug
and CC 0 0 12 O
Lomefloxacin NNP 0 1 UNK B-Drug
reacts NNS 0 0 UNK O
faster RBR 0 1 1 O
with IN 0 0 12 O
sucralfate NN 0 1 0 B-Drug
and CC 0 0 12 O
gelusil NN 0 1 UNK B-Brand
in IN 0 0 12 O
acidic JJ 0 1 UNK O
media NNS 1 1 1 O
whereas NNS 0 0 UNK O
with IN 0 0 12 O
erythromycin NN 0 1 0 B-Drug
in IN 0 0 12 O
basic JJ 0 1 1 O
media NNS 1 1 1 O
and CC 0 0 12 O
multi SYM 0 1 16 B-Group
- : 0 0 2 O
minerals NNS 1 1 16 I-Group
in IN 0 0 12 O
neutral JJ 0 1 1 O
media NNS 1 1 1 O
. . 0 0 12 O

Several JJ 0 1 2 O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that DT 0 0 12 O
olanzapine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
benefits NNS 1 1 1 O
against IN 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
aggression NN 0 1 UNK O
and CC 0 0 12 O
agitation NN 0 1 1 O
while IN 0 0 12 O
other JJ 0 0 12 O
studies NNS 1 1 1 O
strongly RB 0 0 1 O
support VB 0 1 1 O
the DT 0 0 12 O
effectiveness NN 0 1 UNK O
of IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
depressive JJ 0 0 13 O
symptomatology NN 0 0 6 O
. . 0 0 12 O

Histidine NNP 0 1 UNK O
modification NN 0 1 1 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
glucosyl NN 0 0 UNK O
transferase NN 0 1 14 O
enzyme JJ 0 1 14 O
activity NN 0 1 1 O
of IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
. . 0 0 12 O

Everolimus NNP 0 1 UNK B-Drug
exposure NN 0 1 1 O
- : 0 0 2 O
response NN 0 1 1 O
relationships NNS 1 1 13 O
between IN 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
platelets NNS 1 1 14 O
leukocytes NNS 1 1 14 O
and CC 0 0 12 O
lipids NNS 1 1 14 O
were VBD 1 0 12 O
explored VBN 1 0 1 O
with IN 0 0 12 O
the DT 0 0 12 O
median JJ 0 1 1 O
- : 0 0 2 O
effect NN 0 1 1 O
model NN 0 1 UNK O
. . 0 0 12 O

Type $ 0 1 2 O
9 CD 0 0 2 O
diabetes NNS 0 1 6 O
mellitus NN 0 0 6 O
is VBZ 1 0 12 O
a DT 0 0 12 O
growing VBG 1 0 12 O
problem NN 0 1 12 O
not RB 0 1 12 O
only RB 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
United NNP 0 0 2 O
States NNPS 0 1 2 O
but CC 0 0 12 O
also RB 0 0 12 O
across IN 0 0 12 O
the DT 0 0 12 O
world NN 0 1 12 O
. . 0 0 12 O

Morphine NNP 0 1 0 B-Drug
prolonged VBD 1 1 6 O
gastrointestinal JJ 0 1 6 O
transit NN 0 1 1 O
time NN 0 1 12 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
; : 0 0 2 O
this DT 0 0 12 O
was VBD 1 0 12 O
prevented VBN 1 1 UNK O
by IN 0 0 12 O
ADL NNP 0 1 UNK B-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] JJ 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
treatment NN 0 1 6 O
also RB 0 0 12 O
had VBD 1 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
loss NN 0 1 1 O
of IN 0 0 12 O
norepinephrine JJ 0 1 14 O
neurons NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
locus NN 0 1 UNK O
coeruleus NN 0 0 UNK O
and CC 0 0 12 O
adjoining VBG 1 0 UNK O
A9 NNP 0 1 UNK O
and CC 0 0 12 O
A9 NNP 0 1 UNK O
noradrenaline VBP 0 1 UNK O
cell NN 0 1 1 O
groups NNS 1 1 1 O
. . 0 0 12 O

When WRB 0 0 12 O
given VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NNS 0 1 18 O
sandimmune VBP 0 1 16 B-Brand
produced VBN 1 0 1 O
no DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
hexanal JJ 0 1 UNK O
- : 0 0 2 O
induced JJ 0 1 6 O
sleep NN 0 1 12 O
in IN 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
checkerboard NN 0 0 UNK O
method NN 0 1 13 O
with IN 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
fractional JJ 0 1 1 O
IC NNP 0 1 UNK O
index NN 0 1 1 O
( ( 0 0 2 O
FICI NNP 0 0 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
whether IN 0 0 12 O
antibiotic JJ 0 1 6 B-Group
combinations NNS 1 1 1 O
act VBP 0 1 13 O
synergistically RB 0 0 UNK O
against IN 0 0 12 O
these DT 0 0 12 O
isolates NNS 0 1 14 O
. . 0 0 12 O

Ascorbic NNP 0 0 0 B-Drug
acid NN 0 1 14 I-Drug
and CC 0 0 12 O
the DT 0 0 12 O
common JJ 0 1 1 O
cold NN 0 1 3 O
. . 0 0 12 O

Chloral JJ 0 1 UNK B-Drug
hydrate NN 0 1 16 I-Drug
and CC 0 0 12 O
methaqualone NN 0 1 13 B-Drug
interact NN 0 0 UNK O
pharmacologically RB 0 0 UNK O
with IN 0 0 12 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
anticoagulant JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
but CC 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
. . 0 0 12 O

Whenever WRB 0 0 UNK O
increased VBD 1 1 1 O
thioether DT 0 1 UNK O
excretion NN 0 1 14 O
is VBZ 1 0 12 O
observed VBN 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
likely JJ 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
exposure VB 0 1 1 O
to TO 0 0 12 O
one CD 0 1 12 O
or CC 0 0 12 O
more JJR 0 1 12 O
suspect JJ 0 1 12 O
compounds NNS 1 1 13 O
. . 0 0 12 O

Our PRP$ 0 0 2 O
data NNS 0 1 1 O
demonstrate NN 0 0 1 O
that IN 0 0 12 O
chronic JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
metabotropic NN 0 0 UNK O
glutamate NN 0 1 UNK O
receptor NN 0 1 14 O
9 CD 0 0 2 O
antagonist NN 0 1 13 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] FW 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
significantly RB 0 0 1 O
reduces VBZ 1 0 UNK O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
toxicity NN 0 1 6 O
towards NNS 0 0 12 O
dopaminergic NN 0 1 UNK O
and CC 0 0 12 O
noradrenergic JJ 0 1 UNK O
cell NN 0 1 1 O
groups NNS 1 1 1 O
in IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
human JJ 0 1 1 O
primates NNS 1 1 UNK O
. . 0 0 12 O

Unlike IN 0 0 UNK O
nucleolin JJ 0 1 UNK O
/ NN 0 0 2 O
C9 NNP 0 1 UNK O
down RB 0 0 12 O
- : 0 0 2 O
regulation NN 0 1 13 O
of IN 0 0 12 O
nucleophosmin JJ 0 1 UNK O
/ NNP 0 0 2 O
B9 NNP 0 0 UNK O
was VBD 1 0 12 O
thus RB 0 0 1 O
not RB 0 1 12 O
proliferation JJ 0 1 1 O
- : 0 0 2 O
dependent NN 0 1 1 O
but CC 0 0 12 O
caspase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
and CC 0 0 12 O
apoptosis VB 0 1 UNK O
- : 0 0 2 O
dependent NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
latency NN 0 1 1 O
to TO 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
righting NN 0 1 UNK O
reflex NN 0 1 6 O
and CC 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
sleep JJ 0 1 12 O
time NN 0 1 12 O
were VBD 1 0 12 O
recorded VBN 1 1 12 O
while IN 0 0 12 O
the DT 0 0 12 O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
kept VBN 1 1 12 O
in IN 0 0 12 O
sound JJ 0 1 12 O
- : 0 0 2 O
attenuating VBG 1 1 UNK O
chambers NNS 1 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
paper NN 0 1 13 O
critically RB 0 0 1 O
reviews VBZ 1 1 UNK O
the DT 0 0 12 O
suitability NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
urinary JJ 0 1 6 O
thioether NN 0 1 UNK O
assay NN 0 1 14 O
as IN 1 0 12 O
a DT 0 0 12 O
method NN 0 1 13 O
for IN 0 0 12 O
the DT 0 0 12 O
detection NN 0 1 1 O
of IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
electrophilic JJ 0 0 UNK O
agents NNS 1 1 1 O
or CC 0 0 12 O
their PRP$ 0 0 12 O
precursors NNS 1 1 UNK O
. . 0 0 12 O

Retention NN 0 1 UNK O
was VBD 1 0 12 O
calculated VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
balance NN 0 1 1 O
technique NN 0 1 1 O
and CC 0 0 12 O
by IN 0 0 12 O
the DT 0 0 12 O
comparative JJ 0 0 UNK O
slaughter NN 0 0 UNK O
technique NN 0 1 1 O
. . 0 0 12 O

CONCLUSIONS NNP 0 1 UNK O
. . 0 0 12 O

Olanzapine NN 0 1 0 B-Drug
: : 0 0 2 O
an DT 0 0 12 O
updated JJ 0 1 2 O
review NN 0 1 2 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
use NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
. . 0 0 12 O

Currently RB 0 1 2 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
conceived VBN 1 1 UNK O
that IN 0 0 12 O
a DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
events NNS 1 1 12 O
or CC 0 0 12 O
hits NNS 1 1 UNK O
are VBP 1 0 12 O
required VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
tumors NNS 1 1 6 O
by IN 0 0 12 O
chemical NN 0 1 13 O
agents NNS 1 1 1 O
. . 0 0 12 O

Exogenous JJ 0 1 UNK O
estradiol NN 0 1 13 B-Drug
also RB 0 0 12 O
appeared VBD 1 1 12 O
to TO 0 0 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
percentage NN 0 1 1 O
of IN 0 0 12 O
endotoxin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
deaths NNS 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

BACKGROUND NN 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
combined JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
bombesin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
verapamil NN 0 1 0 B-Drug
hydrochloride NN 0 1 0 I-Drug
( ( 0 0 2 O
verapamil NN 0 1 0 B-Drug
) ) 0 0 2 O
a DT 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blocker NN 0 0 3 I-Group
on IN 0 0 12 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
peritoneal JJ 0 1 8 O
metastasis NN 0 1 6 O
of IN 0 0 12 O
intestinal JJ 0 1 13 O
adenocarcinomas NN 1 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
azoxymethane NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
AOM NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
labeling VBG 1 1 UNK O
index NN 0 1 1 O
of IN 0 0 12 O
intestinal JJ 0 1 13 O
cancers NNS 1 1 6 O
were VBD 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
male JJ 0 1 12 O
Wistar NNP 0 1 UNK O
rats NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
behavioral JJ 0 1 13 O
changes NNS 1 1 1 O
of IN 0 0 12 O
mice NN 1 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
acute NN 0 1 6 O
and CC 0 0 12 O
repeated VBD 1 1 1 O
i.p NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
an DT 0 0 12 O
unusually RB 0 0 1 O
high JJ 0 1 1 O
maintenance NN 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
per IN 0 0 1 O
day NN 0 1 12 O
) ) 0 0 2 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
were VBD 1 0 12 O
intravenously RB 0 0 14 O
injected VBN 1 1 3 O
a DT 0 0 12 O
chylomicron NN 0 1 UNK O
- : 0 0 2 O
like IN 0 0 12 O
emulsion NN 0 1 16 O
doubly RB 0 1 UNK O
labeled VBD 1 1 1 O
with IN 0 0 12 O
9C CD 0 0 UNK O
- : 0 0 2 O
cholesteryl NN 0 0 UNK O
oleate NN 0 1 UNK O
and CC 0 0 12 O
9H CD 0 0 UNK O
- : 0 0 2 O
triolein NN 0 1 UNK O
at IN 0 0 12 O
baseline NN 0 1 1 O
and CC 0 0 12 O
after IN 0 0 12 O
treatments NNS 1 1 6 O
. . 0 0 12 O

Olanzapine NNP 0 1 0 B-Drug
treatment NN 0 1 6 O
improves VBZ 1 1 1 O
quality NN 0 1 1 O
of IN 0 0 12 O
life NN 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
schizophrenia NN 0 1 13 O
and CC 0 0 12 O
related JJ 0 1 1 O
psychoses NNS 1 1 6 O
to TO 0 0 12 O
a DT 0 0 12 O
greater JJR 1 1 1 O
extent NN 0 1 1 O
than IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
and CC 0 0 12 O
to TO 0 0 12 O
broadly RB 0 0 1 O
the DT 0 0 12 O
same JJ 0 1 12 O
extent NN 0 1 1 O
as IN 1 0 12 O
risperidone NN 0 1 0 B-Drug
. . 0 0 12 O

Neomycin NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
or CC 0 0 12 O
metabolic JJ 0 1 6 O
responses NNS 1 1 1 O
to TO 0 0 12 O
ACTH NNP 0 1 UNK B-Group
in IN 0 0 12 O
sheep NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
we PRP 0 0 12 O
tested VBD 1 1 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
highly RB 0 1 1 O
specific JJ 0 1 1 O
metabotropic NN 0 0 UNK O
glutamate NN 0 1 UNK O
receptor NN 0 1 14 O
9 CD 0 0 2 O
antagonist NN 0 1 13 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] JJ 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
reduces NNS 0 0 UNK O
dopaminergic NN 0 1 UNK O
and CC 0 0 12 O
noradrenergic JJ 0 1 UNK O
neuronal JJ 0 1 13 O
loss NN 0 1 1 O
in IN 0 0 12 O
monkeys NNS 1 1 UNK O
rendered VBN 1 0 1 O
parkinsonian JJ 0 0 UNK O
by IN 0 0 12 O
chronic JJ 0 1 6 O
treatment NN 0 1 6 O
with IN 0 0 12 O
low JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
. . 0 0 12 O

A DT 0 0 2 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
test NN 0 1 1 O
P NNP 0 1 2 O
. . 0 0 12 O

Maximal JJ 0 1 UNK O
hypotension NN 0 1 6 O
was VBD 1 0 12 O
found VBN 1 1 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
post VBP 0 1 12 O
ethanol NN 0 1 1 B-Drug
and CC 0 0 12 O
returned VBN 1 1 12 O
to TO 0 0 12 O
normal JJ 0 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
after IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
. . 0 0 12 O

These DT 0 0 1 O
factors NNS 1 1 1 O
in IN 0 0 12 O
concert NN 0 0 UNK O
with IN 0 0 12 O
age NN 0 1 12 O
- : 0 0 2 O
dependent JJ 0 1 1 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
immune JJ 0 1 6 O
function NN 0 1 1 O
and CC 0 0 12 O
host NN 0 1 12 O
defense NN 0 1 UNK O
may MD 0 0 1 O
help VB 0 1 12 O
to TO 0 0 12 O
explain VB 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
malignant JJ 0 1 6 O
disease NN 0 1 6 O
in IN 0 0 12 O
aged JJ 0 1 12 O
persons NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ NN 0 0 2 O
vehicle NN 0 1 1 O
- : 0 0 2 O
treated VBN 1 1 1 O
animals NNS 1 1 12 O
almost RB 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
loss NN 0 1 1 O
of IN 0 0 12 O
tyrosine JJ 0 1 13 O
hydroxylase NN 0 1 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
norepinephrine JJ 0 1 14 O
neurons NNS 1 1 UNK O
was VBD 1 0 12 O
found VBN 1 1 12 O
in IN 0 0 12 O
locus NN 0 1 UNK O
coeruleus NN 0 0 UNK O
/ NNP 0 0 2 O
A9 NNP 0 1 UNK O
/ NNP 0 0 2 O
A9 NNP 0 1 UNK O
noradrenaline NN 0 1 UNK O
cell NN 0 1 1 O
groups NNS 1 1 1 O
whereas VBP 0 0 UNK O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
neuronal JJ 0 1 13 O
loss NN 0 1 1 O
was VBD 1 0 12 O
lower JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
control NN 0 1 1 O
values NNS 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ VBZ 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] FW 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
- : 0 0 2 O
treated VBN 1 1 1 O
monkeys NNS 1 1 UNK O
. . 0 0 12 O

Glucose NNP 0 1 7 B-Drug
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
exert VBP 0 1 13 O
additive JJ 0 1 16 O
ocular NN 0 1 6 O
and CC 0 0 12 O
renal JJ 0 1 6 O
vasodilator NN 0 1 14 O
effects NNS 1 1 1 O
on IN 0 0 12 O
healthy JJ 0 1 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
concurrent NN 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
from IN 0 0 12 O
these DT 0 0 12 O
groups NNS 1 1 1 O
is VBZ 1 0 12 O
decreasing VBG 1 1 1 O
according VBG 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
survey NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
hospital JJ 0 1 12 O
medical JJ 0 1 1 O
records NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
article NN 0 1 UNK O
reviews VBZ 1 1 UNK O
the DT 0 0 12 O
impact NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
cardiovascular JJ 0 1 6 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
identifies NNS 0 0 UNK O
clinically RB 0 0 6 O
important JJ 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
these DT 0 0 12 O
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Vesselinovitch NNP 0 0 UNK O
et CC 0 0 13 O
al NN 0 1 16 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
lab NN 0 1 1 O
interactions NNS 1 1 UNK O
: : 0 0 2 O
implications NNS 1 0 UNK O
for IN 0 0 12 O
nutrition NN 0 1 1 O
support NN 0 1 1 O
. . 0 0 12 O

AIM NNP 0 1 UNK O
AND CC 0 0 11 O
BACKGROUND NNP 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
a DT 0 0 12 O
macrolide NN 0 1 UNK B-Group
immunosuppressant NN 0 1 14 I-Group
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blocker NN 0 0 3 I-Group
diltiazem NN 0 1 0 B-Drug
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
low JJ 0 1 1 O
temperatures NNS 1 1 3 O
on IN 0 0 12 O
microtubules NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
myelinated JJ 0 1 UNK O
axons NNS 1 1 UNK O
of IN 0 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
ganglionic JJ 0 1 UNK O
sympathetic JJ 0 0 13 O
nerves NNS 1 1 6 O
. . 0 0 12 O

Phenytoin NNP 0 1 0 O
intoxication NN 0 1 6 O
induced VBN 1 1 6 O
by IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
. . 0 0 12 O

Progestin NNP 0 1 UNK O
- : 0 0 2 O
only RB 0 1 12 O
oral JJ 0 1 6 O
contraception NN 0 1 13 O
: : 0 0 2 O
a DT 0 0 12 O
comprehensive JJ 0 1 13 O
review NN 0 1 2 O
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
levothyroxine NN 0 1 0 B-Drug
with IN 0 0 12 O
infant JJ 0 1 6 O
colic JJ 0 1 6 O
drops NNS 1 1 3 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
thus RB 0 0 1 O
an DT 0 0 12 O
enhancement JJ 0 1 1 O
effect NN 0 1 1 O

No DT 0 0 2 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
noted VBN 1 0 1 O
with IN 0 0 12 O
other JJ 0 0 12 O
drug NN 0 1 1 O
combinations NNS 1 1 1 O
or CC 0 0 12 O
with IN 0 0 12 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
percentage NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
binding NN 0 1 1 O
in IN 0 0 12 O
each DT 0 0 12 O
preparation NN 0 1 1 O
was VBD 1 0 12 O
calculated VBN 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
patient NN 0 1 6 O
had VBD 1 0 12 O
phenytoin VBN 0 1 16 O
intoxication NN 0 1 6 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
a DT 0 0 12 O
selective JJ 0 1 13 O
serotonin NN 0 1 13 O
reuptake NN 0 1 13 O
inhibitor NN 0 1 14 O
. . 0 0 12 O

Prescribing VBG 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
preservation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
microtubules NNS 1 1 UNK O
was VBD 1 0 12 O
improved VBN 1 1 1 O
when WRB 0 0 12 O
D9O NNP 0 0 UNK O
was VBD 1 0 12 O
present JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
incubation NN 0 0 UNK O
medium NN 0 1 3 O
. . 0 0 12 O

OBJECTIVE NN 0 1 UNK O
: : 0 0 2 O
Our PRP$ 0 0 2 O
objective NN 0 1 13 O
was VBD 1 0 12 O
to TO 0 0 12 O
characterize VB 0 0 1 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
everolimus NN 0 1 13 B-Drug
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
( ( 0 0 2 O
INN NNP 0 1 UNK O
ciclosporin NN 0 1 UNK B-Drug
) ) 0 0 2 O
when WRB 0 0 12 O
coadministered VBN 0 0 UNK O
in IN 0 0 12 O
de FW 0 1 2 O
novo FW 0 0 UNK O
kidney NN 0 1 6 O
allograft NN 0 1 8 O
recipients NNS 1 1 UNK O
during IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
year NN 0 1 12 O
after IN 0 0 12 O
transplantation NN 0 1 6 O
. . 0 0 12 O

Rofecoxib NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
plasma NN 0 1 14 O
pharmacokinetics NNS 0 1 UNK O
or CC 0 0 12 O
renal JJ 0 1 6 O
elimination NN 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

PGF9alpha NNP 0 0 UNK B-Drug
produced VBD 1 0 1 O
significantly RB 0 0 1 O
increased VBN 1 1 1 O
vasoconstriction NN 0 1 UNK O
after IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
oxytocin NN 0 1 13 B-Drug
. . 0 0 12 O

Of IN 0 0 2 O
the DT 0 0 12 O
isoform NN 0 1 UNK O
- : 0 0 2 O
specific JJ 0 1 1 O
CYP NNP 0 1 UNK O
inhibitors NNS 1 1 14 O
tested VBD 1 1 1 O
for IN 0 0 12 O
an DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
metabolite VBP 0 1 UNK O
profile IN 0 1 1 O
only RB 0 1 12 O
tranylcypromine NN 0 1 13 B-Drug
was VBD 1 0 12 O
noticeably RB 0 0 3 O
effective JJ 0 1 1 O
indicating VBG 1 0 1 O
a DT 0 0 12 O
role NN 0 1 1 O
of IN 0 0 12 O
CYPs NNP 0 1 UNK O
9A9 CD 0 0 UNK O
9C9 CD 0 0 UNK O
9Cl9 CD 0 0 UNK O
and CC 0 0 12 O
9E9 CD 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
selection NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
their PRP$ 0 0 12 O
dosages NNS 1 1 14 O
may MD 0 0 1 O
be VB 0 0 12 O
improved VBN 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
pharmacogenetic JJ 0 1 UNK O
investigations NNS 1 1 1 O
. . 0 0 12 O

If IN 0 0 12 O
in IN 0 0 12 O
certain JJ 0 1 1 O
cases NNS 1 1 UNK O
an DT 0 0 12 O
antidepressant NN 0 1 6 B-Group
is VBZ 1 0 12 O
considered VBN 1 1 1 O
necessary JJ 0 0 1 O
it PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
advisable JJ 0 0 UNK O
to TO 0 0 12 O
replace VB 0 1 12 O
tamoxifen NN 0 1 0 B-Drug
with IN 0 0 12 O
anastrozole NN 0 1 16 B-Drug
. . 0 0 12 O

Endogenous JJ 0 1 UNK O
respiration NN 0 1 6 O
was VBD 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
at IN 0 0 12 O
a DT 0 0 12 O
concentration NN 0 1 1 O
as RB 0 0 12 O
high JJ 0 1 1 O
as IN 1 0 12 O
9 CD 0 0 2 O
mug NN 0 1 UNK O
/ NNP 0 0 2 O
ml NN 0 1 16 O
whereas RB 0 0 UNK O
exogenous JJ 0 1 UNK O
respiration NN 0 1 6 O
was VBD 1 0 12 O
markedly RB 0 1 1 O
sensitive JJ 0 1 1 O
and CC 0 0 12 O
inhibited VBN 1 1 13 O
to TO 0 0 12 O
an DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Five CD 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
of IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
alone RB 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
of IN 0 0 12 O
metabolite NN 0 1 UNK O
I PRP 0 1 12 O
alone RB 0 1 12 O
produced VBD 1 0 1 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
of IN 0 0 12 O
hypnosis NN 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
secretory NN 0 1 UNK O
diarrhea NN 0 1 6 O
model NN 0 1 UNK O
is VBZ 1 0 12 O
suitable JJ 0 1 1 O
for IN 0 0 12 O
evaluating VBG 1 1 1 O
the DT 0 0 12 O
antidiarrheal JJ 0 1 13 O
activity NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Acetaminophen NNP 0 1 0 B-Drug
lidocaine NN 0 1 14 B-Drug
phenobarbital JJ 0 1 16 B-Drug
quinidine NN 0 1 16 B-Drug
theophylline NN 0 1 16 B-Drug
and CC 0 0 12 O
valproic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
were VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
pooled VB 1 1 UNK O
human JJ 0 1 1 O
serum NN 0 1 14 O
at IN 0 0 12 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Exercise NN 0 1 UNK O
that WDT 0 0 12 O
produces VBZ 1 0 1 O
cardiopulmonary JJ 0 1 6 O
stimulation NN 0 1 6 O
is VBZ 1 0 12 O
a DT 0 0 12 O
helpful JJ 0 1 12 O
means NNS 1 1 13 O
of IN 0 0 12 O
reducing VBG 1 1 1 O
drug NN 0 1 1 O
hunger NN 0 1 12 O
and CC 0 0 12 O
anxiety NN 0 1 6 O
during IN 0 0 12 O
recovery NN 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

AUC NNP 0 1 UNK O
for IN 0 0 12 O
total JJ 0 1 1 O
nitrosoureas NNS 0 1 UNK B-Group
were VBD 1 0 12 O
about RB 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
fold JJ 0 1 3 O
greater JJR 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
i.p NN 0 1 UNK O
. . 0 0 12 O

Sexual JJ 0 1 UNK O
intercourse NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
steady JJ 0 1 1 O
partner NN 0 1 12 O
causes VBZ 1 1 6 O
no DT 0 0 12 O
more RBR 0 1 12 O
cardiovascular JJ 0 1 6 O
risk NN 0 1 1 O
than IN 0 0 12 O
normal JJ 0 1 1 O
daily JJ 0 1 12 O
activities NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
ironing VBG 1 1 13 O
9 CD 0 0 2 O
kilometers NNS 1 1 UNK O
of IN 0 0 12 O
walking VBG 1 1 12 O
without IN 0 0 12 O
climbing VBG 1 1 12 O
paperhanging VBG 0 0 UNK O
playing VBG 1 1 13 O
golf NN 0 1 13 O
or CC 0 0 12 O
gardening NN 0 1 13 O
. . 0 0 12 O

Dexamethasone NN 0 1 0 B-Drug
and CC 0 0 12 O
retinyl NN 0 0 UNK B-Drug
acetate VBP 0 1 14 I-Drug
similarly RB 0 0 1 O
inhibit NN 0 1 13 O
and CC 0 0 12 O
stimulate NN 0 0 UNK O
EGF NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
or CC 0 0 12 O
insulin VB 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
proliferation NN 0 1 1 O
of IN 0 0 12 O
prostatic JJ 0 1 6 O
epithelium NN 0 1 8 O
. . 0 0 12 O

We PRP 0 0 12 O
retrospectively RB 0 0 UNK O
reviewed VBD 1 1 1 O
the DT 0 0 12 O
records NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
pediatric JJ 0 1 6 O
oncology NN 0 1 6 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
ketamine NN 0 1 13 B-Drug
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
propofol NN 0 1 14 B-Drug
for IN 0 0 12 O
total JJ 0 1 1 O
intravenous JJ 0 1 14 O
anesthesia NN 0 1 6 O
( ( 0 0 2 O
TIVA NNP 0 0 UNK O
) ) 0 0 2 O
repeatedly RB 0 1 12 O
for IN 0 0 12 O
radiation NN 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

We PRP 0 0 12 O
evaluated VBD 1 1 1 O
how WRB 0 0 12 O
lapatinib JJ 0 1 13 B-Drug
interacts NNS 0 0 UNK O
with IN 0 0 12 O
Herceptin NNP 0 1 UNK B-Brand
in IN 0 0 12 O
HER9 NNP 0 0 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
with IN 0 0 12 O
a DT 0 0 12 O
particular JJ 0 0 1 O
focus NN 0 1 1 O
on IN 0 0 12 O
Herceptin NNP 0 1 UNK B-Brand
- : 0 0 2 O
mediated VBD 1 1 13 O
antibody JJ 0 1 14 O
- : 0 0 2 O
dependent NN 0 1 1 O
cellular JJ 0 1 13 O
cytotoxicity NN 0 1 UNK O
( ( 0 0 2 O
ADCC NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Spermine NNP 0 1 UNK B-Drug
promotes VBZ 1 1 UNK O
the DT 0 0 12 O
translocation NN 0 1 13 O
of IN 0 0 12 O
phosphatidate JJ 0 1 UNK O
phosphohydrolase NN 0 0 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
cytosol NN 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
microsomal JJ 0 1 UNK O
fraction NN 0 1 1 O
of IN 0 0 12 O
rat NN 0 1 13 O
liver NN 0 1 6 O
and CC 0 0 12 O
it PRP 0 0 12 O
enhances VBZ 1 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
oleate NN 0 1 UNK O
in IN 0 0 12 O
this DT 0 0 12 O
respect NN 0 1 1 O
. . 0 0 12 O

Azithromycin NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
impact NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
Cmax NNP 0 1 UNK O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
of IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
although IN 0 0 12 O
it PRP 0 0 12 O
significantly RB 0 0 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
zidovudine NN 0 1 13 B-Drug
tmax NN 0 1 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
intracellular JJ 0 1 UNK O
exposure NN 0 1 1 O
to TO 0 0 12 O
phosphorylated VBN 0 0 UNK O
zidovudine NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Both DT 0 0 2 O
of IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
endothelium JJ 0 1 UNK O
- : 0 0 2 O
dependent NN 0 1 1 O
. . 0 0 12 O

Intrathecal JJ 0 1 UNK O
injection NN 0 1 3 O
of IN 0 0 12 O
naloxone NN 0 1 16 B-Drug
at IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
caused VBD 1 1 1 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
blockade NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
response NN 0 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
intraventricular JJ 0 1 8 O
injection NN 0 1 3 O
of IN 0 0 12 O
beta NN 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
naloxone NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
) ) 0 0 2 O
completely RB 0 1 12 O
blocked VBD 1 1 13 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
inhibition NN 0 1 13 O
induced VBN 1 1 6 O
by IN 0 0 12 O
intraventricular JJ 0 1 8 O
beta NN 0 1 16 B-Drug_n
- : 0 0 2 O
endorphin NN 0 1 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
purpose NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
sodium NN 0 1 14 B-Drug_n
carboxymethylcellulose NN 0 1 13 I-Drug_n
( ( 0 0 2 O
NaCMC NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
carboxymethylcellulose JJ 0 1 13 B-Drug_n
- : 0 0 2 O
cysteine NN 0 1 13 I-Drug_n
( ( 0 0 2 O
CMC NNP 0 1 13 B-Drug_n
- : 0 0 2 O
Cys NN 0 1 UNK I-Drug_n
) ) 0 0 2 O
conjugates VBZ 1 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
permeation NN 0 1 UNK O
of IN 0 0 12 O
sodium NN 0 1 14 B-Drug
fluorescein NN 0 1 13 I-Drug
( ( 0 0 2 O
NaFlu NNP 0 0 UNK B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
model $ 0 1 UNK O
peptide JJ 0 1 13 O
drugs NNS 1 1 6 O
bacitracin NN 0 1 16 B-Drug
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
. . 0 0 12 O

C9BL NNP 0 0 UNK O
/ VBD 0 0 2 O
9N CD 0 0 UNK O
demonstrated JJ 0 0 1 O
large JJ 0 1 3 O
numbers NNS 1 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
three CD 0 1 12 O
types NNS 1 1 1 O
of IN 0 0 12 O
liver NN 0 1 6 O
tumors NNS 1 1 6 O
seen VBN 1 1 12 O
in IN 0 0 12 O
livers NNS 1 1 UNK O
of IN 0 0 12 O
genetically RB 0 0 UNK O
predisposed VBN 1 1 UNK O
mice NN 1 1 UNK O
one CD 0 1 12 O
of IN 0 0 12 O
which WDT 0 0 12 O
required VBD 1 1 1 O
the DT 0 0 12 O
additional JJ 0 1 1 O
stimulus NN 0 1 1 O
of IN 0 0 12 O
dietary JJ 0 1 6 O
phenobarbital NN 0 1 16 B-Drug
for IN 0 0 12 O
growth NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
L NNP 0 1 2 B-Drug_n
- : 0 0 2 O
NAME NN 0 1 11 I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
l NN 0 1 2 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
reseveratrol NN 0 0 UNK B-Drug_n
on IN 0 0 12 O
arteries NNS 1 1 6 O
from IN 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
giving VBG 1 1 12 O
superimposed JJ 0 0 3 O
concentration NN 0 1 1 O
- : 0 0 2 O
responses VBZ 0 1 1 O
curves NNS 1 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
demonstrates VBZ 1 1 1 O
that IN 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
thiosulfate JJ 0 1 16 B-Drug
permits NNS 1 1 UNK O
at IN 0 0 12 O
least JJS 0 1 12 O
a DT 0 0 12 O
twofold JJ 0 0 UNK O
increase NN 0 1 1 O
in IN 0 0 12 O
dose JJ 0 1 6 O
and CC 0 0 12 O
total JJ 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
cisplatin VB 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
the DT 0 0 12 O
subject NN 0 1 UNK O
of IN 0 0 12 O
much JJ 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
recent JJ 0 1 12 O
years NNS 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
assay VBP 0 1 14 O
lapatinib NN 0 1 13 B-Drug
induced VBN 1 1 6 O
HER9 NNP 0 0 UNK O
expression NN 0 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
cell NN 0 1 1 O
surface NN 0 1 3 O
of IN 0 0 12 O
HER9 NNP 0 0 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
leading VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
Herceptin NNP 0 1 UNK B-Brand
- : 0 0 2 O
mediated VBD 1 1 13 O
ADCC NNP 0 1 UNK O
. . 0 0 12 O

All DT 0 0 2 O
patients NNS 1 1 6 O
had VBD 1 0 12 O
indications NNS 1 1 1 O
for IN 0 0 12 O
antihypertensive JJ 0 1 14 O
therapy NN 0 1 6 O
and CC 0 0 12 O
were VBD 1 0 12 O
randomized VBN 1 1 6 O
either RB 0 1 12 O
to TO 0 0 12 O
fixed VBN 1 1 1 O
combination NN 0 1 1 O
amlodipine NN 0 1 0 B-Drug
/ NNP 0 0 2 O
valsartan NN 0 1 0 B-Drug
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
or CC 0 0 12 O
to TO 0 0 12 O
therapy VB 0 1 6 O
which WDT 0 0 12 O
corresponded VBD 1 0 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
hospital NN 0 1 12 O
formulary NN 0 1 16 O
( ( 0 0 2 O
n=9 JJ 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Paroxetine NNP 0 1 0 B-Drug
and CC 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
reduce VB 0 0 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
endoxifen NN 0 1 UNK B-Drug_n
by IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

Reformed VBN 0 1 UNK O
microtubules NNS 1 1 UNK O
appeared VBD 1 1 12 O
to TO 0 0 12 O
function VB 0 1 1 O
normally RB 0 0 1 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
possible JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
transport NN 0 1 1 O
of IN 0 0 12 O
noradrenaline JJ 0 1 UNK O
storage NN 0 1 UNK O
vesicles NNS 1 1 13 O
along IN 0 0 12 O
the DT 0 0 12 O
axons NNS 1 1 UNK O
. . 0 0 12 O

Pharmacology NNP 0 1 UNK O
and CC 0 0 12 O
pharmacotherapy NN 0 1 UNK O
of IN 0 0 12 O
cardiovascular JJ 0 1 6 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Mean JJ 0 1 2 O
number NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
per IN 0 0 1 O
MAC NNP 0 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
use NN 0 1 1 O
of IN 0 0 12 O
herbal JJ 0 1 6 O
remedies NNS 1 0 6 O
is VBZ 1 0 12 O
becoming VBG 1 0 12 O
increasingly RB 0 0 1 O
popular JJ 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
United NNP 0 0 2 O
States NNPS 0 1 2 O
. . 0 0 12 O

Statistical JJ 0 1 UNK O
analysis NN 0 1 1 O
: : 0 0 2 O
Mantel NNP 0 0 UNK O
- : 0 0 2 O
Haenszel NNP 0 0 UNK O
( ( 0 0 2 O
alpha JJ 0 1 1 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
both DT 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
and CC 0 0 12 O
retinyl NN 0 0 UNK B-Drug
acetate NN 0 1 14 I-Drug
and CC 0 0 12 O
possibly RB 0 1 12 O
other JJ 0 0 12 O
glucocorticoids NNS 1 1 UNK B-Group
and CC 0 0 12 O
retinoids NNS 0 1 UNK B-Group
may MD 0 0 1 O
regulate VB 0 0 UNK O
the DT 0 0 12 O
proliferation NN 0 1 1 O
of IN 0 0 12 O
prostate NN 0 1 6 O
epithelium NN 0 1 8 O
by IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
modification NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
and CC 0 0 12 O
EGF NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

Everolimus NNP 0 1 UNK B-Drug
dose SYM 0 1 6 O
- : 0 0 2 O
proportionality NN 0 1 UNK O
and CC 0 0 12 O
stability NN 0 1 1 O
over IN 0 1 12 O
time NN 0 1 12 O
were VBD 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
context NN 0 1 1 O
of IN 0 0 12 O
linear JJ 0 1 1 O
regression NN 0 1 UNK O
and CC 0 0 12 O
ANOVA NNP 0 0 UNK O
models NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
management NN 0 1 1 O
of IN 0 0 12 O
infection NN 0 1 6 O
is VBZ 1 0 12 O
dealt JJ 0 0 UNK O
with IN 0 0 12 O
as IN 1 0 12 O
a DT 0 0 12 O
separate JJ 0 1 1 O
section NN 0 1 1 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
however RB 0 0 12 O
currently RB 0 1 12 O
no DT 0 0 12 O
data NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
combined VBN 1 1 1 O
hyperglycaemia NN 0 1 UNK O
and CC 0 0 12 O
hyperinsulinaemia NN 0 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
and CC 0 0 12 O
ocular JJ 0 1 6 O
blood NN 0 1 6 O
flow NN 0 1 1 O
seen VBN 1 1 12 O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
patients NNS 1 1 6 O
on IN 0 0 12 O
insulin JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
genotypes NNS 1 1 UNK O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK B-Drug
and CC 0 0 12 O
9C9 CD 0 0 UNK O
the DT 0 0 12 O
enzymes NNS 1 1 14 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
phenytoin JJ 0 1 16 O
metabolism NN 0 1 16 O
were VBD 1 0 12 O
homozygous JJ 0 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
wild JJ 0 1 UNK O
- : 0 0 2 O
type NN 0 1 1 O
alleles NNS 1 1 UNK O
( ( 0 0 2 O
CYP9C9 NNP 0 0 UNK B-Drug
*9 NNP 0 0 UNK O
/ NNP 0 0 2 O
*9 NNP 0 0 UNK O
and CC 0 0 12 O
9C9*9 CD 0 0 UNK O
/ NNP 0 0 2 O
*9 NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
cadmium NN 0 1 13 O
zinc NN 0 1 14 B-Drug
and CC 0 0 12 O
cadmium NN 0 1 13 O
/ NNP 0 0 2 O
zinc NN 0 1 14 O
mixtures NNS 1 1 13 O
at IN 0 0 12 O
concentrations NNS 1 1 13 O
ranging VBG 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
99 CD 0 0 10 O
microg NNS 0 0 UNK O
/ JJ 0 0 2 O
l NN 0 1 2 O
were VBD 1 0 12 O
investigated VBN 1 1 1 O
against IN 0 0 12 O
cercariae NN 1 1 UNK O
and CC 0 0 12 O
metacercariae NN 0 1 UNK O
of IN 0 0 12 O
Parorchis NNP 0 1 UNK O
acanthus NN 0 1 UNK O
obtained VBN 1 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
dog NN 0 1 12 O
whelk NN 0 1 UNK O
Nucella NNP 0 1 UNK O
lapillus NN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
ratio NN 0 1 1 O
of IN 0 0 12 O
norketamine JJ 0 1 UNK B-Drug_n
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
to TO 0 0 12 O
ketamine VB 0 1 13 B-Drug
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
ticlopidine NN 0 1 16 B-Drug
( ( 0 0 2 O
P NNP 0 1 2 O
& CC 0 0 2 O
lt NN 0 1 13 O
; : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
itraconazole JJ 0 1 0 B-Drug
phases NNS 1 1 UNK O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
placebo VB 0 1 13 O
. . 0 0 12 O

Theophylline NNP 0 1 UNK B-Drug
alone RB 0 1 12 O
caused VBD 1 1 1 O
identical JJ 0 1 1 O
insulin NN 0 1 14 O
and CC 0 0 12 O
glucagon NN 0 1 14 O
release NN 0 1 12 O
in IN 0 0 12 O
diabetics NNS 1 1 UNK O
and CC 0 0 12 O
normals NNS 1 1 UNK O
. . 0 0 12 O

Several JJ 0 1 2 O
clinically RB 0 0 6 O
important JJ 0 1 1 O
interactions NNS 1 1 UNK O
have VBP 0 0 12 O
previously RB 0 0 1 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
for IN 0 0 12 O
other JJ 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
enzyme NN 0 1 14 O
and CC 0 0 12 O
for IN 0 0 12 O
calcium NN 0 1 14 B-Group
antagonists NNS 1 1 13 I-Group
. . 0 0 12 O

The DT 0 0 2 O
mean NN 0 1 12 O
( ( 0 0 2 O
SD NNP 0 1 UNK O
) ) 0 0 2 O
cumulative VBP 0 1 13 O
urinary JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
immunoreactive JJ 0 0 UNK O
digoxin NN 0 1 14 B-Drug
after IN 0 0 12 O
concurrent JJ 0 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
or CC 0 0 12 O
placebo NN 0 1 13 O
was VBD 1 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
+ JJ 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
+ JJ 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
micrograms NNS 1 1 14 O
/ $ 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
respectively RB 0 0 1 O
. . 0 0 12 O

Determinations NNS 0 1 UNK O
of IN 0 0 12 O
serum NN 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
utilizing VBG 1 0 1 O
commercially RB 0 0 UNK O
available JJ 0 1 1 O
kits NNS 1 1 UNK O
with IN 0 0 12 O
an DT 0 0 12 O
9I CD 0 1 UNK O
- : 0 0 2 O
labelled VBN 1 1 UNK O
antigen NN 0 1 14 O
were VBD 1 0 12 O
precise JJ 0 1 UNK O
and CC 0 0 12 O
not RB 0 1 12 O
materially RB 0 0 UNK O
different JJ 0 1 1 O
from IN 0 0 12 O
results NNS 1 1 1 O
obtained VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
9H CD 0 0 UNK O
- : 0 0 2 O
labelled VBN 1 1 UNK O
antigen NN 0 1 14 O
. . 0 0 12 O

Thus RB 0 0 1 O
the DT 0 0 12 O
hypothesis NN 0 1 UNK O
of IN 0 0 12 O
Gibaldi NNP 0 0 UNK O
et FW 0 0 13 O
al NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
most RBS 0 0 12 O
common JJ 0 1 1 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
reported VBN 1 1 1 O
with IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
are VBP 1 0 12 O
bodyweight VBN 0 1 UNK O
gain NN 0 1 1 O
somnolence NN 0 1 8 O
dizziness NN 0 1 6 O
anticholinergic JJ 0 1 13 O
effects NNS 1 1 1 O
( ( 0 0 2 O
constipation NN 0 1 6 O
and CC 0 0 12 O
dry JJ 0 1 3 O
mouth NN 0 1 3 O
) ) 0 0 2 O
and CC 0 0 12 O
transient JJ 0 1 1 O
asymptomatic JJ 0 1 6 O
liver NN 0 1 6 O
enzyme NN 0 1 14 O
elevations NNS 1 1 1 O
. . 0 0 12 O

dasatinib NN 0 1 13 B-Drug
: : 0 0 2 O
9 CD 0 0 2 O
vs NN 1 0 2 O
. . 0 0 12 O

injection NN 0 1 3 O
of IN 0 0 12 O
vehicle NN 0 1 1 O
( ( 0 0 2 O
corn NN 0 1 13 O
oil NN 0 1 3 O
9 CD 0 0 2 O
mL NN 0 1 14 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
estradiol NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
/ $ 0 0 2 O
or CC 0 0 12 O
progesterone NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
for IN 0 0 12 O
eight CD 0 1 12 O
days NNS 1 1 12 O
. . 0 0 12 O

Clinicians NNS 0 1 UNK O
and CC 0 0 12 O
parents NNS 1 1 12 O
need VBP 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
aware JJ 0 1 12 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
to TO 0 0 12 O
avoid VB 0 0 12 O
unnecessary JJ 0 0 UNK O
undertreatment NN 0 0 UNK O
and CC 0 0 12 O
prevent VB 0 1 1 O
potential JJ 0 1 1 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
neurological JJ 0 1 6 O
sequelae NN 1 1 6 O
. . 0 0 12 O

Pretreatment NN 0 1 UNK O
of IN 0 0 12 O
megakaryocytes NNS 1 1 UNK O
with IN 0 0 12 O
extracellular JJ 0 1 14 O
RR NNP 0 0 13 B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
microM NN 0 0 UNK O
) ) 0 0 2 O
also RB 0 0 12 O
inhibited VBN 1 1 13 O
InsP9 NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
responses NNS 1 1 1 O
. . 0 0 12 O

Research NN 0 1 UNK O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
herbal JJ 0 1 6 O
remedy NN 0 0 UNK O
use NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
acute JJ 0 1 6 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
a DT 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
difference NN 0 1 UNK O
exists NNS 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
excreted JJ 0 1 UNK O
levels NNS 1 1 1 O
of IN 0 0 12 O
homocysteine NN 0 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
of IN 0 0 12 O
both DT 0 0 12 O
control NN 0 1 1 O
and CC 0 0 12 O
levonorgestrel SYM 0 1 13 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
rats NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
levels NNS 1 1 1 O
shown VBN 1 1 1 O
by IN 0 0 12 O
rats NNS 1 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
ethynyl JJ 0 0 UNK B-Drug
estradiol NN 0 1 13 I-Drug
. . 0 0 12 O

Moreover RB 0 0 1 O
its PRP$ 1 0 12 O
activity NN 0 1 1 O
was VBD 1 0 12 O
enhanced VBN 1 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
azithromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
minocycline NN 0 1 13 B-Drug
with IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
parasite JJ 0 1 13 O
reduction NN 0 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
highest JJS 1 1 1 O
concentration NN 0 1 1 O
tested VBD 1 1 1 O
. . 0 0 12 O

METHODS NNS 0 1 UNK O
: : 0 0 2 O
All DT 0 0 2 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
enrolled VBN 1 0 1 O
in IN 0 0 12 O
two CD 0 1 12 O
sequential JJ 0 1 1 O
trials NNS 1 1 1 O
performed VBN 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
Aviano NNP 0 0 UNK O
Cancer NNP 0 1 7 O
Center NNP 0 1 2 O
Italy NNP 0 1 UNK O
from IN 0 0 12 O
April NNP 0 1 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
December NNP 0 1 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Cypermethrin NNP 0 1 UNK B-Drug
- : 0 0 2 O
induced VBD 1 1 6 O
oxidative JJ 0 1 UNK O
stress NN 0 1 1 O
in IN 0 0 12 O
rat NN 0 1 13 O
brain NN 0 1 6 O
and CC 0 0 12 O
liver NN 0 1 6 O
is VBZ 1 0 12 O
prevented VBN 1 1 UNK O
by IN 0 0 12 O
vitamin NN 0 1 6 B-Drug
E NNP 0 0 2 I-Drug
or CC 0 0 12 O
allopurinol NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
DZNep NNP 0 0 UNK B-Drug_n
insensitivity NN 0 1 13 O
might MD 0 0 12 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
overexpression NN 0 1 UNK O
of IN 0 0 12 O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
ABT NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
and CC 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
could MD 0 0 12 O
synergistically RB 0 0 UNK O
induced VB 1 1 6 O
apoptosis NN 0 1 UNK O
. . 0 0 12 O

Cohort NNP 0 1 UNK O
9 CD 0 0 2 O
then RB 0 1 12 O
received VBD 1 1 12 O
amprenavir JJ 0 1 13 B-Drug
plus CC 0 1 16 O
rifabutin NN 0 1 13 B-Drug
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
and CC 0 0 12 O
cohort NN 0 1 UNK O
9 CD 0 0 2 O
received VBD 1 1 12 O
amprenavir JJ 0 1 13 B-Drug
plus CC 0 1 16 O
rifampin NN 0 1 16 B-Drug
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
lower JJR 1 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
groups NNS 1 1 1 O
receiving VBG 1 1 1 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
Fe NNP 0 1 2 B-Drug
instead RB 0 0 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
Fe NNP 0 1 2 B-Drug
per IN 0 0 1 O
kg FW 0 1 18 O
diet NN 0 1 6 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
decreased JJ 0 1 1 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
of IN 0 0 12 O
cobalt NN 0 1 UNK B-Drug
. . 0 0 12 O

Sirolimus NN 0 1 UNK B-Drug
: : 0 0 2 O
mammalian JJ 0 1 UNK O
target NN 0 1 1 O
of IN 0 0 12 O
rapamycin JJ 0 1 13 B-Drug
inhibitor NN 0 1 14 O
to TO 0 0 12 O
prevent VB 0 1 1 O
kidney NN 0 1 6 O
rejection NN 0 1 1 O
. . 0 0 12 O

abnormal JJ 0 1 6 O
vaginal JJ 0 1 6 O
bleeding NN 0 1 6 O
; : 0 0 2 O

This DT 0 0 2 O
article NN 0 1 UNK O
looks VBZ 1 1 12 O
at IN 0 0 12 O
five CD 0 1 12 O
commonly NNS 0 0 UNK O
used VBN 1 1 12 O
immunosuppressive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
in IN 0 0 12 O
turn NN 0 1 12 O
( ( 0 0 2 O
corticosteroids NNS 1 1 14 B-Group
cyclosporin VBP 0 1 14 B-Drug
azathioprine JJ 0 1 13 B-Drug
methotrexate NN 0 1 16 B-Drug
cyclophosphamide NN 0 1 14 B-Drug
) ) 0 0 2 O
discussing VBG 1 1 12 O
the DT 0 0 12 O
main JJ 0 1 12 O
non NN 0 1 1 O
- : 0 0 2 O
infection NN 0 1 6 O
unwanted JJ 0 0 13 O
effects NNS 1 1 1 O
ways NNS 1 0 UNK O
to TO 0 0 12 O
avoid VB 0 0 12 O
them PRP 0 0 12 O
and CC 0 0 12 O
what WP 0 0 12 O
to TO 0 0 12 O
do VB 0 0 12 O
if IN 0 0 12 O
problems NNS 1 1 1 O
arise VBP 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
neomycin NNS 0 1 16 B-Drug
on IN 0 0 12 O
ACTH NNP 0 1 UNK B-Group
induced JJ 0 1 6 O
hypertension NN 0 1 6 O
were VBD 1 0 12 O
examined VBN 1 1 1 O
in IN 0 0 12 O
conscious JJ 0 1 1 O
sheep NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
biotransformation NN 0 1 UNK O
and CC 0 0 12 O
oxidative JJ 0 1 UNK O
stress NN 0 1 1 O
may MD 0 0 1 O
contribute VB 0 1 UNK O
to TO 0 0 12 O
9 CD 0 0 2 O
9:9 CD 0 0 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
diepoxybutane NN 0 1 UNK O
( ( 0 0 2 O
DEB NNP 0 1 UNK O
) ) 0 0 2 O
- : 0 0 2 O
induced VBN 1 1 6 O
toxicity NN 0 1 6 O
to TO 0 0 12 O
human JJ 0 1 1 O
lymphocytes NNS 1 1 14 O
of IN 0 0 12 O
Fanconi NNP 0 0 UNK O
Anemia NNP 0 1 7 O
( ( 0 0 2 O
FA NNP 0 0 13 O
) ) 0 0 2 O
patients NNS 1 1 6 O
. . 0 0 12 O

Prolonged VBN 0 1 7 O
daily JJ 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
picrotoxin NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg JJ 0 1 18 O
results NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
brain NN 0 1 6 O
edema NN 0 1 6 O
. . 0 0 12 O

forms NNS 1 1 1 O
of IN 0 0 12 O
memory NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
were VBD 1 0 12 O
corroborated VBN 1 0 1 O
by IN 0 0 12 O
quantitative JJ 0 1 1 O
RT NNP 0 1 UNK O
- : 0 0 2 O
PCR NN 0 1 14 O
. . 0 0 12 O

Efficacy NN 0 1 UNK O
and CC 0 0 12 O
tolerability NN 0 1 UNK O
of IN 0 0 12 O
fixed JJ 0 1 1 O
amlodipine NN 0 1 0 B-Drug
/ NNP 0 0 2 O
valsartan NN 0 1 0 B-Drug
combination NN 0 1 1 O
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hypertensive JJ 0 1 6 O
disease NN 0 1 6 O
hospitalized VBN 1 1 6 O
in IN 0 0 12 O
departments NNS 1 1 UNK O
of IN 0 0 12 O
general JJ 0 1 1 O
internal JJ 0 1 1 O
medicine NN 0 1 6 O
or CC 0 0 12 O
cardiology NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
MPTP NNP 0 1 UNK B-Drug
- : 0 0 2 O
induced VBD 1 1 6 O
neuronal JJ 0 1 13 O
damage NN 0 1 1 O
produced VBD 1 0 1 O
a DT 0 0 12 O
tolerance NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
disruptive JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
and CC 0 0 12 O
a DT 0 0 12 O
supersensitivity NN 0 0 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
disruptive JJ 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
apomorphine NN 0 1 UNK B-Drug
in IN 0 0 12 O
rats NNS 1 1 UNK O
responding VBG 1 0 1 O
in IN 0 0 12 O
a DT 0 0 12 O
schedule NN 0 1 12 O
controlled VBN 1 1 1 O
paradigm NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
groups NNS 1 1 1 O
then RB 0 1 12 O
took VBD 1 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
as IN 1 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
( ( 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

For IN 0 0 2 O
the DT 0 0 12 O
calcium NN 0 1 14 B-Group
- : 0 0 2 O
entry NN 0 1 1 I-Group
blocking VBG 1 1 UNK I-Group
agents NNS 1 1 1 I-Group
now RB 0 1 12 O
available JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
United NNP 0 0 2 O
States NNPS 0 1 2 O
( ( 0 0 2 O
verapamil FW 0 1 0 B-Drug
nifedipine NN 0 1 0 B-Drug
and CC 0 0 12 O
diltiazem NN 0 1 0 B-Drug
) ) 0 0 2 O
these DT 0 0 12 O
data NNS 0 1 1 O
appeared VBD 1 1 12 O
well RB 0 1 12 O
after IN 0 0 12 O
clinical JJ 0 1 6 O
patterns NNS 1 1 1 O
of IN 0 0 12 O
use NN 0 1 1 O
evolved VBN 1 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
groups NNS 1 1 1 O
achieving VBG 1 0 1 O
a DT 0 0 12 O
maximum JJ 0 1 1 O
relaxation NN 0 1 1 O
of IN 0 0 12 O
> $ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
at IN 0 0 12 O
a DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
micromol NNS 0 1 UNK O
/ JJ 0 0 2 O
l NN 0 1 2 O
. . 0 0 12 O

Pharmacological JJ 0 1 UNK O
treatment NN 0 1 6 O
of IN 0 0 12 O
depression NN 0 1 6 O
: : 0 0 2 O
the DT 0 0 12 O
role NN 0 1 1 O
of IN 0 0 12 O
paroxetine NN 0 1 16 B-Drug
. . 0 0 12 O

Treatment NN 0 1 7 O
of IN 0 0 12 O
the DT 0 0 12 O
glands NNS 1 1 6 O
with IN 0 0 12 O
cytochalasin NN 0 1 UNK B-Drug_n
D NNP 0 1 2 I-Drug_n
redistributed VBD 1 0 UNK O
type JJ 0 1 1 O
9 CD 0 0 2 O
inositol NN 0 1 UNK O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
trisphosphate NN 0 0 UNK O
receptor NN 0 1 14 O
( ( 0 0 2 O
the DT 0 0 12 O
major JJ 0 1 1 O
subtype NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
parietal NN 0 1 8 O
cell NN 0 1 1 O
) ) 0 0 2 O
from IN 0 0 12 O
the DT 0 0 12 O
fraction NN 0 1 1 O
containing VBG 1 1 1 O
membranes NNS 1 1 6 O
of IN 0 0 12 O
large JJ 0 1 3 O
size NN 0 1 3 O
to TO 0 0 12 O
the DT 0 0 12 O
microsomal JJ 0 1 UNK O
fraction NN 0 1 1 O
suggesting VBG 1 1 1 O
a DT 0 0 12 O
dissociation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
store NN 0 1 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
membrane NN 0 1 3 O
. . 0 0 12 O

Lapatinib NNP 0 1 UNK B-Drug
enhances VBZ 1 1 UNK O
herceptin SYM 0 1 UNK B-Brand
- : 0 0 2 O
mediated VBN 1 1 13 O
antibody NN 0 1 14 O
- : 0 0 2 O
dependent NN 0 1 1 O
cellular JJ 0 1 13 O
cytotoxicity NN 0 1 UNK O
by IN 0 0 12 O
up IN 0 0 12 O
- : 0 0 2 O
regulation NN 0 1 13 O
of IN 0 0 12 O
cell NN 0 1 1 O
surface NN 0 1 3 O
HER9 NNP 0 0 UNK O
expression NN 0 1 1 O
. . 0 0 12 O

Digoxin NNP 0 1 0 B-Drug
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
elimination NN 0 1 UNK O
was VBD 1 0 12 O
prolonged VBN 1 1 6 O
from IN 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
( ( 0 0 2 O
p NN 0 1 2 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
siRNA JJ 0 1 UNK O
knockdown NN 0 0 UNK O
of IN 0 0 12 O
Src NNP 0 1 UNK O
Fyn NNP 0 1 UNK O
or CC 0 0 12 O
Abl9 NNP 0 0 UNK O
enhanced VBD 1 1 1 O
paclitaxel SYM 0 1 13 B-Drug
- : 0 0 2 O
mediated JJ 0 1 13 O
growth NN 0 1 1 O
inhibition NN 0 1 13 O
in IN 0 0 12 O
ovarian JJ 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
compared VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
control NN 0 1 1 O
siRNA NN 0 1 UNK O
. . 0 0 12 O

Cholinergic NNP 0 1 UNK O
role NN 0 1 1 O
in IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
's POS 0 1 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
evoked JJ 0 1 13 O
potentials NNS 1 1 UNK O
in IN 0 0 12 O
visual JJ 0 1 1 O
cortex NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
albino NN 0 1 UNK O
rat NN 0 1 13 O
. . 0 0 12 O

Amiodarone NN 0 1 0 B-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
raise VB 0 0 12 O
serum JJ 0 1 14 O
digoxin NN 0 1 14 B-Drug
levels NNS 1 1 1 O
. . 0 0 12 O

Etofibrate NNP 0 1 UNK B-Drug
elicited VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
heparin NN 0 1 14 B-Drug
lipolytic JJ 0 1 UNK O
activity NN 0 1 1 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
of IN 0 0 12 O
9H CD 0 0 UNK O
- : 0 0 2 O
triglyceride NN 0 1 14 O
fractional JJ 0 1 1 O
clearance NN 0 1 16 O
rate NN 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
placebo NN 0 1 13 O
treatment NN 0 1 6 O
. . 0 0 12 O

N NNP 0 1 2 B-Drug_n
- : 0 0 2 O
methyllevallorphan NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
s.c NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O

epilepsy NN 0 1 13 O
; : 0 0 2 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
that IN 0 0 12 O
health NN 0 1 1 O
care NN 0 1 12 O
professionals NNS 1 1 UNK O
be VB 0 0 12 O
aware JJ 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
medications NNS 1 1 6 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
clinical JJ 0 1 6 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

Altered NNP 0 1 13 O
responsiveness NN 0 1 UNK O
to TO 0 0 12 O
alcohol VB 0 1 1 B-Drug
after IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
organic JJ 0 1 13 O
lead NN 0 1 12 O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
other JJ 0 0 12 O
hand NN 0 1 12 O
the DT 0 0 12 O
density NN 0 1 1 O
of IN 0 0 12 O
D9 NNP 0 1 UNK O
binding VBG 1 1 1 O
sites NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
SST NNP 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
RBC NNP 0 1 13 O
mice NN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
STR NNP 0 0 UNK O
was VBD 1 0 12 O
significantly RB 0 0 1 O
increased VBN 1 1 1 O
in IN 0 0 12 O
cocaine NN 0 1 6 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
groups NNS 1 1 1 O
without IN 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
Kd NNP 0 1 UNK O
. . 0 0 12 O

METHODS NN 0 1 UNK O
: : 0 0 2 O
Hydrocortisone NNP 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
d $ 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
were VBD 1 0 12 O
administered VBN 1 1 1 O
orally RB 0 1 14 O
to TO 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
male NN 0 1 12 O
and CC 0 0 12 O
female JJ 0 1 12 O
volunteers NNS 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
four CD 0 1 12 O
- : 0 0 2 O
session NN 0 1 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled VBN 1 1 1 O
within IN 0 0 1 O
- : 0 0 2 O
subject JJ 0 1 UNK O
crossover NN 0 1 UNK O
design NN 0 1 UNK O
. . 0 0 12 O

MEASUREMENTS NNP 0 1 11 O
and CC 0 0 12 O
MAIN NNP 0 1 11 O
RESULTS NNP 0 1 11 O
: : 0 0 2 O
Blood NN 0 1 2 O
samples NNS 1 1 UNK O
were VBD 1 0 12 O
drawn VBN 1 0 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
lead NN 0 1 12 O
electrocardiograms NN 1 1 8 O
performed VBD 1 1 1 O
at IN 0 0 12 O
specified JJ 0 1 13 O
time NN 0 1 12 O
points NNS 1 1 12 O
after IN 0 0 12 O
the DT 0 0 12 O
last JJ 0 1 12 O
morning NN 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
in IN 0 0 12 O
phases NNS 1 1 UNK O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Additional NNP 0 1 2 O
iron NN 0 1 3 B-Drug
significantly RB 0 0 1 O
inhibited VBD 1 1 13 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
cobalt NN 0 1 UNK B-Drug
in IN 0 0 12 O
both DT 0 0 12 O
dietary JJ 0 1 6 O
cobalt NN 0 1 UNK B-Drug
treatments NNS 1 1 6 O
. . 0 0 12 O

Some DT 0 0 2 O
disorders NNS 1 1 6 O
unrelated VBD 0 1 1 O
to TO 0 0 12 O
sexual JJ 0 1 12 O
dysfunction NN 0 1 6 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
esophageal NN 0 1 6 O
motility NN 0 1 6 O
dysfunction NN 0 1 6 O
) ) 0 0 2 O
may MD 0 0 1 O
also RB 0 0 12 O
respond VB 0 0 1 O
to TO 0 0 12 O
sildenafil VB 0 1 16 B-Drug
. . 0 0 12 O

Here RB 0 0 2 O
we PRP 0 0 12 O
examined VBD 1 1 1 O
its PRP$ 1 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
multiple JJ 0 1 1 O
myeloma NN 0 1 6 O
( ( 0 0 2 O
MM NNP 0 0 13 O
) ) 0 0 2 O
cells NNS 1 1 6 O
and CC 0 0 12 O
found VBD 1 1 12 O
that IN 0 0 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
nM NNS 0 1 UNK O
it PRP 0 0 12 O
potently RB 0 0 UNK O
inhibited VBD 1 1 13 O
growth NN 0 1 1 O
and CC 0 0 12 O
induced JJ 0 1 6 O
apoptosis NN 0 1 UNK O
in IN 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
MM NNP 0 0 13 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
variables NNS 1 1 UNK O
for IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
were VBD 1 0 12 O
determined VBN 1 1 1 O
after IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
intravenous JJ 0 1 14 O
dose NN 0 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
in IN 0 0 12 O
each DT 0 0 12 O
subject NN 0 1 UNK O
before IN 0 1 12 O
and CC 0 0 12 O
after IN 0 0 12 O
oral JJ 0 1 6 O
amiodarone NN 0 1 0 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
provide VB 0 1 1 O
information NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
appropriate JJ 0 1 1 O
package NN 0 1 13 O
insert JJ 0 1 13 O
labeling NN 0 1 UNK O
of IN 0 0 12 O
progestin NN 0 1 UNK B-Group
- : 0 0 2 O
only RB 0 1 12 I-Group
oral JJ 0 1 6 I-Group
contraceptives NNS 1 1 13 I-Group
( ( 0 0 2 O
POC NNP 0 1 UNK B-Group
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
US NNP 0 0 2 O
a DT 0 0 12 O
comprehensive JJ 0 1 13 O
review NN 0 1 2 O
was VBD 1 0 12 O
made VBN 1 1 12 O
of IN 0 0 12 O
norgestrel NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
norethindrone NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
with IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
differences NNS 1 1 UNK O
indicated VBD 1 1 1 O
where WRB 0 0 12 O
applicable JJ 0 1 1 O
. . 0 0 12 O

Either DT 0 1 UNK O
single JJ 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
or CC 0 0 12 O
repeated VBN 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg FW 0 1 18 O
per IN 0 0 1 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
cypermethrin NN 0 1 UNK B-Drug
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
significant JJ 0 1 1 O
oxidative JJ 0 1 UNK O
stress NN 0 1 1 O
in IN 0 0 12 O
cerebral JJ 0 0 6 O
and CC 0 0 12 O
hepatic JJ 0 1 14 O
tissues NNS 1 1 6 O
of IN 0 0 12 O
rats NNS 1 1 UNK O
as IN 1 0 12 O
was VBD 1 0 12 O
evident JJ 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
thiobarbituric JJ 0 0 UNK O
acid NN 0 1 14 O
reactive JJ 0 1 1 O
substances NNS 1 1 1 O
( ( 0 0 2 O
TBARS NNP 0 1 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
both DT 0 0 12 O
tissues NNS 1 1 6 O
either CC 0 1 12 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
after IN 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

filipin NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
more RBR 0 1 12 O
potent JJ 0 1 UNK O
in IN 0 0 12 O
lysing VBG 0 1 UNK O
human JJ 0 1 1 O
red JJ 0 1 3 O
blood NN 0 1 6 O
cells NNS 1 1 6 O
whereas VBP 0 0 UNK O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
was VBD 1 0 12 O
more RBR 0 1 12 O
potent JJ 0 1 UNK O
in IN 0 0 12 O
inhibiting VBG 1 1 UNK O
yeast NN 0 1 6 O
cell NN 0 1 1 O
growth NN 0 1 1 O
; : 0 0 2 O

We PRP 0 0 12 O
examined VBD 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
exogenous JJ 0 1 UNK O
estradiol NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
steroid VBP 0 1 6 O
hormone NN 0 1 6 O
levels NNS 1 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
a DT 0 0 12 O
nonlethal JJ 0 0 UNK O
dose NN 0 1 6 O
of IN 0 0 12 O
Escherichia NNP 0 1 14 O
coli NN 0 0 14 O
endotoxin NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
male JJ 0 1 12 O
rats NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
deaths NNS 1 1 UNK O
due JJ 0 1 1 O
to TO 0 0 12 O
nonlethal JJ 0 0 UNK O
and CC 0 0 12 O
lethal JJ 0 1 13 O
doses NNS 1 1 6 O
of IN 0 0 12 O
endotoxin NN 0 1 UNK B-Drug_n
. . 0 0 12 O

In IN 0 0 2 O
period NN 0 1 1 O
B NNP 0 0 2 O
the DT 0 0 12 O
volunteers NNS 1 1 UNK O
were VBD 1 0 12 O
randomly RB 0 0 UNK O
assigned VBN 1 1 UNK O
to TO 0 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
two CD 0 1 12 O
groups NNS 1 1 1 O
. . 0 0 12 O

We PRP 0 0 12 O
reviewed VBD 1 1 1 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
relating VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
of IN 0 0 12 O
pharmacologic JJ 0 1 14 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ascorbic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
in IN 0 0 12 O
the DT 0 0 12 O
prevention NN 0 1 1 O
and CC 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
common JJ 0 1 1 O
cold NN 0 1 3 O
. . 0 0 12 O

Since IN 0 1 2 O
both DT 0 0 12 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
organoleads NNS 0 0 UNK O
are VBP 1 0 12 O
present JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
environment NN 0 1 1 O
and CC 0 0 12 O
seem VBP 0 0 12 O
to TO 0 0 12 O
influence VB 0 0 UNK O
limbic JJ 0 0 UNK O
integration NN 0 1 13 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
compounds NNS 1 1 13 O
was VBD 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
present JJ 0 1 1 O
experiment NN 0 1 UNK O
. . 0 0 12 O

Those DT 0 0 12 O
for IN 0 0 12 O
which WDT 0 0 12 O
effectiveness NN 0 1 UNK O
is VBZ 1 0 12 O
reported VBN 1 1 1 O
includes VBZ 1 1 1 O
diphenhydramine JJ 0 1 16 B-Drug
hydroxyzine NN 0 1 16 B-Drug
orphenadrine NN 0 1 13 B-Drug
pyrilamine NN 0 1 UNK B-Drug
phenyltoloxamine NN 0 1 UNK B-Drug_n
promethazine NN 0 1 16 B-Drug
methdilazine NN 0 1 UNK B-Drug
and CC 0 0 12 O
tripelennamine NN 0 1 UNK B-Drug
. . 0 0 12 O

Using VBG 0 1 2 O
this DT 0 0 12 O
technique NN 0 1 1 O
it PRP 0 0 12 O
was VBD 1 0 12 O
possible JJ 0 1 1 O
to TO 0 0 12 O
escalate VB 0 0 UNK O
the DT 0 0 12 O
cisplatin NN 0 1 14 B-Drug
dose NN 0 1 6 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
m9 NN 0 1 UNK O
before IN 0 1 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
limiting VBG 1 1 1 O
toxicities NNS 1 1 UNK O
were VBD 1 0 12 O
encountered VBN 1 1 12 O
. . 0 0 12 O

To TO 0 0 2 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
impact NN 0 1 1 O
of IN 0 0 12 O
chemotherapy NN 0 1 6 O
plus CC 0 1 16 O
HAART NNP 0 1 14 O
on IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
course NN 0 1 12 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
systemic JJ 0 1 6 O
non NN 0 1 1 O
- : 0 0 2 O
Hodgkin NNP 0 0 7 O
lymphoma NN 0 1 6 O
( ( 0 0 2 O
HIV NNP 0 1 6 O
- : 0 0 2 O
NHL NN 0 1 UNK O
) ) 0 0 2 O
the DT 0 0 12 O
authors NNS 1 1 UNK O
compared VBN 1 1 1 O
retrospectively RB 0 0 UNK O
a DT 0 0 12 O
group NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
NHL NN 0 1 UNK O
who WP 0 0 12 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
cyclophosphamide NN 0 1 14 B-Drug
doxorubicin NN 0 1 13 B-Drug
vincristine NN 0 1 16 B-Drug
and CC 0 0 12 O
prednisone NN 0 1 0 B-Drug
( ( 0 0 2 O
CHOP NNP 0 1 UNK O
) ) 0 0 2 O
chemotherapy NN 0 1 6 O
regimen NNS 0 1 6 O
plus CC 0 1 16 O
HAART NNP 0 1 14 O
with IN 0 0 12 O
a DT 0 0 12 O
group NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
who WP 0 0 12 O
were VBD 1 0 12 O
treated VBN 1 1 1 O
with IN 0 0 12 O
CHOP NNP 0 1 UNK O
chemotherapy NN 0 1 6 O
or CC 0 0 12 O
a DT 0 0 12 O
CHOP NNP 0 1 UNK O
- : 0 0 2 O
like IN 0 0 12 O
regimen NNS 0 1 6 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
cyclophosphamide NN 0 1 14 B-Drug
doxorubicin NN 0 1 13 B-Drug
teniposide NN 0 1 UNK B-Drug
and CC 0 0 12 O
prednisone NN 0 1 0 B-Drug
with IN 0 0 12 O
vincristine JJ 0 1 16 B-Drug
plus CC 0 1 16 O
bleomycin NN 0 1 13 B-Drug
) ) 0 0 2 O
without IN 0 0 12 O
receiving VBG 1 1 1 O
antiretroviral JJ 0 0 UNK B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
comparison NN 0 1 1 O
of IN 0 0 12 O
digitalis JJ 0 1 14 B-Group
tolerance NN 0 1 1 O
in IN 0 0 12 O
dogs NNS 1 1 UNK O
anesthetized VBN 1 1 13 O
with IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
Innovar NNP 0 1 UNK B-Brand
Vet NNP 0 1 UNK I-Brand
or CC 0 0 12 O
pentobarbital VB 0 1 16 B-Drug
the DT 0 0 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
ouabain NN 0 1 UNK B-Drug
needed VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
ventricular JJ 0 1 8 O
tachycardia NN 0 1 8 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
as IN 1 0 12 O
was VBD 1 0 12 O
the DT 0 0 12 O
LD9 NNP 0 0 UNK O
of IN 0 0 12 O
ouabain NN 0 1 UNK B-Drug
with IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
or CC 0 0 12 O
Innovar NNP 0 1 UNK B-Brand
than IN 0 0 12 O
with IN 0 0 12 O
pentobarbital JJ 0 1 16 B-Drug
. . 0 0 12 O

Here RB 0 0 2 O
we PRP 0 0 12 O
show VBP 0 1 12 O
that IN 0 0 12 O
a DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
galangin NN 0 1 UNK B-Drug
or CC 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
dihydroxyflavone NN 0 0 UNK O
with IN 0 0 12 O
vancomycin NN 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
sensitize VB 0 0 UNK O
resistant JJ 0 1 3 O
strains NNS 1 1 6 O
of IN 0 0 12 O
Enterococcus NNP 0 1 14 O
faecalis NNS 0 0 16 O
and CC 0 0 12 O
Enterococcus NNP 0 1 14 O
faecium NN 0 0 16 O
to TO 0 0 12 O
the DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
vancomycin JJ 0 1 14 O
- : 0 0 2 O
sensitive JJ 0 1 1 O
strains NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
numerous JJ 0 1 1 O
potentiation NN 0 1 UNK O
effects NNS 1 1 1 O
have VBP 0 0 12 O
frequently RB 0 1 1 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
for IN 0 0 12 O
combined JJ 0 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
substances NNS 1 1 1 O
of IN 0 0 12 O
widespread JJ 0 1 1 O
use NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
minor JJ 0 1 1 O
contribution NN 0 1 1 O
of IN 0 0 12 O
adenosine JJ 0 1 14 O
receptors NNS 1 1 13 O
to TO 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
although IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
anxiogenic JJ 0 0 UNK O
effects NNS 1 1 1 O
were VBD 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
an DT 0 0 12 O
A9 NNP 0 1 UNK O
receptor NN 0 1 14 O
agonist NN 0 1 14 O
. . 0 0 12 O

Each DT 0 0 2 O
treatment NN 0 1 6 O
period NN 0 1 1 O
was VBD 1 0 12 O
separated VBN 1 1 3 O
by IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
present JJ 0 1 1 O
study NN 0 1 1 O
reports NNS 1 1 1 O
two CD 0 1 12 O
novel JJ 0 1 13 O
findings NNS 1 1 1 O
: : 0 0 2 O
( ( 0 0 2 O
i NN 0 1 12 O
) ) 0 0 2 O
it PRP 0 0 12 O
was VBD 1 0 12 O
clearly RB 0 0 12 O
evidenced VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
time NN 0 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
acute JJ 0 1 6 O
exposure NN 0 1 1 O
of IN 0 0 12 O
freshly RB 0 0 UNK O
isolated VBN 1 1 1 O
human JJ 0 1 1 O
lymphocytes NNS 1 1 14 O
to TO 0 0 12 O
DEB NNP 0 1 UNK O
results NNS 1 1 1 O
in IN 0 0 12 O
severe JJ 0 1 6 O
GSH NNP 0 1 UNK O
depletion NN 0 1 1 O
and CC 0 0 12 O
loss NN 0 1 1 O
of IN 0 0 12 O
ATP NNP 0 1 UNK O
followed VBN 1 1 12 O
by IN 0 0 12 O
cell NN 0 1 1 O
death NN 0 1 12 O
; : 0 0 2 O

In IN 0 0 2 O
experiment JJ 0 1 UNK O
9 CD 0 0 2 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
GSLS NNP 0 1 UNK B-Drug_n
at IN 0 0 12 O
a DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NN 0 1 18 O
of IN 0 0 12 O
BW NNP 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
d NN 0 1 16 O
on IN 0 0 12 O
the DT 0 0 12 O
immune JJ 0 1 6 O
response NN 0 1 1 O
in IN 0 0 12 O
chickens NNS 1 1 UNK O
intramuscularly RB 0 0 UNK O
injected VBN 1 1 3 O
with IN 0 0 12 O
inactivated JJ 0 0 UNK B-Drug
ND NNP 0 0 2 I-Drug
vaccine NN 0 1 6 I-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Contradictory JJ 0 0 UNK O
results NNS 1 1 1 O
regarding VBG 1 0 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
proton NN 0 1 14 B-Group
pump NN 0 1 3 I-Group
inhibitors NNS 1 1 14 I-Group
on IN 0 0 12 O
platelet NN 0 1 14 O
reactivity NN 0 1 14 O
and CC 0 0 12 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
outcome NN 0 1 1 O
in IN 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
literature NN 0 1 UNK O
. . 0 0 12 O

Cysteine NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
covalently RB 0 0 UNK O
linked VBN 1 1 UNK O
to TO 0 0 12 O
carbodiimide VB 0 0 UNK O
activated JJ 0 1 1 O
NaCMC NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

Peripheral JJ 0 1 7 O
mononuclear NN 0 1 14 O
cells NNS 1 1 6 O
were VBD 1 0 12 O
also RB 0 0 12 O
collected VBN 1 1 1 O
for IN 0 0 12 O
quantitation NN 0 1 UNK O
of IN 0 0 12 O
phosphorylated JJ 0 0 UNK O
zidovudine NN 0 1 13 B-Drug
. . 0 0 12 O

Standard JJ 0 1 2 O
dialysis NN 0 1 6 O
related JJ 0 1 1 O
biochemical JJ 0 1 UNK O
indices NNS 1 1 UNK O
and CC 0 0 12 O
medications NNS 1 1 6 O
used VBN 1 1 12 O
were VBD 1 0 12 O
recorded VBN 1 1 12 O
. . 0 0 12 O

Powder NNP 0 1 2 O
x NNP 0 0 10 O
- : 0 0 2 O
ray NN 0 1 3 O
diffraction NN 0 0 UNK O
differential JJ 0 1 1 O
scanning VBG 1 1 UNK O
calorimetry NN 0 1 UNK O
differential JJ 0 1 1 O
thermal JJ 0 0 13 O
analysis NN 0 1 1 O
and CC 0 0 12 O
scanning VBG 1 1 UNK O
electron NN 0 1 13 O
microscopy NN 0 1 16 O
were VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
characterize VB 0 0 1 O
the DT 0 0 12 O
aerosol NN 0 1 3 O
particles NNS 1 1 UNK O
and CC 0 0 12 O
starting VBG 1 1 12 O
material NN 0 1 1 O
. . 0 0 12 O

Analysis NN 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
dimethylprostaglandin NN 0 0 UNK I-Drug_n
E9 NNP 0 0 UNK I-Drug_n
- : 0 0 2 O
induced VBD 1 1 6 O
diarrhea NN 0 1 6 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
rats NNS 1 1 UNK O
. . 0 0 12 O

Guidelines NNS 0 1 UNK O
are VBP 1 0 12 O
provided VBN 1 1 1 O
to TO 0 0 12 O
assist VB 0 1 1 O
the DT 0 0 12 O
clinician NN 0 1 13 O
in IN 0 0 12 O
his PRP$ 0 0 12 O
logical JJ 0 1 UNK O
approach NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
identification NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
when WRB 0 0 12 O
serious JJ 0 1 12 O
drug NN 0 1 1 O
toxicity NN 0 1 6 O
is VBZ 1 0 12 O
encountered VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
pateint NN 0 0 UNK O
. . 0 0 12 O

Rearrangements NNS 0 1 UNK O
of IN 0 0 12 O
genomes NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
accompany VB 0 0 UNK O
cellular JJ 0 1 13 O
aging NN 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
considerable JJ 0 0 1 O
evidence NN 0 1 1 O
suggesting VBG 1 1 1 O
that IN 0 0 12 O
histaminergic NN 0 0 UNK O
and CC 0 0 12 O
serotoninergic JJ 0 0 UNK O
central JJ 0 1 1 O
pathways NNS 1 1 13 O
are VBP 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
nociception NN 0 1 UNK O
and CC 0 0 12 O
that IN 0 0 12 O
antihistaminic JJ 0 1 UNK B-Group
drugs NNS 1 1 6 O
can MD 0 0 12 O
modulate VB 0 1 UNK O
their PRP$ 0 0 12 O
responses NNS 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

route NN 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
experiments NNS 1 1 UNK O
reported VBN 1 1 1 O
here RB 0 0 12 O
we PRP 0 0 12 O
examined VBD 1 1 1 O
the DT 0 0 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
OH NNP 0 1 UNK I-Drug
) ) 0 0 2 O
9D9 CD 0 0 UNK I-Drug
and CC 0 0 12 O
the DT 0 0 12 O
antiestrogen NN 0 1 UNK B-Group
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxytamoxifen NN 0 1 UNK I-Drug_n
( ( 0 0 2 O
TAM NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
which WDT 0 0 12 O
also RB 0 0 12 O
induces VBZ 1 1 UNK O
apoptosis NN 0 1 UNK O
in IN 0 0 12 O
MCF NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
. . 0 0 12 O

Changes NNS 0 1 2 O
in IN 0 0 12 O
urinary JJ 0 1 6 O
homocysteine NN 0 1 13 O
following VBG 1 1 1 O
synthetic JJ 0 1 3 B-Group
steroidal JJ 0 1 UNK I-Group
estrogen NN 0 1 6 I-Group
and CC 0 0 12 O
progestogen NN 0 1 UNK B-Group
administration NN 0 1 1 O
to TO 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Studies NNS 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
food NN 0 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
fluvastatin NNS 0 1 13 B-Drug
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
marked JJ 0 1 1 O
reductions NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
bioavailability NN 0 1 UNK O
- : 0 0 2 O
- : 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
; : 0 0 2 O

Diagnostic JJ 0 1 7 O
treatment NN 0 1 6 O
and CC 0 0 12 O
aftercare NN 0 1 13 O
approaches NNS 1 1 UNK O
to TO 0 0 12 O
cocaine VB 0 1 6 B-Drug
abuse NN 0 1 12 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Combined VBN 0 1 UNK O
treatment NN 0 1 6 O
induced VBD 1 1 6 O
more JJR 0 1 12 O
TUNEL NNP 0 1 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
apoptotic JJ 0 1 UNK O
cells NNS 1 1 6 O
than IN 0 0 12 O
did VBD 1 0 12 O
either CC 0 1 12 O
agent VB 0 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
proposed VBN 1 1 UNK O
that IN 0 0 12 O
the DT 0 0 12 O
phosphohydrolase NN 0 0 UNK O
becomes VBZ 1 0 12 O
metabolically RB 0 0 UNK O
active JJ 0 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
combines VBZ 1 1 UNK O
with IN 0 0 12 O
membranes NNS 1 1 6 O
and CC 0 0 12 O
that DT 0 0 12 O
polyamines NNS 0 1 UNK O
might MD 0 0 12 O
help VB 0 1 12 O
to TO 0 0 12 O
regulate VB 0 0 UNK O
this DT 0 0 12 O
interaction NN 0 1 UNK O
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
Sildenafil NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
demonstrated VBN 1 0 1 O
effectiveness NN 0 1 UNK O
in IN 0 0 12 O
men NNS 0 1 13 O
with IN 0 0 12 O
erectile JJ 0 1 13 O
dysfunction NN 0 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
prostatectomy NN 0 1 8 O
radiation NN 0 1 1 O
therapy NN 0 1 6 O
diabetes VBZ 0 1 6 O
mellitus VBP 0 0 6 O
certain JJ 0 1 1 O
neurologic JJ 0 1 6 O
disorders NNS 1 1 6 O
and CC 0 0 12 O
drug NN 0 1 1 O
therapy NN 0 1 6 O
( ( 0 0 2 O
eg JJ 0 1 UNK O
selective JJ 0 1 13 B-Group
serotonin NN 0 1 13 I-Group
reuptake NN 0 1 13 I-Group
inhibitors NNS 1 1 14 I-Group
[ VBP 0 0 2 O
SSRIs NNP 0 1 UNK B-Group
] NNP 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

[ JJ 0 0 2 O
Importance NNP 0 1 UNK O
of IN 0 0 12 O
pharmacogenetics NNS 0 1 UNK O
] VBP 0 0 2 O
; : 0 0 2 O
Pharmacogenetics NNS 0 1 UNK O
deals NNS 1 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
caused VBN 1 1 1 O
by IN 0 0 12 O
genetic JJ 0 1 13 O
variation NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
several JJ 0 1 12 O
cardiovascular JJ 0 1 6 O
drugs NNS 1 1 6 O
directly RB 0 1 1 O
affect VBP 0 1 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

We PRP 0 0 12 O
sought VBD 1 0 UNK O
to TO 0 0 12 O
evaluate VB 0 1 1 O
whether IN 0 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
antidepressant JJ 0 1 6 B-Group
increases VBZ 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
hospitalization NN 0 1 6 O
for IN 0 0 12 O
gastrointestinal JJ 0 1 6 O
bleeding NN 0 1 6 O
in IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
users NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
we PRP 0 0 12 O
present VBP 0 1 1 O
clearly RB 0 0 12 O
show VBP 0 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
alters VBZ 1 1 UNK O
the DT 0 0 12 O
cellular JJ 0 1 13 O
permeability NN 0 1 UNK O
and CC 0 0 12 O
thus RB 0 0 1 O
the DT 0 0 12 O
exogenous JJ 0 1 UNK O
respiration NN 0 1 6 O
becomes VBZ 1 0 12 O
sensitive JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

Dual JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
ouabain NN 0 1 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
palytoxin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
contraction NN 0 1 6 O
and CC 0 0 12 O
norepinephrine JJ 0 1 14 O
release NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
guinea NN 0 1 UNK O
- : 0 0 2 O
pig NN 0 1 UNK O
vas NN 1 1 13 O
deferens NNS 0 0 13 O
. . 0 0 12 O

These DT 0 0 1 O
findings NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
intracellular JJ 0 1 UNK O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
release NN 0 1 12 O
by IN 0 0 12 O
cholinergic JJ 0 1 13 O
stimulation NN 0 1 6 O
is VBZ 1 0 12 O
critical JJ 0 1 1 O
for IN 0 0 12 O
determining VBG 1 0 UNK O
synergism NN 0 1 UNK O
with IN 0 0 12 O
cAMP NN 0 1 UNK O
in IN 0 0 12 O
parietal JJ 0 1 8 O
cell NN 0 1 1 O
activation NN 0 1 13 O
and CC 0 0 12 O
that IN 0 0 12 O
functional JJ 0 1 1 O
coupling NN 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
store NN 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
receptor NN 0 1 14 O
is VBZ 1 0 12 O
maintained VBN 1 1 1 O
by IN 0 0 12 O
actin JJ 0 1 14 O
microfilaments NNS 0 1 UNK O
. . 0 0 12 O

Coingestion NN 0 0 UNK O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
with IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
with IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
and CC 0 0 12 O
valproic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
with IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
at IN 0 0 12 O
high JJ 0 1 1 O
to TO 0 0 12 O
toxic JJ 0 1 1 O
concentrations NNS 1 1 13 O
decreases VBZ 1 1 UNK O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
target NN 0 1 1 O
drug NN 0 1 1 O
. . 0 0 12 O

NaCMC NNP 0 0 UNK B-Drug_n
at IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
m JJ 0 1 2 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
free JJ 0 1 12 O
cysteine NN 0 1 13 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
R NNP 0 1 2 O
- : 0 0 2 O
value NN 0 1 1 O
of IN 0 0 12 O
NaFlu NNP 0 0 UNK B-Drug
compared VBN 1 1 1 O
to TO 0 0 12 O
NaCMC NNP 0 0 UNK B-Drug_n
alone RB 0 1 12 O
. . 0 0 12 O

Whether IN 0 0 12 O
an DT 0 0 12 O
alteration NN 0 1 1 O
in IN 0 0 12 O
norepinephrine JJ 0 1 14 B-Drug
uptake JJ 0 1 14 O
- : 0 0 2 O
9 CD 0 0 2 O
occurs NN 0 1 1 O
is VBZ 1 0 12 O
still RB 0 0 12 O
unresolved JJ 0 1 13 O
. . 0 0 12 O

Gentamycin NNP 0 1 0 B-Drug
reduced VBD 1 1 1 O
twitch JJ 0 1 3 O
strength NN 0 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
mean JJ 0 1 12 O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
sem NN 0 0 13 O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
within IN 0 0 1 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
min NN 0 1 16 O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
As NNP 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
readily RB 0 0 1 O
penetrates VBZ 1 1 UNK O
both CC 0 0 12 O
the DT 0 0 12 O
mucosal NN 0 1 8 O
and CC 0 0 12 O
serosal JJ 0 1 8 O
surfaces NNS 1 1 3 O
of IN 0 0 12 O
the DT 0 0 12 O
epithelial JJ 0 1 14 O
membrane NN 0 1 3 O
. . 0 0 12 O

After IN 0 0 2 O
incubation NN 0 0 UNK O
at IN 0 0 12 O
9 CD 0 0 2 O
degrees NNS 1 1 1 O
C NNP 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
this DT 0 0 12 O
number NN 0 1 1 O
fell VBD 0 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
plus CC 0 1 16 O
or CC 0 0 12 O
minus CC 0 1 3 O
9 CD 0 0 2 O
S.E.M NNP 0 1 UNK O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
genetic JJ 0 1 13 O
data NNS 0 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
instances NNS 1 1 UNK O
has VBZ 1 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
regulated VBN 1 1 1 O
. . 0 0 12 O

Systemic NNP 0 1 7 O
antibiotic JJ 0 1 6 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Atracurium NN 0 1 UNK B-Drug
was VBD 1 0 12 O
again RB 0 0 12 O
given VBN 1 1 12 O
by IN 0 0 12 O
infusion NN 0 1 14 O
to TO 0 0 12 O
maintain VB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
twitch NN 0 1 3 O
for IN 0 0 12 O
a DT 0 0 12 O
second JJ 0 1 12 O
hour NN 0 1 12 O
then RB 0 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
gentamycin JJ 0 1 14 B-Drug
/ NNP 0 0 2 O
kg NN 0 1 18 O
bwt NN 0 0 16 O
were VBD 1 0 12 O
given VBN 1 1 12 O
i.v NNS 0 1 13 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
an DT 0 0 12 O
urgent JJ 0 1 1 O
need NN 0 1 12 O
to TO 0 0 12 O
develop VB 0 0 1 O
therapies NNS 1 1 6 O
that WDT 0 0 12 O
slow VBP 0 1 12 O
down RP 0 0 12 O
the DT 0 0 12 O
progression NN 0 1 1 O
of IN 0 0 12 O
neurodegeneration NN 0 1 UNK O
in IN 0 0 12 O
Parkinson NNP 0 1 6 O
's POS 0 1 12 O
disease NN 0 1 6 O
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
and CC 0 0 12 O
antitumor JJ 0 1 UNK O
effects NNS 1 1 1 O
were VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
proposed VBN 1 1 UNK O
mechanism NN 0 1 13 O
for IN 0 0 12 O
the DT 0 0 12 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
cAMP NN 0 1 UNK O
- : 0 0 2 O
mediated VBN 1 1 13 O
acid JJ 0 1 14 O
secretion NN 0 1 14 O
by IN 0 0 12 O
carbachol NN 0 1 13 B-Drug
. . 0 0 12 O

Herbal NNP 0 1 UNK O
remedies VBZ 1 0 6 O
nephropathies NNS 1 1 UNK O
and CC 0 0 12 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
at IN 0 0 12 O
doses NNS 1 1 6 O
higher JJR 1 1 1 O
than IN 0 0 12 O
previously RB 0 0 1 O
reported VBN 1 1 1 O
from IN 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
meal NN 0 1 12 O
studies NNS 1 1 1 O
starting VBG 1 1 12 O
at IN 0 0 12 O
~9 NNP 0 0 UNK O
mg NN 0 1 0 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
. . 0 0 12 O

Etodolac NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
DTIC NNP 0 1 15 B-Drug
and CC 0 0 12 O
imexon VB 0 1 UNK B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
for IN 0 0 12 O
growth NN 0 1 1 O
inhibition NN 0 1 13 O
( ( 0 0 2 O
MTT NNP 0 1 UNK O
) ) 0 0 2 O
radiolabeled VBD 0 1 UNK O
drug NN 0 1 1 O
uptake NN 0 1 14 O
cellular JJ 0 1 13 O
thiol NN 0 1 UNK O
content NN 0 1 13 O
( ( 0 0 2 O
HPLC NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
DNA NNP 0 1 1 O
strand VBP 0 1 UNK O
breaks NNS 1 1 UNK O
( ( 0 0 2 O
Comet NNP 0 1 UNK O
assay RB 0 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

However RB 0 0 1 O
halothane NN 0 1 13 B-Drug
anesthetic JJ 0 1 13 O
requirement NN 0 1 1 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
MAC NNP 0 1 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
depressed VBN 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
fashion NN 0 0 12 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
and CC 0 0 12 O
as RB 0 0 12 O
much JJ 0 0 12 O
as IN 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
injection NN 0 1 3 O
of IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
im NN 0 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
examined VBD 1 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
ketamine NN 0 1 13 I-Drug
with IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
( ( 0 0 2 O
CYP NNP 0 1 UNK O
) ) 0 0 2 O
9B9 CD 0 0 UNK O
inhibitor NN 0 1 14 O
ticlopidine NN 0 1 16 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
CYP9A NNP 0 0 UNK O
inhibitor NN 0 1 14 O
itraconazole NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
proposed VBN 1 1 UNK O
that IN 0 0 12 O
the DT 0 0 12 O
opioids NNS 0 1 14 B-Group
applied VBD 1 1 1 O
to TO 0 0 12 O
supraspinal JJ 0 0 UNK O
brain NN 0 1 6 O
sites NNS 1 1 1 O
produced VBD 1 0 1 O
their PRP$ 0 0 12 O
analgesic JJ 0 1 13 O
effects NNS 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
activation NN 0 1 13 O
of IN 0 0 12 O
different JJ 0 1 1 O
descending VBG 1 1 3 O
pain NN 0 1 6 O
inhibitory JJ 0 1 UNK O
systems NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
pulmonary JJ 0 1 6 B-Group
surfactant NN 0 1 14 I-Group
extract NN 0 1 13 O
from IN 0 0 12 O
bovine NN 0 1 13 O
lung NN 0 1 6 O
Survanta NNP 0 1 0 B-Brand
on IN 0 0 12 O
the DT 0 0 12 O
dissolution NN 0 0 UNK O
rate NN 0 1 1 O
of IN 0 0 12 O
aerosol JJ 0 1 3 O
particles NNS 1 1 UNK O
of IN 0 0 12 O
budesonide NN 0 1 16 B-Drug
was VBD 1 0 12 O
determined VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
atropine NN 0 1 14 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
amplitudes NNS 1 1 UNK O
of IN 0 0 12 O
components NNS 1 1 1 O
P9 NNP 0 1 UNK O
and CC 0 0 12 O
P9 NNP 0 1 UNK O
while IN 0 0 12 O
decreasing VBG 1 1 1 O
components NNS 1 1 1 O
N9 NNP 0 0 UNK O
N9 NNP 0 0 UNK O
and CC 0 0 12 O
N9 NNP 0 0 UNK O
for IN 0 0 12 O
varying VBG 1 0 1 O
durations NNS 1 1 1 O
of IN 0 0 12 O
time NN 0 1 12 O
. . 0 0 12 O

Celecoxib NNP 0 1 UNK B-Drug
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
cyclooxygenase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
is VBZ 1 0 12 O
being VBG 1 0 12 O
investigated VBN 1 1 1 O
for IN 0 0 12 O
enhancement NN 0 1 1 O
of IN 0 0 12 O
chemotherapy NN 0 1 6 O
efficacy NN 0 1 UNK O
in IN 0 0 12 O
cancer NN 0 1 6 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
examine VB 0 0 1 O
some DT 0 0 12 O
molecular JJ 0 1 1 O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
behavioral JJ 0 1 13 O
changes NNS 1 1 1 O
Northern NNP 0 1 UNK O
blot NN 0 0 UNK O
analysis NN 0 1 1 O
of IN 0 0 12 O
total JJ 0 1 1 O
RNA NNP 0 1 UNK O
from IN 0 0 12 O
prefrontal JJ 0 0 UNK O
cortical JJ 0 1 8 O
tissues NNS 1 1 6 O
of IN 0 0 12 O
mice NNS 1 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
DCG NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
IV NN 0 1 2 I-Drug_n
and CC 0 0 12 O
L NNP 0 1 2 B-Drug_n
- : 0 0 2 O
CCG NNP 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
was VBD 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
. . 0 0 12 O

Compared VBN 0 1 2 O
with IN 0 0 12 O
conventional JJ 0 1 1 B-Group
antipsychotics NNS 1 1 14 I-Group
it PRP 0 0 12 O
has VBZ 1 0 12 O
greater JJR 1 1 1 O
affinity NN 0 1 UNK O
for IN 0 0 12 O
serotonin NN 0 1 13 O
9 CD 0 0 2 O
- : 0 0 2 O
HT9A NN 0 0 UNK O
than IN 0 0 12 O
for IN 0 0 12 O
dopamine JJ 0 1 14 O
D9 NNP 0 1 UNK O
receptors NNS 1 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
study NN 0 1 1 O
we PRP 0 0 12 O
investigated VBD 1 1 1 O
whether IN 0 0 12 O
also RB 0 0 12 O
glycine NN 0 1 UNK B-Drug
fulfils VBZ 1 0 UNK O
the DT 0 0 12 O
function NN 0 1 1 O
as IN 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
activator NN 0 0 UNK O
in IN 0 0 12 O
glutamatergic JJ 0 0 UNK O
activation NN 0 1 13 O
of IN 0 0 12 O
NMDA NNP 0 1 UNK O
receptors NNS 1 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
neuronal JJ 0 1 13 O
apparatus NN 0 1 13 O
of IN 0 0 12 O
spontaneous JJ 0 1 1 O
motility NN 0 1 6 O
in IN 0 0 12 O
chick JJ 0 1 UNK O
embryos NN 1 1 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Ventricular JJ 0 1 7 O
tachycardia NN 0 1 8 O
induced VBN 1 1 6 O
by IN 0 0 12 O
ouabain NN 0 1 UNK B-Drug
was VBD 1 0 12 O
generally RB 0 0 1 O
converted VBN 1 0 1 O
to TO 0 0 12 O
sinus VB 0 1 6 O
rhythm NN 0 1 3 O
following VBG 1 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
Innovar NNP 0 1 UNK B-Brand
ketamine NN 0 1 13 B-Drug
or CC 0 0 12 O
droperidol NN 0 1 0 B-Drug
but CC 0 0 12 O
not RB 0 1 12 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
fentayl JJ 0 0 UNK B-Drug
alone NN 0 1 12 O
or CC 0 0 12 O
after IN 0 0 12 O
pentobarbital JJ 0 1 16 B-Drug
. . 0 0 12 O

Src NNP 0 1 UNK O
family NN 0 1 12 O
and CC 0 0 12 O
Abl NNP 0 1 UNK O
kinases NNS 1 1 14 O
were VBD 1 0 12 O
identified VBN 1 1 1 O
as IN 1 0 12 O
modulators NNS 0 1 13 O
of IN 0 0 12 O
paclitaxel JJ 0 1 13 B-Drug
sensitivity NN 0 1 1 O
in IN 0 0 12 O
SKOv9 NNP 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
single JJ 0 1 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
elixir NN 0 1 16 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
9th CD 0 0 13 O
day NN 0 1 12 O
of IN 0 0 12 O
each DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
period NN 0 1 1 O
. . 0 0 12 O

OBJECTIVE NN 0 1 UNK O
: : 0 0 2 O
This DT 0 0 2 O
paper NN 0 1 13 O
reviews VBZ 1 1 UNK O
recent JJ 0 1 12 O
studies NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
sildenafil NN 0 1 16 B-Drug
its PRP$ 1 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
and CC 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
and CC 0 0 12 O
socioeconomic JJ 0 1 UNK O
factors NNS 1 1 1 O
involved VBN 1 1 12 O
in IN 0 0 12 O
its PRP$ 1 0 12 O
use NN 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
focus NN 0 1 1 O
on IN 0 0 12 O
specific JJ 0 1 1 O
patient JJ 0 1 6 O
populations NNS 1 1 UNK O
( ( 0 0 2 O
prostate JJ 0 1 6 O
cancer NN 0 1 6 O
diabetes VBZ 0 1 6 O
mellitus VBP 0 0 6 O
ischemic JJ 0 1 6 O
heart NN 0 1 12 O
disease NN 0 1 6 O
spinal JJ 0 1 6 O
cord NN 0 1 3 O
injuries NNS 1 1 6 O
neurologic IN 0 1 6 O
disorders NNS 1 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

Further RB 0 1 2 O
designs NNS 1 1 UNK O
can MD 0 0 12 O
be VB 0 0 12 O
expressed VBN 1 0 1 O
in IN 0 0 12 O
terms NNS 1 1 1 O
of IN 0 0 12 O
proportionate NN 0 1 UNK O
responses NNS 1 1 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
individual JJ 0 1 1 O
compounds VBZ 1 1 13 O
rather RB 0 0 12 O
than IN 0 0 12 O
dose JJ 0 1 6 O
levels NNS 1 1 1 O
thereby RB 0 0 UNK O
providing VBG 1 1 1 O
for IN 0 0 12 O
results NNS 1 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
applicable JJ 0 1 1 O
across IN 0 0 12 O
compounds NNS 1 1 13 O
. . 0 0 12 O

However RB 0 0 1 O
retinyl JJ 0 0 UNK B-Drug
acetate NN 0 1 14 I-Drug
stimulated VBD 1 1 13 O
but CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
inhibit VB 0 1 13 O
proliferation NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
insulin NN 0 1 14 B-Drug
. . 0 0 12 O

Behavioral NNP 0 1 2 O
mechanisms NNS 1 1 UNK O
underlying VBG 1 0 1 O
the DT 0 0 12 O
link NN 0 1 12 O
between IN 0 0 12 O
smoking NN 0 1 12 O
and CC 0 0 12 O
drinking NN 0 1 12 O
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
mediated VBN 1 1 13 O
by IN 0 0 12 O
the DT 0 0 12 O
ability NN 0 1 1 O
of IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
to TO 0 0 12 O
induce VB 0 1 6 O
microsomal JJ 0 1 UNK O
enzymes NNS 1 1 14 O
and CC 0 0 12 O
thus RB 0 0 1 O
the DT 0 0 12 O
catabolism NN 0 1 UNK O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
achieve VB 0 0 1 O
the DT 0 0 12 O
effective JJ 0 1 1 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
appropriate JJ 0 1 1 O
time NN 0 1 12 O
intervals NNS 1 1 1 O
between IN 0 0 12 O
administrations NNS 1 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
is VBZ 1 0 12 O
essential JJ 0 1 13 O
. . 0 0 12 O

Quetiapine JJ 0 1 0 B-Drug
fumarate NN 0 1 16 I-Drug
( ( 0 0 2 O
Seroquel NNP 0 1 0 B-Brand
) ) 0 0 2 O
is VBZ 1 0 12 O
a DT 0 0 12 O
newly RB 0 1 12 O
introduced VBN 1 1 12 O
atypical JJ 0 1 6 B-Group
antipsychotic JJ 0 1 UNK I-Group
with IN 0 0 12 O
demonstrated JJ 0 0 1 O
efficacy NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
positive JJ 0 1 1 O
and CC 0 0 12 O
negative JJ 0 1 1 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Serial JJ 0 1 2 O
plasma NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
samples NNS 1 1 UNK O
for IN 0 0 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
rifabutin NN 0 1 13 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
their PRP$ 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
O NNP 0 1 2 I-Drug_n
- : 0 0 2 O
desacetyl NN 0 0 UNK I-Drug_n
metabolites NNS 1 1 UNK I-Drug_n
were VBD 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
performance NN 0 1 13 O
liquid NN 0 1 3 O
chromatography NN 0 1 UNK O
. . 0 0 12 O

However RB 0 0 1 O
a DT 0 0 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
proportion NN 0 1 UNK O
of IN 0 0 12 O
neurons NNS 1 1 UNK O
fired VBN 1 1 12 O
spontaneous JJ 0 1 1 O
action NN 0 1 13 O
potentials NNS 1 1 UNK O
with IN 0 0 12 O
either DT 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
biocytin NN 0 1 UNK O
compared VBN 1 1 1 O
to TO 0 0 12 O
no DT 0 0 12 O
biocytin NN 0 1 UNK O
. . 0 0 12 O

asthma NN 0 1 6 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
antipsychotics NNS 1 1 14 B-Group
. . 0 0 12 O

An DT 0 0 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
effect NN 0 1 1 O
occurs VBZ 1 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
medication NN 0 1 6 O
interferes VBZ 1 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
assay NN 0 1 14 O
and CC 0 0 12 O
the DT 0 0 12 O
result NN 0 1 1 O
is VBZ 1 0 12 O
erroneous JJ 0 1 UNK O
and CC 0 0 12 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
interpreted VBN 1 1 UNK O
. . 0 0 12 O

Although IN 0 0 12 O
one CD 0 1 12 O
study NN 0 1 1 O
tentatively RB 0 0 UNK O
supports VBZ 1 1 1 O
the DT 0 0 12 O
hypothesis NN 0 1 UNK O
that IN 0 0 12 O
such JJ 0 0 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ascorbic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
may MD 0 0 1 O
be VB 0 0 12 O
efficacious JJ 0 1 UNK O
a DT 0 0 12 O
second JJ 0 1 12 O
study NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
group NN 0 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
confirm VB 0 1 1 O
the DT 0 0 12 O
significant JJ 0 1 1 O
findings NNS 1 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
clear JJ 0 1 12 O
reproducible JJ 0 1 1 O
pattern NN 0 1 3 O
of IN 0 0 12 O
efficacy NN 0 1 UNK O
has VBZ 1 0 12 O
emerged VBN 1 0 12 O
from IN 0 0 12 O
the DT 0 0 12 O
review NN 0 1 2 O
of IN 0 0 12 O
all PDT 0 0 12 O
the DT 0 0 12 O
evidence NN 0 1 1 O
. . 0 0 12 O

Release NN 0 1 2 O
of IN 0 0 12 O
arachidonic JJ 0 0 UNK O
acid NN 0 1 14 O
from IN 0 0 12 O
membrane NN 0 1 3 O
phospholipids NNS 1 1 UNK O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
subsequent JJ 0 1 1 O
synthesis NN 0 1 UNK O
and CC 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
vasoconstrictor NN 0 1 UNK O
thromboxane NN 0 1 UNK O
A9 NNP 0 1 UNK O
are VBP 1 0 12 O
also RB 0 0 12 O
regulated VBN 1 1 1 O
by IN 0 0 12 O
movement NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 O
ions NNS 1 1 UNK O
. . 0 0 12 O

p NN 0 1 2 O
& CC 0 0 2 O
lt NN 0 1 13 O
; : 0 0 2 O

Valproic NNP 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
diminished VBD 1 1 1 O
binding NN 0 1 1 O
of IN 0 0 12 O
phenobarbital NN 0 1 16 B-Drug
by IN 0 0 12 O
a DT 0 0 12 O
net JJ 0 1 1 O
change NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
percentage NN 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
FDF NNP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
at IN 0 0 12 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
L NNP 0 1 2 O
. . 0 0 12 O

Here RB 0 0 2 O
we PRP 0 0 12 O
have VBP 0 0 12 O
examined VBN 1 1 1 O
whether IN 0 0 12 O
METH NNP 0 1 UNK B-Drug
administration NN 0 1 1 O
affects VBZ 1 1 1 O
expression NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
effector NN 0 0 UNK O
IEG NNP 0 0 UNK O
arc NN 0 0 13 O
( ( 0 0 2 O
activity NN 0 1 1 O
- : 0 0 2 O
regulated VBN 1 1 1 O
cytoskeleton NN 0 1 UNK O
- : 0 0 2 O
associated VBN 1 1 1 O
) ) 0 0 2 O
that WDT 0 0 12 O
encodes VBZ 1 1 UNK O
a DT 0 0 12 O
protein NN 0 1 14 O
with IN 0 0 12 O
homology NN 0 1 UNK O
to TO 0 0 12 O
spectrin VB 0 1 UNK O
. . 0 0 12 O

Similarly RB 0 0 1 O
there EX 0 0 12 O
is VBZ 1 0 12 O
currently RB 0 1 12 O
little JJ 0 1 12 O
adequate JJ 0 1 1 O
evidence NN 0 1 1 O
on IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
or CC 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
serious JJ 0 1 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
to TO 0 0 12 O
such JJ 0 0 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
ascorbic JJ 0 0 16 B-Drug
acid CC 0 1 14 I-Drug
although IN 0 0 12 O
many JJ 0 0 12 O
such JJ 0 0 1 O
reactions NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
hypothesized VBN 1 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
reaction NN 0 1 1 O
after IN 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
remained VBD 1 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
in IN 0 0 12 O
both DT 0 0 12 O
groups NNS 1 1 1 O
of IN 0 0 12 O
experiments NNS 1 1 UNK O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
stress NN 0 1 1 O
and CC 0 0 12 O
glucocorticoids NNS 1 1 UNK B-Group
on IN 0 0 12 O
the DT 0 0 12 O
subjective JJ 0 1 1 O
and CC 0 0 12 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
psychostimulants NNS 0 1 13 B-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
well RB 0 1 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Theophylline NN 0 1 UNK B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
by IN 0 0 12 O
a DT 0 0 12 O
net JJ 0 1 1 O
change NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
percentage NN 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
FDF NNP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
at IN 0 0 12 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
L NNP 0 1 2 O
; : 0 0 2 O

Little NNP 0 1 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
of IN 0 0 12 O
the DT 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
exposure NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
with IN 0 0 12 O
its PRP$ 1 0 12 O
congeners NNS 1 1 13 O
and CC 0 0 12 O
acetaldehyde JJ 0 1 UNK B-Drug_n
coexisting NN 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
contents NNS 1 1 1 O
of IN 0 0 12 O
alcoholic JJ 0 1 12 O
beverages NNS 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
was VBD 1 0 12 O
established VBN 1 1 1 O
that IN 0 0 12 O
both DT 0 0 12 O
angiotensins NNS 1 1 UNK O
inhibited VBN 1 1 13 O
gastric JJ 0 1 6 O
acid NN 0 1 14 O
secretion NN 0 1 14 O
stimulated VBN 1 1 13 O
by IN 0 0 12 O
pentagastrin NNS 0 1 UNK B-Drug
but CC 0 0 12 O
not RB 0 1 12 O
by IN 0 0 12 O
histamine NN 0 1 UNK B-Drug
. . 0 0 12 O

All DT 0 0 2 O
9 CD 0 0 2 O
strains NNS 1 1 6 O
of IN 0 0 12 O
Staphylococcus NNP 0 1 14 O
aureus JJ 0 0 14 O
Diplococcus NNP 0 0 UNK O
pneumoniae NN 0 1 14 O
Streptococcus NNP 0 1 14 O
pyogenes NNS 0 0 UNK O
and CC 0 0 12 O
anaerobic JJ 0 1 14 O
bacteria NNS 0 1 6 O
( ( 0 0 2 O
except IN 0 0 12 O
for IN 0 0 12 O
three CD 0 1 12 O
strains NNS 1 1 6 O
of IN 0 0 12 O
Clostridium NNP 0 1 14 O
) ) 0 0 2 O
were VBD 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
9 CD 0 0 2 O
mug NNS 0 1 UNK O
or CC 0 0 12 O
less JJR 0 1 12 O
of IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
per IN 0 0 1 O
ml NN 0 1 16 O
. . 0 0 12 O

were VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
elevated JJ 0 1 1 O
plus CC 0 1 16 O
maze JJ 0 1 13 O
test NN 0 1 1 O
on IN 0 0 12 O
C9BL NNP 0 0 UNK O
/ NNP 0 0 2 O
9 CD 0 0 2 O
mice NN 1 1 UNK O
. . 0 0 12 O

Available JJ 0 1 UNK O
data NNS 0 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
and CC 0 0 12 O
arachidonic JJ 0 0 UNK O
acid NN 0 1 14 O
metabolism NN 0 1 16 O
are VBP 1 0 12 O
important JJ 0 1 1 O
factors NNS 1 1 1 O
in IN 0 0 12 O
hemostasis NN 0 1 UNK O
and CC 0 0 12 O
regulation NN 0 1 13 O
of IN 0 0 12 O
vascular JJ 0 1 6 O
tone NN 0 1 3 O
. . 0 0 12 O

by IN 0 0 12 O
the DT 0 0 12 O
nonlinear JJ 0 0 UNK O
kinetic JJ 0 1 13 O
characteristics NNS 1 1 UNK O
for IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
and CC 0 0 12 O
diltiazem NN 0 1 0 B-Drug
( ( 0 0 2 O
and CC 0 0 12 O
probably RB 0 1 12 O
for IN 0 0 12 O
nifedipine NN 0 1 0 B-Drug
as RB 0 0 12 O
well RB 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
derivative JJ 0 1 13 O
implications NNS 1 0 UNK O
for IN 0 0 12 O
decreased JJ 0 1 1 O
dosing NN 0 0 14 O
frequency NN 0 1 1 O
requirements NNS 1 1 1 O
; : 0 0 2 O

The DT 0 0 2 O
antimicrobial JJ 0 1 14 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
benzoxazinorifamycin NN 0 1 UNK B-Drug_n
KRM NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
either CC 0 1 12 O
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
ofloxacin NN 0 1 0 B-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
against IN 0 0 12 O
two CD 0 1 12 O
type NN 0 1 1 O
strains NNS 1 1 6 O
and CC 0 0 12 O
six CD 0 1 12 O
clinical JJ 0 1 6 O
isolates NNS 0 1 14 O
of IN 0 0 12 O
Mycobacterium NNP 0 1 UNK O
ulcerans NNPS 0 0 UNK O
. . 0 0 12 O

aeruginosa JJ 0 0 14 O
infections NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
colic JJ 0 1 6 O
drops NNS 1 1 3 O
were VBD 1 0 12 O
immediately RB 0 1 12 O
discontinued VBN 1 1 1 O
and CC 0 0 12 O
TSH NNP 0 0 14 O
promptly RB 0 0 12 O
normalised VBD 1 0 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
thyroxine JJ 0 1 14 O
requirement NN 0 1 1 O
to TO 0 0 12 O
an DT 0 0 12 O
age NN 0 1 12 O
appropriate JJ 0 1 1 O
dosage NN 0 1 0 O
. . 0 0 12 O

A DT 0 0 2 O
library NN 0 1 UNK O
of IN 0 0 12 O
silencing VBG 1 1 UNK O
RNAs NNP 0 1 UNK O
( ( 0 0 2 O
siRNAs NN 0 1 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
identify VB 0 0 1 O
kinases NNS 1 1 14 O
that WDT 0 0 12 O
regulate VBP 0 0 UNK O
paclitaxel JJ 0 1 13 B-Drug
sensitivity NN 0 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
ovarian JJ 0 1 6 O
cancer NN 0 1 6 O
SKOv9 NNP 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
order NN 0 1 1 O
to TO 0 0 12 O
use VB 0 1 1 O
the DT 0 0 12 O
pharmacological JJ 0 1 14 O
properties NNS 1 1 UNK O
of IN 0 0 12 O
induced JJ 0 1 6 O
therapeutic JJ 0 1 6 O
hypermagnesaemia NN 0 1 UNK O
high JJ 0 1 1 O
oral JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
( ( 0 0 2 O
> JJ 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
are VBP 1 0 12 O
advisable JJ 0 0 UNK O
for IN 0 0 12 O
chronic JJ 0 1 6 O
indications NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
parenteral JJ 0 1 14 O
route NN 0 1 12 O
is VBZ 1 0 12 O
suitable JJ 0 1 1 O
for IN 0 0 12 O
acute JJ 0 1 6 O
indications NNS 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

However RB 0 0 1 O
cohort NN 0 1 UNK O
data NNS 0 1 1 O
and CC 0 0 12 O
selected VBN 1 1 UNK O
patient NN 0 1 6 O
data NNS 0 1 1 O
from IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
suggest VBP 0 1 1 O
comparable JJ 0 0 1 O
activity NN 0 1 1 O
to TO 0 0 12 O
PI NNP 0 1 UNK B-Group
- : 0 0 2 O
based VBN 1 1 1 O
regimens NNS 1 1 UNK O
in IN 0 0 12 O
these DT 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
olanzapine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
agranulocytosis NN 0 1 UNK O
as IN 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
or CC 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
hyperprolactinaemia NN 0 1 UNK O
as IN 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
risperidone NN 0 1 0 B-Drug
or CC 0 0 12 O
prolongation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
QT NNP 0 1 13 O
interval NN 0 1 1 O
. . 0 0 12 O

He PRP 0 0 12 O
was VBD 1 0 12 O
treated VBN 1 1 1 O
aggressively RB 0 0 1 O
with IN 0 0 12 O
intravenous JJ 0 1 14 O
hydration NN 0 1 3 O
sodium NN 0 1 14 B-Drug
bicarbonate NN 0 1 14 I-Drug
and CC 0 0 12 O
hemodialysis NN 0 1 14 O
. . 0 0 12 O

Also RB 0 0 2 O
although IN 0 0 12 O
minimal JJ 0 1 1 O
alterations NNS 1 1 1 O
of IN 0 0 12 O
fluvastatin JJ 0 1 13 B-Drug
clearance NN 0 1 16 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
are VBP 1 0 12 O
anticipated VBN 1 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
limited JJ 0 1 1 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
a DT 0 0 12 O
study NN 0 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
patient NN 0 1 6 O
group NN 0 1 12 O
is VBZ 1 0 12 O
currently RB 0 1 12 O
underway JJ 0 0 UNK O
to TO 0 0 12 O
examine VB 0 0 1 O
this DT 0 0 12 O
further JJ 0 1 1 O
. . 0 0 12 O

HAART NNP 0 1 14 O
was VBD 1 0 12 O
included VBN 1 1 1 O
with IN 0 0 12 O
combination NN 0 1 1 O
therapy NN 0 1 6 O
from IN 0 0 12 O
January NNP 0 1 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Thus RB 0 0 1 O
there EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
tendency NN 0 0 1 O
toward IN 0 0 12 O
a DT 0 0 12 O
more RBR 0 1 12 O
pronounced JJ 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hydroxylation NN 0 1 UNK O
during IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
d NN 0 1 16 O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
compared VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
d NN 0 1 16 O
but CC 0 0 12 O
the DT 0 0 12 O
difference NN 0 1 UNK O
was VBD 1 0 12 O
not RB 0 1 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
secretions NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
colostrum NN 0 1 UNK O
IgA NNP 0 1 14 O
is VBZ 1 0 12 O
the DT 0 0 12 O
only JJ 0 1 12 O
protein NN 0 1 14 O
precipitated VBN 1 1 1 O
by IN 0 0 12 O
jacalin NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Without IN 0 0 2 O
the DT 0 0 12 O
addition NN 0 1 1 O
of IN 0 0 12 O
enzymes NNS 1 1 14 O
transduction NN 0 1 UNK O
was VBD 1 0 12 O
limited VBN 1 1 1 O
to TO 0 0 12 O
occasional JJ 0 1 12 O
cells NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
retinal JJ 0 1 6 O
ganglion NN 0 1 8 O
cell NN 0 1 1 O
layer NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
resveratrol NN 0 1 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
vasorelaxation NN 0 1 UNK O
differs NNS 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
mesenteric JJ 0 1 8 O
resistance NN 0 1 1 O
arteries NNS 1 1 6 O
of IN 0 0 12 O
lean JJ 0 0 13 O
and CC 0 0 12 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
large JJ 0 1 3 O
well RB 0 1 12 O
controlled VBN 1 1 1 O
trials NNS 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
schizophrenia NN 0 1 13 O
or CC 0 0 12 O
related JJ 0 1 1 O
psychoses NNS 1 1 6 O
olanzapine VBP 0 1 16 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
superior JJ 0 1 1 O
to TO 0 0 12 O
haloperidol VB 0 1 16 B-Drug
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
in IN 0 0 12 O
overall JJ 0 1 1 O
improvements NNS 1 1 1 O
in IN 0 0 12 O
psychopathology NN 0 1 UNK O
rating NN 0 1 UNK O
scales NNS 1 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
depressive JJ 0 0 13 O
and CC 0 0 12 O
negative JJ 0 1 1 O
symptoms NNS 1 1 6 O
and CC 0 0 12 O
was VBD 1 0 12 O
comparable JJ 0 0 1 O
in IN 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
positive JJ 0 1 1 O
psychotic JJ 0 1 6 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

No DT 0 0 2 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
evident JJ 0 1 1 O
on IN 0 0 12 O
excystment JJ 0 0 UNK O
rates NNS 1 1 1 O
of IN 0 0 12 O
cyst NN 0 1 6 O
- : 0 0 2 O
exposed VBN 1 1 3 O
parasites NNS 1 1 6 O
. . 0 0 12 O

A DT 0 0 2 O
common JJ 0 1 1 O
phenotypic NN 0 1 UNK O
subset NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
serotype NN 0 1 UNK O
O9 NNP 0 0 UNK O
strains VBZ 1 1 6 O
from IN 0 0 12 O
drug NN 0 1 1 O
addicts NNS 1 1 UNK O
was VBD 1 0 12 O
especially RB 0 0 12 O
resistant JJ 0 1 3 O
to TO 0 0 12 O
the DT 0 0 12 O
inhibitory JJ 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

Optimal JJ 0 1 UNK O
conditions NNS 1 1 1 O
kinetics NNS 0 1 UNK O
equilibrium NN 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
acid JJ 0 1 14 O
- : 0 0 2 O
catalyzed VBN 1 0 UNK O
ethanolysis NN 0 0 UNK O
are VBP 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
its PRP$ 1 0 12 O
introduction NN 0 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
Implanon NNP 0 1 UNK B-Brand
remains VBZ 1 0 12 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
preferred JJ 0 1 UNK O
contraceptive NN 0 1 13 O
choices NNS 1 1 12 O
for IN 0 0 12 O
many JJ 0 0 12 O
women NNS 1 1 UNK O
as IN 1 0 12 O
it PRP 0 0 12 O
offers VBZ 1 0 1 O
a DT 0 0 12 O
highly RB 0 1 1 O
effective JJ 0 1 1 O
means NNS 1 1 13 O
of IN 0 0 12 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
contraception NN 0 1 13 O
for IN 0 0 12 O
three CD 0 1 12 O
years NNS 1 1 12 O
that WDT 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
rely VB 0 0 UNK O
on IN 0 0 12 O
adherence NN 0 1 UNK O
. . 0 0 12 O

Treatment NN 0 1 7 O
of IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
with IN 0 0 12 O
[ NNP 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
C NNP 0 0 2 O
] NNP 0 0 2 O
- : 0 0 2 O
diethyl NN 0 0 UNK B-Drug_n
pyrocarbonate NN 0 1 UNK I-Drug_n
revealed VBD 1 1 12 O
concentration NN 0 1 1 O
dependent JJ 0 1 1 O
labelling NN 0 1 UNK O
of IN 0 0 12 O
histidine NN 0 1 13 O
residues NNS 1 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
toxin NN 0 1 14 O
molecules NNS 1 1 UNK O
. . 0 0 12 O

Cinacalcet NNP 0 1 UNK B-Drug
dose NN 0 1 6 O
increased VBD 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
p VBD 0 1 2 O
< NN 0 0 16 O

There EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
reduction NN 0 1 1 O
that WDT 0 0 12 O
reached VBD 1 1 12 O
borderline JJ 0 1 6 O
statistical JJ 0 1 UNK O
significance NN 0 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
group NN 0 1 12 O
that WDT 0 0 12 O
received VBD 1 1 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
d NN 0 1 16 O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
. . 0 0 12 O

Sixty NNP 0 1 13 O
- : 0 0 2 O
two CD 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
strains NNS 1 1 6 O
of IN 0 0 12 O
Enterobacteriaceae NNP 0 1 UNK O
and CC 0 0 12 O
Pseudomonas NNP 0 1 14 O
aeruginosa NN 0 0 14 O
were VBD 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
9 CD 0 0 2 O
mug NNS 0 1 UNK O
or CC 0 0 12 O
less JJR 0 1 12 O
of IN 0 0 12 O
gentamicin NN 0 1 14 B-Drug
per IN 0 0 1 O
ml NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
resulting VBG 1 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
free JJ 0 1 12 O
drug NN 0 1 1 O
concentration NN 0 1 1 O
may MD 0 0 1 O
lead VB 0 1 12 O
to TO 0 0 12 O
enhanced JJ 0 1 1 O
drug NN 0 1 1 O
effect NN 0 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

We PRP 0 0 12 O
evaluated VBD 1 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
doses NNS 1 1 6 O
between IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
nonheme JJ 0 0 UNK B-Drug
iron NN 0 1 3 I-Drug
( ( 0 0 2 O
as IN 1 0 12 O
ferrous JJ 0 1 14 B-Drug
sulfate NN 0 1 14 I-Drug
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
the DT 0 0 12 O
pancreatic JJ 0 1 6 O
alpha NN 0 1 1 O
cell NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
diabetic JJ 0 1 6 O
Chinese NNP 0 1 UNK O
hamster NN 0 1 UNK O
responds VBZ 1 0 1 O
excessively RB 0 1 3 O
to TO 0 0 12 O
arginine VB 0 1 13 B-Drug
as IN 1 0 12 O
is VBZ 1 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
diabetic NN 0 1 6 O
. . 0 0 12 O

Nonetheless RB 0 0 1 O
their PRP$ 0 0 12 O
relevance NN 0 1 UNK O
continues VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
demonstrated VBN 1 0 1 O
by IN 0 0 12 O
the DT 0 0 12 O
dependence NN 0 1 1 O
of IN 0 0 12 O
each DT 0 0 12 O
agent NN 0 1 1 O
on IN 0 0 12 O
intact JJ 0 1 1 O
liver JJ 0 1 6 O
blood NN 0 1 6 O
flow NN 0 1 1 O
and CC 0 0 12 O
function NN 0 1 1 O
for IN 0 0 12 O
normal JJ 0 1 1 O
rates NNS 1 1 1 O
of IN 0 0 12 O
elimination NN 0 1 UNK O
; : 0 0 2 O

Antiretroviral JJ 0 0 UNK B-Group
regimens NNS 1 1 UNK O
consisted VBN 1 1 1 O
of IN 0 0 12 O
two CD 0 1 12 O
reverse JJ 0 1 1 B-Group
transcriptase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
and CC 0 0 12 O
one CD 0 1 12 O
protease NN 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

However RB 0 0 1 O
these DT 0 0 12 O
studies NNS 1 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
show VB 0 1 12 O
whether IN 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
currents NNS 1 1 UNK O
discriminates VBZ 1 1 UNK O
among IN 0 0 12 O
the DT 0 0 12 O
various JJ 0 1 1 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
channel NN 0 1 1 O
subtypes VBZ 0 1 UNK O
although IN 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
that IN 0 0 12 O
there EX 0 0 12 O
are VBP 1 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
five CD 0 1 12 O
different JJ 0 1 1 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
channel NN 0 1 1 O
subtypes NNS 0 1 UNK O
in IN 0 0 12 O
neuronal JJ 0 1 13 O
cells NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
approach NN 0 1 1 O
is VBZ 1 0 12 O
applicable JJ 0 1 1 O
across IN 0 0 12 O
a DT 0 0 12 O
wide JJ 0 1 3 O
variety NN 0 1 1 O
of IN 0 0 12 O
settings NNS 1 1 1 O
commonly RB 0 0 UNK O
associated VBN 1 1 1 O
with IN 0 0 12 O
joint JJ 0 1 1 O
action NN 0 1 13 O
data NNS 0 1 1 O
including VBG 1 1 1 O
continuous JJ 0 1 1 O
and CC 0 0 12 O
discrete JJ 0 1 1 O
responses NNS 1 1 1 O
alternative JJ 0 1 1 O
error NN 0 1 UNK O
structures NNS 1 1 1 O
and CC 0 0 12 O
nonzero JJ 0 0 UNK O
background NN 0 1 12 O
response NN 0 1 1 O
. . 0 0 12 O

Less JJR 0 1 2 O
than IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
ovarian JJ 0 1 6 O
cancers NNS 1 1 6 O
respond VBP 0 0 1 O
to TO 0 0 12 O
paclitaxel VB 0 1 13 B-Drug
. . 0 0 12 O

Similarly RB 0 0 1 O
the DT 0 0 12 O
acute JJ 0 1 6 O
toxicity NN 0 1 6 O
was VBD 1 0 12 O
also RB 0 0 12 O
diminished VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
DMF NNP 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
uptake JJ 0 1 14 O
inhibitors NNS 1 1 14 O
cocaine NN 0 1 6 B-Drug
and CC 0 0 12 O
desipramine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mumol NN 0 0 UNK O
/ NNP 0 0 2 O
liter NN 0 1 3 O
) ) 0 0 2 O
potentiated VBD 1 0 UNK O
the DT 0 0 12 O
positive JJ 0 1 1 O
inotropic NN 0 0 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
in IN 0 0 12 O
nonfailing VBG 0 0 UNK O
myocardium NN 0 1 8 O
( ( 0 0 2 O
p JJ 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
but CC 0 0 12 O
not RB 0 1 12 O
in IN 0 0 12 O
functional JJ 0 1 1 O
class NN 0 1 12 O
IV NNP 0 1 2 O
myocardium NN 0 1 8 O
. . 0 0 12 O

Sodium NN 0 1 14 B-Drug
thiosulfate NN 0 1 16 I-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
neutralizing JJ 0 0 UNK O
agent NN 0 1 1 O
for IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
that WDT 0 0 12 O
protects VBZ 1 0 UNK O
against IN 0 0 12 O
renal JJ 0 1 6 O
damage NN 0 1 1 O
. . 0 0 12 O

Sunitinib NNP 0 1 UNK B-Drug
exhibited VBD 1 1 1 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
growth NN 0 1 1 O
inhibition NN 0 1 13 O
in IN 0 0 12 O
NSCLC NNP 0 1 UNK O
cell NN 0 1 1 O
lines NNS 1 1 3 O
and CC 0 0 12 O
arrested VBN 1 1 12 O
cell NN 0 1 1 O
cycle NN 0 1 1 O
at IN 0 0 12 O
G9 NNP 0 0 13 O
phase NN 0 1 1 O
whereas NNS 0 0 UNK O
docetaxel VBP 0 1 13 B-Drug
arrested VBN 1 1 12 O
at IN 0 0 12 O
S NNP 0 1 2 O
phase NN 0 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
and CC 0 0 12 O
gentamicin NN 0 1 14 B-Drug
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Our PRP$ 0 0 2 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
important JJ 0 1 1 O
relationships NNS 1 1 13 O
among IN 0 0 12 O
ras JJ 0 1 UNK O
nucleophosmin NNS 0 1 UNK O
/ VBP 0 0 2 O
B9 NNP 0 0 UNK O
activation NN 0 1 13 O
of IN 0 0 12 O
caspase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
induction NN 0 1 1 O
of IN 0 0 12 O
apoptosis NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
emerging VBG 1 0 13 O
roles NNS 1 1 UNK O
of IN 0 0 12 O
non JJ 0 1 1 B-Group
- : 0 0 2 O
nucleoside JJ 0 1 UNK I-Group
reverse NN 0 1 1 I-Group
transcriptase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
in IN 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

They PRP 0 0 12 O
are VBP 1 0 12 O
part NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
organ JJ 0 1 6 O
transplants NNS 1 1 13 O
malignancy NN 0 1 6 O
and CC 0 0 12 O
increasingly RB 0 0 1 O
those DT 0 0 12 O
with IN 0 0 12 O
conditions NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
psoriasis NN 0 1 6 O
rheumatoid NN 0 0 6 O
arthritis NN 0 1 6 O
and CC 0 0 12 O
liver NN 0 1 6 O
and CC 0 0 12 O
bowel NN 0 1 6 O
disease NN 0 1 6 O
in IN 0 0 12 O
which WDT 0 0 12 O
inflammation NN 0 1 6 O
is VBZ 1 0 12 O
an DT 0 0 12 O
aetiological JJ 0 1 UNK O
factor NN 0 1 1 O
. . 0 0 12 O

Treatment NN 0 1 7 O
plans NNS 1 1 12 O
for IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
anticoagulants NNS 1 1 13 B-Group
can MD 0 0 12 O
become VB 0 0 12 O
complicated JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
PTX NNP 0 1 15 B-Drug_n
was VBD 1 0 12 O
discussed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
relation NN 0 1 13 O
with IN 0 0 12 O
Na NNP 0 1 13 O
K NNP 0 1 2 O
- : 0 0 2 O
ATPase NN 0 1 UNK O
. . 0 0 12 O

Chapter NN 0 1 UNK O
9 CD 0 0 2 O
covers NNS 1 1 UNK O
pharmacology NN 0 1 UNK O
( ( 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
pharmacodynamics NNS 0 1 UNK O
and CC 0 0 12 O
potency NN 0 1 UNK O
and CC 0 0 12 O
clinical JJ 0 1 6 O
implications NNS 1 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
availability NN 0 1 UNK O
of IN 0 0 12 O
potent NN 0 1 UNK O
non SYM 0 1 1 B-Group
- : 0 0 2 O
nucleoside JJ 0 1 UNK I-Group
reverse NN 0 1 1 I-Group
transcriptase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
NNRTI NNP 0 1 UNK B-Group
) ) 0 0 2 O
- : 0 0 2 O
based VBN 1 1 1 O
regimens NNS 1 1 UNK O
for IN 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
therapy NN 0 1 6 O
and CC 0 0 12 O
concerns NNS 1 1 1 O
regarding VBG 1 0 1 O
protease NN 0 1 13 B-Group
inhibitor NN 0 1 14 I-Group
( ( 0 0 2 O
PI NNP 0 1 UNK B-Group
) ) 0 0 2 O
- : 0 0 2 O
related VBN 1 1 1 O
metabolic JJ 0 1 6 O
disturbances NNS 1 1 6 O
have VBP 0 0 12 O
led VBN 1 1 12 O
to TO 0 0 12 O
significant JJ 0 1 1 O
shifts NNS 1 1 1 O
in IN 0 0 12 O
treatment NN 0 1 6 O
practices NNS 1 1 UNK O
in IN 0 0 12 O
HIV NNP 0 1 6 O
infection NN 0 1 6 O
. . 0 0 12 O

Treatment NN 0 1 7 O
of IN 0 0 12 O
HEY NNP 0 0 UNK O
xenograft NNP 0 1 UNK O
- : 0 0 2 O
bearing NN 0 1 3 O
mice NN 1 1 UNK O
with IN 0 0 12 O
dasatinib JJ 0 1 13 B-Drug
plus CC 0 1 16 O
paclitaxel JJ 0 1 13 B-Drug
inhibited JJ 0 1 13 O
tumor NN 0 1 6 O
growth NN 0 1 1 O
more JJR 0 1 12 O
than IN 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
alone RB 0 1 12 O
( ( 0 0 2 O
average JJ 0 1 1 O
tumor NN 0 1 6 O
volume NN 0 1 1 O
per IN 0 0 1 O
mouse NN 0 1 UNK O
dasatinib NN 0 1 13 B-Drug
+ NNP 0 0 2 O
paclitaxel NN 0 1 13 B-Drug
vs NN 1 0 2 O
paclitaxel NN 0 1 13 B-Drug
: : 0 0 2 O
9 CD 0 0 2 O
vs. IN 0 1 2 O
9 CD 0 0 2 O
cm9 NN 0 0 UNK O
difference NN 0 1 UNK O
= VBD 0 0 2 O
9 CD 0 0 2 O
cm9 JJ 0 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
confidence NN 0 1 UNK O
interval NN 0 1 1 O
[ NNP 0 0 2 O
CI NNP 0 1 UNK O
] NNP 0 0 2 O
= VBD 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
cm9 NNS 0 0 UNK O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
; : 0 0 2 O

Synergism NN 0 1 UNK O
was VBD 1 0 12 O
also RB 0 0 12 O
noted VBN 1 0 1 O
when WRB 0 0 12 O
methylglyoxal NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
combined VBN 1 1 1 O
with IN 0 0 12 O
carbenicillin NN 0 1 UNK B-Drug
and CC 0 0 12 O
amikacin NN 0 1 0 B-Drug
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
this DT 0 0 12 O
experience NN 0 1 12 O
we PRP 0 0 12 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
ketamine NN 0 1 13 B-Drug
added VBD 1 1 12 O
to TO 0 0 12 O
propofol VB 0 1 14 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
prevention NN 0 1 1 O
of IN 0 0 12 O
EA NNP 0 1 UNK O
in IN 0 0 12 O
children NNS 1 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
history NN 0 1 12 O
of IN 0 0 12 O
EA NNP 0 1 UNK O
with IN 0 0 12 O
propofol JJ 0 1 14 B-Drug
TIVA NNP 0 0 UNK O
. . 0 0 12 O

9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
PICR NNP 0 0 UNK O
detected VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
MAC NNP 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
augmentation NN 0 1 13 O
persisted VBD 1 0 1 O
even RB 0 0 12 O
after IN 0 0 12 O
carbachol NN 0 1 13 B-Drug
was VBD 1 0 12 O
washed VBN 1 1 13 O
out RP 0 1 12 O
and CC 0 0 12 O
was VBD 1 0 12 O
resistant JJ 0 1 3 O
to TO 0 0 12 O
chelated VB 1 0 UNK O
extracellular JJ 0 1 14 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
and CC 0 0 12 O
to TO 0 0 12 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
either DT 0 1 12 O
protein JJ 0 1 14 O
kinase NN 0 1 14 O
C NNP 0 0 2 O
or CC 0 0 12 O
calmodulin VB 0 1 UNK O
kinase NN 0 1 14 O
II NNP 0 0 2 O
. . 0 0 12 O

BACKGROUND NN 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
feasibility NN 0 0 UNK O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
chemotherapy NN 0 1 6 O
and CC 0 0 12 O
highly RB 0 1 1 B-Group
active JJ 0 1 1 I-Group
antiretroviral JJ 0 0 UNK I-Group
therapy NN 0 1 6 O
( ( 0 0 2 O
HAART NNP 0 1 14 O
) ) 0 0 2 O
is VBZ 1 0 12 O
still RB 0 0 12 O
unknown JJ 0 1 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
human JJ 0 1 1 O
immunodeficiency NN 0 1 14 O
virus NN 0 1 6 O
( ( 0 0 2 O
HIV NNP 0 1 6 O
) ) 0 0 2 O
- : 0 0 2 O
related JJ 0 1 1 O
malignancies NNS 1 1 16 O
. . 0 0 12 O

Studies NNS 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
miconazole NN 0 1 16 B-Drug
: : 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
miconazole NN 0 1 16 B-Drug
on IN 0 0 12 O
respiration NN 0 1 6 O
and CC 0 0 12 O
cell NN 0 1 1 O
permeability NN 0 1 UNK O
of IN 0 0 12 O
Candida NNP 0 1 6 O
albicans NNS 0 0 14 O
. . 0 0 12 O

Echistatin NNP 0 1 UNK B-Drug_n
alone RB 0 1 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
tyrosine NN 0 1 13 O
phosphorylation NN 0 1 UNK O
in IN 0 0 12 O
T9 NNP 0 1 13 O
cells NNS 1 1 6 O
but CC 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependently RB 0 0 UNK O
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
contortrostatin NN 0 1 UNK B-Drug_n
when WRB 0 0 12 O
both DT 0 0 12 O
are VBP 1 0 12 O
added VBN 1 1 12 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

Thus RB 0 0 1 O
the DT 0 0 12 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
cypermethrin NN 0 1 UNK B-Drug
exposure NN 0 1 1 O
of IN 0 0 12 O
rats NNS 1 1 UNK O
results NNS 1 1 1 O
in IN 0 0 12 O
free JJ 0 1 12 O
radical JJ 0 1 1 O
- : 0 0 2 O
mediated VBN 1 1 13 O
tissue NN 0 1 6 O
damage NN 0 1 1 O
as IN 1 0 12 O
indicated VBN 1 1 1 O
by IN 0 0 12 O
elevated JJ 0 1 1 O
cerebral JJ 0 0 6 O
and CC 0 0 12 O
hepatic JJ 0 1 14 O
lipid NN 0 1 14 O
peroxidation NN 0 1 UNK O
which WDT 0 0 12 O
was VBD 1 0 12 O
prevented VBN 1 1 UNK O
by IN 0 0 12 O
allopurinol NN 0 1 13 B-Drug
and CC 0 0 12 O
Vitamin NNP 0 1 2 B-Drug
E NNP 0 0 2 I-Drug
. . 0 0 12 O

Dexmedetomidine VB 0 1 UNK B-Drug
a DT 0 0 12 O
highly RB 0 1 1 O
selective JJ 0 1 13 O
alpha NN 0 1 1 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
adrenoceptor NN 0 1 UNK O
agonist NN 0 1 14 O
was VBD 1 0 12 O
recently RB 0 1 12 O
introduced VBN 1 1 12 O
into IN 0 0 12 O
clinical JJ 0 1 6 O
practice NN 0 1 UNK O
for IN 0 0 12 O
its PRP$ 1 0 12 O
sedative JJ 0 1 6 O
and CC 0 0 12 O
analgesic JJ 0 1 13 O
properties NNS 1 1 UNK O
. . 0 0 12 O

Magnesium NN 0 1 7 B-Drug
infusions NNS 1 1 14 O
can MD 0 0 12 O
only RB 0 1 12 O
be VB 0 0 12 O
envisaged VBN 1 0 UNK O
in IN 0 0 12 O
intensive JJ 0 1 1 O
care NN 0 1 12 O
units NNS 1 1 1 O
with IN 0 0 12 O
careful JJ 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
pulse JJ 0 1 3 O
arterial JJ 0 1 6 O
pressure NN 0 1 1 O
deep JJ 0 1 3 O
tendon NN 0 1 6 O
reflexes NNS 1 1 6 O
hourly RB 0 1 1 O
diuresis VBP 0 1 14 O
electrocardiogram NN 0 1 8 O
and CC 0 0 12 O
respiratory NN 0 1 6 O
recordings NNS 1 0 1 O
. . 0 0 12 O

Rifampin NNP 0 1 0 B-Drug
and CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
: : 0 0 2 O
a DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
. . 0 0 12 O

aeruginosa NN 0 0 14 O
as IN 1 0 12 O
common JJ 0 1 1 O
pathogens NNS 1 1 6 O
of IN 0 0 12 O
drug NN 0 1 1 O
addicts NNS 1 1 UNK O
in IN 0 0 12 O
areas NNS 1 1 1 O
where WRB 0 0 12 O
abuse NN 0 1 12 O
of IN 0 0 12 O
this DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
has VBZ 1 0 12 O
increased VBN 1 1 1 O
. . 0 0 12 O

We PRP 0 0 12 O
elucidated VBD 1 0 UNK O
the DT 0 0 12 O
expression NN 0 1 1 O
of IN 0 0 12 O
HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NN 0 0 UNK O
in IN 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
ALL DT 0 1 11 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
and CC 0 0 12 O
evaluated VBD 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
CRM9 NNP 0 0 UNK B-Drug_n
on IN 0 0 12 O
these DT 0 0 12 O
cells NNS 1 1 6 O
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
anticancer JJ 0 0 UNK B-Group
agent NN 0 1 1 I-Group
. . 0 0 12 O

Studies NNS 0 1 2 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
neomycin JJ 0 1 16 B-Drug
administration NN 0 1 1 O
attenuates VBZ 1 1 UNK O
certain JJ 0 1 1 O
types NNS 1 1 1 O
of IN 0 0 12 O
adrenocortical JJ 0 1 UNK B-Group
steroid NN 0 1 6 I-Group
dependent JJ 0 1 1 O
hypertension NN 0 1 6 O
including VBG 1 1 1 O
ACTH NNP 0 1 UNK B-Drug
hypertension NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
L NNP 0 1 2 B-Drug_n
- : 0 0 2 O
CCG NNP 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
were VBD 1 0 12 O
not RB 0 1 12 O
so RB 0 1 12 O
strong JJ 0 1 12 O
. . 0 0 12 O

It PRP 0 0 12 O
was VBD 1 0 12 O
concluded VBN 1 1 1 O
that IN 0 0 12 O
oral JJ 0 1 6 O
oxycodone NN 0 1 0 B-Drug
and CC 0 0 12 O
levofloxacin NN 0 1 0 B-Drug
can MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
without IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
Cmax NNP 0 1 UNK O
or CC 0 0 12 O
tmax NN 0 1 UNK O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
ketoconazole JJ 0 1 16 B-Drug
- : 0 0 2 O
mediated VBN 1 1 13 O
CYP9A9 NNP 0 0 UNK O
inhibition NN 0 1 13 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
panobinostat NN 0 1 UNK B-Drug
( ( 0 0 2 O
LBH9 NNP 0 0 UNK B-Drug
) ) 0 0 2 O
an DT 0 0 12 O
orally RB 0 1 14 O
active JJ 0 1 1 O
histone NN 0 1 UNK B-Group
deacetylase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
. . 0 0 12 O

Neonatal JJ 0 1 7 O
quinpirole NN 0 1 UNK B-Drug_n
treatment NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
dopamine JJ 0 1 14 O
D9 NNP 0 1 UNK O
- : 0 0 2 O
like IN 0 0 12 O
receptor NN 0 1 14 O
sensitivity NN 0 1 1 O
that WDT 0 0 12 O
persists VBZ 1 0 1 O
throughout IN 0 0 12 O
the DT 0 0 12 O
subject NN 0 1 UNK O
's POS 0 1 12 O
lifetime NN 0 1 12 O
. . 0 0 12 O

As IN 0 0 2 O
immediate JJ 0 1 1 O
- : 0 0 2 O
early JJ 0 1 12 O
genes NNS 1 1 UNK O
( ( 0 0 2 O
IEGs NNP 0 0 UNK O
) ) 0 0 2 O
are VBP 1 0 12 O
thought VBN 1 1 12 O
to TO 0 0 12 O
play VB 0 1 13 O
a DT 0 0 12 O
critical JJ 0 1 1 O
role NN 0 1 1 O
in IN 0 0 12 O
mediating VBG 1 1 UNK O
stimulus JJ 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
neural JJ 0 1 6 O
plasticity NN 0 1 UNK O
IEG NNP 0 0 UNK O
response NN 0 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
methamphetamine NN 0 1 UNK B-Drug
( ( 0 0 2 O
METH NNP 0 1 UNK B-Drug
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
characterized VBN 1 1 1 O
to TO 0 0 12 O
define VB 0 0 1 O
the DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
gene NN 0 1 13 O
expression NN 0 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
underlie VB 0 0 UNK O
its PRP$ 1 0 12 O
long JJ 0 1 12 O
- : 0 0 2 O
lasting JJ 0 0 1 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
metabotropic NN 0 0 UNK O
glutamate NN 0 1 UNK O
receptor NN 0 1 14 O
9 CD 0 0 2 O
antagonists NNS 1 1 13 O
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
useful JJ 0 1 UNK O
strategy NN 0 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
degeneration NN 0 1 6 O
of IN 0 0 12 O
catecholaminergic JJ 0 0 UNK O
neurons NNS 1 1 UNK O
in IN 0 0 12 O
Parkinson NNP 0 1 6 O
's POS 0 1 12 O
disease NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
core NN 0 1 1 O
temperature NN 0 1 3 O
returned VBD 1 1 12 O
to TO 0 0 12 O
normal JJ 0 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
after IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
successive JJ 0 0 UNK O
application NN 0 1 1 O
of IN 0 0 12 O
glycine NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg FW 0 1 18 O
egg NN 0 1 13 O
weight NN 0 1 3 O
( ( 0 0 2 O
e.w FW 0 0 UNK O
. . 0 0 12 O
) ) 0 0 2 O

There EX 0 0 12 O
is VBZ 1 0 12 O
thus RB 0 0 1 O
an DT 0 0 12 O
enhancement JJ 0 1 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
PGF9alpha NNP 0 0 UNK B-Drug
upon IN 0 0 12 O
the DT 0 0 12 O
reaction NN 0 1 1 O
of IN 0 0 12 O
placental JJ 0 1 13 O
vessels NNS 1 1 1 O
to TO 0 0 12 O
oxytocin VB 0 1 13 B-Drug
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

and CC 0 0 12 O
( ( 0 0 2 O
ii NN 0 0 13 O
) ) 0 0 2 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
filipin NN 0 1 UNK B-Drug_n
were VBD 1 0 12 O
more RBR 0 1 12 O
efficiently RB 0 0 UNK O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
added VBN 1 1 12 O
cholesterol NN 0 1 6 O
the DT 0 0 12 O
major JJ 0 1 1 O
membrane NN 0 1 3 O
sterol NN 0 1 UNK O
in IN 0 0 12 O
human JJ 0 1 1 O
cells NNS 1 1 6 O
whereas IN 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
were VBD 1 0 12 O
more RBR 0 1 12 O
efficiently RB 0 0 UNK O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
ergosterol VBG 0 1 UNK O
the DT 0 0 12 O
major JJ 0 1 1 O
membrane NN 0 1 3 O
sterol NN 0 1 UNK O
in IN 0 0 12 O
yeast NN 0 1 6 O
. . 0 0 12 O

Using VBG 0 1 2 O
in IN 0 0 12 O
situ JJ 0 0 1 O
hybridization NN 0 1 UNK O
we PRP 0 0 12 O
observed VBD 1 1 1 O
that IN 0 0 12 O
METH NNP 0 1 UNK B-Drug
caused VBD 1 1 1 O
a DT 0 0 12 O
rapid JJ 0 1 1 O
and CC 0 0 12 O
transient NN 0 1 1 O
dose NN 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
arc JJ 0 0 13 O
mRNA NNS 0 1 UNK O
level NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
striatum NN 0 1 13 O
and CC 0 0 12 O
cortex NN 0 1 6 O
that WDT 0 0 12 O
was VBD 1 0 12 O
abolished VBN 1 0 UNK O
by IN 0 0 12 O
pretreatment NN 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
specific JJ 0 1 1 O
dopamine NN 0 1 14 O
D9 NNP 0 1 UNK O
receptor NN 0 1 14 O
antagonist NN 0 1 13 O
SCH NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
99 CD 0 0 10 I-Drug_n
but CC 0 0 12 O
not RB 0 1 12 O
by IN 0 0 12 O
an DT 0 0 12 O
atypical JJ 0 1 6 B-Group
neuroleptic JJ 0 1 13 I-Group
clozapine NN 0 1 13 B-Drug
. . 0 0 12 O

Viable JJ 0 1 UNK O
counts NNS 1 1 1 O
for IN 0 0 12 O
type JJ 0 1 1 O
culture NN 0 1 1 O
E NNP 0 0 2 O
. . 0 0 12 O

Repeated VBN 0 1 7 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
coumaphos NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
sheep NN 0 1 UNK O
: : 0 0 2 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
coumaphos NN 0 1 UNK B-Drug_n
with IN 0 0 12 O
bishydroxycoumarin JJ 0 1 UNK B-Drug
trichlorfon NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
. . 0 0 12 O

Toxicodynamic JJ 0 0 UNK O
interference NN 0 1 13 O
between IN 0 0 12 O
solvents NNS 1 1 13 O
can MD 0 0 12 O
give VB 0 1 12 O
rise NN 0 0 1 O
to TO 0 0 12 O
additive JJ 0 1 16 O
potentiation NN 0 1 UNK O
synergistic JJ 0 1 UNK O
antagonistic JJ 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
platelet NN 0 1 14 O
nucleotide IN 0 1 UNK O
release NN 0 1 12 O
and CC 0 0 12 O
thromboxane NN 0 1 UNK O
A9 NNP 0 1 UNK O
generation NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
both DT 0 0 12 O
periods NNS 1 1 1 O
blood NN 0 1 6 O
and CC 0 0 12 O
urine NN 0 1 6 O
were VBD 1 0 12 O
sampled VBN 1 1 1 O
at IN 0 0 12 O
regular JJ 0 1 12 O
intervals NNS 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
cm9 NN 0 0 UNK O
difference NN 0 1 UNK O
= VBD 0 0 2 O
9 CD 0 0 2 O
cm9 JJ 0 0 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
= VBZ 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
cm9 NNS 0 0 UNK O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

A DT 0 0 2 O
total NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
clinical JJ 0 1 6 O
isolates NNS 0 1 14 O
of IN 0 0 12 O
MRSA NNP 0 1 6 O
collected VBD 1 1 1 O
from IN 0 0 12 O
three CD 0 1 12 O
Chinese JJ 0 1 UNK O
hospitals NNS 1 1 1 O
were VBD 1 0 12 O
included VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
interindividual JJ 0 0 UNK O
pharmacokinetic JJ 0 1 UNK O
variability NN 0 1 UNK O
for IN 0 0 12 O
AUC NNP 0 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
intraindividual JJ 0 0 UNK O
interoccasion NN 0 0 UNK O
variability NN 0 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
permeability NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
cell NN 0 1 1 O
membrane NN 0 1 3 O
was VBD 1 0 12 O
changed VBN 1 1 12 O
as IN 1 0 12 O
evidenced VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
leakage NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
nm NN 0 1 UNK O
absorbing VBG 1 0 UNK O
materials NNS 1 1 1 O
amino JJ 0 0 16 O
acids NNS 1 1 14 O
proteins NNS 1 1 14 O
and CC 0 0 12 O
inorganic JJ 0 1 13 O
cations NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
ERMBT NNP 0 0 UNK O
after IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
and CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
therapy NN 0 1 6 O
were VBD 1 0 12 O
increased VBN 1 1 1 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
. . 0 0 12 O

Also RB 0 0 2 O
mirtazapine NN 0 1 0 B-Drug
which WDT 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
believed VBN 1 0 12 O
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
increased VBD 1 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
GI NNP 0 1 6 O
bleeding NN 0 1 6 O
( ( 0 0 2 O
OR NNP 0 0 11 O
= VBZ 0 0 2 O
9 CD 0 0 2 O
[ JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
main JJ 0 1 12 O
indications NNS 1 1 1 O
are VBP 1 0 12 O
eclampsia JJ 0 1 13 O
some DT 0 0 12 O
dysrhythmias NN 0 1 13 O
( ( 0 0 2 O
torsades FW 0 0 13 O
de FW 0 1 2 O
pointe FW 0 0 UNK O
particularly RB 0 0 1 O
) ) 0 0 2 O
and CC 0 0 12 O
myocardial JJ 0 1 6 O
ischaemias NN 1 1 UNK O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
predispose VBP 0 0 UNK O
a DT 0 0 12 O
patient NN 0 1 6 O
to TO 0 0 12 O
bleeding VBG 1 1 6 O
problems NNS 1 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
absolute JJ 0 1 1 O
number NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
deaths NNS 1 1 UNK O
is VBZ 1 0 12 O
far RB 0 1 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
deaths NNS 1 1 UNK O
in IN 0 0 12 O
amphetamine NN 0 1 13 B-Drug
or CC 0 0 12 O
heroin NN 0 1 13 B-Drug_n
users NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
noradrenaline JJ 0 1 UNK B-Drug
- : 0 0 2 O
precontracted JJ 0 0 UNK O
arteries NNS 1 1 6 O
from IN 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
responses NNS 1 1 1 O
to TO 0 0 12 O
resveratrol VB 0 1 UNK B-Drug_n
were VBD 1 0 12 O
not RB 0 1 12 O
attenuated VBN 1 1 UNK O
by IN 0 0 12 O
endothelial JJ 0 1 13 O
denudation NN 0 0 UNK O
indicating VBG 1 0 1 O
an DT 0 0 12 O
action NN 0 1 13 O
independent JJ 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
endothelium NN 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
data NNS 0 1 1 O
emphasize VBP 0 0 1 O
that IN 0 0 12 O
apoptosis NN 0 1 UNK O
can MD 0 0 12 O
be VB 0 0 12 O
induced VBN 1 1 6 O
in IN 0 0 12 O
MCF NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
either RB 0 1 12 O
by IN 0 0 12 O
activation NN 0 1 13 O
of IN 0 0 12 O
vitamin NN 0 1 6 B-Group
- : 0 0 2 O
D NNP 0 1 2 I-Group
- : 0 0 2 O
mediated VBD 1 1 13 O
signalling NN 0 1 UNK O
or CC 0 0 12 O
disruption NN 0 1 1 O
of IN 0 0 12 O
estrogen NN 0 1 6 B-Group
- : 0 0 2 O
dependent NN 0 1 1 O
signalling NN 0 1 UNK O
. . 0 0 12 O

Weekly JJ 0 1 2 O
intramuscular NN 0 1 14 O
9 CD 0 0 2 O
- : 0 0 2 O
methyl NN 0 0 13 O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
phenyl NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK O
injections NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
daily JJ 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] JJ 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
or CC 0 0 12 O
vehicle NN 0 1 1 O
were VBD 1 0 12 O
performed VBN 1 1 1 O
until IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
parkinsonian JJ 0 0 UNK O
motor NN 0 1 3 O
symptoms NNS 1 1 6 O
in IN 0 0 12 O
either DT 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
experimental JJ 0 1 UNK O
groups NNS 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ VBZ 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] JJ 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
versus NN 0 0 1 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ NNP 0 0 2 O
vehicle NN 0 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

Anticoagulants NNS 0 1 UNK B-Group
. . 0 0 12 O

In IN 0 0 2 O
monkeys PDT 1 1 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
( ( 0 0 2 B-Drug_n
- : 0 0 2 O
) ) 0 0 2 I-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
but CC 0 0 12 O
not RB 0 1 12 O
( ( 0 0 2 O
+ NN 0 0 2 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
or CC 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
were VBD 1 0 12 O
antagonized VBN 1 0 UNK O
by IN 0 0 12 O
naloxone NN 0 1 16 B-Drug
; : 0 0 2 O

The DT 0 0 2 O
antifungal JJ 0 1 14 B-Group
drug NN 0 1 1 I-Group
miconazole NN 0 1 16 B-Drug
nitrate NN 0 1 14 I-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
growth NN 0 1 1 O
of IN 0 0 12 O
several JJ 0 1 12 O
species NNS 1 1 1 O
of IN 0 0 12 O
Candida NNP 0 1 6 O
. . 0 0 12 O

Effect NN 0 1 UNK O
of IN 0 0 12 O
dofetillide NN 0 0 UNK B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

CONCLUSIONS NNP 0 1 UNK O
/ NNP 0 0 2 O
INTERPRETATION NNP 0 1 11 O
: : 0 0 2 O
Glucose NNP 0 1 7 B-Drug
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
can MD 0 0 12 O
exert VB 0 1 13 O
additive JJ 0 1 16 O
vasodilator NN 0 1 14 O
properties NNS 1 1 UNK O
on IN 0 0 12 O
renal JJ 0 1 6 O
and CC 0 0 12 O
ocular JJ 0 1 6 O
circulation NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
investigates VBZ 1 1 UNK O
the DT 0 0 12 O
ability NN 0 1 1 O
of IN 0 0 12 O
cyclooxygenase NN 0 1 UNK B-Group
- : 0 0 2 O
9 CD 0 0 2 I-Group
inhibitors NNS 1 1 14 I-Group
to TO 0 0 12 O
sensitize VB 0 0 UNK O
cells NNS 1 1 6 O
from IN 0 0 12 O
different JJ 0 1 1 O
origins NNS 1 1 13 O
to TO 0 0 12 O
several JJ 0 1 12 O
chemotherapeutic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Correction NN 0 1 UNK O
of IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
therapy NN 0 1 6 O
was VBD 1 0 12 O
performed VBN 1 1 1 O
by IN 0 0 12 O
treating VBG 1 1 6 O
physician NN 0 1 6 O
at IN 0 0 12 O
daily JJ 0 1 12 O
rounds NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
second JJ 0 1 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
identical JJ 0 1 1 O
but CC 0 0 12 O
endogenous JJ 0 1 14 O
insulin NN 0 1 14 O
secretion NN 0 1 14 O
was VBD 1 0 12 O
blocked VBN 1 1 13 O
with IN 0 0 12 O
somatostatin NN 0 1 14 B-Drug
. . 0 0 12 O

both DT 0 0 12 O
compounds NNS 1 1 13 O
attenuate VBP 0 1 UNK O
morphine JJ 0 1 14 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
locomotion NN 0 1 UNK O
in IN 0 0 12 O
morphine NN 0 1 14 B-Drug
- : 0 0 2 O
experienced JJ 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
dofetilide NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
randomized JJ 0 1 6 O
double JJ 0 1 3 O
- : 0 0 2 O
blind NN 0 1 12 O
study NN 0 1 1 O
. . 0 0 12 O

Dependent JJ 0 1 7 O
measures NNS 1 1 1 O
included VBD 1 1 1 O
self PRP 0 1 12 O
- : 0 0 2 O
reported VBD 1 1 1 O
mood NN 0 1 12 O
and CC 0 0 12 O
subjective JJ 0 1 1 O
effects NNS 1 1 1 O
( ( 0 0 2 O
Addiction NNP 0 1 UNK O
Research NNP 0 1 UNK O
Center NNP 0 1 2 O
inventory NN 0 1 UNK O
the DT 0 0 12 O
profile NN 0 1 1 O
of IN 0 0 12 O
mood NN 0 1 12 O
states NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
series NN 0 1 12 O
of IN 0 0 12 O
visual JJ 0 1 1 O
analogue NN 0 1 UNK O
scales NNS 1 1 UNK O
) ) 0 0 2 O
vital VBP 0 1 1 O
signs NNS 1 1 12 O
salivary JJ 0 1 6 O
cortisol NN 0 1 14 O
and CC 0 0 12 O
psychomotor NN 0 0 13 O
performance NN 0 1 13 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
etofibrate NN 0 1 UNK B-Drug
upon IN 0 0 12 O
the DT 0 0 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
chylomicron NN 0 1 UNK O
- : 0 0 2 O
like IN 0 0 12 O
emulsions NNS 1 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Acetaminophen NNP 0 1 0 B-Drug
diminished VBD 1 1 1 O
the DT 0 0 12 O
binding NN 0 1 1 O
of IN 0 0 12 O
theophylline NN 0 1 16 B-Drug
to TO 0 0 12 O
human JJ 0 1 1 O
serum NN 0 1 14 O
by IN 0 0 12 O
a DT 0 0 12 O
net JJ 0 1 1 O
change NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
percentage NN 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
free JJ 0 1 12 O
drug NN 0 1 1 O
fraction NN 0 1 1 O
[ NNP 0 0 2 O
FDF NNP 0 1 UNK O
] VBD 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
at IN 0 0 12 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
L NNP 0 1 2 O
and CC 0 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
net JJ 0 1 1 O
change NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
percentage NN 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
FDF NNP 0 1 UNK O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
at IN 0 0 12 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
L NNP 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
raise VBP 0 0 12 O
the DT 0 0 12 O
possibility NN 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
ethanolysis NN 0 0 UNK O
reaction NN 0 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
stomach NN 0 1 6 O
of IN 0 0 12 O
people NNS 0 1 12 O
who WP 0 0 12 O
consume VBP 0 0 1 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
9 CD 0 0 2 B-Group
- : 0 0 2 O
hydroxy NN 0 1 14 I-Group
- : 0 0 2 O
9 CD 0 0 2 I-Group
9 CD 0 0 2 I-Group
- : 0 0 2 O
benzodiazepine NN 0 1 14 I-Group
on IN 0 0 12 O
a DT 0 0 12 O
regular JJ 0 1 12 O
basis NN 0 1 1 O
. . 0 0 12 O

Serial JJ 0 1 2 O
pharmacokinetic JJ 0 1 UNK O
dosing NN 0 0 14 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
proposed VBN 1 1 UNK O
as IN 1 0 12 O
a DT 0 0 12 O
method NN 0 1 13 O
to TO 0 0 12 O
accomplish VB 0 0 UNK O
this DT 0 0 12 O
goal NN 0 1 12 O
. . 0 0 12 O

Genetic JJ 0 1 UNK O
variation NN 0 1 1 O
in IN 0 0 12 O
metabolism NN 0 1 16 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
high JJ 0 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
and CC 0 0 12 O
an DT 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
in IN 0 0 12 O
slow JJ 0 1 12 O
metabolizers NNS 0 0 UNK O
which WDT 0 0 12 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
when WRB 0 0 12 O
using VBG 1 1 1 O
for IN 0 0 12 O
example NN 0 1 1 O
antidepressants NNS 1 1 13 B-Group
or CC 0 0 12 O
chemotherapy NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
defect NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
acute JJ 0 1 6 O
insulin NN 0 1 14 O
release NN 0 1 12 O
or CC 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
glucose NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
randomized VBN 1 1 6 O
blinded VBD 1 1 UNK O
crossover NN 0 1 UNK O
study NN 0 1 1 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
ingested VBD 1 1 14 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
ketamine NN 0 1 13 I-Drug
after IN 0 0 12 O
pretreatments NNS 0 1 UNK O
with IN 0 0 12 O
oral JJ 0 1 6 O
ticlopidine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
itraconazole NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
placebo NN 0 1 13 O
in IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
treatment NN 0 1 6 O
periods NNS 1 1 1 O
at IN 0 0 12 O
intervals NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
. . 0 0 12 O

Taken VBN 0 1 UNK O
together RB 0 1 12 O
this DT 0 0 12 O
study NN 0 1 1 O
shows VBZ 1 1 12 O
one CD 0 1 12 O
of IN 0 0 12 O
mechanisms NN 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
efficacy NN 0 1 UNK O
on IN 0 0 12 O
MM NNP 0 0 13 O
correlates VBZ 1 0 UNK O
with IN 0 0 12 O
its PRP$ 1 0 12 O
ability NN 0 1 1 O
to TO 0 0 12 O
down VB 0 0 12 O
- : 0 0 2 O
regulate VB 0 0 UNK O
the DT 0 0 12 O
ALOX9 NNP 0 0 UNK O
levels NNS 1 1 1 O
. . 0 0 12 O

Recovery NN 0 1 2 O
programs NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
flexible JJ 0 1 1 O
and CC 0 0 12 O
involve VB 0 0 1 O
individual JJ 0 1 1 O
and CC 0 0 12 O
family NN 0 1 12 O
education NN 0 1 1 O
on IN 0 0 12 O
recovery NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
nature NN 0 1 1 O
of IN 0 0 12 O
addictive JJ 0 1 UNK O
disease NN 0 1 6 O
. . 0 0 12 O

Gastrointestinal NNP 0 1 7 O
transit NN 0 1 1 O
time NN 0 1 12 O
( ( 0 0 2 O
lactulose JJ 0 1 14 O
hydrogen NN 0 1 13 O
breath NN 0 1 3 O
test NN 0 1 1 O
) ) 0 0 2 O
was VBD 1 0 12 O
measured VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
volunteers NNS 1 1 UNK O
with IN 0 0 12 O
oral JJ 0 1 6 O
and CC 0 0 12 O
intravenous JJ 0 1 14 O
placebo NN 0 1 13 O
oral JJ 0 1 6 O
placebo NN 0 1 13 O
and CC 0 0 12 O
intravenous JJ 0 1 14 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
x NN 0 0 10 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
oral JJ 0 1 6 O
ADL NNP 0 1 UNK B-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
intravenous JJ 0 1 14 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
x NN 0 0 10 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
in IN 0 0 12 O
a DT 0 0 12 O
double JJ 0 1 3 O
blind NN 0 1 12 O
cross NN 0 1 12 O
- : 0 0 2 O
over IN 0 1 12 O
study NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
's POS 0 1 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
and CC 0 0 12 O
sequence NN 0 1 UNK O
of IN 0 0 12 O
administration NN 0 1 1 O
are VBP 1 0 12 O
also RB 0 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

After IN 0 0 2 O
9 CD 0 0 2 O
min NN 0 1 16 O
fasting VBG 1 1 6 O
glycemia NN 0 1 UNK O
was VBD 1 0 12 O
measured VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
etofibrate NN 0 1 UNK B-Drug
on IN 0 0 12 O
both DT 0 0 12 O
chylomicron JJ 0 1 UNK O
lipolysis NN 0 1 UNK O
and CC 0 0 12 O
remnant JJ 0 1 3 O
removal NN 0 1 1 O
was VBD 1 0 12 O
achieved VBN 1 0 1 O
indicating VBG 1 0 1 O
that IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
improve VB 0 0 1 O
this DT 0 0 12 O
metabolism NN 0 1 16 O
in IN 0 0 12 O
future JJ 0 1 12 O
prospective JJ 0 1 UNK O
studies NNS 1 1 1 O
. . 0 0 12 O

and CC 0 0 12 O
by IN 0 0 12 O
observations NNS 1 1 1 O
now RB 0 1 12 O
appearing VBG 1 1 12 O
on IN 0 0 12 O
the DT 0 0 12 O
relation NN 0 1 13 O
between IN 0 0 12 O
plasma JJ 0 1 14 O
drug NN 0 1 1 O
levels NNS 1 1 1 O
and CC 0 0 12 O
drug NN 0 1 1 O
effects NNS 1 1 1 O
both DT 0 0 12 O
therapeutic JJ 0 1 6 O
and CC 0 0 12 O
toxic NN 0 1 1 O
. . 0 0 12 O

Because IN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
broadening NN 0 0 UNK O
indications NNS 1 1 1 O
for IN 0 0 12 O
immunosuppressive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
the DT 0 0 12 O
prolonged JJ 0 1 6 O
survival NN 0 1 1 O
in IN 0 0 12 O
conditions NNS 1 1 1 O
for IN 0 0 12 O
which WDT 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
being VBG 1 0 12 O
used VBN 1 1 12 O
many JJ 0 0 12 O
patients NNS 1 1 6 O
on IN 0 0 12 O
immunosuppression NN 0 1 14 O
are VBP 1 0 12 O
now RB 0 1 12 O
cared VBN 1 1 12 O
for IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
community NN 0 1 12 O
or CC 0 0 12 O
seen VBN 1 1 12 O
in IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
specialist NN 0 1 1 O
hospitals NNS 1 1 1 O
usually RB 0 1 12 O
in IN 0 0 12 O
close JJ 0 1 12 O
collaboration NN 0 1 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
specialist NN 0 1 1 O
. . 0 0 12 O

Nucleophosmin NNP 0 1 UNK O
/ NNP 0 0 2 O
B9 NNP 0 0 UNK O
in IN 0 0 12 O
serum NN 0 1 14 O
- : 0 0 2 O
deprived VBN 1 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
serum NN 0 1 14 O
) ) 0 0 2 O
NIH NNP 0 1 1 O
- : 0 0 2 O
9T9 CD 0 0 UNK O
cells NNS 1 1 6 O
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
highly RB 0 1 1 O
unstable JJ 0 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
tamoxifen NN 0 1 0 B-Drug
with IN 0 0 12 O
isoenzyme JJ 0 1 13 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
reduces VBZ 1 0 UNK O
this DT 0 0 12 O
metabolism NN 0 1 16 O
. . 0 0 12 O

Rat NNP 0 1 UNK O
kidney NN 0 1 6 O
homogenates NNS 1 1 UNK O
supplemented VBD 1 1 1 O
with IN 0 0 12 O
coenzyme NN 0 1 16 O
A NNP 0 0 2 O
ATP NNP 0 1 UNK O
oxaloacetate NN 0 1 UNK O
and CC 0 0 12 O
Mg9+ NNP 0 0 UNK O
converted VBD 1 0 1 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
to TO 0 0 12 O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
erythro SYM 0 1 13 B-Drug_n
- : 0 0 2 O
fluorocitrate NN 0 1 UNK I-Drug_n
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Imipramine NNP 0 1 UNK B-Drug
and CC 0 0 12 O
clonazepam NN 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
change VB 0 1 1 O
fasting VBG 1 1 6 O
or CC 0 0 12 O
overload JJ 0 0 1 O
glycemia NN 0 1 UNK O
. . 0 0 12 O

Celecoxib NN 0 1 UNK B-Drug
with IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
three CD 0 1 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
remaining VBG 1 1 1 O
four CD 0 1 12 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
variable JJ 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
concomitant JJ 0 1 6 O
phenytoin JJ 0 1 16 B-Drug
administration NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
quetiapine NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
data NN 0 1 1 O
suggest NN 0 1 1 O
that IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
has VBZ 1 0 12 O
a DT 0 0 12 O
narrower JJR 1 0 UNK O
spectrum NN 0 1 1 O
of IN 0 0 12 O
actions NNS 1 1 UNK O
and CC 0 0 12 O
will MD 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
substantially RB 0 0 1 O
greater JJR 1 1 1 O
therapeutic JJ 0 1 6 O
index NN 0 1 1 O
than IN 0 0 12 O
ibogaine NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Ethyl NNP 0 0 UNK B-Drug
alcohol NN 0 1 1 I-Drug
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
effect NN 0 1 1 O
the DT 0 0 12 O
functional JJ 0 1 1 O
integrity NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
limbic JJ 0 0 UNK O
system NN 0 1 1 O
particularly RB 0 0 1 O
the DT 0 0 12 O
hippocampus NN 0 1 8 O
and CC 0 0 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
behaviors NNS 1 1 1 O
which WDT 0 0 12 O
are VBP 1 0 12 O
thought VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
mediated VBN 1 1 13 O
through IN 0 0 12 O
limbic JJ 0 0 UNK O
function NN 0 1 1 O
. . 0 0 12 O

Misonidazole NNP 0 1 UNK B-Drug_n
has VBZ 1 0 12 O
a DT 0 0 12 O
complex JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
oral JJ 0 1 6 O
CCNU NNP 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
percentage NN 0 1 1 O
of IN 0 0 12 O
neurons NNS 1 1 UNK O
hyperpolarized VBN 0 0 UNK O
by IN 0 0 12 O
mu SYM 0 1 13 B-Group
- : 0 0 2 O
delta NN 0 1 3 I-Group
( ( 0 0 2 I-Group
9 CD 0 0 2 B-Group
) ) 0 0 2 O
- : 0 0 2 I-Group
and CC 0 0 12 O
kappa VB 0 1 13 B-Group
- : 0 0 2 O
selective JJ 0 1 13 I-Group
opioids NNS 0 1 14 I-Group
was VBD 1 0 12 O
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
when WRB 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
but CC 0 0 12 O
not RB 0 1 12 O
< VB 0 0 16 O

The DT 0 0 2 O
animals NNS 1 1 12 O
were VBD 1 0 12 O
received VBN 1 1 12 O
; : 0 0 2 O

With IN 0 0 2 O
combined VBN 1 1 1 O
use NN 0 1 1 O
clinicians NNS 1 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
aware JJ 0 1 12 O
when WRB 0 0 12 O
phenytoin NN 0 1 16 B-Drug
is VBZ 1 0 12 O
added VBN 1 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
reexacerbation NN 0 0 UNK O
of IN 0 0 12 O
pulmonary JJ 0 1 6 O
symptomatology NN 0 0 6 O
due JJ 0 1 1 O
to TO 0 0 12 O
lowered JJ 0 1 3 O
serum NN 0 1 14 O
theophylline NN 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

for IN 0 0 12 O
some DT 0 0 12 O
strains NNS 1 1 6 O
combinations NNS 1 1 1 O
were VBD 1 0 12 O
synergistic JJ 0 1 UNK O
. . 0 0 12 O

Advantages NNS 0 0 UNK O
offered VBN 1 1 12 O
by IN 0 0 12 O
this DT 0 0 12 O
class NN 0 1 12 O
of IN 0 0 12 O
antibiotics NNS 1 1 6 B-Group
include VBP 0 1 1 O
optimal JJ 0 1 1 O
pharmacokinetics NNS 0 1 UNK O
effectiveness NN 0 1 UNK O
against IN 0 0 12 O
multidrug JJ 0 0 UNK O
- : 0 0 2 O
resistant JJ 0 1 3 O
organisms NNS 1 1 1 O
and CC 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
even RB 0 0 12 O
when WRB 0 0 12 O
parenteral JJ 0 1 14 O
antibiotics NNS 1 1 6 B-Drug
are VBP 1 0 12 O
generally RB 0 0 1 O
used VBN 1 1 12 O
. . 0 0 12 O

At IN 0 0 2 O
similar JJ 0 1 1 O
median JJ 0 1 1 O
follow NN 0 1 12 O
- : 0 0 2 O
up RB 0 0 12 O
opportunistic JJ 0 0 1 O
infection NN 0 1 6 O
( ( 0 0 2 O
OI NNP 0 1 UNK O
) ) 0 0 2 O
rates NNS 1 1 1 O
and CC 0 0 12 O
mortality NN 0 1 13 O
were VBD 1 0 12 O
significantly RB 0 0 1 O
lower JJR 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
CHOP NNP 0 1 UNK O
- : 0 0 2 O
HAART NN 0 1 14 O
patients NNS 1 1 6 O
than IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
CHOP NNP 0 1 UNK O
patients NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs. FW 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
; : 0 0 2 O
P NNP 0 1 2 O
= VBZ 0 0 2 O
9 CD 0 0 2 O
; : 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs. FW 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
; : 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Efavirenz NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
demonstrated VBN 1 0 1 O
superiority NN 0 1 UNK O
over IN 0 1 12 O
nelfinavir NN 0 1 16 B-Drug
in IN 0 0 12 O
nucleoside JJ 0 1 UNK O
- : 0 0 2 O
experienced JJ 0 0 12 O
patients NNS 1 1 6 O
although IN 0 0 12 O
combining VBG 1 1 UNK O
these DT 0 0 12 O
9 CD 0 0 2 O
agents NNS 1 1 1 O
may MD 0 0 1 O
represent VB 0 1 1 O
the DT 0 0 12 O
best JJS 0 1 12 O
approach NN 0 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
circumstances NNS 1 0 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
had VBD 1 0 12 O
asymptomatic JJ 0 1 6 O
hypophosphatemia NN 0 1 8 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
and CC 0 0 12 O
urine JJ 0 1 6 O
analysis NN 0 1 1 O
suggested VBD 1 1 12 O
renal JJ 0 1 6 O
phosphate NN 0 1 14 O
wasting NN 0 1 12 O
. . 0 0 12 O

however RB 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
moderate JJ 0 1 1 O
to TO 0 0 12 O
severe VB 0 1 6 O
cardiovascular JJ 0 1 6 O
disease NN 0 1 6 O
or CC 0 0 12 O
those DT 0 0 12 O
taking VBG 1 0 12 O
nitrate JJ 0 1 14 B-Group
therapy NN 0 1 6 O
are VBP 1 0 12 O
at IN 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
for IN 0 0 12 O
potentially RB 0 0 1 O
serious JJ 0 1 12 O
cardiovascular JJ 0 1 6 O
adverse JJ 0 0 1 O
effects NNS 1 1 1 O
with IN 0 0 12 O
sildenafil JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
preliminary JJ 0 1 1 O
results NNS 1 1 1 O
from IN 0 0 12 O
an DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
trial NN 0 1 12 O
showed VBD 1 1 12 O
comparable JJ 0 0 1 O
cognitive JJ 0 1 1 O
enhancing VBG 1 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
and CC 0 0 12 O
risperidone NN 0 1 0 B-Drug
treatment NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
schizophrenia NN 0 1 13 O
or CC 0 0 12 O
schizoaffective JJ 0 0 13 O
disorder NN 0 1 6 O
. . 0 0 12 O

Since IN 0 1 2 O
the DT 0 0 12 O
arrival NN 0 1 12 O
of IN 0 0 12 O
oral JJ 0 1 6 O
erection NN 0 1 UNK B-Group
- : 0 0 2 O
supporting VBG 1 1 1 I-Group
medication NN 0 1 6 I-Group
patients NNS 1 1 6 O
want VBP 0 0 12 O
to TO 0 0 12 O
know VB 0 0 12 O
how WRB 0 0 12 O
safe JJ 0 0 12 O
sexual JJ 0 1 12 O
activity NN 0 1 1 O
is VBZ 1 0 12 O
in IN 0 0 12 O
cardiovascular JJ 0 1 6 O
disease NN 0 1 6 O
in IN 0 0 12 O
general JJ 0 1 1 O
and CC 0 0 12 O
during IN 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
erection NN 0 1 UNK B-Group
- : 0 0 2 O
supporting VBG 1 1 1 I-Group
medication NN 0 1 6 I-Group
in IN 0 0 12 O
particular JJ 0 0 1 O
. . 0 0 12 O

Growth NNP 0 1 2 O
of IN 0 0 12 O
M NNP 0 1 2 O
. . 0 0 12 O

Infacol NNP 0 0 UNK B-Brand
( ( 0 0 2 O
Forest NNP 0 1 UNK O
Laboratories NNPS 0 1 2 O
UK NNP 0 1 UNK O
Kent NNP 0 1 19 O
UK NNP 0 1 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
a DT 0 0 12 O
widely RB 0 0 1 O
available JJ 0 1 1 O
over IN 0 1 12 O
- : 0 0 2 O
the DT 0 0 12 O
- : 0 0 2 O
counter NN 0 1 3 O
preparation NN 0 1 1 O
used VBN 1 1 12 O
to TO 0 0 12 O
relieve VB 0 1 6 O
colic NN 0 1 6 O
symptoms NNS 1 1 6 O
in IN 0 0 12 O
neonates NNS 1 1 16 O
and CC 0 0 12 O
infants NNS 1 1 6 O
. . 0 0 12 O

surgery NN 0 1 6 O
; : 0 0 2 O

When WRB 0 0 12 O
cocaine NN 0 1 6 B-Drug
is VBZ 1 0 12 O
the DT 0 0 12 O
primary JJ 0 1 1 O
addiction NN 0 1 12 O
after IN 0 0 12 O
withdrawal WP 0 1 1 O
the DT 0 0 12 O
most RBS 0 0 12 O
effective JJ 0 1 1 O
treatment NN 0 1 6 O
is VBZ 1 0 12 O
group NN 0 1 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
other JJ 0 0 12 O
recovering VBG 1 1 12 O
cocaine JJ 0 1 6 O
abusers NNS 1 0 UNK O
. . 0 0 12 O

On IN 0 0 2 O
day NN 0 1 12 O
9 CD 0 0 2 O
a DT 0 0 12 O
single JJ 0 1 12 O
panobinostat NN 0 1 UNK B-Drug
dose NN 0 1 6 O
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
significantly RB 0 0 1 O
decreases VBZ 1 1 UNK O
clearance NN 0 1 16 O
of IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
O NNP 0 1 2 I-Drug_n
- : 0 0 2 O
desacetylrifabutin NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
is VBZ 1 0 12 O
poorly RB 0 1 1 O
tolerated VBN 1 0 1 O
. . 0 0 12 O

These DT 0 0 1 O
steps NNS 1 1 12 O
include VBP 0 1 1 O
regular JJ 0 1 12 O
reevaluations NNS 1 0 UNK O
of IN 0 0 12 O
dosages NNS 1 1 14 O
and CC 0 0 12 O
plasma JJ 0 1 14 O
drug NN 0 1 1 O
concentrations NNS 1 1 13 O
recognition NN 0 1 1 O
and CC 0 0 12 O
understanding NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
side NN 0 1 3 O
effects NNS 1 1 1 O
and CC 0 0 12 O
avoidance NN 0 1 1 O
of IN 0 0 12 O
certain JJ 0 1 1 O
agents NNS 1 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
9 CD 0 0 2 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
noted VBN 1 0 1 O
that IN 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
melarsoprol NN 0 1 UNK B-Drug
reaction NN 0 1 1 O
had VBD 1 0 12 O
increased VBN 1 1 1 O
systematically RB 0 0 UNK O
between IN 0 0 12 O
June NNP 0 1 2 O
and CC 0 0 12 O
October NNP 0 1 2 O
of IN 0 0 12 O
each DT 0 0 12 O
year NN 0 1 12 O
indicating VBG 1 0 1 O
strong JJ 0 1 12 O
seasonal JJ 0 1 1 O
variation NN 0 1 1 O
. . 0 0 12 O

Age NNP 0 1 2 O
( ( 0 0 2 O
range VBP 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
years NNS 1 1 12 O
) ) 0 0 2 O
weight NN 0 1 3 O
( ( 0 0 2 O
range NN 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
and CC 0 0 12 O
sex NN 0 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
men NNS 0 1 13 O
and CC 0 0 12 O
9 CD 0 0 2 O
women NNS 1 1 UNK O
) ) 0 0 2 O
were VBD 1 0 12 O
not RB 0 1 12 O
significant JJ 0 1 1 O
contributors NNS 1 0 UNK O
to TO 0 0 12 O
variability NN 0 1 UNK O
. . 0 0 12 O

( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
the DT 0 0 12 O
higher JJR 1 1 1 O
serum JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
penicillins NNS 1 1 14 B-Group
and CC 0 0 12 O
cephaloridine NN 0 1 UNK B-Drug
reached VBN 1 1 12 O
after IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
probenecid NNS 0 1 13 B-Drug
are VBP 1 0 12 O
due JJ 0 1 1 O
not RB 0 1 12 O
only RB 0 1 12 O
to TO 0 0 12 O
slower VB 0 1 UNK O
renal JJ 0 1 6 O
elimination NN 0 1 UNK O
but CC 0 0 12 O
also RB 0 0 12 O
to TO 0 0 12 O
an DT 0 0 12 O
altered JJ 0 1 1 O
distribution NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
piperine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
antinociceptive JJ 0 0 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
evaluated VBN 1 1 1 O
by IN 0 0 12 O
both DT 0 0 12 O
acetic JJ 0 1 14 B-Drug
acid NN 0 1 14 I-Drug
writhing NN 0 0 UNK O
and CC 0 0 12 O
formalin JJ 0 1 UNK O
test NN 0 1 1 O
when WRB 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
with IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
comparison NN 0 1 1 O
to TO 0 0 12 O
saline VB 0 1 14 O
values NNS 1 1 1 O
all DT 0 0 12 O
three CD 0 1 12 O
agents NNS 1 1 1 O
produced VBD 1 0 1 O
reliable JJ 0 1 UNK O
increases NNS 1 1 1 O
in IN 0 0 12 O
peak JJ 0 1 1 O
latency NN 0 1 1 O
for IN 0 0 12 O
most JJS 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
components NNS 1 1 1 O
with IN 0 0 12 O
only JJ 0 1 12 O
N9 NNP 0 0 UNK O
showing VBG 1 1 12 O
no DT 0 0 12 O
effects NNS 1 1 1 O
. . 0 0 12 O

( ( 0 0 2 O
ii NN 0 0 13 O
) ) 0 0 2 O
acetyl VBZ 0 0 UNK B-Drug
- : 0 0 2 O
l NN 0 1 2 I-Drug
- : 0 0 2 O
carnitine NN 0 1 13 I-Drug
elicits VBZ 1 1 UNK O
a DT 0 0 12 O
significant JJ 0 1 1 O
protective JJ 0 0 3 O
effect NN 0 1 1 O
on IN 0 0 12 O
DEB NNP 0 1 UNK O
induced VBD 1 1 6 O
toxicity NN 0 1 6 O
which WDT 0 0 12 O
was VBD 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
alpha JJ 0 1 1 B-Drug
- : 0 0 2 O
lipoic NN 0 0 UNK I-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
concluded VBN 1 1 1 O
that IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
short JJ 0 1 12 O
- : 0 0 2 O
acting JJ 0 1 12 O
drug NN 0 1 1 O
and CC 0 0 12 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
with IN 0 0 12 O
halothane NN 0 1 13 B-Drug
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
prolong VB 0 0 13 O
further RB 1 1 1 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
action NN 0 1 13 O
on IN 0 0 12 O
the DT 0 0 12 O
central JJ 0 1 1 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
literature NN 0 1 UNK O
provides VBZ 1 1 UNK O
considerable JJ 0 0 1 O
evidence NN 0 1 1 O
indicating VBG 1 0 1 O
that IN 0 0 12 O
several JJ 0 1 12 O
but CC 0 0 12 O
not RB 0 1 12 O
all DT 0 0 12 O
antihistaminics NNS 0 1 UNK B-Group
are VBP 1 0 12 O
indeed RB 0 0 12 O
analgesic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
and CC 0 0 12 O
some DT 0 0 12 O
are VBP 1 0 12 O
analgesic JJ 0 1 13 B-Group
adjuvants NNS 1 1 UNK I-Group
as IN 1 0 12 O
well RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
primary JJ 0 1 1 O
objective NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
ascertain VB 0 0 1 O
the DT 0 0 12 O
difference NN 0 1 UNK O
in IN 0 0 12 O
darbepoetin NN 0 0 13 B-Drug
responsiveness NN 0 1 UNK O
before IN 0 1 12 O
and CC 0 0 12 O
after IN 0 0 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
of IN 0 0 12 O
cinacalcet JJ 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Lack NN 0 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
levofloxacin NN 0 1 0 B-Drug
and CC 0 0 12 O
oxycodone NN 0 1 0 B-Drug
: : 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
drug NN 0 1 1 O
disposition NN 0 1 1 O
. . 0 0 12 O

Moxifloxacin NNP 0 1 UNK B-Drug
and CC 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
are VBP 1 0 12 O
fluoroquinolone JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
used VBN 1 1 12 O
in IN 0 0 12 O
treating VBG 1 1 6 O
urinary JJ 0 1 6 O
and CC 0 0 12 O
respiratory JJ 0 1 6 O
tract NN 0 1 6 O
infections NNS 1 1 6 O
. . 0 0 12 O

As IN 0 0 2 O
a DT 0 0 12 O
precursor NN 0 1 UNK O
to TO 0 0 12 O
this DT 0 0 12 O
effort NN 0 1 12 O
optimal NN 0 1 1 O
and CC 0 0 12 O
minimal JJ 0 1 1 O
experimental JJ 0 1 UNK O
designs NNS 1 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
case NN 0 1 12 O
in IN 0 0 12 O
which WDT 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
compound NN 0 1 13 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
developed VBN 1 0 1 O
. . 0 0 12 O

Considering VBG 0 1 UNK O
that IN 0 0 12 O
the DT 0 0 12 O
involvement NN 0 1 1 O
of IN 0 0 12 O
reactive JJ 0 1 1 O
oxygen NN 0 1 3 O
species NNS 1 1 1 O
( ( 0 0 2 O
ROS NNP 0 0 14 O
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
implicated VBN 1 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
various JJ 0 1 1 O
pesticides NNS 1 1 13 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
designed VBN 1 1 UNK O
to TO 0 0 12 O
investigate VB 0 1 1 O
the DT 0 0 12 O
possibility NN 0 1 1 O
of IN 0 0 12 O
oxidative JJ 0 1 UNK O
stress NN 0 1 1 O
induction NN 0 1 1 O
by IN 0 0 12 O
cypermethrin VBG 0 1 UNK B-Drug
a DT 0 0 12 O
Type NNP 0 1 2 B-Drug_n
II NNP 0 0 2 I-Drug_n
pyrethroid NN 0 1 UNK I-Drug_n
. . 0 0 12 O

In IN 0 0 2 O
male JJ 0 1 12 O
Sprague NNP 0 0 UNK O
- : 0 0 2 O
Dawley NNP 0 0 UNK O
rats NNS 1 1 UNK O
fasted VBD 1 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
i.p NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O

However RB 0 0 1 O
there EX 0 0 12 O
are VBP 1 0 12 O
several JJ 0 1 12 O
instances NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
animal JJ 0 1 13 O
literature NN 0 1 UNK O
showing VBG 1 1 12 O
that IN 0 0 12 O
hippocampal JJ 0 1 8 O
lesions NNS 1 1 6 O
actually RB 0 0 12 O
produced VBD 1 0 1 O
enhanced JJ 0 1 1 O
learning NN 0 1 13 O
and CC 0 0 12 O
memory NN 0 1 1 O
function NN 0 1 1 O
. . 0 0 12 O

Of IN 0 0 2 O
the DT 0 0 12 O
remaining VBG 1 1 1 O
cases NNS 1 1 UNK O
two CD 0 1 12 O
were VBD 1 0 12 O
cardiac JJ 0 1 6 O
two CD 0 1 12 O
hepatic JJ 0 1 14 O
and CC 0 0 12 O
the DT 0 0 12 O
rest NN 0 1 12 O
were VBD 1 0 12 O
mixed JJ 0 1 3 O
drug NN 0 1 1 O
overdose NN 0 1 6 O
. . 0 0 12 O

As IN 0 0 2 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
our PRP$ 0 0 12 O
liver NN 0 1 6 O
slice NN 0 1 UNK O
metabolite JJ 0 1 UNK O
identification NN 0 1 1 O
procedure NN 0 1 1 O
a DT 0 0 12 O
minor JJ 0 1 1 O
glutathione NN 0 1 13 O
adduct NN 0 1 UNK O
and CC 0 0 12 O
previously RB 0 0 1 O
unreported VBD 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
O NNP 0 1 2 O
- : 0 0 2 O
desmethyl NN 0 0 UNK O
and CC 0 0 12 O
glucuronidated JJ 0 0 UNK O
metabolites NNS 1 1 UNK O
of IN 0 0 12 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
are VBP 1 0 12 O
reported VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
ouabain NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
PTX NNP 0 1 15 B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
failed VBD 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
contraction NN 0 1 6 O
; : 0 0 2 O

Patients NNS 0 1 7 O
' POS 0 0 2 O
mean JJ 0 1 12 O
age NN 0 1 12 O
was VBD 1 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

benign NN 0 1 6 O
breast NN 0 1 6 O
disease NN 0 1 6 O
; : 0 0 2 O

Pulmonary NNP 0 1 7 O
granulomata NNS 1 1 UNK O
subacute NN 0 1 8 O
hepatitis NN 0 1 6 O
and CC 0 0 12 O
other JJ 0 0 12 O
lesions NNS 1 1 6 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
intravenous JJ 0 1 14 O
drug NN 0 1 1 O
use NN 0 1 1 O
were VBD 1 0 12 O
common JJ 0 1 1 O
findings NNS 1 1 1 O
at IN 0 0 12 O
autopsy NN 0 1 6 O
. . 0 0 12 O

Moreover RB 0 0 1 O
the DT 0 0 12 O
basal NN 0 1 6 O
and CC 0 0 12 O
dmPGE9 VB 0 0 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
jejunal JJ 0 1 8 O
net NN 0 1 1 O
fluid NN 0 1 3 O
transfers NNS 1 1 UNK O
were VBD 1 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
control NN 0 1 1 O
rats NNS 1 1 UNK O
. . 0 0 12 O

From IN 0 0 2 O
this DT 0 0 12 O
study NN 0 1 1 O
it PRP 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
concluded VBN 1 1 1 O
that IN 0 0 12 O
piperine NN 0 1 UNK B-Drug_n
can MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
bioenhancer NN 0 0 UNK O
along IN 0 0 12 O
with IN 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
. . 0 0 12 O

Reversal NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
block NN 0 1 3 O
with IN 0 0 12 O
edrophonium NN 0 1 16 B-Drug
and CC 0 0 12 O
subsequent JJ 0 1 1 O
recovery NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
horses NNS 1 1 UNK O
from IN 0 0 12 O
anaesthesia NN 0 1 UNK O
were VBD 1 0 12 O
uneventful JJ 0 0 12 O
. . 0 0 12 O

A DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
month NN 0 1 12 O
washout IN 0 1 3 O
period NN 0 1 1 O
was VBD 1 0 12 O
inserted VBN 1 1 3 O
between IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
periods NNS 1 1 1 O
. . 0 0 12 O

Small JJ 0 1 2 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
chemotherapy VB 0 1 6 O
can MD 0 0 12 O
have VB 0 0 12 O
a DT 0 0 12 O
dramatic JJ 0 1 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
cure NN 0 1 6 O
rates NNS 1 1 1 O
and CC 0 0 12 O
therefore RB 0 0 1 O
subtle JJ 0 1 3 O
cell NN 0 1 1 O
type NN 0 1 1 O
- : 0 0 2 O
specific JJ 0 1 1 O
differences NNS 1 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
important JJ 0 1 1 O
determinants NNS 1 1 UNK O
of IN 0 0 12 O
drug NN 0 1 1 O
sensitivity NN 0 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
induce VBP 0 1 6 O
or CC 0 0 12 O
inhibit VBP 0 1 13 O
this DT 0 0 12 O
enzyme NN 0 1 14 O
may MD 0 0 1 O
affect VB 0 1 1 O
quetiapine NN 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

ulcerans NNS 0 0 UNK O
was VBD 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
plate NN 0 1 3 O
counts NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
BACTEC NNP 0 0 UNK O
radiometric JJ 0 1 UNK O
method NN 0 1 13 O
. . 0 0 12 O

ulcerans NNS 0 0 UNK O
was VBD 1 0 12 O
between IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
l NN 0 1 2 O
while IN 0 0 12 O
corresponding VBG 1 0 1 O
values NNS 1 1 1 O
for IN 0 0 12 O
rifampicin NN 0 1 UNK B-Drug
and CC 0 0 12 O
rifabutin NN 0 1 13 B-Drug
were VBD 1 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
l NN 0 1 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
l NN 0 1 2 O
respectively RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
intramuscularly RB 0 0 UNK O
injected VBN 1 1 3 O
ketamine NN 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
N NNP 0 1 2 O
- : 0 0 2 O
demethylated VBN 0 0 UNK O
metabolite NN 0 1 UNK O
( ( 0 0 2 O
metabolite JJ 0 1 UNK O
I PRP 0 1 12 O
) ) 0 0 2 O
with IN 0 0 12 O
halothane NN 0 1 13 B-Drug
was VBD 1 0 12 O
evaluated VBN 1 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
specificity NN 0 1 UNK O
we PRP 0 0 12 O
describe VBP 0 0 1 O
a DT 0 0 12 O
simple JJ 0 1 1 O
and CC 0 0 12 O
reliable JJ 0 1 UNK O
affinity NN 0 1 UNK O
chromatography NN 0 1 UNK O
procedure NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
purification NN 0 1 UNK O
of IN 0 0 12 O
both DT 0 0 12 O
human JJ 0 1 1 O
serum NN 0 1 14 O
and CC 0 0 12 O
colostrum NN 0 1 UNK O
IgA NNP 0 1 14 O
. . 0 0 12 O

HEY NNP 0 0 UNK O
cells NNS 1 1 6 O
treated VBD 1 1 1 O
with IN 0 0 12 O
dasatinib JJ 0 1 13 B-Drug
plus CC 0 1 16 O
paclitaxel JJ 0 1 13 B-Drug
formed VBN 1 1 UNK O
fewer JJR 1 1 UNK O
colonies NNS 1 1 1 O
than IN 0 0 12 O
did VBD 1 0 12 O
cells NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
agent NN 0 1 1 O
alone RB 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
metabolite NN 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
in IN 0 0 12 O
rat NN 0 1 13 O
liver NN 0 1 6 O
slices NNS 1 1 UNK O
shares NNS 1 1 UNK O
some DT 0 0 12 O
features NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
profile NN 0 1 1 O
but CC 0 0 12 O
also RB 0 0 12 O
had VBD 1 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
difference NN 0 1 UNK O
in IN 0 0 12 O
that DT 0 0 12 O
epoxide JJ 0 1 UNK O
dihydrodiol NN 0 1 UNK O
hydrolysis NN 0 1 UNK O
products NNS 1 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
observed VBN 1 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
measurable JJ 0 1 1 O
extent NN 0 1 1 O
. . 0 0 12 O

Pancreatic JJ 0 1 7 O
content NN 0 1 13 O
after IN 0 0 12 O
perfusion NN 0 1 8 O
did VBD 1 0 12 O
not RB 0 1 12 O
correlate VB 0 0 1 O
with IN 0 0 12 O
release NN 0 1 12 O
during IN 0 0 12 O
perfusion NN 0 1 8 O
. . 0 0 12 O

Morphine NNP 0 1 0 B-Drug
prolonged VBD 1 1 6 O
gastrointestinal JJ 0 1 6 O
transit NN 0 1 1 O
time NN 0 1 12 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
; : 0 0 2 O

The DT 0 0 2 O
objective NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
ginseng JJ 0 1 14 B-Drug_n
stem NN 0 1 3 I-Drug_n
- : 0 0 2 O
and CC 0 0 12 I-Drug_n
- : 0 0 2 O
leaf NN 0 1 UNK I-Drug_n
saponins NNS 1 1 UNK I-Drug_n
( ( 0 0 2 O
GSLS NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
on IN 0 0 12 O
the DT 0 0 12 O
humoral JJ 0 1 14 O
immune JJ 0 1 6 O
responses NNS 1 1 1 O
of IN 0 0 12 O
chickens NNS 1 1 UNK O
to TO 0 0 12 O
inactivated VB 1 0 UNK B-Drug
ND NNP 0 0 2 I-Drug
and CC 0 0 12 O
AI NNP 0 1 13 B-Drug
vaccines NNS 1 1 6 I-Drug
. . 0 0 12 O

Core NN 0 1 UNK O
temperature NN 0 1 3 O
was VBD 1 0 12 O
decreased VBN 1 1 1 O
in IN 0 0 12 O
rats NNS 1 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
when WRB 0 0 12 O
ethanol NN 0 1 1 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
rats NNS 1 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
disulfiram JJ 0 1 13 B-Drug
9 CD 0 0 2 O
hours NNS 1 1 12 O
before IN 0 1 12 O
the DT 0 0 12 O
ethanol NN 0 1 1 B-Drug
challenge NN 0 1 12 O
. . 0 0 12 O

All DT 0 0 2 O
statistical JJ 0 1 UNK O
tests NNS 1 1 1 O
were VBD 1 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
sided VBD 1 1 3 O
. . 0 0 12 O

Phencyclidine NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
PCP NNP 0 1 13 B-Drug_n
) ) 0 0 2 O
produces VBZ 1 0 1 O
psychotomimetic JJ 0 0 UNK O
effects NNS 1 1 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
that WDT 0 0 12 O
resemble VBP 0 0 UNK O
schizophrenia NN 0 1 13 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
drug NN 0 1 1 O
uptake NN 0 1 14 O
or CC 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
DNA NNP 0 1 1 O
strand NN 0 1 UNK O
breaks NNS 1 1 UNK O
. . 0 0 12 O

All DT 0 0 2 O
drugs NNS 1 1 6 O
were VBD 1 0 12 O
injected VBN 1 1 3 O
intraperitoneally RB 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
renal JJ 0 1 6 O
plasma NN 0 1 14 O
flow NN 0 1 1 O
glomerular JJ 0 1 UNK O
filtration NN 0 1 3 O
rate NN 0 1 1 O
and CC 0 0 12 O
pulsatile NN 0 1 8 O
choroidal NN 0 1 13 O
blood NN 0 1 6 O
flow NN 0 1 1 O
were VBD 1 0 12 O
measured VBN 1 1 1 O
using VBG 1 1 1 O
the DT 0 0 12 O
paraaminohippurate NN 0 1 UNK O
method VBD 0 1 13 O
the DT 0 0 12 O
inulin NN 0 1 UNK O
method NN 0 1 13 O
and CC 0 0 12 O
a DT 0 0 12 O
laser NN 0 1 3 O
interferometric JJ 0 1 UNK O
measurement NN 0 1 1 O
of IN 0 0 12 O
fundus JJ 0 1 8 O
pulsation NN 0 0 13 O
amplitude NN 0 1 1 O
respectively RB 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
homodimeric JJ 0 0 UNK O
disintegrin NN 0 0 UNK O
contortrostatin NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
compared VBN 1 1 1 O
directly RB 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
monomeric JJ 0 1 UNK O
disintegrins NNS 0 1 UNK O
echistatin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
flavoridin NN 0 0 UNK B-Drug_n
for IN 0 0 12 O
the DT 0 0 12 O
ability NN 0 1 1 O
to TO 0 0 12 O
affect VB 0 1 1 O
protein JJ 0 1 14 O
tyrosine JJ 0 1 13 O
phosphorylation NN 0 1 UNK O
in IN 0 0 12 O
tumor NN 0 1 6 O
cells NNS 1 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
that IN 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
fluoroquinolones NNS 0 1 UNK B-Group
was VBD 1 0 12 O
more JJR 0 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
C NNP 0 0 2 O
than IN 0 0 12 O
at IN 0 0 12 O
room NN 0 1 12 O
temperature NN 0 1 3 O
. . 0 0 12 O

Azithromycin NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
dideoxyinosine NN 0 1 UNK B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Radioligand NNP 0 1 UNK O
binding VBG 1 1 1 O
experiments NNS 1 1 UNK O
using VBG 1 1 1 O
the DT 0 0 12 O
uptake JJ 0 1 14 O
inhibitor NN 0 1 14 O
hydrogen NN 0 1 13 O
- : 0 0 2 O
9 CD 0 0 2 O
mazindol NN 0 1 UNK B-Drug
revealed VBD 1 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
by IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
norepinephrine JJ 0 1 14 B-Drug
uptake JJ 0 1 14 O
- : 0 0 2 O
9 CD 0 0 2 O
carrier NN 0 1 1 O
density NN 0 1 1 O
in IN 0 0 12 O
functional JJ 0 1 1 O
classes NNS 1 1 UNK O
II NNP 0 0 2 O
to TO 0 0 12 O
III NNP 0 1 2 O
and CC 0 0 12 O
IV NNP 0 1 2 O
myocardium NN 0 1 8 O
versus NN 0 0 1 O
nonfailing VBG 0 0 UNK O
myocardium NN 0 1 8 O
( ( 0 0 2 O
p JJ 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Most JJS 0 0 2 O
frequently RB 0 1 1 O
reported VBN 1 1 1 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
were VBD 1 0 12 O
gastrointestinal JJ 0 1 6 O
related VBN 1 1 1 O
. . 0 0 12 O

Studies NNS 0 1 2 O
of IN 0 0 12 O
other JJ 0 0 12 O
isoenzyme JJ 0 1 13 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
showed VBD 1 1 12 O
no DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
recurrence NN 0 1 6 O
but CC 0 0 12 O
they PRP 0 0 12 O
lacked VBD 1 1 UNK O
statistical JJ 0 1 UNK O
power NN 0 1 1 O
. . 0 0 12 O

Newcastle JJ 0 0 UNK O
disease NN 0 1 6 O
( ( 0 0 2 O
ND NNP 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
avian JJ 0 1 13 O
influenza NN 0 1 6 O
( ( 0 0 2 O
AI NNP 0 1 13 O
) ) 0 0 2 O
are VBP 1 0 12 O
common JJ 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
poultry NN 0 1 UNK O
industry NN 0 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
assessed VBD 1 1 1 O
the DT 0 0 12 O
ability NN 0 1 1 O
of IN 0 0 12 O
gene NN 0 1 13 O
transfer NN 0 1 1 O
to TO 0 0 12 O
reverse VB 0 1 1 O
vancomycin JJ 0 1 14 B-Drug
resistance NN 0 1 1 O
in IN 0 0 12 O
class NN 0 1 12 O
A NNP 0 0 2 O
( ( 0 0 2 O
VanA NNP 0 0 UNK O
) ) 0 0 2 O
glycopeptide VBP 0 1 UNK O
- : 0 0 2 O
resistant JJ 0 1 3 O
Enterococcus NNP 0 1 14 O
faecalis NN 0 0 16 O
. . 0 0 12 O

Maximum NNP 0 1 2 O
calculated VBD 1 1 1 O
theophylline JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
ranged VBD 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
/ NN 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
/ NN 0 0 2 O
9 CD 0 0 2 O
times NNS 1 1 12 O
baseline JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
remainder NN 0 0 1 O
of IN 0 0 12 O
the DT 0 0 12 O
dialysis NN 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
biochemistry NN 0 1 6 O
( ( 0 0 2 O
electrolytes VBZ 0 1 14 O
calcium NN 0 1 14 O
phosphate NN 0 1 14 O
iron NN 0 1 3 O
status NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
vitamin $ 0 1 6 O
D NNP 0 1 2 O
use NN 0 1 1 O
remained VBD 1 0 12 O
unchanged JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
latter JJ 0 0 UNK O
might MD 0 0 12 O
arise VB 0 0 1 O
from IN 0 0 12 O
a DT 0 0 12 O
hit NN 0 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
genetically RB 0 0 UNK O
initiated VBN 1 1 1 O
cell NN 0 1 1 O
the DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
more RBR 0 1 12 O
rapid JJ 0 1 1 O
progression NN 0 1 1 O
in IN 0 0 12 O
tumor NN 0 1 6 O
type NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
digoxin NN 0 1 14 B-Drug
median JJ 0 1 1 O
tmax NN 0 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
for IN 0 0 12 O
both DT 0 0 12 O
treatments NNS 1 1 6 O
. . 0 0 12 O

We PRP 0 0 12 O
also RB 0 0 12 O
evaluated VBD 1 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
doses NNS 1 1 6 O
between IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
on IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
heme JJ 0 1 14 B-Drug
iron NN 0 1 3 I-Drug
[ NN 0 0 2 O
as IN 1 0 12 O
concentrated JJ 0 1 16 O
RBC NNP 0 1 13 O
( ( 0 0 2 O
CRBC NNP 0 0 UNK O
) ) 0 0 2 O
] NN 0 0 2 O
. . 0 0 12 O

Nimodipine NNP 0 1 0 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
response NN 0 1 1 O
. . 0 0 12 O

Phase NN 0 1 UNK O
I PRP 0 1 12 O
trial NN 0 1 12 O
of IN 0 0 12 O
lenalidomide NN 0 1 UNK B-Drug
and CC 0 0 12 O
CCI NNP 0 1 UNK B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
relapsed JJ 0 1 6 O
multiple JJ 0 1 1 O
myeloma NN 0 1 6 O
: : 0 0 2 O
evidence NN 0 1 1 O
for IN 0 0 12 O
lenalidomide JJ 0 1 UNK B-Drug
- : 0 0 2 O
CCI NNP 0 1 UNK B-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
interaction NN 0 1 UNK O
via IN 0 0 1 O
P NNP 0 1 2 O
- : 0 0 2 O
glycoprotein NN 0 1 UNK O
. . 0 0 12 O

Mixtures NNS 0 1 UNK O
of IN 0 0 12 O
cadmium NN 0 1 13 O
and CC 0 0 12 O
zinc NN 0 1 14 B-Drug
had VBD 1 0 12 O
a DT 0 0 12 O
synergistic JJ 0 1 UNK O
effect NN 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
single JJ 0 1 12 O
metal NN 0 1 3 O
toxicity NN 0 1 6 O
but CC 0 0 12 O
only RB 0 1 12 O
at IN 0 0 12 O
99 CD 0 0 10 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
l NN 0 1 2 O
. . 0 0 12 O

The DT 0 0 2 O
amplitude NN 0 1 1 O
data NNS 0 1 1 O
from IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
's POS 0 1 12 O
augmentation NN 0 1 13 O
of IN 0 0 12 O
component JJ 0 1 1 O
P9 NNP 0 1 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
at IN 0 0 12 O
least JJS 0 1 12 O
in IN 0 0 12 O
part NN 0 1 12 O
from IN 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
cholinergic JJ 0 1 13 O
functions NNS 1 1 13 O
. . 0 0 12 O

Gentamicin NNP 0 1 0 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
within IN 0 0 1 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
concentrations NNS 1 1 13 O
tested VBN 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mug NNS 0 1 UNK O
/ NNP 0 0 2 O
ml NN 0 1 16 O
) ) 0 0 2 O
; : 0 0 2 O

Plasma NNP 0 1 UNK O
membrane NN 0 1 3 O
and CC 0 0 12 O
intracellular JJ 0 1 UNK O
mobilization NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 O
ions NNS 1 1 UNK O
are VBP 1 0 12 O
intimately RB 0 0 UNK O
related VBN 1 1 1 O
to TO 0 0 12 O
platelet VB 0 1 14 O
activation NN 0 1 13 O
and CC 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
platelet NN 0 1 14 O
contents NNS 1 1 1 O
. . 0 0 12 O

After IN 0 0 2 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
treatment NN 0 1 6 O
all DT 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ NN 0 0 2 O
vehicle NN 0 1 1 O
- : 0 0 2 O
treated VBN 1 1 1 O
animals NNS 1 1 12 O
displayed VBD 1 1 1 O
parkinsonian JJ 0 0 UNK O
symptoms NNS 1 1 6 O
whereas IN 0 0 UNK O
none NN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ VBZ 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] FW 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
- : 0 0 2 O
treated VBN 1 1 1 O
monkeys NNS 1 1 UNK O
were VBD 1 0 12 O
significantly RB 0 0 1 O
affected VBN 1 1 1 O
. . 0 0 12 O

Clostridium NNP 0 1 14 B-Drug_n
difficile NN 0 0 14 I-Drug_n
toxin NN 0 1 14 I-Drug_n
A NNP 0 0 2 I-Drug_n
displays VBZ 1 1 UNK O
both DT 0 0 12 O
cytotoxic NN 0 1 UNK O
and CC 0 0 12 O
enterotoxic JJ 0 1 UNK O
activities NNS 1 1 1 O
. . 0 0 12 O

We PRP 0 0 12 O
investigated VBD 1 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
adenosine JJ 0 1 14 O
receptor NN 0 1 14 O
antagonists NNS 1 1 13 O
caffeine VBP 0 1 6 B-Drug
theophylline NN 0 1 16 B-Drug
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
phenyltheophylline NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
cyclopentyl NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 O
- : 0 0 2 I-Drug_n
dipropylxanthine NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
DPCPX NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
in IN 0 0 12 O
a DT 0 0 12 O
light JJ 0 1 3 O
/ NN 0 0 2 O
dark JJ 0 1 3 O
test NN 0 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
given VBN 1 1 12 O
i.p. VBP 0 1 UNK O
dmPGE9 NN 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
induced VBD 1 1 6 O
a DT 0 0 12 O
watery NN 0 1 UNK O
stool NN 0 1 3 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
and CC 0 0 12 O
control NN 0 1 1 O
rats NNS 1 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
efficacy NN 0 1 UNK O
although IN 0 0 12 O
these DT 0 0 12 O
effects NNS 1 1 1 O
were VBD 1 0 12 O
short JJ 0 1 12 O
- : 0 0 2 O
lasting NN 0 0 1 O
as IN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
group NN 0 1 12 O
of IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
had VBD 1 0 12 O
had VBN 1 0 12 O
a DT 0 0 12 O
new JJ 0 1 12 O
acute NN 0 1 6 O
episode NN 0 1 12 O
despite IN 0 0 12 O
seemingly RB 0 0 UNK O
adequate JJ 0 1 1 O
treatment NN 0 1 6 O
were VBD 1 0 12 O
selected VBN 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
affinity NN 0 1 UNK O
( ( 0 0 2 O
Kd NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
D9 NNP 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
NAC NNP 0 1 UNK O
decreased VBD 1 1 1 O
significantly RB 0 0 1 O
without IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
density NN 0 1 1 O
( ( 0 0 2 O
Bmax NNP 0 0 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
cocaine NN 0 1 6 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
SST NNP 0 1 UNK O
and CC 0 0 12 O
RBC NNP 0 1 13 O
mice NN 1 1 UNK O
. . 0 0 12 O

Midazolam NNP 0 1 0 B-Drug
used VBD 1 1 12 O
at IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NNS 0 1 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
metamizol NN 0 1 UNK B-Drug
( ( 0 0 2 O
only RB 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick JJ 0 0 UNK O
test NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
indomethacin NN 0 1 14 B-Drug
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
The DT 0 0 2 O
geometric JJ 0 1 UNK O
mean NN 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
confidence NN 0 1 UNK O
interval NN 0 1 1 O
) ) 0 0 2 O
whole VBD 0 1 12 O
blood NN 0 1 6 O
sirolimus JJ 0 1 16 B-Drug
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
plasma JJ 0 1 14 O
concentration NN 0 1 1 O
time NN 0 1 12 O
- : 0 0 2 O
curve NN 0 1 13 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
ng NNS 0 1 13 O
x JJ 0 0 10 O
h JJ 0 1 16 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
and CC 0 0 12 O
maximum JJ 0 1 1 O
concentration NN 0 1 1 O
increased VBD 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
ng NNS 0 1 13 O
/ JJ 0 0 2 O
mL NN 0 1 14 O
with IN 0 0 12 O
diltiazem JJ 0 1 0 B-Drug
coadministration NN 0 1 UNK O
whereas IN 0 0 UNK O
the DT 0 0 12 O
mean JJ 0 1 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
decreased VBN 1 1 1 O
slightly RB 0 1 3 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
. . 0 0 12 O

[ VB 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
sandimmune NN 0 1 16 B-Brand
on IN 0 0 12 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
mixed JJ 0 1 3 O
- : 0 0 2 O
function NN 0 1 1 O
mono FW 0 1 13 O
- : 0 0 2 O
oxidases NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
microsomes VBZ 0 1 UNK O
] VBP 0 0 2 O
The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
immunodepressant JJ 0 0 UNK B-Group
- : 0 0 2 O
- : 0 0 2 O
the DT 0 0 12 O
drug NN 0 1 1 O
sandimmune SYM 0 1 16 B-Brand
- : 0 0 2 O
- : 0 0 2 O
on IN 0 0 12 O
hepatic JJ 0 1 14 O
microsomal JJ 0 1 UNK O
monooxygenase NN 0 1 UNK O
activities NNS 1 1 1 O
were VBD 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Additionally RB 0 0 1 O
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
circulating VBG 1 1 13 O
active JJ 0 1 1 O
metabolites NNS 1 1 UNK O
or CC 0 0 12 O
accumulation NN 0 1 1 O
during IN 0 0 12 O
chronic JJ 0 1 6 O
dosing NN 0 0 14 O
. . 0 0 12 O

The DT 0 0 2 O
response NN 0 1 1 O
of IN 0 0 12 O
moxifloxacin NN 0 1 16 B-Drug
and CC 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
after IN 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
drugs NNS 1 1 6 O
at IN 0 0 12 O
different JJ 0 1 1 O
conditions NNS 1 1 1 O
and CC 0 0 12 O
temperature NN 0 1 3 O
were VBD 1 0 12 O
noted VBN 1 0 1 O
using VBG 1 1 1 O
a DT 0 0 12 O
Shimadzu NNP 0 0 UNK O
HPLC NNP 0 1 UNK O
system NN 0 1 1 O
with IN 0 0 12 O
PDA NNP 0 1 13 O
detector NN 0 1 UNK O
. . 0 0 12 O

Animals NNS 0 1 UNK O
dosed VBD 1 1 14 O
with IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
did VBD 1 0 12 O
not RB 0 1 12 O
display VB 0 1 UNK O
the DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
hour NN 0 1 12 O
lag NN 0 1 13 O
phase NN 0 1 1 O
in IN 0 0 12 O
either DT 0 1 12 O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
erythro SYM 0 1 13 B-Drug_n
- : 0 0 2 O
fluorocitrate JJ 0 1 UNK I-Drug_n
synthesis NN 0 1 UNK O
or CC 0 0 12 O
in IN 0 0 12 O
citrate NN 0 1 14 O
and CC 0 0 12 O
fluoride JJ 0 1 16 O
accumulation NN 0 1 1 O
characteristic NN 0 1 UNK O
of IN 0 0 12 O
animals NNS 1 1 12 O
dosed VBN 1 1 14 O
with IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
. . 0 0 12 O

An DT 0 0 2 O
intravenous JJ 0 1 14 O
injection NN 0 1 3 O
of IN 0 0 12 O
perchlorate NN 0 1 UNK B-Drug_n
given VBN 1 1 12 O
later RB 0 1 12 O
also RB 0 0 12 O
produces VBZ 1 0 1 O
a DT 0 0 12 O
complete JJ 0 1 1 O
and CC 0 0 12 O
immediately RB 0 1 12 O
beginning VBG 1 1 12 O
depletion NN 0 1 1 O
of IN 0 0 12 O
pertechnetate NN 0 1 UNK B-Drug
already RB 0 0 12 O
accumulated VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
thyroid NN 0 1 6 O
within IN 0 0 1 O
a DT 0 0 12 O
period NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
min NNS 0 1 16 O
after IN 0 0 12 O
9m CD 0 0 UNK O
- : 0 0 2 O
TcO NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
injection NN 0 1 3 O
with IN 0 0 12 O
a DT 0 0 12 O
corresponding JJ 0 0 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
. . 0 0 12 O

Hypothermia NNP 0 1 UNK O
as IN 1 0 12 O
an DT 0 0 12 O
index NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
disulfiram NN 0 1 13 B-Drug
- : 0 0 2 O
ethanol JJ 0 1 1 B-Drug
reaction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
rat NN 0 1 13 O
. . 0 0 12 O

This DT 0 0 2 O
decrease NN 0 1 1 O
in IN 0 0 12 O
absorption NN 0 1 1 O
results NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
lower JJR 1 1 1 O
AUC NNP 0 1 UNK O
for IN 0 0 12 O
trovafloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
respectively RB 0 0 1 O
which WDT 0 0 12 O
could MD 0 0 12 O
cause VB 0 1 12 O
clinical JJ 0 1 6 O
failures NNS 1 1 UNK O
. . 0 0 12 O

A DT 0 0 2 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
coumaphos NN 0 1 UNK B-Drug_n
/ NNP 0 0 2 O
kg NN 0 1 18 O
of IN 0 0 12 O
body NN 0 1 3 O
weight NN 0 1 3 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
enzymes VBZ 0 1 14 O
or CC 0 0 12 O
the DT 0 0 12 O
antiprothrombinemic JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
bishydroxy JJ 0 0 UNK B-Drug
- : 0 0 2 O
coumarin NN 0 1 UNK I-Drug
in IN 0 0 12 O
wethers NNS 1 0 UNK O
. . 0 0 12 O

Keys NNS 0 0 UNK O
to TO 0 0 12 O
maximizing VBG 1 0 1 O
benefit NN 0 1 1 O
while IN 0 0 12 O
avoiding VBG 1 0 1 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Exposed VBN 0 1 UNK O
histidines NNS 1 1 UNK O
on IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A DT 0 0 2 I-Drug_n
are VBP 1 0 12 O
available JJ 0 1 1 O
for IN 0 0 12 O
zinc NN 0 1 14 B-Drug
chelation NN 0 1 UNK O
and CC 0 0 12 O
these DT 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
exploited VBN 1 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
novel JJ 0 1 13 O
purification NN 0 1 UNK O
protocol NN 0 1 1 O
for IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
using VBG 1 1 1 O
zinc SYM 0 1 14 B-Drug
- : 0 0 2 O
chelating VBG 1 1 13 O
chromatography NN 0 1 UNK O
. . 0 0 12 O

Each DT 0 0 2 O
group NN 0 1 12 O
took VBD 1 1 12 O
either RB 0 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
( ( 0 0 2 O
day NN 0 1 12 O
- : 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Cisapride NNP 0 1 0 B-Drug
was VBD 1 0 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
alone RB 0 1 12 O
or CC 0 0 12 O
with IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
. . 0 0 12 O

Systemic NNP 0 1 7 O
and CC 0 0 12 O
apparent JJ 0 1 1 O
oral JJ 0 1 6 O
midazolam NN 0 1 16 B-Drug
clearance NN 0 1 16 O
were VBD 1 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
vs. NN 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
ml NN 0 1 16 O
/ NNP 0 0 2 O
min NN 0 1 16 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
vs. NN 0 1 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
ml NN 0 1 16 O
/ NNP 0 0 2 O
min NN 0 1 16 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
respectively RB 0 0 1 O
lower JJR 1 1 1 O
in IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
than IN 0 0 12 O
in IN 0 0 12 O
matched JJ 0 1 1 O
tacrolimus NN 0 1 16 B-Drug
- : 0 0 2 O
treated JJ 0 1 1 O
patients NNS 1 1 6 O
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
dosage NN 0 1 0 O
adjustment NN 0 1 1 O
of IN 0 0 12 O
quetiapine NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
necessary JJ 0 0 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
given VBN 1 1 12 O
concurrently RB 0 0 1 O
and CC 0 0 12 O
that IN 0 0 12 O
caution NN 0 0 1 O
may MD 0 0 1 O
be VB 0 0 12 O
required VBN 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
or CC 0 0 12 O
induce VBP 0 1 6 O
cytochromes NNS 1 1 UNK O
particularly RB 0 0 1 O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
antimicrobial JJ 0 1 14 O
combinations NNS 1 1 1 O
of IN 0 0 12 O
GL NNP 0 1 UNK B-Drug_n
with IN 0 0 12 O
four CD 0 1 12 O
antibiotics NNS 1 1 6 B-Group
resulted VBD 1 1 1 O
in IN 0 0 12 O
additive JJ 0 1 16 O
effect NN 0 1 1 O
in IN 0 0 12 O
most JJS 0 0 12 O
instances NNS 1 1 UNK O
synergism NN 0 1 UNK O
in IN 0 0 12 O
two CD 0 1 12 O
instances NNS 1 1 UNK O
and CC 0 0 12 O
antagonism NN 0 1 UNK O
in IN 0 0 12 O
two CD 0 1 12 O
instances NNS 1 1 UNK O
. . 0 0 12 O

[ RB 0 0 2 O
Quantitative JJ 0 1 UNK O
approach NN 0 1 1 O
to TO 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
incisive JJ 0 0 UNK O
neuroleptics NNS 1 1 13 B-Group
by IN 0 0 12 O
therapeutic JJ 0 1 6 O
monitoring NN 0 1 1 O
] NN 0 0 2 O
; : 0 0 2 O
The DT 0 0 2 O
problems NNS 1 1 1 O
encountered VBD 1 1 12 O
during IN 0 0 12 O
the DT 0 0 12 O
longterm JJ 0 0 UNK O
treatment NN 0 1 6 O
of IN 0 0 12 O
psychotic JJ 0 1 6 O
patients NNS 1 1 6 O
with IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
are VBP 1 0 12 O
illustrated VBN 1 0 UNK O
by IN 0 0 12 O
six CD 0 1 12 O
typical JJ 0 1 1 O
case NN 0 1 12 O
reports NNS 1 1 1 O
. . 0 0 12 O

Lapatinib NNP 0 1 UNK B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
convert VB 0 0 1 O
Herceptin NNP 0 1 UNK B-Brand
- : 0 0 2 O
refractory NN 0 1 6 O
to TO 0 0 12 O
Herceptin NNP 0 1 UNK B-Brand
- : 0 0 2 O
sensitive JJ 0 1 1 O
tumors NNS 1 1 6 O
in IN 0 0 12 O
HER9 NNP 0 0 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
by IN 0 0 12 O
up IN 0 0 12 O
- : 0 0 2 O
regulation NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
cell NN 0 1 1 O
surface NN 0 1 3 O
expression NN 0 1 1 O
of IN 0 0 12 O
HER9 NNP 0 0 UNK O
. . 0 0 12 O

dmPGE9 NN 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
p.o NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O

Multiple JJ 0 1 2 O
myeloma NN 0 1 6 O
( ( 0 0 2 O
MM NNP 0 0 13 O
) ) 0 0 2 O
is VBZ 1 0 12 O
an DT 0 0 12 O
incurable JJ 0 0 UNK O
plasma NN 0 1 14 O
- : 0 0 2 O
cell NN 0 1 1 O
neoplasm NN 0 1 8 O
for IN 0 0 12 O
which WDT 0 0 12 O
most JJS 0 0 12 O
treatments NNS 1 1 6 O
involve VBP 0 0 1 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
agent NN 0 1 1 O
combined VBN 1 1 1 O
with IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
regulation NN 0 1 13 O
of IN 0 0 12 O
topoisomerases NNS 0 1 UNK O
is VBZ 1 0 12 O
no DT 0 0 12 O
doubt NN 0 1 UNK O
complex NN 0 1 1 O
and CC 0 0 12 O
multifaceted VBN 0 1 UNK O
and CC 0 0 12 O
is VBZ 1 0 12 O
probably RB 0 1 12 O
accomplished VBN 1 0 1 O
through IN 0 0 12 O
redundancy NN 0 1 UNK O
at IN 0 0 12 O
many JJ 0 0 12 O
control NN 0 1 1 O
levels NNS 1 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
. . 0 0 12 O

Note NN 0 1 2 O
: : 0 0 2 O
dissolution NN 0 0 UNK O
of IN 0 0 12 O
aerosol JJ 0 1 3 O
particles NNS 1 1 UNK O
of IN 0 0 12 O
budesonide NN 0 1 16 B-Drug
in IN 0 0 12 O
Survanta NNP 0 1 0 B-Brand
a DT 0 0 12 O
model NN 0 1 UNK O
lung NN 0 1 6 B-Group
surfactant NN 0 1 14 I-Group
. . 0 0 12 O

Acid NNP 0 1 2 O
- : 0 0 2 O
catalyzed JJ 0 0 UNK O
ethanolysis NN 0 0 UNK O
of IN 0 0 12 O
temazepam NN 0 1 16 B-Drug
in IN 0 0 12 O
anhydrous JJ 0 0 UNK O
and CC 0 0 12 O
aqueous JJ 0 1 16 O
ethanol JJ 0 1 1 B-Drug
solutions NNS 1 1 UNK O
. . 0 0 12 O

STUDY NNP 0 1 11 O
OBJECTIVE NNP 0 1 UNK O
: : 0 0 2 O
To TO 0 0 2 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
cardiovascular JJ 0 1 6 O
safety NN 0 1 1 O
of IN 0 0 12 O
cisapride NN 0 1 UNK B-Drug
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
men NNS 0 1 13 O
. . 0 0 12 O

At IN 0 0 2 O
the DT 0 0 12 O
same JJ 0 1 12 O
time NN 0 1 12 O
the DT 0 0 12 O
locomotor NN 0 0 UNK O
inhibitory JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
dexmedetomidine NN 0 1 16 B-Drug
was VBD 1 0 12 O
counteracted VBN 1 0 UNK O
by IN 0 0 12 O
ephedrine NN 0 1 13 B-Drug
. . 0 0 12 O

Transient NN 0 1 7 O
and CC 0 0 12 O
minor JJ 0 1 1 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
occurred VBD 1 1 1 O
with IN 0 0 12 O
similar JJ 0 1 1 O
frequency NN 0 1 1 O
on IN 0 0 12 O
placebo NN 0 1 13 O
and CC 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
treatments NNS 1 1 6 O
and CC 0 0 12 O
no DT 0 0 12 O
treatment NN 0 1 6 O
- : 0 0 2 O
related JJ 0 1 1 O
pattern NN 0 1 3 O
was VBD 1 0 12 O
apparent JJ 0 1 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
with IN 0 0 12 O
a DT 0 0 12 O
very RB 0 1 12 O
low JJ 0 1 1 O
cardiac JJ 0 1 6 O
capacity NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
advised VBN 1 0 12 O
to TO 0 0 12 O
refrain VB 0 0 12 O
from IN 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
erection NN 0 1 UNK O
disorder NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
growth NN 0 1 1 O
of IN 0 0 12 O
Pseudomonas NNP 0 1 14 O
aeruginosa VBP 0 0 14 O
particularly RB 0 0 1 O
serotype JJ 0 1 UNK O
O9 NNP 0 0 UNK O
in IN 0 0 12 O
pentazocine NN 0 1 UNK B-Drug
and CC 0 0 12 O
tripelennamine NN 0 1 UNK B-Drug

To TO 0 0 2 O
investigate VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
disease NN 0 1 6 O
states NNS 1 1 1 O
or CC 0 0 12 O
concomitant JJ 0 1 6 O
drug NN 0 1 1 O
administration NN 0 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
patient NN 0 1 6 O
's POS 0 1 12 O
response NN 0 1 1 O
to TO 0 0 12 O
etodolac VB 0 1 13 B-Drug
additional JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
in IN 0 0 12 O
special JJ 0 1 12 O
populations NNS 1 1 UNK O
. . 0 0 12 O

Two CD 0 1 2 O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
infected JJ 0 1 6 O
subjects NNS 1 1 UNK O
to TO 0 0 12 O
assess VB 0 1 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
and CC 0 0 12 O
dideoxyinosine NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
Deazaneplanocin NN 0 0 UNK I-Drug_n
A NNP 0 0 2 I-Drug_n
( ( 0 0 2 O
DZNep NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
one CD 0 1 12 O
of IN 0 0 12 O
S NNP 0 1 2 O
- : 0 0 2 O
adenosylhomocysteine NN 0 0 UNK O
( ( 0 0 2 O
AdoHcy NNP 0 1 UNK O
) ) 0 0 2 O
hydrolase NN 0 1 UNK O
inhibitors NNS 1 1 14 O
has VBZ 1 0 12 O
shown VBN 1 1 1 O
antitumor JJ 0 1 UNK O
activities NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
broad JJ 0 1 1 O
range NN 0 1 1 O
of IN 0 0 12 O
solid JJ 0 1 3 O
tumors NNS 1 1 6 O
and CC 0 0 12 O
acute JJ 0 1 6 O
myeloid NN 0 1 14 O
leukemia NN 0 1 6 O
. . 0 0 12 O

Recommendations NNS 0 1 2 O
were VBD 1 0 12 O
to TO 0 0 12 O
avoid VB 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
diffusible JJ 0 0 UNK O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
helminthic JJ 0 1 UNK I-Group
treatment NN 0 1 6 O
during IN 0 0 12 O
the DT 0 0 12 O
cure NN 0 1 6 O
and CC 0 0 12 O
to TO 0 0 12 O
improve VB 0 0 1 O
the DT 0 0 12 O
general JJ 0 1 1 O
conditions NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
before IN 0 1 12 O
the DT 0 0 12 O
cure NN 0 1 6 O
of IN 0 0 12 O
melarsoprol NN 0 1 UNK B-Drug
. . 0 0 12 O

Component NNP 0 1 UNK O
P9 NNP 0 1 UNK O
however RB 0 0 12 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
in IN 0 0 12 O
amplitude NN 0 1 1 O
. . 0 0 12 O

Heart NNP 0 1 2 O
rate NN 0 1 1 O
increased VBD 1 1 1 O
initially RB 0 1 12 O
and CC 0 0 12 O
returned VBN 1 1 12 O
to TO 0 0 12 O
normal JJ 0 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
after IN 0 0 12 O
ethanol JJ 0 1 1 B-Drug
challenge NN 0 1 12 O
. . 0 0 12 O

could MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
confirmed VBN 1 1 12 O
for IN 0 0 12 O
cloxacillin NN 0 1 UNK B-Drug
in IN 0 0 12 O
patients NNS 1 1 6 O
lacking VBG 1 1 13 O
kidney NN 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
superiority NN 0 1 UNK O
of IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
over IN 0 1 12 O
indinavir JJ 0 1 16 B-Drug
- : 0 0 2 O
based VBN 1 1 1 O
regimens NNS 1 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
comparative JJ 0 0 UNK O
data NNS 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
subset NN 0 1 UNK O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
high JJ 0 1 1 O
viral JJ 0 1 6 O
loads NNS 1 1 13 O
. . 0 0 12 O

Nephrotoxicity NNP 0 1 UNK O
frequently RB 0 1 1 O
limits VBZ 1 1 1 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
to TO 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ NNP 0 0 2 O
m9 NN 0 1 UNK O
per IN 0 0 1 O
injection NN 0 1 3 O
. . 0 0 12 O

However RB 0 0 1 O
when WRB 0 0 12 O
addiction NN 0 1 12 O
is VBZ 1 0 12 O
defined VBN 1 1 1 O
as IN 1 0 12 O
compulsion NN 0 1 UNK O
loss NN 0 1 1 O
of IN 0 0 12 O
control NN 0 1 1 O
and CC 0 0 12 O
continued VBN 1 1 12 O
use NN 0 1 1 O
in IN 0 0 12 O
spite NN 0 0 UNK O
of IN 0 0 12 O
adverse JJ 0 0 1 O
consequences NNS 1 1 UNK O
cocaine VBP 0 1 6 B-Drug
drug NN 0 1 1 O
hunger NN 0 1 12 O
can MD 0 0 12 O
be VB 0 0 12 O
seen VBN 1 1 12 O
as IN 1 0 12 O
an DT 0 0 12 O
agent NN 0 1 1 O
of IN 0 0 12 O
addictive JJ 0 1 UNK O
disease NN 0 1 6 O
. . 0 0 12 O

During IN 0 0 2 O
amiodarone JJ 0 1 0 B-Drug
administration NN 0 1 1 O
systemic JJ 0 1 6 O
clearance NN 0 1 16 O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
was VBD 1 0 12 O
reduced VBN 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
ml NN 0 1 16 O
/ NN 0 0 2 O
min NN 0 1 16 O
( ( 0 0 2 O
mean JJ 0 1 12 O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
standard JJ 0 1 1 O
deviation NN 0 1 1 O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
ml NN 0 1 16 O
/ NN 0 0 2 O
min NN 0 1 16 O
( ( 0 0 2 O
p NN 0 1 2 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

OBJECTIVE NN 0 1 UNK O
: : 0 0 2 O
Our PRP$ 0 0 2 O
objective NN 0 1 13 O
was VBD 1 0 12 O
to TO 0 0 12 O
examine VB 0 0 1 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
and CC 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
to TO 0 0 12 O
confirm VB 0 1 1 O
that DT 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
inhibits VBZ 1 1 UNK O
CYP9C9 NNP 0 0 UNK O
. . 0 0 12 O

Tumor NNP 0 1 7 O
phenotype NN 0 1 UNK O
and CC 0 0 12 O
susceptibility NN 0 1 6 O
to TO 0 0 12 O
progression NN 0 1 1 O
as IN 1 0 12 O
an DT 0 0 12 O
expression NN 0 1 1 O
of IN 0 0 12 O
subpopulations NNS 1 1 13 O
of IN 0 0 12 O
initiated JJ 0 1 1 O
murine NN 0 1 13 O
cells NNS 1 1 6 O
. . 0 0 12 O

We PRP 0 0 12 O
concluded VBD 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
combined JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
dexmedetomidine NN 0 1 16 B-Drug
with IN 0 0 12 O
ephedrine NN 0 1 13 B-Drug
may MD 0 0 1 O
have VB 0 0 12 O
beneficial JJ 0 0 UNK O
effects NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
pain NN 0 1 6 O
without IN 0 0 12 O
causing VBG 1 1 1 O
sedation NN 0 1 6 O
which WDT 0 0 12 O
limits VBZ 1 1 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
dexmedetomidine NN 0 1 16 B-Drug
as IN 1 0 12 O
an DT 0 0 12 O
analgesic JJ 0 1 13 B-Group
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Physostigmine NNP 0 1 UNK B-Drug
pretreatment NN 0 1 UNK O
augmented VBD 1 1 1 O
the DT 0 0 12 O
depressant JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
early JJ 0 1 12 O
components NNS 1 1 1 O
P9 NNP 0 1 UNK O
and CC 0 0 12 O
N9 NNP 0 0 UNK O
while IN 0 0 12 O
attenuating VBG 1 1 UNK O
alcohol NN 0 1 1 B-Drug
's POS 0 1 12 O
influence NN 0 0 UNK O
on IN 0 0 12 O
components NNS 1 1 1 O
P9 NNP 0 1 UNK O
and CC 0 0 12 O
P9 NNP 0 1 UNK O
. . 0 0 12 O

At IN 0 0 2 O
low JJ 0 1 1 O
- : 0 0 2 O
levels NNS 1 1 1 O
of IN 0 0 12 O
exposure NN 0 1 1 O
the DT 0 0 12 O
toxicokinetic JJ 0 1 UNK O
interferences NNS 1 1 UNK O
between IN 0 0 12 O
solvents NNS 1 1 13 O
have VBP 0 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
man NN 0 1 12 O
and CC 0 0 12 O
presumably RB 0 0 12 O
a DT 0 0 12 O
threshold JJ 0 1 1 O
limit NN 0 1 1 O
exists NNS 0 1 UNK O
. . 0 0 12 O

Further RB 0 1 2 O
these DT 0 0 12 O
results NNS 1 1 1 O
confirm VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
diabetic JJ 0 1 6 O
Chinese NNP 0 1 UNK O
hamster NN 0 1 UNK O
's POS 0 1 12 O
alpha NN 0 1 1 O
and CC 0 0 12 O
beta NN 0 1 16 O
cells NNS 1 1 6 O
respond VBP 0 0 1 O
normally RB 0 0 1 O
to TO 0 0 12 O
theophylline VB 0 1 16 B-Drug
but CC 0 0 12 O
are VBP 1 0 12 O
relatively RB 0 0 1 O
insensitive JJ 0 1 UNK O
to TO 0 0 12 O
glucose VB 0 1 14 B-Drug
. . 0 0 12 O

Precocene NNP 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
induced VBD 1 1 6 O
hepatocellular JJ 0 1 8 O
necrosis NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
and CC 0 0 12 O
time NN 0 1 12 O
- : 0 0 2 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

Animals NNS 0 1 UNK O
studies NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
various JJ 0 1 1 O
dual JJ 0 1 3 O
- : 0 0 2 O
memory NN 0 1 1 O
theories NNS 1 1 UNK O
have VBP 0 0 12 O
been VBN 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
mainly RB 0 0 1 O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
hippocampal JJ 0 1 8 O
system NN 0 1 1 O
function NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
reluctance NN 0 1 UNK O
to TO 0 0 12 O
treat VB 0 1 12 O
aggressively RB 0 0 1 O
is VBZ 1 0 12 O
understandable JJ 0 0 UNK O
because IN 0 0 12 O
the DT 0 0 12 O
geriatric JJ 0 1 UNK O
population NN 0 1 13 O
is VBZ 1 0 12 O
susceptible JJ 0 1 1 O
to TO 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Secondary JJ 0 1 2 O
prevention NN 0 1 1 O
of IN 0 0 12 O
atherosclerotic JJ 0 1 8 O
risk NN 0 1 1 O
factors NNS 1 1 1 O
is VBZ 1 0 12 O
also RB 0 0 12 O
important JJ 0 1 1 O
: : 0 0 2 O
regulation NN 0 1 13 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
and CC 0 0 12 O
blood NN 0 1 6 O
sugar NN 0 1 3 O
level NN 0 1 1 O
hyperlipidaemia NN 0 1 UNK O
and CC 0 0 12 O
obesity NN 0 1 6 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
a DT 0 0 12 O
change NN 0 1 1 O
of IN 0 0 12 O
lifestyle NN 0 1 12 O
( ( 0 0 2 O
giving VBG 1 1 12 O
up RP 0 0 12 O
smoking VBG 1 1 12 O
adapting NN 0 1 UNK O
of IN 0 0 12 O
diet JJ 0 1 6 O
and CC 0 0 12 O
more RBR 0 1 12 O
physical JJ 0 1 1 O
exertion NN 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

Suppression NN 0 1 UNK O
by IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
of IN 0 0 12 O
bombesin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
enhanced JJ 0 1 1 O
peritoneal JJ 0 1 8 O
metastasis NN 0 1 6 O
of IN 0 0 12 O
intestinal JJ 0 1 13 O
adenocarcinomas NN 1 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
azoxymethane NN 0 1 UNK B-Drug_n
in IN 0 0 12 O
wistar NN 0 1 UNK O
rats NNS 1 1 UNK O
. . 0 0 12 O

Based VBN 0 1 2 O
on IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
studies NNS 1 1 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
concluded VBN 1 1 1 O
that IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
safely RB 0 0 UNK O
coadministered VBN 0 0 UNK O
with IN 0 0 12 O
both DT 0 0 12 O
zidovudine NN 0 1 13 B-Drug
and CC 0 0 12 O
dideoxyinosine NN 0 1 UNK B-Drug
. . 0 0 12 O

Physostigmine NNP 0 1 UNK B-Drug
briefly NN 0 0 12 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
amplitude NN 0 1 1 O
of IN 0 0 12 O
most JJS 0 0 12 O
components NNS 1 1 1 O
including VBG 1 1 1 O
P9 NNP 0 1 UNK O
. . 0 0 12 O

After IN 0 0 2 O
prolonged JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
the DT 0 0 12 O
displacing VBG 1 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
cerulein NN 0 1 UNK B-Drug_n
an DT 0 0 12 O
analog NN 0 1 UNK O
of IN 0 0 12 O
cholecystokinin NN 0 1 UNK O
octapeptide NN 0 0 UNK O
was VBD 1 0 12 O
replaced VBN 1 1 12 O
by IN 0 0 12 O
the DT 0 0 12 O
stimulant JJ 0 1 13 O
action NN 0 1 13 O
on IN 0 0 12 O
9H CD 0 0 UNK B-Drug_n
- : 0 0 2 O
spiroperidol NN 0 1 UNK I-Drug_n
binding NN 0 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
previously RB 0 0 1 O
reported VBN 1 1 1 O
that IN 0 0 12 O
lapatinib NN 0 1 13 B-Drug
combined VBN 1 1 1 O
with IN 0 0 12 O
Herceptin NNP 0 1 UNK B-Brand
improved VBD 1 1 1 O
the DT 0 0 12 O
progression NN 0 1 1 O
- : 0 0 2 O
free JJ 0 1 12 O
survival NN 0 1 1 O
rate NN 0 1 1 O
compared VBN 1 1 1 O
with IN 0 0 12 O
lapatinib JJ 0 1 13 B-Drug
alone RB 0 1 12 O
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
Herceptin NNP 0 1 UNK B-Brand
- : 0 0 2 O
refractory NN 0 1 6 O
HER9 NNP 0 0 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
metastatic JJ 0 1 6 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
is VBZ 1 0 12 O
purported VBN 1 0 UNK O
to TO 0 0 12 O
be VB 0 0 12 O
an DT 0 0 12 O
antiproliferative JJ 0 0 UNK O
effect NN 0 1 1 O
relating VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
synergism NN 0 1 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
two CD 0 1 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

Interaction NN 0 1 2 O
of IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
and CC 0 0 12 O
halothane NN 0 1 13 B-Drug
in IN 0 0 12 O
rats NNS 1 1 UNK O
. . 0 0 12 O

it PRP 0 0 12 O
was VBD 1 0 12 O
independent JJ 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
influence NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
nueronal JJ 0 0 UNK O
cell NN 0 1 1 O
body NN 0 1 3 O
and CC 0 0 12 O
of IN 0 0 12 O
protein JJ 0 1 14 O
synthesis NN 0 1 UNK O
within IN 0 0 1 O
the DT 0 0 12 O
axon NN 0 1 UNK O
. . 0 0 12 O

Haemodynamic NNP 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
glucose NN 0 1 14 B-Drug
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
were VBD 1 0 12 O
additive JJ 0 1 16 O
when WRB 0 0 12 O
somatostatin NN 0 1 14 B-Drug
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
but CC 0 0 12 O
not RB 0 1 12 O
under IN 0 0 12 O
basal NN 0 1 6 O
conditions NNS 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
if IN 0 0 12 O
confirmed VBN 1 1 12 O
in IN 0 0 12 O
- : 0 0 2 O
vivo NN 0 1 13 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
suitable JJ 0 1 1 O
chemosensitizer NN 0 1 UNK O
for IN 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
or CC 0 0 12 O
with IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
for IN 0 0 12 O
other JJ 0 0 12 O
cancers NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
in IN 0 0 12 O
plasma NN 0 1 14 O
and CC 0 0 12 O
brain NN 0 1 6 O
was VBD 1 0 12 O
longer RBR 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
halothane NN 0 1 13 B-Drug
than IN 0 0 12 O
when WRB 0 0 12 O
ketamine NN 0 1 13 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Slow NNP 0 1 UNK O
chylomicron NN 0 1 UNK O
intravascular NN 0 1 8 O
catabolism NN 0 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
disease NN 0 1 6 O
and CC 0 0 12 O
screening NN 0 1 1 O
for IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
can MD 0 0 12 O
speed VB 0 1 1 O
- : 0 0 2 O
up RP 0 0 12 O
this DT 0 0 12 O
process NN 0 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
important JJ 0 1 1 O
. . 0 0 12 O

Sunitinib NNP 0 1 UNK B-Drug
as IN 1 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
agent NN 0 1 1 O
exhibits NNS 1 1 UNK O
anti VBP 0 0 3 O
- : 0 0 2 O
proliferative JJ 0 1 13 O
effects NNS 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
in IN 0 0 12 O
NSCLC NNP 0 1 UNK O
cell NN 0 1 1 O
lines NNS 1 1 3 O
with IN 0 0 12 O
EGFR NNP 0 1 UNK O
T9M NNP 0 0 UNK O
and CC 0 0 12 O
K NNP 0 1 2 O
- : 0 0 2 O
ras NN 1 1 UNK O
mutations NNS 1 1 13 O
but CC 0 0 12 O
the DT 0 0 12 O
sequential JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
docetaxel NN 0 1 13 B-Drug
followed VBN 1 1 12 O
by IN 0 0 12 O
sunitinib NN 0 1 13 B-Drug
is VBZ 1 0 12 O
superior JJ 0 1 1 O
to TO 0 0 12 O
sunitinib VB 0 1 13 B-Drug
followed VBN 1 1 12 O
by IN 0 0 12 O
docetaxel NN 0 1 13 B-Drug
and CC 0 0 12 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
. . 0 0 12 O

However RB 0 0 1 O
modification NN 0 1 1 O
abolished VBD 1 0 UNK O
the DT 0 0 12 O
'cold NNP 0 1 UNK O
' POS 0 0 2 O
binding NN 0 1 1 O
of IN 0 0 12 O
toxin NN 0 1 14 O
to TO 0 0 12 O
bovine VB 0 1 13 O
thyroglobulin NN 0 1 14 O
in IN 0 0 12 O
an DT 0 0 12 O
ELISA NNP 0 1 UNK O
and CC 0 0 12 O
reduced VBN 1 1 1 O
ligand NN 0 1 UNK O
binding VBG 1 1 1 O
activity NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
rabbit NN 0 1 16 O
erythrocyte JJ 0 1 14 O
haemagglutination NN 0 1 UNK O
assay NN 0 1 14 O
. . 0 0 12 O

Thiolated VBN 0 0 UNK B-Drug_n
carboxymethylcellulose NN 0 1 13 I-Drug_n
: : 0 0 2 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
evaluation NN 0 1 1 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
permeation NN 0 1 UNK O
enhancing VBG 1 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
peptide NN 0 1 13 O
drugs NNS 1 1 6 O
. . 0 0 12 O

To TO 0 0 2 O
investigate VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antimicrobial JJ 0 1 14 O
combinations NNS 1 1 1 O
of IN 0 0 12 O
GL NNP 0 1 UNK B-Drug_n
with IN 0 0 12 O
four CD 0 1 12 O
kinds NNS 1 1 UNK O
of IN 0 0 12 O
antibiotics NNS 1 1 6 B-Group
( ( 0 0 2 O
ampicillin JJ 0 1 0 B-Drug
cefazolin NN 0 1 14 B-Drug
oxytetracycline NN 0 1 UNK B-Drug
and CC 0 0 12 O
chloramphenicol NN 0 1 14 B-Drug
) ) 0 0 2 O
the DT 0 0 12 O
fractional JJ 0 1 1 O
inhibitory NN 0 1 UNK O
concentration NN 0 1 1 O
index NN 0 1 1 O
( ( 0 0 2 O
FICI NNP 0 0 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
checkerboard NNS 0 0 UNK O
assay VBP 0 1 14 O
for IN 0 0 12 O
each DT 0 0 12 O
strain NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
serum JJ 0 1 14 O
concentration NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
increased VBN 1 1 1 O
dramatically RB 0 0 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
microg NNS 0 0 UNK O
/ JJ 0 0 2 O
mL NN 0 1 14 O
when WRB 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
was VBD 1 0 12 O
coadministered VBN 0 0 UNK O
although IN 0 0 12 O
the DT 0 0 12 O
daily JJ 0 1 12 O
dosage NN 0 1 0 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 B-Drug
had VBD 1 0 12 O
not RB 0 1 12 O
changed VBN 1 1 12 O
. . 0 0 12 O

Recovery NN 0 1 2 O
of IN 0 0 12 O
hoof NN 0 1 UNK O
twitch NN 0 1 3 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
took VBD 1 1 12 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
min NN 0 1 16 O
for IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
min NN 0 1 16 O
for IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
plus CC 0 1 16 O
gentamycin NN 0 1 14 B-Drug
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Buforin NNP 0 0 UNK B-Drug_n
II NNP 0 0 2 I-Drug_n
showed VBD 1 1 12 O
moderate JJ 0 1 1 O
activity NN 0 1 1 O
which WDT 0 0 12 O
increased VBD 1 1 1 O
with IN 0 0 12 O
increasing VBG 1 1 1 O
concentration NN 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
suppression NN 0 1 1 O
of IN 0 0 12 O
growth NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
microM NN 0 0 UNK O
. . 0 0 12 O

At IN 0 0 2 O
a DT 0 0 12 O
low JJ 0 1 1 O
cocaine NN 0 1 6 B-Drug
dose NN 0 1 6 O
and CC 0 0 12 O
long JJ 0 1 12 O
withdrawal NN 0 1 1 O
period NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
twice RB 0 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
withdrawal NN 0 1 1 O
) ) 0 0 2 O
the DT 0 0 12 O
LST NNP 0 1 UNK O
mice NN 1 1 UNK O
showed VBD 1 1 12 O
tolerance NN 0 1 1 O
development NN 0 1 1 O
. . 0 0 12 O

By IN 0 0 2 O
this DT 0 0 12 O
procedure NN 0 1 1 O
it PRP 0 0 12 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
that IN 0 0 12 O
arsenate NN 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
rapidly RB 0 1 1 O
and CC 0 0 12 O
essentially RB 0 0 1 O
completely RB 0 1 12 O
absorbed VBN 1 0 3 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
from IN 0 0 12 O
the DT 0 0 12 O
lumen NNS 0 1 8 O
at IN 0 0 12 O
As NNP 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
concentrations VBZ 0 1 13 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mM NNS 0 0 UNK O
declining VBG 1 1 1 O
to TO 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
absorption NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
incubations NNS 1 0 UNK O
were VBD 1 0 12 O
performed VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
and CC 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
non NN 0 1 1 O
- : 0 0 2 O
specific JJ 0 1 1 O
CYP NNP 0 1 UNK O
inhibitor NN 0 1 14 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
aminobenzotriazole NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
ABT NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
isoform VB 0 1 UNK O
- : 0 0 2 O
specific JJ 0 1 1 O
inhibitors NNS 1 1 14 O
. . 0 0 12 O

The DT 0 0 2 O
harmonic JJ 0 0 UNK O
mean NN 0 1 12 O
elimination NN 0 1 UNK O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
was VBD 1 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
for IN 0 0 12 O
rofecoxib NN 0 1 16 B-Drug
+ NNP 0 0 2 O
digoxin NN 0 1 14 B-Drug
and CC 0 0 12 O
placebo NN 0 1 13 O
+ NNP 0 0 2 O
digoxin NN 0 1 14 B-Drug
treatments NNS 1 1 6 O
respectively RB 0 0 1 O
. . 0 0 12 O

dose JJ 0 1 6 O
- : 0 0 2 O
dependently RB 0 0 UNK O
increased VBD 1 1 1 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
defecation NN 0 1 13 O
episodes NNS 1 1 12 O
and CC 0 0 12 O
induced VBD 1 1 6 O
a DT 0 0 12 O
soft JJ 0 1 3 O
and CC 0 0 12 O
watery JJ 0 1 UNK O
stool NN 0 1 3 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
rats NNS 1 1 UNK O
. . 0 0 12 O

Increased VBN 0 1 7 O
stability NN 0 1 1 O
of IN 0 0 12 O
nucleophosmin JJ 0 1 UNK O
/ NNP 0 0 2 O
B9 NNP 0 0 UNK O
in IN 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
apoptotic JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
ras NNS 1 1 UNK O
during IN 0 0 12 O
serum JJ 0 1 14 O
deprivation NN 0 1 13 O
. . 0 0 12 O

CONCLUSION NN 0 1 11 O
: : 0 0 2 O
These DT 0 0 1 O
findings NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
inhibits NNS 0 1 UNK O
cancer NN 0 1 6 O
metastasis NN 0 1 6 O
through IN 0 0 12 O
actions NNS 1 1 UNK O
that WDT 0 0 12 O
do VBP 0 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
growth NN 0 1 1 O
of IN 0 0 12 O
intestinal JJ 0 1 13 O
cancers NNS 1 1 6 O
. . 0 0 12 O

When WRB 0 0 12 O
the DT 0 0 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
picrotoxin NN 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
minimized VBN 1 0 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NNS 0 1 18 O
such JJ 0 0 1 O
an DT 0 0 12 O
effect NN 0 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
( ( 0 0 2 O
carotid JJ 0 1 8 O
cannulation NN 0 1 13 O
) ) 0 0 2 O
decreased VBD 1 1 1 O
along IN 0 0 12 O
with IN 0 0 12 O
the DT 0 0 12 O
core NN 0 1 1 O
temperature NN 0 1 3 O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
other JJ 0 0 12 O
hand NN 0 1 12 O
intrathecal JJ 0 1 16 O
naloxone NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
) ) 0 0 2 O
had VBD 1 0 12 O
only RB 0 1 12 O
a DT 0 0 12 O
very RB 0 1 12 O
weak JJ 0 1 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
inhibition NN 0 1 13 O
induced VBN 1 1 6 O
by IN 0 0 12 O
intraventricular JJ 0 1 8 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
) ) 0 0 2 O
. . 0 0 12 O

Many JJ 0 0 UNK O
people NNS 0 1 12 O
use VBP 0 1 1 O
both DT 0 0 12 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
nicotine NN 0 1 6 B-Drug
( ( 0 0 2 O
i.e. JJ 0 1 1 O
cigarettes NNS 1 1 3 O
and CC 0 0 12 O
other JJ 0 0 12 O
tobacco NN 0 1 1 O
products NNS 1 1 1 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
high JJ 0 1 1 O
acquisition NN 0 1 UNK O
cost NN 0 1 UNK O
of IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
offset VBN 0 1 UNK O
by IN 0 0 12 O
reductions NNS 1 1 1 O
in IN 0 0 12 O
other JJ 0 0 12 O
treatment NN 0 1 6 O
costs NNS 1 1 UNK O
( ( 0 0 2 O
inpatient JJ 0 1 6 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
outpatient JJ 0 1 6 O
services NNS 1 1 1 O
) ) 0 0 2 O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
. . 0 0 12 O

Thus RB 0 0 1 O
certain JJ 0 1 1 O
factors NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
reinforcing VBG 1 0 UNK O
drug NN 0 1 1 O
effects NNS 1 1 1 O
conditioning VBG 1 1 13 O
processes NNS 1 1 1 O
automatic JJ 0 1 13 O
behavior NN 0 1 1 O
and CC 0 0 12 O
stress NN 0 1 1 O
may MD 0 0 1 O
influence VB 0 0 UNK O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
dependence NN 0 1 1 O
on IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Continued JJ 0 1 2 O
admistration NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
to TO 0 0 12 O
maintain VB 0 1 1 O
barpress JJ 0 0 UNK O
response NN 0 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
strain NN 0 1 3 O
of IN 0 0 12 O
dogs NNS 1 1 UNK O
. . 0 0 12 O

Effects NNS 0 1 UNK O
of IN 0 0 12 O
xanthine JJ 0 1 UNK B-Group
derivatives NNS 1 1 13 I-Group
in IN 0 0 12 O
a DT 0 0 12 O
light JJ 0 1 3 O
/ NN 0 0 2 O
dark JJ 0 1 3 O
test NN 0 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
contribution NN 0 1 1 O
of IN 0 0 12 O
adenosine JJ 0 1 14 O
receptors NNS 1 1 13 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
postulated VBN 1 0 UNK O
that IN 0 0 12 O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
observed JJ 0 1 1 O
training NN 0 1 1 O
- : 0 0 2 O
induced JJ 0 1 6 O
neurobiological JJ 0 1 UNK O
alterations NNS 1 1 1 O
might MD 0 0 12 O
reflect VB 0 1 1 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
two CD 0 1 12 O
( ( 0 0 2 O
or CC 0 0 12 O
more JJR 0 1 12 O
) ) 0 0 2 O
competing VBG 1 0 UNK O
memory JJ 0 1 1 O
systems NNS 1 1 1 O
at IN 0 0 12 O
the DT 0 0 12 O
hippocampal JJ 0 1 8 O
level NN 0 1 1 O
. . 0 0 12 O

Loperamide NNP 0 1 UNK B-Drug
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
s.c NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O

Only RB 0 1 2 O
with IN 0 0 12 O
knowledge NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
can MD 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
regimen NNS 0 1 6 O
be VB 0 0 12 O
altered VBN 1 1 1 O
so RB 0 1 12 O
as IN 1 0 12 O
to TO 0 0 12 O
provide VB 0 1 1 O
therapeutic JJ 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
necessary JJ 0 0 1 O
drugs NNS 1 1 6 O
while IN 0 0 12 O
avoiding VBG 1 0 1 O
toxicity NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
total JJ 0 1 1 O
9 CD 0 0 2 O
9 CD 0 0 2 O
warfarin NN 0 1 14 B-Drug
users NNS 1 1 UNK O
contributed VBD 1 1 1 O
9 CD 0 0 2 O
9 CD 0 0 2 O
person NN 0 1 12 O
- : 0 0 2 O
years NNS 1 1 12 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
use NN 0 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
recommended VBN 1 1 1 O
that IN 0 0 12 O
GABA NNP 0 1 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
drugs NNS 1 1 6 O
be VB 0 0 12 O
included VBN 1 1 1 O
into IN 0 0 12 O
a DT 0 0 12 O
complex NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
measures NNS 1 1 1 O
for IN 0 0 12 O
edema NN 0 1 6 O
. . 0 0 12 O

Pretreatment NN 0 1 UNK O
with IN 0 0 12 O
atropine JJ 0 1 14 B-Drug
likewise NN 0 0 1 O
further RBR 1 1 1 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
amplitudes NNS 1 1 UNK O
of IN 0 0 12 O
components NNS 1 1 1 O
P9 NNP 0 1 UNK O
and CC 0 0 12 O
N9 NNP 0 0 UNK O
and CC 0 0 12 O
produced VBD 1 0 1 O
a DT 0 0 12 O
similar JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
component NN 0 1 1 O
N9 NNP 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
identified VBN 1 1 1 O
cyclosporine NN 0 1 14 B-Drug
and CC 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
as IN 1 0 12 O
CYP9A NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
. . 0 0 12 O

[ JJ 0 0 2 O
Efficacy NNP 0 1 UNK O
of IN 0 0 12 O
fixed JJ 0 1 1 O
combination NN 0 1 1 O
amlodipine NN 0 1 0 B-Drug
/ NNP 0 0 2 O
valsartan NN 0 1 0 B-Drug
in IN 0 0 12 O
hospitalized JJ 0 1 6 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hypertensive JJ 0 1 6 O
disease NN 0 1 6 O
] NN 0 0 2 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
possess VB 0 1 UNK O
both DT 0 0 12 O
anticancer NN 0 0 UNK O
and CC 0 0 12 O
antibacterial JJ 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

Compared VBN 0 1 2 O
with IN 0 0 12 O
lean JJ 0 0 13 O
rats NNS 1 1 UNK O
arteries NNS 1 1 6 O
from IN 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
showed VBD 1 1 12 O
significant JJ 0 1 1 O
( ( 0 0 2 O
P NNP 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
endothelial JJ 0 1 13 O
dysfunction NN 0 1 6 O
as IN 1 0 12 O
indicated VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
( ( 0 0 2 O
> JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
in IN 0 0 12 O
maximal JJ 0 1 1 O
acetylcholine NN 0 1 14 O
- : 0 0 2 O
induced JJ 0 1 6 O
vasorelaxation NN 0 1 UNK O
. . 0 0 12 O

Miracidia NNP 0 0 UNK O
demonstrated VBD 1 0 1 O
a DT 0 0 12 O
rapid JJ 0 1 1 O
avoidance NN 0 1 1 O
behaviour NN 0 1 UNK O
when WRB 0 0 12 O
briefly NN 0 0 12 O
exposed VBD 1 1 3 O
to TO 0 0 12 O
heavy JJ 0 1 3 O
metals NNS 1 1 13 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
difference NN 0 1 UNK O
( ( 0 0 2 O
p JJ 0 1 2 O
> NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
in IN 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
vs. IN 0 1 2 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
Cmax NNP 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
vs. IN 0 1 2 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
tmax NN 0 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
+ NN 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
vs. IN 0 1 2 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
levofloxacin NN 0 1 0 B-Drug
versus NN 0 0 1 O
levofloxacin NN 0 1 0 B-Drug
/ NNP 0 0 2 O
oxycodone NN 0 1 0 B-Drug
regimens NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
conjugates NNS 1 1 UNK O
so RB 0 1 12 O
formed VBD 1 1 UNK O
often RB 0 1 12 O
appear JJ 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
urine NN 0 1 6 O
as IN 1 0 12 O
mercapturic JJ 0 0 UNK O
acids NNS 1 1 14 O
or CC 0 0 12 O
other JJ 0 0 12 O
thioether NN 0 1 UNK O
products NNS 1 1 1 O
. . 0 0 12 O

was VBD 1 0 12 O
evaluated VBN 1 1 1 O
as IN 1 0 12 O
a DT 0 0 12 O
possible JJ 0 1 1 O
explanation NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
association NN 0 1 1 O
of IN 0 0 12 O
deep JJ 0 1 3 O
- : 0 0 2 O
seated VBN 1 1 3 O
infection NN 0 1 6 O
with IN 0 0 12 O
this DT 0 0 12 O
organism NN 0 1 1 O
and CC 0 0 12 O
abuse NN 0 1 12 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Whether NNP 0 0 12 O
abnormal JJ 0 1 6 O
topoisomerase NN 0 1 UNK O
quantity NN 0 1 1 O
and CC 0 0 12 O
specific JJ 0 1 1 O
activity NN 0 1 1 O
are VBP 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
resistance NN 0 1 1 O
or CC 0 0 12 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
topoisomerase VB 0 1 UNK O
- : 0 0 2 O
targeted VBN 1 1 UNK O
chemotherapy NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
clinic NN 0 1 6 O
is VBZ 1 0 12 O
now RB 0 1 12 O
being VBG 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
but CC 0 0 12 O
returned VBN 1 1 12 O
to TO 0 0 12 O
normal JJ 0 1 1 O
levels NNS 1 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
nerves NNS 1 1 6 O
were VBD 1 0 12 O
rewarmed VBN 0 0 15 O
. . 0 0 12 O

We PRP 0 0 12 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
MCF NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
nM NNS 0 1 UNK O
9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
OH NNP 0 1 UNK I-Drug
) ) 0 0 2 O
9D9 CD 0 0 UNK I-Drug
exhibit NN 0 1 1 O
characteristic JJ 0 1 UNK O
apoptotic JJ 0 1 UNK O
morphology NN 0 1 6 O
( ( 0 0 2 O
pyknotic JJ 0 1 UNK O
nuclei NN 1 1 UNK O
chromatin NN 0 1 UNK O
and CC 0 0 12 O
cytoplasmic JJ 0 1 13 O
condensation NN 0 1 UNK O
nuclear JJ 0 1 1 O
matrix NN 0 1 1 O
protein NN 0 1 14 O
reorganization NN 0 1 UNK O
) ) 0 0 2 O
within IN 0 0 1 O
9 CD 0 0 2 O
h NN 0 1 16 O
. . 0 0 12 O

Higher JJR 0 1 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
dexamethasone NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
or CC 0 0 12 O
retinyl JJ 0 0 UNK B-Drug
acetate NN 0 1 14 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
X RB 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
mitogenic JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
EGF NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

CONCLUSION NN 0 1 11 O
: : 0 0 2 O
Fluvoxamine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
a DT 0 0 12 O
moderate JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9C9 NNP 0 0 UNK O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

BACKGROUND NN 0 1 UNK O
: : 0 0 2 O
Since IN 0 1 2 O
its PRP$ 1 0 12 O
approval NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
US NNP 0 0 2 O
Food NNP 0 1 2 O
and CC 0 0 12 O
Drug NNP 0 1 2 O
Administration NNP 0 1 UNK O
in IN 0 0 12 O
March NNP 0 1 2 O
9 CD 0 0 2 O
sildenafil NN 0 1 16 B-Drug
citrate NN 0 1 14 I-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
by IN 0 0 12 O
millions NNS 1 1 UNK O
of IN 0 0 12 O
men NNS 0 1 13 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
erectile JJ 0 1 13 O
dysfunction NN 0 1 6 O
. . 0 0 12 O

Determinants NNS 0 1 UNK O
of IN 0 0 12 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
induced JJ 0 1 6 O
apoptosis NN 0 1 UNK O
in IN 0 0 12 O
multiple JJ 0 1 1 O
myeloma NN 0 1 6 O
cells NNS 1 1 6 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
mice NN 1 1 UNK O
caused VBD 1 1 1 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
curve NN 0 1 13 O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
but CC 0 0 12 O
the DT 0 0 12 O
combination NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
effective JJ 0 1 1 O
in IN 0 0 12 O
reducing VBG 1 1 1 O
human JJ 0 1 1 O
A9 NNP 0 1 UNK O
melanoma NN 0 1 6 O
tumors NNS 1 1 6 O
in IN 0 0 12 O
vivo NN 0 1 13 O
. . 0 0 12 O

Analgesic JJ 0 1 7 O
effects NNS 1 1 1 O
of IN 0 0 12 O
antihistaminics NNS 0 1 UNK B-Group
. . 0 0 12 O

Severe JJ 0 1 7 O
anemia NN 0 1 6 O
( ( 0 0 2 O
Grade NNP 0 1 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
according VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
World NNP 0 1 2 O
Health NNP 0 1 2 O
Organization NNP 0 1 UNK O
criteria NNS 1 1 1 O
) ) 0 0 2 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
greater JJR 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
CHOP NNP 0 1 UNK O
- : 0 0 2 O
HAART NNP 0 1 14 O
compared VBN 1 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
CHOP NNP 0 1 UNK O
alone RB 0 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs. FW 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
; : 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

CRM9 NNP 0 0 UNK B-Drug_n
induced VBD 1 1 6 O
apoptosis NN 0 1 UNK O
and CC 0 0 12 O
furthermore VB 0 0 UNK O
the DT 0 0 12 O
combination NN 0 1 1 O
of IN 0 0 12 O
CRM9 NNP 0 0 UNK B-Drug_n
plus CC 0 1 16 O
doxorubicin NN 0 1 13 B-Drug
enhanced JJ 0 1 1 O
cytotoxicity NN 0 1 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
ALL DT 0 1 11 O
cell NN 0 1 1 O
line NN 0 1 12 O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
other JJ 0 0 12 O
hand NN 0 1 12 O
surprisingly RB 0 0 12 O
green JJ 0 1 3 B-Drug
tea NN 0 1 13 I-Drug
gallocatechins NNS 0 0 UNK I-Drug
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
epigallocatechin JJ 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
O NNP 0 1 2 O
- : 0 0 2 O
gallate NN 0 0 UNK O
and CC 0 0 12 O
theasinensin VB 0 0 UNK O
A NNP 0 0 2 O
potently RB 0 0 UNK O
enhanced VBD 1 1 1 O
the DT 0 0 12 O
promoter NN 0 1 UNK O
activity NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
activity NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
microM NNS 0 0 UNK O
respectively RB 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

METH NNP 0 1 UNK B-Drug
induced VBD 1 1 6 O
arc JJ 0 0 13 O
mRNA NN 0 1 UNK O
in IN 0 0 12 O
layers NNS 1 1 UNK O
IV NNP 0 1 2 O
and CC 0 0 12 O
VI NNP 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
cortex NN 0 1 6 O
which WDT 0 0 12 O
dopamine NN 0 1 14 O
receptor NN 0 1 14 O
are VBP 1 0 12 O
localized VBN 1 1 1 O
to TO 0 0 12 O
. . 0 0 12 O

suppression NN 0 1 1 O
of IN 0 0 12 O
midcycle NN 0 1 UNK O
gonadotropin NN 0 1 13 O
peaks NNS 1 1 UNK O
; : 0 0 2 O

Activity NN 0 1 2 O
of IN 0 0 12 O
buforin NN 0 0 UNK B-Drug_n
II NNP 0 0 2 I-Drug_n
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
minocycline NN 0 1 13 B-Drug
against IN 0 0 12 O
Cryptosporidium NNP 0 1 UNK O
parvum NN 0 1 13 O
in IN 0 0 12 O
cell NN 0 1 1 O
culture NN 0 1 1 O
. . 0 0 12 O

Magnesium NN 0 1 7 B-Drug
and CC 0 0 12 O
therapeutics NNS 1 1 UNK O
. . 0 0 12 O

Acute NNP 0 1 7 O
hydrocortisone CD 0 1 14 B-Drug
administration NN 0 1 1 O
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
subjective JJ 0 1 1 O
responses NNS 1 1 1 O
to TO 0 0 12 O
d VB 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Rifabutin NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
amprenavir NN 0 1 13 B-Drug
's POS 0 1 12 O
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Cytochalasin NNP 0 1 UNK B-Drug_n
D NNP 0 1 2 I-Drug_n
inhibited VBD 1 1 13 O
the DT 0 0 12 O
carbachol NN 0 1 13 B-Drug
- : 0 0 2 O
stimulated VBN 1 1 13 O
intracellular JJ 0 1 UNK O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
concentration NN 0 1 1 O
( ( 0 0 2 O
[ JJ 0 0 2 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
] NN 0 0 2 O
( ( 0 0 2 O
i NN 0 1 12 O
) ) 0 0 2 O
) ) 0 0 2 O
increase NN 0 1 1 O
due JJ 0 1 1 O
to TO 0 0 12 O
release VB 0 1 12 O
from IN 0 0 12 O
the DT 0 0 12 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
store NN 0 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
ninth JJ 0 1 12 O
day NN 0 1 12 O
the DT 0 0 12 O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
sacrificed VBN 1 1 UNK O
and CC 0 0 12 O
aortic JJ 0 1 8 O
rings NNS 1 1 3 O
with IN 0 0 12 O
or CC 0 0 12 O
without IN 0 0 12 O
endothelium NN 0 1 UNK O
were VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
generate VB 0 0 UNK O
concentration NN 0 1 1 O
- : 0 0 2 O
response NN 0 1 1 O
curves VBZ 1 1 UNK O
to TO 0 0 12 O
noradrenaline VB 0 1 UNK B-Drug
. . 0 0 12 O

Rifampin NNP 0 1 0 B-Drug
significantly RB 0 0 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
ss NN 1 1 16 O
) ) 0 0 2 O
of IN 0 0 12 O
amprenavir NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
but CC 0 0 12 O
amprenavir NN 0 1 13 B-Drug
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
rifampin NN 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
of IN 0 0 12 O
cobalt NN 0 1 UNK B-Drug
and CC 0 0 12 O
iron NN 0 1 3 B-Drug
in IN 0 0 12 O
absorption NN 0 1 1 O
and CC 0 0 12 O
retention NN 0 1 1 O
. . 0 0 12 O

Repeated VBN 0 1 7 O
injection NN 0 1 3 O
of IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
into IN 0 0 12 O
mice NN 1 1 UNK O
induced VBD 1 1 6 O
lower JJR 1 1 1 O
locomotor NN 0 0 UNK O
activity NN 0 1 1 O
than IN 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
acutely RB 0 0 6 O
injected JJ 0 1 3 O
mice NN 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
v NN 0 0 16 O
/ NNP 0 0 2 O
v JJ 0 0 16 O
solution NN 0 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
was VBD 1 0 12 O
prepared VBN 1 1 12 O
in IN 0 0 12 O
water NN 0 1 3 O
from IN 0 0 12 O
a DT 0 0 12 O
stock NN 0 1 13 O
solution NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
ethanol NN 0 1 1 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
human JJ 0 1 1 O
heart NN 0 1 12 O
failure NN 0 1 1 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
presynaptic JJ 0 0 UNK O
defect NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
sympathetic JJ 0 0 13 O
nervous JJ 0 1 6 O
system NN 0 1 1 O
leading VBG 1 1 1 O
to TO 0 0 12 O
reduced VB 1 1 1 O
uptake JJ 0 1 14 O
- : 0 0 2 O
9 CD 0 0 2 O
activity NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
introductory NN 0 0 UNK O
chapter NN 0 1 UNK O
discusses VBZ 1 1 UNK O
the DT 0 0 12 O
advantages NNS 1 0 UNK O
and CC 0 0 12 O
disadvantages NNS 1 0 UNK O
of IN 0 0 12 O
POCs NNP 0 1 UNK B-Group
and CC 0 0 12 O
the DT 0 0 12 O
magnitude NN 0 1 UNK O
and CC 0 0 12 O
prevalence NN 0 1 UNK O
of IN 0 0 12 O
their PRP$ 0 0 12 O
use NN 0 1 1 O
. . 0 0 12 O

Resistance NN 0 1 UNK O
was VBD 1 0 12 O
measured VBN 1 1 1 O
near IN 0 1 12 O
the DT 0 0 12 O
placental JJ 0 1 13 O
margin NN 0 1 1 O
after IN 0 0 12 O
spontaneous JJ 0 1 1 O
term NN 0 1 1 O
delivery NN 0 1 1 O
. . 0 0 12 O

Twenty CD 0 1 2 O
four CD 0 1 12 O
male NN 0 1 12 O
Wistar NNP 0 1 UNK O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
divided VBN 1 1 1 O
into IN 0 0 12 O
four CD 0 1 12 O
groups NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
existence NN 0 1 13 O
of IN 0 0 12 O
PI NNP 0 1 UNK O
was VBD 1 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
prescribed VBN 1 1 1 O
to TO 0 0 12 O
each DT 0 0 12 O
patient NN 0 1 6 O
( ( 0 0 2 O
p JJ 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
significantly RB 0 0 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
curve NN 0 1 13 O
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
( ( 0 0 2 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
ss NN 1 1 16 O
) ) 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
and CC 0 0 12 O
the DT 0 0 12 O
AUC NNP 0 1 UNK O
( ( 0 0 2 O
ss NN 1 1 16 O
) ) 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
O NNP 0 1 2 I-Drug_n
- : 0 0 2 O
desacetylrifabutin NN 0 0 UNK I-Drug_n
by IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
. . 0 0 12 O

The DT 0 0 2 O
mean JJ 0 1 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
growth NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
was VBD 1 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
fold NN 0 1 3 O
greater JJR 1 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
Pseudomonas NNP 0 1 14 O
strains NNS 1 1 6 O
from IN 0 0 12 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
than IN 0 0 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
strains NNS 1 1 6 O
from IN 0 0 12 O
drug NN 0 1 1 O
addicts NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
vs. FW 0 1 2 O
9 CD 0 0 2 O
logs NNS 1 1 UNK O
of IN 0 0 12 O
reduction NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
hr NN 0 0 16 O
P NNP 0 1 2 O
less JJR 0 1 12 O
than IN 0 0 12 O
.9 NN 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
investigated VBD 1 1 1 O
the DT 0 0 12 O
role NN 0 1 1 O
of IN 0 0 12 O
neuronal JJ 0 1 13 O
uptake NN 0 1 14 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 B-Drug
( ( 0 0 2 O
uptake JJ 0 1 14 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
in IN 0 0 12 O
human JJ 0 1 1 O
heart NN 0 1 12 O
failure NN 0 1 1 O
as IN 1 0 12 O
a DT 0 0 12 O
local JJ 0 1 12 O
factor NN 0 1 1 O
for IN 0 0 12 O
altering VBG 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 O
at IN 0 0 12 O
the DT 0 0 12 O
cardiac JJ 0 1 6 O
myocyte NN 0 1 UNK O
membranes NNS 1 1 6 O
. . 0 0 12 O

Interference NN 0 1 UNK O
of IN 0 0 12 O
biocytin NN 0 1 UNK O
with IN 0 0 12 O
opioid JJ 0 1 13 B-Group
- : 0 0 2 O
evoked VBN 1 1 13 O
hyperpolarization NN 0 0 UNK O
and CC 0 0 12 O
membrane NN 0 1 3 O
properties NNS 1 1 UNK O
of IN 0 0 12 O
rat NN 0 1 13 O
spinal JJ 0 1 6 O
substantia NN 0 0 UNK O
gelatinosa NN 0 0 UNK O
neurons NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
acid JJ 0 1 14 O
- : 0 0 2 O
catalyzed VBN 1 0 UNK O
ethanol JJ 0 1 1 B-Drug
- : 0 0 2 O
drug NN 0 1 1 O
reaction NN 0 1 1 O
is VBZ 1 0 12 O
a DT 0 0 12 O
relatively RB 0 0 1 O
unexplored JJ 0 0 UNK O
area NN 0 1 12 O
and CC 0 0 12 O
may MD 0 0 1 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacological JJ 0 1 14 O
action NN 0 1 13 O
of IN 0 0 12 O
some DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Withdrawal NN 0 1 7 O
from IN 0 0 12 O
cocaine JJ 0 1 6 B-Drug
dependence NN 0 1 1 O
usually RB 0 1 12 O
involves VBZ 1 0 UNK O
depression NN 0 1 6 O
anxiety NN 0 1 6 O
and CC 0 0 12 O
lethargy NN 0 1 6 O
. . 0 0 12 O

Interaction NN 0 1 2 O
between IN 0 0 12 O
oxytocin NN 0 1 13 B-Drug
and CC 0 0 12 O
antidiuretic JJ 0 1 UNK O
hormone NN 0 1 6 O
and CC 0 0 12 O
its PRP$ 1 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
milk NN 0 1 3 O
secretion NN 0 1 14 O
by IN 0 0 12 O
alveoli NN 1 1 8 O
of IN 0 0 12 O
the DT 0 0 12 O
mammary JJ 0 1 6 O
gland NN 0 1 6 O
of IN 0 0 12 O
lactating VBG 1 1 13 O
rats NNS 1 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
elements NNS 1 1 1 O
only RB 0 1 12 O
take VBP 0 1 12 O
place NN 0 1 12 O
at IN 0 0 12 O
the DT 0 0 12 O
site NN 0 1 12 O
of IN 0 0 12 O
absorption NN 0 1 1 O
. . 0 0 12 O

Effective JJ 0 1 UNK O
strategies NNS 1 1 UNK O
are VBP 1 0 12 O
needed VBN 1 1 12 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
paclitaxel JJ 0 1 13 B-Drug
sensitivity NN 0 1 1 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
decreased VBD 1 1 1 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
ERMBT NNP 0 0 UNK O
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
year NN 0 1 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
relapse NN 0 1 6 O
( ( 0 0 2 O
rehospitalisation NN 0 0 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
lower JJR 1 1 1 O
with IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
than IN 0 0 12 O
with IN 0 0 12 O
haloperidol JJ 0 1 16 B-Drug
treatment NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
study NN 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
etofibrate NN 0 1 UNK B-Drug
upon IN 0 0 12 O
chylomicron NN 0 1 UNK O
metabolism NN 0 1 16 O
was VBD 1 0 12 O
tested VBN 1 1 1 O
by IN 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
kinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
chylomicron NN 0 1 UNK O
- : 0 0 2 O
like IN 0 0 12 O
emulsion NN 0 1 16 O
model NN 0 1 UNK O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
with IN 0 0 12 O
coronary JJ 0 1 6 O
artery NN 0 1 6 O
disease NN 0 1 6 O
aged VBD 1 1 12 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
years NNS 1 1 12 O
( ( 0 0 2 O
total JJ 0 1 1 O
cholesterol NN 0 1 6 O
: : 0 0 2 O
9+ CD 0 0 16 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
dl NN 0 1 13 O
; : 0 0 2 O
triglycerides NNS 1 1 14 O
: : 0 0 2 O
9+ CD 0 0 16 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
dl NN 0 1 13 O
) ) 0 0 2 O
submitted VBD 1 1 UNK O
to TO 0 0 12 O
a DT 0 0 12 O
randomized VBN 1 1 6 O
crossover NN 0 1 UNK O
double JJ 0 1 3 O
- : 0 0 2 O
blind NN 0 1 12 O
placebo NN 0 1 13 O
- : 0 0 2 O
controlled VBN 1 1 1 O
study NN 0 1 1 O
with IN 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
g NNS 0 1 16 O
per IN 0 0 1 O
day NN 0 1 12 O
etofibrate NN 0 1 UNK B-Drug
or CC 0 0 12 O
placebo NN 0 1 13 O
for IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
month NN 0 1 12 O
. . 0 0 12 O

Degeneration NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
dopaminergic JJ 0 1 UNK O
nigrostriatal JJ 0 0 UNK O
system NN 0 1 1 O
and CC 0 0 12 O
of IN 0 0 12 O
noradrenergic JJ 0 1 UNK O
neurons NNS 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
locus NN 0 1 UNK O
coeruleus NN 0 0 UNK O
are VBP 1 0 12 O
important JJ 0 1 1 O
pathological JJ 0 1 13 O
features NNS 1 1 1 O
of IN 0 0 12 O
Parkinson NNP 0 1 6 O
's POS 0 1 12 O
disease NN 0 1 6 O
. . 0 0 12 O

Endothelium NNP 0 1 UNK O
- : 0 0 2 O
intact JJ 0 1 1 O
aortic JJ 0 1 8 O
rings NNS 1 1 3 O
from IN 0 0 12 O
high JJ 0 1 1 O
- : 0 0 2 O
estradiol NN 0 1 13 B-Drug
rats NNS 1 1 UNK O
were VBD 1 0 12 O
supersensitive JJ 0 0 UNK O
to TO 0 0 12 O
noradrenaline VB 0 1 UNK B-Drug
when WRB 0 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
vehicle NN 0 1 1 O
- : 0 0 2 O
progesterone NN 0 1 13 B-Drug
- : 0 0 2 O
and CC 0 0 12 O
progesterone VB 0 1 13 B-Drug
+ NNP 0 0 2 O
high JJ 0 1 1 O
- : 0 0 2 O
estradiol SYM 0 1 13 B-Drug
- : 0 0 2 O
treated VBN 1 1 1 O
rats NNS 1 1 UNK O
( ( 0 0 2 O
pD9 NN 0 0 UNK O
values NNS 1 1 1 O
= VBP 0 0 2 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
9+ CD 0 0 16 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
9+ CD 0 0 16 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
respectively RB 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

Gentamicin NNP 0 1 0 B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
aminoglycoside JJ 0 1 14 B-Group
antibiotic NN 0 1 6 I-Group
used VBN 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
a DT 0 0 12 O
wide JJ 0 1 3 O
variety NN 0 1 1 O
of IN 0 0 12 O
infections NNS 1 1 6 O
caused VBN 1 1 1 O
by IN 0 0 12 O
gram JJ 0 1 16 O
- : 0 0 2 O
negative JJ 0 1 1 O
organisms NNS 1 1 1 O
but CC 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
potentially RB 0 0 1 O
toxic JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
kidneys NNS 1 1 6 O
. . 0 0 12 O

Considering VBG 0 1 UNK O
the DT 0 0 12 O
safety NN 0 1 1 O
of IN 0 0 12 O
GSLS NNP 0 1 UNK B-Drug_n
because IN 0 0 12 O
no DT 0 0 12 O
adverse JJ 0 0 1 O
effect NN 0 1 1 O
was VBD 1 0 12 O
found VBN 1 1 12 O
throughout IN 0 0 12 O
the DT 0 0 12 O
experiments NNS 1 1 UNK O
GSLS NNP 0 1 UNK B-Drug_n
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
promising JJ 0 1 UNK O
oral JJ 0 1 6 O
adjuvant NN 0 1 14 O
to TO 0 0 12 O
improve VB 0 0 1 O
immunization NN 0 1 6 O
in IN 0 0 12 O
poultry NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
treatment NN 0 1 6 O
of IN 0 0 12 O
ewes NN 1 1 UNK O
with IN 0 0 12 O
an DT 0 0 12 O
intravenous JJ 0 1 14 O
( ( 0 0 2 O
IV NNP 0 1 2 O
) ) 0 0 2 O
injection NN 0 1 3 O
of IN 0 0 12 O
trichlorfon JJ 0 1 UNK B-Drug_n
insufficient NN 0 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
significant JJ 0 1 1 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
erythrocyte JJ 0 1 14 O
acetylcholinesterase NN 0 1 UNK O
( ( 0 0 2 O
AChE NNP 0 1 UNK O
) ) 0 0 2 O
activity NN 0 1 1 O
appeared VBD 1 1 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
additive JJ 0 1 16 O
effects NNS 1 1 1 O
with IN 0 0 12 O
those DT 0 0 12 O
produced VBN 1 0 1 O
by IN 0 0 12 O
subsequent JJ 0 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
of IN 0 0 12 O
coumaphos NN 0 1 UNK B-Drug_n
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
. . 0 0 12 O

METHODS NN 0 1 UNK O
: : 0 0 2 O
The DT 0 0 2 O
study NN 0 1 1 O
was VBD 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
as IN 1 0 12 O
an DT 0 0 12 O
open JJ 0 1 12 O
randomized VBN 1 1 6 O
crossover NN 0 1 UNK O
design NN 0 1 UNK O
with IN 0 0 12 O
9 CD 0 0 2 O
healthy JJ 0 1 12 O
participants NNS 1 1 UNK O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
treatments NNS 1 1 6 O
with IN 0 0 12 O
coumaphos JJ 0 1 UNK B-Drug_n
bishydroxycoumarin NN 0 1 UNK B-Drug
( ( 0 0 2 O
an DT 0 0 12 O
anticoagulant NN 0 1 13 B-Group
) ) 0 0 2 O
trichlorfon NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
an DT 0 0 12 O
organophosphorous JJ 0 0 UNK B-Group
compound NN 0 1 13 I-Group
) ) 0 0 2 O
and CC 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
( ( 0 0 2 O
an DT 0 0 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
microsomal JJ 0 1 UNK O
enzymes NNS 1 1 14 O
) ) 0 0 2 O
were VBD 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
sheep NN 0 1 UNK O
. . 0 0 12 O

Much JJ 0 0 2 O
higher JJR 1 1 1 O
changes NNS 1 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
liver NN 0 1 6 O
increasing VBG 1 1 1 O
from IN 0 0 12 O
a DT 0 0 12 O
level NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
at IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
up RB 0 0 12 O
to TO 0 0 12 O
nearly RB 0 1 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
the DT 0 0 12 O
control NN 0 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
for IN 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
reduction NN 0 1 1 O
in IN 0 0 12 O
MAC NNP 0 1 UNK O
was VBD 1 0 12 O
correlated VBN 1 1 1 O
with IN 0 0 12 O
brain NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
ketamine NN 0 1 13 B-Drug
or CC 0 0 12 O
metabolite NN 0 1 UNK O
I PRP 0 1 12 O
suggesting VBG 1 1 1 O
a DT 0 0 12 O
ketamine NN 0 1 13 B-Drug
: : 0 0 2 O
metabolite NN 0 1 UNK O
I PRP 0 1 12 O
potency VBP 0 1 UNK O
ration NN 0 0 UNK O
of IN 0 0 12 O
9:9 CD 0 0 UNK O
. . 0 0 12 O

Candida NNP 0 1 6 O
albicans VBZ 0 0 14 O
one CD 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
pathogenic JJ 0 1 UNK O
species NNS 1 1 1 O
was VBD 1 0 12 O
totally RB 0 0 12 O
inhibited VBN 1 1 13 O
at IN 0 0 12 O
a DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
mug NNS 0 1 UNK O
/ JJ 0 0 2 O
ml NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
anti JJ 0 0 3 B-Group
- : 0 0 2 O
parkinsonian JJ 0 0 UNK I-Group
drug NN 0 1 1 I-Group
hemantane NN 0 1 UNK B-Drug_n
[ NNP 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
adamantyl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
hexamethylenimine NN 0 0 UNK I-Drug_n
] NNP 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
p NN 0 1 2 O
. . 0 0 12 O
o NN 0 1 2 O
. . 0 0 12 O
) ) 0 0 2 O

Therefore RB 0 0 1 O
etodolac NN 0 1 13 B-Drug
can MD 0 0 12 O
generally RB 0 0 1 O
be VB 0 0 12 O
given VBN 1 1 12 O
without IN 0 0 12 O
the DT 0 0 12 O
need NN 0 1 12 O
for IN 0 0 12 O
dosage NN 0 1 0 O
modifications NNS 1 1 UNK O
in IN 0 0 12 O
special JJ 0 1 12 O
populations NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
uncompromised JJ 0 0 UNK O
elderly JJ 0 1 12 O
patients NNS 1 1 6 O
those DT 0 0 12 O
with IN 0 0 12 O
moderate JJ 0 1 1 O
renal JJ 0 1 6 O
impairment NN 0 1 16 O
and CC 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
stable JJ 0 1 1 O
hepatic JJ 0 1 14 O
disease NN 0 1 6 O
. . 0 0 12 O

Interaction NN 0 1 2 O
between IN 0 0 12 O
glycine NN 0 1 UNK B-Drug
and CC 0 0 12 O
glutamate NN 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
spontaneous JJ 0 1 1 O
motility NN 0 1 6 O
in IN 0 0 12 O
chick JJ 0 1 UNK O
embryos NN 1 1 UNK O
. . 0 0 12 O

Anaesthesia NNP 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
epileptic JJ 0 1 13 O
pateint NN 0 0 UNK O
. . 0 0 12 O

Similarly RB 0 0 1 O
dialyzed VBN 1 0 UNK O
were VBD 1 0 12 O
phenobarbital JJ 0 1 16 B-Drug
quinidine NN 0 1 16 B-Drug
and CC 0 0 12 O
theophylline VB 0 1 16 B-Drug
both DT 0 0 12 O
alone RB 0 1 12 O
at IN 0 0 12 O
therapeutic JJ 0 1 6 O
concentrations NNS 1 1 13 O
in IN 0 0 12 O
serum NN 0 1 14 O
and CC 0 0 12 O
with IN 0 0 12 O
ethanol NN 0 1 1 B-Drug
at IN 0 0 12 O
three CD 0 1 12 O
different JJ 0 1 1 O
concentrations NNS 1 1 13 O
in IN 0 0 12 O
serum NN 0 1 14 O
. . 0 0 12 O

also RB 0 0 12 O
induced JJ 0 1 6 O
diarrhea NNS 0 1 6 O
but CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
watery NN 0 1 UNK O
stool NN 0 1 3 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
rats NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
acute JJ 0 1 6 O
toxicity NN 0 1 6 O
tests NNS 1 1 1 O
showed VBD 1 1 12 O
that IN 0 0 12 O
oral JJ 0 1 6 O
CCNU NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
9 CD 0 0 2 O
times NNS 1 1 12 O
less RBR 0 1 12 O
toxic JJ 0 1 1 O
to TO 0 0 12 O
normal JJ 0 1 1 O
tissue NN 0 1 6 O
although IN 0 0 12 O
the DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
limiting VBG 1 1 1 O
organ NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
different JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
routes NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
specific JJ 0 1 1 O
objectives NNS 1 1 UNK O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
were VBD 1 0 12 O
to TO 0 0 12 O
elucidate VB 0 0 UNK O
metal JJ 0 1 3 O
toxicity NN 0 1 6 O
to TO 0 0 12 O
hatching VBG 1 1 UNK O
survival NN 0 1 1 O
and CC 0 0 12 O
avoidance VB 0 1 1 O
behaviour NN 0 1 UNK O
of IN 0 0 12 O
Schistosoma NNP 0 1 UNK O
mansoni NNP 0 0 13 O
miracidia NN 0 0 UNK O
. . 0 0 12 O

Exposure NN 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
muscle NN 0 1 6 O
to TO 0 0 12 O
ouabain VB 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
) ) 0 0 2 O
markedly RB 0 1 1 O
increased VBD 1 1 1 O
the DT 0 0 12 O
PTX NNP 0 1 15 B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
release NN 0 1 12 O
. . 0 0 12 O

Resveratrol NNP 0 1 UNK B-Drug_n
has VBZ 1 0 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
induce VB 0 1 6 O
vasorelaxation NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
both DT 0 0 12 O
plasma NN 0 1 14 O
and CC 0 0 12 O
KHT NNP 0 0 UNK O
tumour VBP 0 1 UNK O
the DT 0 0 12 O
peak JJ 0 1 1 O
concentration NN 0 1 1 O
and CC 0 0 12 O
`` `` 0 0 13 O
early JJ 0 1 12 O
'' '' 0 0 13 O

Etodolac NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
characterised VBN 1 0 UNK O
by IN 0 0 12 O
a DT 0 0 12 O
high JJ 0 1 1 O
oral JJ 0 1 6 O
bioavailability NN 0 1 UNK O
low JJ 0 1 1 O
clearance NN 0 1 16 O
a DT 0 0 12 O
small JJ 0 1 12 O
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
hour NN 0 1 12 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
. . 0 0 12 O

A DT 0 0 2 O
smaller JJR 1 1 3 O
9 CD 0 0 2 O
- : 0 0 2 O
week NN 0 1 12 O
study NN 0 1 1 O
has VBZ 1 0 12 O
suggested VBN 1 1 12 O
nevirapine NN 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
superior JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
PI NNP 0 1 UNK B-Group
nelfinavir NN 0 1 16 B-Drug
. . 0 0 12 O

Failure NN 0 1 2 O
of IN 0 0 12 O
neomycin NN 0 1 16 B-Drug
to TO 0 0 12 O
modify VB 0 1 UNK O
ACTH NNP 0 1 UNK B-Group
induced JJ 0 1 6 O
hypertension NN 0 1 6 O
in IN 0 0 12 O
sheep NN 0 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
conclude VBP 0 1 1 O
that IN 0 0 12 O
an DT 0 0 12 O
ability NN 0 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
P NNP 0 1 2 O
. . 0 0 12 O

However RB 0 0 1 O
total JJ 0 1 1 O
mucosal JJ 0 1 8 O
accumulation NN 0 1 1 O
of IN 0 0 12 O
As NNP 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
that DT 0 0 12 O
transferred VBD 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
increase NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
linear JJ 0 1 1 O
logarithmic JJ 0 1 UNK O
fashion NN 0 0 12 O
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
mm NN 0 0 18 O
As IN 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
and CC 0 0 12 O
second JJ 0 1 12 O
contractile NN 0 1 8 O
responses NNS 1 1 1 O
to TO 0 0 12 O
PTX NNP 0 1 15 B-Drug_n
have VBP 0 0 12 O
entirely RB 0 0 12 O
different JJ 0 1 1 O
properties NNS 1 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
difference NN 0 1 UNK O
in IN 0 0 12 O
panobinostat JJ 0 1 UNK B-Drug
- : 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
between IN 0 0 12 O
patients NNS 1 1 6 O
carrying VBG 1 1 12 O
CYP9A9*9 NNP 0 0 UNK O
/ NNP 0 0 2 O
*9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9*9 NNP 0 0 UNK O
/ NNP 0 0 2 O
*9 NNP 0 0 UNK O
alleles NNS 1 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

It PRP 0 0 12 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
that IN 0 0 12 O
contortrostatin NN 0 1 UNK B-Drug_n
had VBD 1 0 12 O
a DT 0 0 12 O
dramatic JJ 0 1 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
tyrosine NN 0 1 13 O
phosphorylation NN 0 1 UNK O
status NN 0 1 1 O
of IN 0 0 12 O
several JJ 0 1 12 O
proteins NNS 1 1 14 O
in IN 0 0 12 O
T9 NNP 0 1 13 O
human JJ 0 1 1 O
bladder NN 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
including VBG 1 1 1 O
robust JJ 0 1 1 O
induction NN 0 1 1 O
of IN 0 0 12 O
phosphorylation NN 0 1 UNK O
of IN 0 0 12 O
proteins NNS 1 1 14 O
in IN 0 0 12 O
the DT 0 0 12 O
range NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
kDa NN 0 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
evaluated VBD 1 1 1 O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
alkyating VBG 0 0 UNK O
agent NN 0 1 1 O
dacarbazine NN 0 1 13 B-Drug
( ( 0 0 2 O
DTIC NNP 0 1 15 B-Drug
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
pro JJ 0 1 12 O
- : 0 0 2 O
oxidant NN 0 1 UNK O
imexon NN 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
human JJ 0 1 1 O
A9 NNP 0 1 UNK O
melanoma NN 0 1 6 O
cell NN 0 1 1 O
line NN 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
it PRP 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
important JJ 0 1 1 O
also RB 0 0 12 O
in IN 0 0 12 O
case NN 0 1 12 O
of IN 0 0 12 O
medical JJ 0 1 1 O
examinations NNS 1 1 1 O
for IN 0 0 12 O
insurances NNS 1 1 UNK O
and CC 0 0 12 O
job NN 0 1 12 O
appointments NNS 1 1 1 O
since IN 0 1 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
may MD 0 0 1 O
turn VB 0 1 12 O
out RP 0 1 12 O
to TO 0 0 12 O
need VB 0 1 12 O
expensive JJ 0 1 UNK O
drugs NNS 1 1 6 O
or CC 0 0 12 O
to TO 0 0 12 O
be VB 0 0 12 O
susceptible JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
certain JJ 0 1 1 O
disease NN 0 1 6 O
. . 0 0 12 O

acetaminophen NN 0 1 16 B-Drug
/ NNP 0 0 2 O
theophylline NN 0 1 16 B-Drug
lidocaine NN 0 1 14 B-Drug
/ NNP 0 0 2 O
quinidine NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
/ NNP 0 0 2 O
acetaminophen NN 0 1 16 B-Drug
phenobarbital NN 0 1 16 B-Drug
/ NNP 0 0 2 O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
quinidine NN 0 1 16 B-Drug
/ NNP 0 0 2 O
lidocaine NN 0 1 14 B-Drug
theophylline NN 0 1 16 B-Drug
/ NNP 0 0 2 O
acetaminophen NN 0 1 16 B-Drug
and CC 0 0 12 O
valproic NN 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
/ NNP 0 0 2 O
phenobarbital NN 0 1 16 B-Drug
. . 0 0 12 O

ABT NNP 0 1 UNK B-Drug_n
decreased VBD 1 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
increased VBD 1 1 1 O
exposure NN 0 1 1 O
to TO 0 0 12 O
parent VB 0 1 13 O
compound NN 0 1 13 O
and CC 0 0 12 O
decreased VBD 1 1 1 O
metabolite NN 0 1 UNK O
levels NNS 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
dose JJ 0 1 6 O
- : 0 0 2 O
dependent JJ 0 1 1 O
manner NN 0 0 1 O
. . 0 0 12 O

The DT 0 0 2 O
purpose NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
evaluate VB 0 1 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
psychostimulant JJ 0 1 13 O
drug NN 0 1 1 O
ephedrine NN 0 1 13 B-Drug
has VBZ 1 0 12 O
any DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
dexmedetomidine NN 0 1 16 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
antinociception NN 0 0 UNK O
and CC 0 0 12 O
locomotor NN 0 0 UNK O
inhibitor NN 0 1 14 O
activity NN 0 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
in IN 0 0 12 O
acute JJ 0 1 6 O
application NN 0 1 1 O
. . 0 0 12 O

subjects NNS 1 1 UNK O
. . 0 0 12 O

We PRP 0 0 12 O
also RB 0 0 12 O
found VBD 1 1 12 O
that IN 0 0 12 O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
was VBD 1 0 12 O
overexpressed VBN 0 1 UNK O
in IN 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
insensitive JJ 0 1 UNK O
cells NNS 1 1 6 O
and CC 0 0 12 O
cotreatment NN 0 1 UNK O
with IN 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
and CC 0 0 12 O
ABT NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
a DT 0 0 12 O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
family NN 0 1 12 O
inhibitor NN 0 1 14 O
synergistically RB 0 0 UNK O
inhibited JJ 0 1 13 O
growth NN 0 1 1 O
and CC 0 0 12 O
induced JJ 0 1 6 O
apoptosis NN 0 1 UNK O
of IN 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
insensitive JJ 0 1 UNK O
MM NNP 0 0 13 O
cells NNS 1 1 6 O
. . 0 0 12 O

Among IN 0 0 UNK O
the DT 0 0 12 O
proteins NNS 1 1 14 O
that WDT 0 0 12 O
undergo VBP 0 0 1 O
tyrosine JJ 0 1 13 O
phosphorylation NN 0 1 UNK O
in IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
contortrostatin VB 0 1 UNK B-Drug_n
treatment NN 0 1 6 O
is VBZ 1 0 12 O
CAS NNP 0 0 UNK O
a DT 0 0 12 O
9 CD 0 0 2 O
kDa NN 0 1 UNK O
adapter NN 0 1 UNK O
protein NN 0 1 14 O
involved VBN 1 1 12 O
in IN 0 0 12 O
integrin JJ 0 1 UNK O
signaling NN 0 1 UNK O
. . 0 0 12 O

Anticoagulant JJ 0 1 UNK O
inhibition NN 0 1 13 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
secobarbital NN 0 1 UNK B-Drug
and CC 0 0 12 O
glutethimide NN 0 1 13 B-Drug
; : 0 0 2 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
interaction NN 0 1 UNK O
of IN 0 0 12 O
prostaglandin NN 0 1 13 B-Drug
F9alpha NNP 0 0 UNK I-Drug
and CC 0 0 12 O
oxytocin NN 0 1 13 B-Drug
in IN 0 0 12 O
placental JJ 0 1 13 O
vessels NNS 1 1 1 O
. . 0 0 12 O

Among IN 0 0 UNK O
fifteen JJ 0 1 12 O
species NNS 1 1 1 O
of IN 0 0 12 O
bacteria NNS 0 1 6 O
tested VBN 1 1 1 O
the DT 0 0 12 O
antimicrobial JJ 0 1 14 O
activity NN 0 1 1 O
of IN 0 0 12 O
GL NNP 0 1 UNK B-Drug_n
was VBD 1 0 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
potent JJ 0 1 UNK O
against IN 0 0 12 O
Micrococcus NNP 0 1 UNK O
luteus NN 0 0 UNK O
( ( 0 0 2 O
MIC NNP 0 1 13 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
ml NN 0 1 16 O
) ) 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
differences NNS 1 1 UNK O
between IN 0 0 12 O
treatment NN 0 1 6 O
groups NNS 1 1 1 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
for IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
calculated JJ 0 1 1 O
digoxin NN 0 1 14 B-Drug
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
dextrorotatory NN 0 1 UNK O
isomer NN 0 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
hand NN 0 1 12 O
had VBD 1 0 12 O
effects NNS 1 1 1 O
similar JJ 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
in IN 0 0 12 O
both DT 0 0 12 O
species NNS 1 1 1 O
. . 0 0 12 O

Intracellular JJ 0 1 UNK O
and CC 0 0 12 O
extracellular JJ 0 1 14 O
application NN 0 1 1 O
of IN 0 0 12 O
RR NNP 0 0 13 B-Drug_n
reduced VBD 1 1 1 O
ADP NNP 0 1 UNK O
- : 0 0 2 O
induced JJ 0 1 6 O
increases NNS 1 1 1 O
in IN 0 0 12 O
[ NN 0 0 2 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
] NN 0 0 2 O
( ( 0 0 2 O
i NN 0 1 12 O
) ) 0 0 2 O
. . 0 0 12 O

Implanon NNP 0 1 UNK B-Brand
failure NN 0 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
positive JJ 0 1 1 O
woman NN 0 1 12 O
on IN 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
therapy NN 0 1 6 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
two CD 0 1 12 O
ectopic NN 0 1 6 O
pregnancies NNS 1 1 6 O
. . 0 0 12 O

thus RB 0 0 1 O
novel RB 0 1 13 O
targeted JJ 0 1 UNK O
therapies NNS 1 1 6 O
are VBP 1 0 12 O
urgently RB 0 0 1 O
needed VBN 1 1 12 O
. . 0 0 12 O

Possible JJ 0 1 2 O
extrarenal JJ 0 0 UNK O
mechanisms NNS 1 1 UNK O
of IN 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
on IN 0 0 12 O
verografine NN 0 0 UNK B-Drug
and CC 0 0 12 O
iodamide JJ 0 1 UNK B-Drug
transport NN 0 1 1 O
were VBD 1 0 12 O
also RB 0 0 12 O
examined VBN 1 1 1 O
. . 0 0 12 O

Among IN 0 0 UNK O
the DT 0 0 12 O
responders NNS 1 0 1 O
the DT 0 0 12 O
fall NN 0 1 12 O
in IN 0 0 12 O
PTH NNP 0 0 14 O
and CC 0 0 12 O
reduction NN 0 1 1 O
darbepoetin NN 0 0 13 B-Drug
requirement NN 0 1 1 O
were VBD 1 0 12 O
related VBN 1 1 1 O
( ( 0 0 2 O
R NNP 0 1 2 O
= NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
p NN 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
ratio NN 0 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
weight NN 0 1 3 O
and CC 0 0 12 O
body NN 0 1 3 O
weight NN 0 1 3 O
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
lower JJR 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
treated JJ 0 1 1 O
animals NNS 1 1 12 O
than IN 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
control NN 0 1 1 O
group NN 0 1 12 O
. . 0 0 12 O

Determinants NNS 0 1 UNK O
downstream NN 0 1 UNK O
of IN 0 0 12 O
cleavable JJ 0 0 UNK O
complex JJ 0 1 1 O
formation NN 0 1 1 O
that WDT 0 0 12 O
affect VBP 0 1 1 O
the DT 0 0 12 O
sensitivity NN 0 1 1 O
of IN 0 0 12 O
tumor NN 0 1 6 O
versus NN 0 0 1 O
normal JJ 0 1 1 O
cells NNS 1 1 6 O
to TO 0 0 12 O
topo VB 0 1 UNK O
drugs NNS 1 1 6 O
in IN 0 0 12 O
particular JJ 0 0 1 O
and CC 0 0 12 O
DNA NNP 0 1 1 O
- : 0 0 2 O
damaging NN 0 1 UNK O
agents NNS 1 1 1 O
in IN 0 0 12 O
general JJ 0 1 1 O
are VBP 1 0 12 O
little JJ 0 1 12 O
known JJ 0 1 12 O
. . 0 0 12 O

Jacalin NN 0 1 UNK B-Drug_n
: : 0 0 2 O
an DT 0 0 12 O
IgA NNP 0 1 14 O
- : 0 0 2 O
binding NN 0 1 1 O
lectin NN 0 1 UNK O
. . 0 0 12 O

Previous JJ 0 1 2 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
a DT 0 0 12 O
significant JJ 0 1 1 O
reduction NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
trovafloxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
when WRB 0 0 12 O
administered VBN 1 1 1 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
an DT 0 0 12 O
intravenous JJ 0 1 14 O
opiate NN 0 1 6 B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
to TO 0 0 12 O
this DT 0 0 12 O
pharmacological JJ 0 1 14 O
interaction NN 0 1 UNK O
this DT 0 0 12 O
report NN 0 1 1 O
describes VBZ 1 0 1 O
a DT 0 0 12 O
novel JJ 0 1 13 O
chemical NN 0 1 13 O
reaction NN 0 1 1 O
between IN 0 0 12 O
temazepam NN 0 1 16 B-Drug
( ( 0 0 2 O
a DT 0 0 12 O
benzodiazepine NN 0 1 14 B-Group
) ) 0 0 2 O
and CC 0 0 12 O
ethanol $ 0 1 1 B-Drug
under IN 0 0 12 O
acidic JJ 0 1 UNK O
conditions NNS 1 1 1 O
similar JJ 0 1 1 O
to TO 0 0 12 O
those DT 0 0 12 O
found VBN 1 1 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
ethoxylated VBN 0 0 UNK O
product NN 0 1 1 O
. . 0 0 12 O

Cytochalasin NNP 0 1 UNK B-Drug_n
D NNP 0 1 2 I-Drug_n
at IN 0 0 12 O
9 CD 0 0 2 O
microM NNS 0 0 UNK O
preferentially RB 0 0 UNK O
blocked VBD 1 1 13 O
the DT 0 0 12 O
secretory JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
carbachol NN 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
synergism NN 0 1 UNK O
with IN 0 0 12 O
cAMP NN 0 1 UNK O
whereas NNS 0 0 UNK O
it PRP 0 0 12 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
histamine NN 0 1 UNK O
- : 0 0 2 O
or CC 0 0 12 O
cAMP VB 0 1 UNK O
- : 0 0 2 O
stimulated VBN 1 1 13 O
acid JJ 0 1 14 O
secretion NN 0 1 14 O
within IN 0 0 1 O
9 CD 0 0 2 O
min NNS 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
onset NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
those DT 0 0 12 O
`` `` 0 0 13 O
epidemic JJ 0 1 13 O
'' '' 0 0 13 O

Evidence NN 0 1 2 O
for IN 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
norepinephrine JJ 0 1 14 B-Drug
uptake NN 0 1 14 O
sites NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
failing NN 0 1 13 O
human JJ 0 1 1 O
heart NN 0 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
pigeons NNS 1 1 UNK O
naloxone RB 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
systematically RB 0 0 UNK O
alter VB 0 1 13 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
( ( 0 0 2 O
- : 0 0 2 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
+ NNP 0 0 2 I-Drug_n
) ) 0 0 2 B-Drug_n
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
or CC 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
. . 0 0 12 O

These DT 0 0 1 O
data NNS 0 1 1 O
raise VBP 0 0 12 O
the DT 0 0 12 O
question NN 0 1 12 O
of IN 0 0 12 O
whether IN 0 0 12 O
sertraline NN 0 1 16 B-Drug
is VBZ 1 0 12 O
the DT 0 0 12 O
best JJS 0 1 12 O
choice NN 0 1 12 O
for IN 0 0 12 O
prolonged JJ 0 1 6 O
use NN 0 1 1 O
for IN 0 0 12 O
diabetic JJ 0 1 6 O
individuals NNS 1 1 1 O
because IN 0 0 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
antihyperglycemic JJ 0 1 UNK O
effects NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
mechanisms NN 1 1 UNK O
of IN 0 0 12 O
metal NN 0 1 3 O
toxicity NN 0 1 6 O
to TO 0 0 12 O
miracidia VB 0 0 UNK O
are VBP 1 0 12 O
briefly DT 0 0 12 O
discussed VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
agents NNS 1 1 1 O
including VBG 1 1 1 O
norfloxacin JJ 0 1 UNK B-Drug
ciprofloxacin NN 0 1 0 B-Drug
ofloxacin NN 0 1 0 B-Drug
enoxacin NN 0 1 UNK B-Drug
and CC 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
extensively RB 0 0 1 O
studied VBN 1 0 1 O
and CC 0 0 12 O
have VBP 0 0 12 O
demonstrated VBN 1 0 1 O
efficacy NN 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
profiles NNS 1 1 UNK O
comparable JJ 0 0 1 O
to TO 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
traditional JJ 0 1 UNK O
agents NNS 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
complicated VBN 1 1 1 O
or CC 0 0 12 O
uncomplicated JJ 0 1 1 O
urinary JJ 0 1 6 O
tract NN 0 1 6 O
infections NNS 1 1 6 O
and CC 0 0 12 O
prostatitis NN 0 1 6 O
. . 0 0 12 O

Enhanced NNP 0 1 UNK O
theophylline JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
phenytoin VB 0 1 16 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

Q9H NNP 0 1 UNK O
and CC 0 0 12 O
levofloxacin $ 0 1 0 B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
p.o NN 0 1 UNK O
. . 0 0 12 O

Tamoxifen NNP 0 1 0 B-Drug
an DT 0 0 12 O
estrogen NN 0 1 6 B-Group
antagonist NN 0 1 13 I-Group
is VBZ 1 0 12 O
the DT 0 0 12 O
standard JJ 0 1 1 O
hormone NN 0 1 6 O
treatment NN 0 1 6 O
for IN 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
macrolide JJ 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
and CC 0 0 12 O
other JJ 0 0 12 O
hydroxymethylglutaryl NN 0 0 UNK B-Group
coenzyme VBZ 0 1 16 I-Group
A DT 0 0 2 I-Group
HMG NNP 0 0 UNK I-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
have VBP 0 0 12 O
resulted VBN 1 1 1 O
in IN 0 0 12 O
previous JJ 0 1 12 O
reports NNS 1 1 1 O
of IN 0 0 12 O
rhabdomyolysis NN 0 1 8 O
. . 0 0 12 O

However RB 0 0 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
thioether NN 0 1 UNK O
concentration NN 0 1 1 O
ranges VBZ 1 1 1 O
within IN 0 0 1 O
the DT 0 0 12 O
limits NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
normal JJ 0 1 1 O
value NN 0 1 1 O
one CD 0 1 12 O
must MD 0 0 12 O
not RB 0 1 12 O
conclude VB 0 1 1 O
that IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
or CC 0 0 12 O
negligible JJ 0 1 UNK O
exposure NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
total JJ 0 1 1 O
drug NN 0 1 1 O
exposure NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
was VBD 1 0 12 O
approximately RB 0 1 1 O
twofold VBN 0 0 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
higher JJR 1 1 1 O
cisplatin NN 0 1 14 B-Drug
dose NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
incidence NN 0 1 6 O
of IN 0 0 12 O
cancer NN 0 1 6 O
increases NNS 1 1 1 O
progressively RB 0 0 1 O
with IN 0 0 12 O
age NN 0 1 12 O
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
Olanzapine NNP 0 1 0 B-Drug
demonstrated VBD 1 0 1 O
superior JJ 0 1 1 O
antipsychotic JJ 0 1 UNK O
efficacy NN 0 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
acute JJ 0 1 6 O
phase NN 0 1 1 O
schizophrenia NN 0 1 13 O
and CC 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
episode NN 0 1 12 O
or CC 0 0 12 O
treatment NN 0 1 6 O
- : 0 0 2 O
resistant JJ 0 1 3 O
schizophrenia NN 0 1 13 O
. . 0 0 12 O

reproductive JJ 0 1 13 O
tract NN 0 1 6 O
infections NNS 1 1 6 O
; : 0 0 2 O

Improved VBN 0 1 2 O
parathyroid JJ 0 1 14 O
hormone NN 0 1 6 O
control NN 0 1 1 O
by IN 0 0 12 O
cinacalcet NN 0 1 16 B-Drug
is VBZ 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
darbepoetin JJ 0 0 13 B-Drug
requirement NN 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
end JJ 0 1 12 O
- : 0 0 2 O
stage NN 0 1 12 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
administrative JJ 0 1 13 O
arrangements NNS 1 1 1 O
in IN 0 0 12 O
an DT 0 0 12 O
area NN 0 1 12 O
of IN 0 0 12 O
Scotland NNP 0 1 UNK O
were VBD 1 0 12 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
admissions NNS 1 1 1 O
for IN 0 0 12 O
mania NN 0 1 6 O
whereas NNS 0 0 UNK O
in IN 0 0 12 O
an DT 0 0 12 O
area NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
West NNP 0 1 2 O
Midlands VBZ 0 0 UNK O
a DT 0 0 12 O
large JJ 0 1 3 O
decrease NN 0 1 1 O
was VBD 1 0 12 O
achieved VBN 1 0 1 O
. . 0 0 12 O

Decreased VBN 0 1 7 O
core NN 0 1 1 O
temperature NN 0 1 3 O
in IN 0 0 12 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
as IN 1 0 12 O
one CD 0 1 12 O
possible JJ 0 1 1 O
index NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
disulfiram NN 0 1 13 B-Drug
- : 0 0 2 O
ethanol JJ 0 1 1 B-Drug
reaction NN 0 1 1 O
( ( 0 0 2 O
DER NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

Metal NN 0 1 UNK O
mixtures NNS 1 1 13 O
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
egg NN 0 1 13 B-Drug
hatching NN 0 1 UNK O
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
as IN 1 0 12 O
effective JJ 0 1 1 O
in IN 0 0 12 O
women NNS 1 1 UNK O
with IN 0 0 12 O
sexual JJ 0 1 12 O
dysfunction NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
exception NN 0 1 12 O
of IN 0 0 12 O
SSRI NNP 0 1 UNK B-Group
- : 0 0 2 O
associated VBN 1 1 1 O
sexual JJ 0 1 12 O
dysfunction NN 0 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
careful JJ 0 1 12 O
attention NN 0 1 12 O
must MD 0 0 12 O
be VB 0 0 12 O
directed VBN 1 1 1 O
to TO 0 0 12 O
cross VB 0 1 12 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
possible JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
and CC 0 0 12 O
antineoplastic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

After IN 0 0 2 O
etofibrate JJ 0 1 UNK B-Drug
treatment NN 0 1 6 O
there EX 0 0 12 O
was VBD 1 0 12 O
decrease NN 0 1 1 O
of IN 0 0 12 O
total JJ 0 1 1 O
cholesterol NN 0 1 6 O
and CC 0 0 12 O
triglyceride VB 0 1 14 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
a DT 0 0 12 O
trend NN 0 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
high JJ 0 1 1 O
- : 0 0 2 O
density NN 0 1 1 O
lipoprotein VBP 0 1 13 O
cholesterol NN 0 1 6 O
plasma NN 0 1 14 O
levels NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
review NN 0 1 2 O
discusses VBZ 1 1 UNK O
the DT 0 0 12 O
actions NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
on IN 0 0 12 O
certain JJ 0 1 1 O
brain NN 0 1 6 O
chemical NN 0 1 13 O
( ( 0 0 2 O
i.e. JJ 0 1 1 O
neurotransmitter NN 0 1 UNK O
) ) 0 0 2 O
systems NNS 1 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
to TO 0 0 12 O
which WDT 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
interact VB 0 0 UNK O
. . 0 0 12 O

There EX 0 0 12 O
were VBD 1 0 12 O
several JJ 0 1 12 O
factors NNS 1 1 1 O
that WDT 0 0 12 O
could MD 0 0 12 O
have VB 0 0 12 O
increased VBN 1 1 1 O
his PRP$ 0 0 12 O
risk NN 0 1 1 O
for IN 0 0 12 O
developing VBG 1 0 1 O
rhabdomyolysis NN 0 1 8 O
including VBG 1 1 1 O
chronic JJ 0 1 6 O
renal JJ 0 1 6 O
failure NN 0 1 1 O
. . 0 0 12 O

Then RB 0 1 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
metabotropic NN 0 0 UNK O
glutamate NN 0 1 UNK O
receptor NN 0 1 14 O
( ( 0 0 2 O
mGluR NN 0 0 UNK O
) ) 0 0 2 O
agonists VBZ 0 1 UNK O
DCG NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
IV NN 0 1 2 I-Drug_n
and CC 0 0 12 O
L NNP 0 1 2 B-Drug_n
- : 0 0 2 O
CCG NNP 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
on IN 0 0 12 O
the DT 0 0 12 O
above JJ 0 1 12 O
behavioral NN 0 1 13 O
changes NNS 1 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
were VBD 1 0 12 O
found VBN 1 1 12 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
work NN 0 1 12 O
we PRP 0 0 12 O
studied VBD 1 0 1 O
the DT 0 0 12 O
contribution NN 0 1 1 O
of IN 0 0 12 O
several JJ 0 1 12 O
biochemical JJ 0 1 UNK O
pathways NNS 1 1 13 O
for IN 0 0 12 O
DEB NNP 0 1 UNK O
- : 0 0 2 O
induced VBD 1 1 6 O
acute JJ 0 1 6 O
toxicity NN 0 1 6 O
in IN 0 0 12 O
human JJ 0 1 1 O
lymphocyte NN 0 1 13 O
suspensions NNS 1 1 UNK O
by IN 0 0 12 O
using VBG 1 1 1 O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
epoxide JJ 0 1 UNK O
hydrolases NNS 0 1 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
protective JJ 0 0 3 O
enzymes NNS 1 1 14 O
as IN 1 0 12 O
glutathione NN 0 1 13 O
S NNP 0 1 2 O
- : 0 0 2 O
transferase NN 0 1 14 O
and CC 0 0 12 O
catalase VB 0 1 UNK O
the DT 0 0 12 O
depletion NN 0 1 1 O
of IN 0 0 12 O
glutathione NN 0 1 13 O
( ( 0 0 2 O
GSH NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
the DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
protein JJ 0 1 14 O
synthesis NN 0 1 UNK O
; : 0 0 2 O

Hyperglycaemia NNP 0 1 UNK O
increased VBD 1 1 1 O
all PDT 0 0 12 O
the DT 0 0 12 O
renal JJ 0 1 6 O
and CC 0 0 12 O
ocular JJ 0 1 6 O
parameters NNS 1 1 1 O
studied VBN 1 0 1 O
. . 0 0 12 O

Co NNP 0 1 2 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
panobinostat NN 0 1 UNK B-Drug
with IN 0 0 12 O
CYP9A NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
is VBZ 1 0 12 O
feasible JJ 0 0 1 O
as IN 1 0 12 O
the DT 0 0 12 O
observed JJ 0 1 1 O
increase NN 0 1 1 O
in IN 0 0 12 O
panobinostat JJ 0 1 UNK B-Drug
PK NNP 0 0 UNK O
parameters NNS 1 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
considered VBN 1 1 1 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
. . 0 0 12 O

[ JJ 0 0 2 O
Drug NNP 0 1 2 O
treatment NN 0 1 6 O
of IN 0 0 12 O
erection NN 0 1 UNK O
disorders NNS 1 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
cardiovascular JJ 0 1 6 O
disease NN 0 1 6 O
] NNP 0 0 2 O
Erectile NNP 0 1 UNK O
dysfunction NN 0 1 6 O
is VBZ 1 0 12 O
a DT 0 0 12 O
frequent JJ 0 1 1 O
condition NN 0 1 1 O
in IN 0 0 12 O
cardiovascular JJ 0 1 6 O
patients NNS 1 1 6 O
. . 0 0 12 O

they PRP 0 0 12 O
also RB 0 0 12 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
alcoholic JJ 0 1 12 O
beverages NNS 1 1 1 O
are VBP 1 0 12 O
not RB 0 1 12 O
equivalent JJ 0 1 1 O
in IN 0 0 12 O
their PRP$ 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
cause VB 0 1 12 O
liver JJ 0 1 6 O
damage NN 0 1 1 O
. . 0 0 12 O

Exposure NN 0 1 2 O
to TO 0 0 12 O
oral JJ 0 1 6 O
S NNP 0 1 2 B-Drug
- : 0 0 2 O
ketamine NN 0 1 13 I-Drug
is VBZ 1 0 12 O
unaffected VBN 0 1 UNK O
by IN 0 0 12 O
itraconazole NN 0 1 0 B-Drug
but CC 0 0 12 O
greatly RB 0 1 1 O
increased VBN 1 1 1 O
by IN 0 0 12 O
ticlopidine NN 0 1 16 B-Drug
. . 0 0 12 O

Development NNP 0 1 2 O
and CC 0 0 12 O
pharmacology NN 0 1 UNK O
of IN 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
. . 0 0 12 O

We PRP 0 0 12 O
present VBP 0 1 1 O
an DT 0 0 12 O
interesting JJ 0 1 UNK O
case NN 0 1 12 O
of IN 0 0 12 O
an DT 0 0 12 O
HIV NNP 0 1 6 O
- : 0 0 2 O
positive JJ 0 1 1 O
woman NN 0 1 12 O
on IN 0 0 12 O
antiretroviral JJ 0 0 UNK B-Group
therapy NN 0 1 6 O
having VBG 1 0 12 O
tubal JJ 0 1 6 O
pregnancies NNS 1 1 6 O
on IN 0 0 12 O
two CD 0 1 12 O
separate JJ 0 1 1 O
occasions NNS 1 0 12 O
with IN 0 0 12 O
Implanon NNP 0 1 UNK B-Brand
in IN 0 0 12 O
place NN 0 1 12 O
. . 0 0 12 O

Treatment NN 0 1 7 O
of IN 0 0 12 O
both DT 0 0 12 O
parental JJ 0 1 UNK O
and CC 0 0 12 O
resistant JJ 0 1 3 O
MCF NNP 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
cells NNS 1 1 6 O
with IN 0 0 12 O
TAM NNP 0 1 UNK B-Drug_n
induces NNS 0 1 UNK O
apoptosis NN 0 1 UNK O
and CC 0 0 12 O
clusterin NN 0 1 UNK O
. . 0 0 12 O

Antinociception NN 0 0 UNK O
was VBD 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
hot JJ 0 1 3 O
- : 0 0 2 O
plate NN 0 1 3 O
method NN 0 1 13 O
. . 0 0 12 O

Cell NNP 0 1 2 O
permeable JJ 0 1 UNK O
caspase NN 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
inhibitor NN 0 1 14 O
added VBD 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
medium NN 0 1 3 O
blocked VBD 1 1 13 O
the DT 0 0 12 O
decrease NN 0 1 1 O
of IN 0 0 12 O
nucleophosmin JJ 0 1 UNK O
/ NNP 0 0 2 O
B9 NNP 0 0 UNK O
and CC 0 0 12 O
apoptosis NN 0 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
serum JJ 0 1 14 O
deprivation NN 0 1 13 O
in IN 0 0 12 O
NIH NNP 0 1 1 O
- : 0 0 2 O
9T9 CD 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

Digoxin NNP 0 1 0 B-Drug
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
changed VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
fluoroquinolones NNS 0 1 UNK B-Group
are VBP 1 0 12 O
also RB 0 0 12 O
extensively RB 0 0 1 O
used VBN 1 1 12 O
in IN 0 0 12 O
urologic JJ 0 1 UNK O
surgery NN 0 1 6 O
. . 0 0 12 O

Compared VBN 0 1 2 O
with IN 0 0 12 O
risperidone NN 0 1 0 B-Drug
olanzapine NN 0 1 16 B-Drug
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
decrease VB 0 1 1 O
overall JJ 0 1 1 O
treatment NN 0 1 6 O
costs NNS 1 1 UNK O
despite IN 0 0 12 O
the DT 0 0 12 O
several JJ 0 1 12 O
- : 0 0 2 O
fold NN 0 1 3 O
higher JJR 1 1 1 O
daily JJ 0 1 12 O
acquisition NN 0 1 UNK O
cost NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
literature NN 0 1 UNK O
suggests VBZ 1 1 1 O
that IN 0 0 12 O
more JJR 0 1 12 O
than IN 0 0 12 O
one CD 0 1 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
action NN 0 1 13 O
exists NNS 0 1 UNK O
for IN 0 0 12 O
them PRP 0 0 12 O
. . 0 0 12 O

To TO 0 0 2 O
prevent VB 0 1 1 O
stomach NN 0 1 6 O
irritation NN 0 1 6 O
subjects VBZ 1 1 UNK O
received VBN 1 1 12 O
rantidine JJ 0 0 UNK B-Drug
hydrochloride NN 0 1 0 I-Drug
before IN 0 1 12 O
each DT 0 0 12 O
experimental JJ 0 1 UNK O
session NN 0 1 12 O
. . 0 0 12 O

Survanta NNP 0 1 0 B-Brand
also RB 0 0 12 O
increased VBD 1 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
dissolution NN 0 0 UNK O
in IN 0 0 12 O
a DT 0 0 12 O
manner NN 0 0 1 O
similar JJ 0 1 1 O
to TO 0 0 12 O
sodium VB 0 1 14 B-Drug_n
dodecyl JJ 0 0 UNK I-Drug_n
sulfate NN 0 1 14 I-Drug_n
. . 0 0 12 O

Between JJ 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
more JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
were VBD 1 0 12 O
diagnosed VBN 1 1 6 O
and CC 0 0 12 O
treated VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
inhibitor NN 0 1 14 O
on IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
hand NN 0 1 12 O
promoted VBD 1 1 UNK O
significant JJ 0 1 1 O
decrease NN 0 1 1 O
of IN 0 0 12 O
nucleolin JJ 0 1 UNK O
/ NNP 0 0 2 O
C9 NNP 0 1 UNK O
in IN 0 0 12 O
NIH NNP 0 1 1 O
- : 0 0 2 O
9T9 CD 0 0 UNK O
cells NNS 1 1 6 O
during IN 0 0 12 O
serum JJ 0 1 14 O
deprivation NN 0 1 13 O
. . 0 0 12 O

CONCLUSION NN 0 1 11 O
: : 0 0 2 O
Cisapride NN 0 1 0 B-Drug
can MD 0 0 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
safely RB 0 0 UNK O
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
low JJ 0 1 1 O
therapeutic JJ 0 1 6 O
dosages NNS 1 1 14 O
of IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
cadmium NN 0 1 13 O
zinc NN 0 1 14 B-Drug
and CC 0 0 12 O
cadmium NN 0 1 13 O
/ NNP 0 0 2 O
zinc NN 0 1 14 O
mixtures NNS 1 1 13 O
at IN 0 0 12 O
concentrations NNS 1 1 13 O
ranging VBG 1 1 1 O
from IN 0 0 12 O
99 CD 0 0 10 O
to TO 0 0 12 O
9 CD 0 0 2 O
microg NNS 0 0 UNK O
/ JJ 0 0 2 O
l NN 0 1 2 O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
hot JJ 0 1 3 O
plate NN 0 1 3 O
test NN 0 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
g NNS 0 1 16 O
/ JJ 0 0 2 O
kg NNS 0 1 18 O
dexmedetomidine VBP 0 1 16 B-Drug
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg FW 0 1 18 O
ephedrine NN 0 1 13 B-Drug
intraperitoneally RB 0 0 UNK O
not RB 0 1 12 O
only RB 0 1 12 O
enhanced VBD 1 1 1 O
but CC 0 0 12 O
also RB 0 0 12 O
prolonged VBD 1 1 6 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
antinociception NN 0 0 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
dexmedetomidine NN 0 1 16 B-Drug
. . 0 0 12 O

High JJ 0 1 2 O
oral JJ 0 1 6 O
magnesium NN 0 1 14 B-Drug
doses NNS 1 1 6 O
besides IN 0 0 12 O
their PRP$ 0 0 12 O
laxative JJ 0 1 6 O
action NN 0 1 13 O
may MD 0 0 1 O
bring VB 0 0 12 O
latent NN 0 1 13 O
complications NNS 1 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
reduce VB 0 0 1 O
lifespan NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
patient NN 0 1 6 O
continued VBD 1 1 12 O
to TO 0 0 12 O
receive VB 0 1 1 O
intermittent JJ 0 1 1 O
hemodialysis NN 0 1 14 O
until IN 0 0 12 O
his PRP$ 0 0 12 O
death NN 0 1 12 O
from IN 0 0 12 O
infectious JJ 0 1 6 O
complications NNS 1 1 6 O
that WDT 0 0 12 O
occurred VBD 1 1 1 O
three CD 0 1 12 O
months NNS 1 1 12 O
after IN 0 0 12 O
admission NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
we PRP 0 0 12 O
have VBP 0 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
RR NNP 0 0 13 B-Drug_n
is VBZ 1 0 12 O
a DT 0 0 12 O
useful JJ 0 1 UNK O
pharmacological JJ 0 1 14 O
tool NN 0 1 13 O
with IN 0 0 12 O
which WDT 0 0 12 O
to TO 0 0 12 O
examine VB 0 0 1 O
the DT 0 0 12 O
InsP9 NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
mediated VBD 1 1 13 O
responses NNS 1 1 1 O
of IN 0 0 12 O
megakaryocytes NNS 1 1 UNK O
. . 0 0 12 O

as IN 1 0 12 O
judged VBN 1 1 1 O
by IN 0 0 12 O
increased JJ 0 1 1 O
serum NN 0 1 14 O
enzyme NN 0 1 14 O
activities NNS 1 1 1 O
and CC 0 0 12 O
increased VBD 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
hepatic JJ 0 1 14 O
necrosis NN 0 1 6 O
. . 0 0 12 O

Induction NN 0 1 UNK O
of IN 0 0 12 O
apoptosis NN 0 1 UNK O
was VBD 1 0 12 O
assessed VBN 1 1 1 O
by IN 0 0 12 O
TUNEL NNP 0 1 UNK O
assay NN 0 1 14 O
. . 0 0 12 O

Hitherto NNP 0 0 UNK O
unrecognized JJ 0 0 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
homopolyribonucleotides NNS 0 0 UNK O
and CC 0 0 12 O
complexes NNS 1 1 1 O
thereof NNS 0 0 UNK O
are VBP 1 0 12 O
suggested VBN 1 1 12 O
by IN 0 0 12 O
interferon NN 0 1 14 O
induction NN 0 1 1 O
data NNS 0 1 1 O
obtained VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
highly RB 0 1 1 O
sensitive JJ 0 1 1 O
assay NN 0 1 14 O
system NN 0 1 1 O
of IN 0 0 12 O
primary JJ 0 1 1 O
rabbit NN 0 1 16 O
kidney NN 0 1 6 O
cell NN 0 1 1 O
cultures NNS 1 1 1 O
superinduced VBN 0 0 UNK O
by IN 0 0 12 O
metabolic JJ 0 1 6 O
inhibitors NNS 1 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
response NN 0 1 1 O
to TO 0 0 12 O
cocaine VB 0 1 6 B-Drug
the DT 0 0 12 O
locomotor NN 0 0 UNK O
activities NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
SST NNP 0 1 UNK O
were VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
different JJ 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
RBC NNP 0 1 13 O
group NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
median JJ 0 1 1 O
survival NN 0 1 1 O
for IN 0 0 12 O
CHOP NNP 0 1 UNK O
- : 0 0 2 O
HAART NN 0 1 14 O
patients NNS 1 1 6 O
was VBD 1 0 12 O
not RB 0 1 12 O
reached VBN 1 1 12 O
whereas IN 0 0 UNK O
the DT 0 0 12 O
medial JJ 0 1 8 O
survival NN 0 1 1 O
of IN 0 0 12 O
CHOP NNP 0 1 UNK O
patients NNS 1 1 6 O
was VBD 1 0 12 O
9 CD 0 0 2 O
months NNS 1 1 12 O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

New NNP 0 1 2 O
oral JJ 0 1 6 O
therapies NNS 1 1 6 O
for IN 0 0 12 O
type NN 0 1 1 O
9 CD 0 0 2 O
diabetes NNS 0 1 6 O
mellitus NN 0 0 6 O
: : 0 0 2 O
The DT 0 0 2 O
glitazones NNS 0 1 UNK B-Group
or CC 0 0 12 O
insulin NN 0 1 14 O
sensitizers NNS 1 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
second JJ 0 1 12 O
experiment NN 0 1 UNK O
non SYM 0 1 1 O
- : 0 0 2 O
diabetic JJ 0 1 6 O
and CC 0 0 12 O
streptozotocin JJ 0 1 UNK O
- : 0 0 2 O
induced VBN 1 1 6 O
diabetic JJ 0 1 6 O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
fasted VBN 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
procedures NNS 1 1 1 O
were VBD 1 0 12 O
followed VBN 1 1 12 O
for IN 0 0 12 O
estimation NN 0 1 UNK O
of IN 0 0 12 O
glucose JJ 0 1 14 B-Drug
tolerance NN 0 1 1 O
9 CD 0 0 2 O
min NN 0 1 16 O
after IN 0 0 12 O
glucose JJ 0 1 14 B-Drug
overload NN 0 0 1 O
. . 0 0 12 O

These DT 0 0 1 O
observations NNS 1 1 1 O
are VBP 1 0 12 O
discussed VBN 1 1 1 O
in IN 0 0 12 O
reference NN 0 1 UNK O
to TO 0 0 12 O
possible JJ 0 1 1 O
deleterious JJ 0 0 6 O
effects NNS 1 1 1 O
following VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
pargyline NN 0 1 UNK B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
Parkinson NNP 0 1 6 O
's POS 0 1 12 O
Disease NNP 0 1 7 O
. . 0 0 12 O

The DT 0 0 2 O
following JJ 0 1 1 O
eight CD 0 1 12 O
target NNS 0 1 1 O
drug NN 0 1 1 O
/ NNP 0 0 2 O
added VBD 1 1 12 O
drug NN 0 1 1 O
combinations NNS 1 1 1 O
were VBD 1 0 12 O
studied VBN 1 0 1 O
: : 0 0 2 O
acetaminophen NN 0 1 16 B-Drug
/ NNP 0 0 2 O
phenobarbital NN 0 1 16 B-Drug
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
an DT 0 0 12 O
increasing VBG 1 1 1 O
incidence NN 0 1 6 O
of IN 0 0 12 O
transient NN 0 1 1 O
thrombocytopenia NN 0 1 14 O
( ( 0 0 2 O
or CC 0 0 12 O
=9 VB 0 0 UNK O
x JJ 0 0 10 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
/ FW 0 0 2 O
L NNP 0 1 2 O
) ) 0 0 2 O
with IN 0 0 12 O
increasing VBG 1 1 1 O
everolimus NN 0 1 13 B-Drug
AUC NNP 0 1 UNK O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

We PRP 0 0 12 O
previously RB 0 0 1 O
reported VBD 1 1 1 O
that DT 0 0 12 O
seeds NNS 1 1 13 O
of IN 0 0 12 O
Artocarpus NNP 0 1 UNK O
integrifolia NN 0 0 UNK O
( ( 0 0 2 O
jackfruit NN 0 1 UNK O
) ) 0 0 2 O
contain VBP 0 1 UNK O
a DT 0 0 12 O
lectin NN 0 1 UNK O
which WDT 0 0 12 O
we PRP 0 0 12 O
call VBP 0 1 12 O
jacalin NN 0 1 UNK B-Drug_n
that WDT 0 0 12 O
is VBZ 1 0 12 O
both DT 0 0 12 O
a DT 0 0 12 O
potent NN 0 1 UNK O
T NNP 0 1 2 O
cell NN 0 1 1 O
mitogen NN 0 1 UNK O
and CC 0 0 12 O
an DT 0 0 12 O
apparently RB 0 1 12 O
T NNP 0 1 2 O
cell NN 0 1 1 O
- : 0 0 2 O
independent JJ 0 1 1 O
activator NN 0 0 UNK O
of IN 0 0 12 O
human JJ 0 1 1 O
B NNP 0 0 2 O
cells NNS 1 1 6 O
for IN 0 0 12 O
the DT 0 0 12 O
secretion NN 0 1 14 O
of IN 0 0 12 O
immunoglobulins NNS 1 1 UNK O
. . 0 0 12 O

More RBR 0 1 UNK O
importantly RB 0 0 UNK O
we PRP 0 0 12 O
demonstrate VBP 0 0 1 O
that DT 0 0 12 O
IgA NNP 0 1 14 O
is VBZ 1 0 12 O
probably RB 0 1 12 O
the DT 0 0 12 O
major JJ 0 1 1 O
serum NN 0 1 14 O
constituent NN 0 1 UNK O
precipitated VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
lectin NN 0 1 UNK O
and CC 0 0 12 O
that IN 0 0 12 O
no DT 0 0 12 O
IgG NNP 0 0 14 O
or CC 0 0 12 O
IgM NNP 0 1 UNK O
can MD 0 0 12 O
be VB 0 0 12 O
detected VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
precipitates NNS 1 1 UNK O
. . 0 0 12 O

CFUs NNP 0 1 UNK O
were VBD 1 0 12 O
maintained VBN 1 1 1 O
at IN 0 0 12 O
low JJ 0 1 1 O
levels NNS 1 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
CFU NNP 0 0 UNK O
mL NN 0 1 14 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
by IN 0 0 12 O
vancomycin NN 0 1 14 B-Drug
/ NNP 0 0 2 O
flavone NN 0 1 UNK O
combinations NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
data NN 0 1 1 O
presented VBD 1 1 1 O
here RB 0 0 12 O
demonstrate JJ 0 0 1 O
that IN 0 0 12 O
with IN 0 0 12 O
serial JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
dosing NN 0 0 14 O
of IN 0 0 12 O
gentamicin NN 0 1 14 B-Drug
the DT 0 0 12 O
iatrogenic JJ 0 1 13 O
alteration NN 0 1 1 O
caused VBN 1 1 1 O
by IN 0 0 12 O
gentamicin JJ 0 1 14 B-Drug
therapy NN 0 1 6 O
can MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O
. . 0 0 12 O

Prior NNP 0 1 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug
- : 0 0 2 O
methylpyrazole NN 0 1 UNK I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
was VBD 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
prevent VB 0 1 1 O
the DT 0 0 12 O
conversion NN 0 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
kg NN 0 1 18 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
to TO 0 0 12 O
( ( 0 0 2 O
- : 0 0 2 O
) ) 0 0 2 O
- : 0 0 2 O
erythro SYM 0 1 13 B-Drug_n
- : 0 0 2 O
fluorocitrate NN 0 1 UNK I-Drug_n
in IN 0 0 12 O
vivo NN 0 1 13 O
and CC 0 0 12 O
to TO 0 0 12 O
eliminate VB 0 0 1 O
the DT 0 0 12 O
fluoride NN 0 1 16 O
and CC 0 0 12 O
citrate NN 0 1 14 O
elevations NNS 1 1 1 O
seen VBN 1 1 12 O
in IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
- : 0 0 2 O
intoxicated JJ 0 0 12 O
animals NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
dissolution NN 0 0 UNK O
medium NN 0 1 3 O
simulating VBG 1 1 UNK O
various JJ 0 1 1 O
body NN 0 1 3 O
environments NNS 1 1 UNK O
with IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
pH NN 0 1 14 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
examined VBN 1 1 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
elucidate VB 0 0 UNK O
the DT 0 0 12 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

Samples NNS 0 1 UNK O
for IN 0 0 12 O
plasma NN 0 1 14 O
and CC 0 0 12 O
urine JJ 0 1 6 O
immunoreactive JJ 0 0 UNK O
digoxin NN 0 1 14 B-Drug
concentrations NNS 1 1 13 O
were VBD 1 0 12 O
collected VBN 1 1 1 O
through IN 0 0 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
the DT 0 0 12 O
digoxin NN 0 1 14 B-Drug
dose NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
chlordiazepoxide JJ 0 1 16 B-Drug
amphetamine NN 0 1 13 B-Drug
and CC 0 0 12 O
cocaine NN 0 1 6 B-Drug
on IN 0 0 12 O
bar NN 0 1 3 O
- : 0 0 2 O
press NN 0 0 13 O
behavior NN 0 1 1 O
in IN 0 0 12 O
normal JJ 0 1 1 O
and CC 0 0 12 O
genetically RB 0 0 UNK O
nervous JJ 0 1 6 O
dogs NNS 1 1 UNK O
. . 0 0 12 O

Nonketotic NNP 0 0 UNK O
genetically RB 0 0 UNK O
diabetic JJ 0 1 6 O
Cinese JJ 0 0 UNK O
hamsters NNS 1 1 UNK O
show VBP 0 1 12 O
subnormal JJ 0 0 UNK O
pancreatic JJ 0 1 6 O
insulin NN 0 1 14 O
release NN 0 1 12 O
and CC 0 0 12 O
impaired JJ 0 1 6 O
suppression NN 0 1 1 O
of IN 0 0 12 O
glucagon NN 0 1 14 O
in IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
glucose VB 0 1 14 O
. . 0 0 12 O

Two CD 0 1 2 O
weeks NNS 1 1 12 O
after IN 0 0 12 O
bilateral JJ 0 1 6 O
ovariectomy JJ 0 1 UNK O
female NN 0 1 12 O
rats NNS 1 1 UNK O
received VBD 1 1 12 O
a DT 0 0 12 O
s.c NN 0 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
now RB 0 1 12 O
strong JJ 0 1 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
intensive JJ 0 1 1 O
control NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
can MD 0 0 12 O
significantly RB 0 0 1 O
reduce VB 0 0 1 O
and CC 0 0 12 O
retard VB 0 1 13 O
the DT 0 0 12 O
microvascular JJ 0 1 8 O
complications NNS 1 1 6 O
of IN 0 0 12 O
retinopathy JJ 0 1 6 O
nephropathy JJ 0 1 14 O
and CC 0 0 12 O
neuropathy JJ 0 1 6 O
. . 0 0 12 O

Furthermore RB 0 0 1 O
no DT 0 0 12 O
significant JJ 0 1 1 O
difference NN 0 1 UNK O
in IN 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
effect NN 0 1 1 O
( ( 0 0 2 O
reduction NN 0 1 1 O
in IN 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
density NN 0 1 1 O
lipoprotein VBP 0 1 13 O
cholesterol NN 0 1 6 O
levels NNS 1 1 1 O
) ) 0 0 2 O
could MD 0 0 12 O
be VB 0 0 12 O
ascertained VBN 1 0 UNK O
between IN 0 0 12 O
mealtime NN 0 1 UNK O
dosing NN 0 0 14 O
and CC 0 0 12 O
bedtime NN 0 1 3 O
dosing NN 0 0 14 O
. . 0 0 12 O

Death NN 0 1 UNK O
in IN 0 0 12 O
amphetamine JJ 0 1 13 B-Drug
users NNS 1 1 UNK O
: : 0 0 2 O
causes NNS 1 1 6 O
and CC 0 0 12 O
rates NNS 1 1 1 O
. . 0 0 12 O

Improved VBN 0 1 2 O
transduction NN 0 1 UNK O
efficiency NN 0 1 UNK O
may MD 0 0 1 O
allow VB 0 1 1 O
intravitreal NN 0 0 UNK O
injection NN 0 1 3 O
to TO 0 0 12 O
become VB 0 0 12 O
the DT 0 0 12 O
preferred JJ 0 1 UNK O
route NN 0 1 12 O
for IN 0 0 12 O
delivering VBG 1 1 UNK O
gene NN 0 1 13 O
therapy NN 0 1 6 O
to TO 0 0 12 O
both DT 0 0 12 O
the DT 0 0 12 O
inner NN 0 1 3 O
and CC 0 0 12 O
outer NN 0 1 UNK O
retina NN 0 1 13 O
. . 0 0 12 O

Interaction NN 0 1 2 O
between IN 0 0 12 O
exogenous JJ 0 1 UNK O
and CC 0 0 12 O
endogenous JJ 0 1 14 O
oxytocin NN 0 1 13 B-Drug
and CC 0 0 12 O
vasopressin NN 0 1 13 O
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
of IN 0 0 12 O
milk NN 0 1 3 O
ejection NN 0 1 3 O
by IN 0 0 12 O
the DT 0 0 12 O
alveoli NN 1 1 8 O
of IN 0 0 12 O
the DT 0 0 12 O
mammary JJ 0 1 6 O
gland NN 0 1 6 O
in IN 0 0 12 O
lactating VBG 1 1 13 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Two CD 0 1 2 O
epidemiological JJ 0 1 UNK O
studies NNS 1 1 1 O
involving VBG 1 1 1 O
about IN 0 1 12 O
9 CD 0 0 2 O
women NNS 1 1 UNK O
have VBP 0 0 12 O
shown VBN 1 1 1 O
a DT 0 0 12 O
link NN 0 1 12 O
between IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
SSRI NNP 0 1 UNK B-Group
antidepressants NNS 1 1 13 I-Group
and CC 0 0 12 O
an DT 0 0 12 O
increased JJ 0 1 1 O
frequency NN 0 1 1 O
of IN 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
recurrence NN 0 1 6 O
. . 0 0 12 O

Results NNS 0 1 2 O
revealed VBD 1 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
strains NNS 1 1 6 O
were VBD 1 0 12 O
resistant JJ 0 1 3 O
to TO 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
at IN 0 0 12 O
high JJ 0 1 1 O
levels NNS 1 1 1 O
only RB 0 1 12 O
piperacillin VBP 0 1 16 B-Drug
carbenicillin JJ 0 1 UNK B-Drug
amikacin NN 0 1 0 B-Drug
and CC 0 0 12 O
ciprofloxacin NN 0 1 0 B-Drug
showed VBD 1 1 12 O
resistances NNS 1 1 UNK O
at IN 0 0 12 O
comparatively RB 0 0 UNK O
lower JJR 1 1 1 O
levels NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
was VBD 1 0 12 O
designed VBN 1 1 UNK O
to TO 0 0 12 O
evaluate VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
basis NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
in IN 0 0 12 O
9 CD 0 0 2 O
normal JJ 0 1 1 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

Spermine NNP 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
) ) 0 0 2 O
promoted VBD 1 1 UNK O
the DT 0 0 12 O
translocation NN 0 1 13 O
of IN 0 0 12 O
phosphatidate JJ 0 1 UNK O
phosphohydrolase NN 0 0 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
soluble JJ 0 1 16 O
to TO 0 0 12 O
the DT 0 0 12 O
microsomal JJ 0 1 UNK O
fraction NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
cell NN 0 1 1 O
- : 0 0 2 O
free JJ 0 1 12 O
system NN 0 1 1 O
derived VBN 1 1 UNK O
from IN 0 0 12 O
rat NN 0 1 13 O
liver NN 0 1 6 O
. . 0 0 12 O

Results NNS 0 1 2 O
of IN 0 0 12 O
BP NNP 0 1 13 O
self PRP 0 1 12 O
- : 0 0 2 O
control NN 0 1 1 O
were VBD 1 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
clinical JJ 0 1 6 O
measurements NNS 1 1 1 O
in IN 0 0 12 O
order NN 0 1 1 O
to TO 0 0 12 O
detect VB 0 1 UNK O
concealed JJ 0 1 UNK O
inefficacy NN 0 0 UNK O
of IN 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

Diazepam NNP 0 1 UNK B-Drug
at IN 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg NNS 0 1 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
injected VBD 1 1 3 O
with IN 0 0 12 O
morphine NN 0 1 14 B-Drug
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
incidence NN 0 1 6 O
of IN 0 0 12 O
cardiovascular JJ 0 1 6 O
morbidity NN 0 1 13 O
and CC 0 0 12 O
mortality NN 0 1 13 O
is VBZ 1 0 12 O
not RB 0 1 12 O
higher JJR 1 1 1 O
among IN 0 0 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
sildenafil NN 0 1 16 B-Drug
. . 0 0 12 O

[ JJ 0 0 2 O
Stimulation NNP 0 1 UNK O
by IN 0 0 12 O
cerulein NN 0 1 UNK B-Drug_n
- : 0 0 2 O
- : 0 0 2 O
an DT 0 0 12 O
analog NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
octapeptide NN 0 0 UNK O
cholecystokinin NN 0 1 UNK O
- : 0 0 2 O
- : 0 0 2 O
of IN 0 0 12 O
9H CD 0 0 UNK B-Drug_n
- : 0 0 2 O
spiroperidol NN 0 1 UNK I-Drug_n
binding NN 0 1 1 O
after IN 0 0 12 O
the DT 0 0 12 O
long JJ 0 1 12 O
- : 0 0 2 O
term NN 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
] VBP 0 0 2 O
It PRP 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
established VBN 1 1 1 O
in IN 0 0 12 O
experiments NNS 1 1 UNK O
on IN 0 0 12 O
white JJ 0 1 3 O
male NN 0 1 12 O
rats NNS 1 1 UNK O
that WDT 0 0 12 O
prolonged VBD 1 1 6 O
administration NN 0 1 1 O
( ( 0 0 2 O
twice RB 0 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
of IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
and CC 0 0 12 O
pyreneperone NN 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
reduced JJ 0 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
9H CD 0 0 UNK B-Drug_n
- : 0 0 2 O
spiroperidol NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
low JJ 0 1 1 O
affinity NN 0 1 UNK O
binding NN 0 1 1 O
sites NNS 1 1 1 O
for IN 0 0 12 O
apomorphine NN 0 1 UNK B-Drug
in IN 0 0 12 O
subcortical JJ 0 1 8 O
structures NNS 1 1 1 O
whereas VBP 0 0 UNK O
9H CD 0 0 UNK B-Drug_n
- : 0 0 2 O
spiroperidol NN 0 1 UNK I-Drug_n
binding VBG 1 1 1 O
with IN 0 0 12 O
high JJ 0 1 1 O
affinity NN 0 1 UNK O
binding NN 0 1 1 O
sites NNS 1 1 1 O
for IN 0 0 12 O
apomorphine NN 0 1 UNK B-Drug
increased VBN 1 1 1 O
both DT 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
frontal JJ 0 1 3 O
cortex NN 0 1 6 O
and CC 0 0 12 O
subcortical JJ 0 1 8 O
structures NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
forebrain NN 0 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
not RB 0 1 12 O
only RB 0 1 12 O
improve VB 0 0 1 O
insulin NN 0 1 14 O
sensitivity NN 0 1 1 O
and CC 0 0 12 O
glycemic JJ 0 1 14 O
control NN 0 1 1 O
with IN 0 0 12 O
reduced JJ 0 1 1 O
insulin NN 0 1 14 O
requirements NNS 1 1 1 O
but CC 0 0 12 O
also RB 0 0 12 O
have VBP 0 0 12 O
potentially RB 0 0 1 O
favorable JJ 0 1 UNK O
effects NNS 1 1 1 O
on IN 0 0 12 O
other JJ 0 0 12 O
components NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
cardiovascular JJ 0 1 6 O
dysmetabolic JJ 0 0 13 O
syndrome NN 0 1 6 O
. . 0 0 12 O

[ NN 0 0 2 O
Dose NNP 0 1 7 O
- : 0 0 2 O
time NN 0 1 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
competitive JJ 0 1 UNK O
displacement NN 0 1 1 O
of IN 0 0 12 O
radiopertechnetate NN 0 0 UNK B-Drug
by IN 0 0 12 O
sodium NN 0 1 14 B-Drug_n
perchlorate NN 0 1 UNK I-Drug_n
following VBG 1 1 1 O
oral JJ 0 1 6 O
and CC 0 0 12 O
intravenous JJ 0 1 14 O
administration NN 0 1 1 O
] IN 0 0 2 O
The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
various JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
sodium NN 0 1 14 B-Drug_n
perchlorate NN 0 1 UNK I-Drug_n
in IN 0 0 12 O
several JJ 0 1 12 O
dose JJ 0 1 6 O
fractions NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
and CC 0 0 12 O
the DT 0 0 12 O
time NN 0 1 12 O
scale NN 0 1 1 O
of IN 0 0 12 O
displacement NN 0 1 1 O
of IN 0 0 12 O
radiopertechnetate NN 0 0 UNK B-Drug
in IN 0 0 12 O
dependence NN 0 1 1 O
on IN 0 0 12 O
application NN 0 1 1 O
mode NN 0 1 1 O
was VBD 1 0 12 O
studied VBN 1 0 1 O
. . 0 0 12 O

Plasma NNP 0 1 UNK O
was VBD 1 0 12 O
analyzed VBN 1 1 13 O
for IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
and CC 0 0 12 O
urine NN 0 1 6 O
was VBD 1 0 12 O
analyzed VBN 1 1 13 O
for IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
two CD 0 1 12 O
metabolites NNS 1 1 UNK O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
hydroxytolbutamide NN 0 0 UNK I-Drug_n
and CC 0 0 12 O
carboxytolbutamide NN 0 1 UNK B-Drug_n
by IN 0 0 12 O
means NNS 1 1 13 O
of IN 0 0 12 O
HPLC NNP 0 1 UNK O
. . 0 0 12 O

Our PRP$ 0 0 2 O
secondary JJ 0 1 1 O
objective NN 0 1 13 O
was VBD 1 0 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
there EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
relationship NN 0 1 12 O
between IN 0 0 12 O
the DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
PTH NNP 0 0 14 O
and CC 0 0 12 O
darbepoetin JJ 0 0 13 B-Drug
requirement NN 0 1 1 O
. . 0 0 12 O

Neurochemical JJ 0 0 UNK O
and CC 0 0 12 O
functional JJ 0 1 1 O
consequences NNS 1 1 UNK O
following VBG 1 1 1 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
( ( 0 0 2 O
MPTP NNP 0 1 UNK B-Drug_n
) ) 0 0 2 O
and CC 0 0 12 O
methamphetamine NN 0 1 UNK B-Drug
. . 0 0 12 O

Also RB 0 0 2 O
included VBN 1 1 1 O
in IN 0 0 12 O
this DT 0 0 12 O
paper NN 0 1 13 O
is VBZ 1 0 12 O
a DT 0 0 12 O
study NN 0 1 1 O
which WDT 0 0 12 O
confirms VBZ 1 1 UNK O
the DT 0 0 12 O
identity NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
HPLC NNP 0 1 UNK O
peak NN 0 1 1 O
as IN 1 0 12 O
being VBG 1 0 12 O
homocysteine NN 0 1 13 O
by IN 0 0 12 O
forming VBG 1 1 3 O
a DT 0 0 12 O
radioactive JJ 0 1 1 O
derivative NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
particular JJ 0 0 1 O
sulphydryl NN 0 1 UNK O
- : 0 0 2 O
containing NN 0 1 1 O
amino NN 0 0 16 O
acid NN 0 1 14 O
and CC 0 0 12 O
then RB 0 1 12 O
analysing VBG 1 0 UNK O
the DT 0 0 12 O
resulting JJ 0 1 1 O
mixture NN 0 1 3 O
by IN 0 0 12 O
TLC NNP 0 0 13 O
. . 0 0 12 O

Other JJ 0 0 2 O
factors NNS 1 1 1 O
may MD 0 0 1 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
including VBG 1 1 1 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
myopathy JJ 0 1 8 O
underlying VBG 1 0 1 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
and CC 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
HMG NNP 0 0 UNK B-Group
- : 0 0 2 O
CoA NNP 0 0 UNK I-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
. . 0 0 12 O

Slow NNP 0 1 UNK B-Group
- : 0 0 2 O
channel NN 0 1 1 I-Group
calcium NN 0 1 14 I-Group
blockers NNS 1 0 6 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
verapamil NN 0 1 0 B-Drug
diltiazem NN 0 1 0 B-Drug
and CC 0 0 12 O
nifedipine JJ 0 1 0 B-Drug
inhibit NN 0 1 13 O
platelet NN 0 1 14 O
activation NN 0 1 13 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
decrease NN 0 1 1 O
platelet NN 0 1 14 O
adhesion NN 0 1 13 O
intravascularly RB 0 0 UNK O
. . 0 0 12 O

Coadministration NN 0 1 UNK O
of IN 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
significantly RB 0 0 1 O
decreased VBD 1 1 1 O
cisapride JJ 0 1 UNK B-Drug
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
. . 0 0 12 O

Analgesia NNP 0 1 UNK O
and CC 0 0 12 O
pupil JJ 0 1 1 O
constriction NN 0 1 8 O
were VBD 1 0 12 O
measured VBN 1 1 1 O
. . 0 0 12 O

n SYM 0 1 12 B-Drug
- : 0 0 2 O
dodecyl NN 0 0 UNK I-Drug
gallate NN 0 0 UNK I-Drug
showed VBD 1 1 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
potent JJ 0 1 UNK O
inhibition NN 0 1 13 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
inhibition NN 0 1 13 O
at IN 0 0 12 O
9 CD 0 0 2 O
microM NN 0 0 UNK O
) ) 0 0 2 O
which WDT 0 0 12 O
was VBD 1 0 12 O
far RB 0 1 12 O
more RBR 0 1 12 O
potent JJ 0 1 UNK O
than IN 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
crude NN 0 0 UNK O
tannic JJ 0 0 UNK B-Drug
acid NN 0 1 14 I-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
now RB 0 1 12 O
clear JJ 0 1 12 O
that IN 0 0 12 O
topoisomerase NN 0 1 UNK O
activity NN 0 1 1 O
level NN 0 1 1 O
is VBZ 1 0 12 O
an DT 0 0 12 O
important JJ 0 1 1 O
determinant NN 0 1 UNK O
of IN 0 0 12 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
topo VB 0 1 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

But CC 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
fixed JJ 0 1 1 O
combination NN 0 1 1 O
amlodipine NN 0 1 0 B-Drug
/ NNP 0 0 2 O
valsartan NN 0 1 0 B-Drug
compared VBN 1 1 1 O
with IN 0 0 12 O
traditional JJ 0 1 UNK O
therapy NN 0 1 6 O
was VBD 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
lower JJR 1 1 1 O
clinical NN 0 1 6 O
and CC 0 0 12 O
self NN 0 1 12 O
measured VBN 1 1 1 O
BP NNP 0 1 13 O
quicker RBR 0 1 UNK O
achievement NN 0 1 UNK O
of IN 0 0 12 O
target NN 0 1 1 O
BP NNP 0 1 13 O
( ( 0 0 2 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
respectively RB 0 0 1 O
9 CD 0 0 2 O
) ) 0 0 2 O
lesser JJR 1 1 1 O
number NN 0 1 1 O
of IN 0 0 12 O
antihypertensive JJ 0 1 14 B-Group
drugs NNS 1 1 6 I-Group
( ( 0 0 2 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9+ CD 0 0 16 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
respectively RB 0 0 1 O
) ) 0 0 2 O
lower JJR 1 1 1 O
rate NN 0 1 1 O
of IN 0 0 12 O
concealed JJ 0 1 UNK O
inefficacy NN 0 0 UNK O
of IN 0 0 12 O
treatment NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

All DT 0 0 2 O
subjects NNS 1 1 UNK O
received VBN 1 1 12 O
amprenavir RB 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
twice RB 0 1 12 O
a DT 0 0 12 O
day NN 0 1 12 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
washout IN 0 1 3 O
period NN 0 1 1 O
followed VBN 1 1 12 O
by IN 0 0 12 O
either DT 0 1 12 O
rifabutin NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
a DT 0 0 12 O
day NN 0 1 12 O
[ NNP 0 0 2 O
QD NNP 0 1 13 O
] NNP 0 0 2 O
) ) 0 0 2 O
( ( 0 0 2 O
cohort $ 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
or CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
QD NNP 0 1 13 O
) ) 0 0 2 O
( ( 0 0 2 O
cohort $ 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
basal NN 0 1 6 O
colonic JJ 0 1 6 O
fluid NN 0 1 3 O
contents NNS 1 1 1 O
and CC 0 0 12 O
transits NNS 1 1 UNK O
were VBD 1 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
control NN 0 1 1 O
rats NNS 1 1 UNK O
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
In IN 0 0 2 O
contrast NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
glucocorticoids NNS 1 1 UNK B-Group
in IN 0 0 12 O
rodent JJ 0 1 UNK O
studies NNS 1 1 1 O
these DT 0 0 12 O
results NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
an DT 0 0 12 O
acute JJ 0 1 6 O
increase NN 0 1 1 O
in IN 0 0 12 O
cortisol NN 0 1 14 O
does VBZ 1 0 12 O
not RB 0 1 12 O
enhance VB 0 1 UNK O
the DT 0 0 12 O
psychostimulant JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
d JJ 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
in IN 0 0 12 O
humans NNS 1 1 UNK O
. . 0 0 12 O

Diabetic JJ 0 1 7 O
patients NNS 1 1 6 O
have VBP 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
higher JJR 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
depression NN 0 1 6 O
than IN 0 0 12 O
the DT 0 0 12 O
general JJ 0 1 1 O
population NN 0 1 13 O
. . 0 0 12 O

Onset NNP 0 1 7 O
of IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
began VBD 1 1 12 O
within IN 0 0 1 O
five CD 0 1 12 O
days NNS 1 1 12 O
of IN 0 0 12 O
beginning VBG 1 1 12 O
concurrent JJ 0 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

Two CD 0 1 2 O
different JJ 0 1 1 O
types NNS 1 1 1 O
of IN 0 0 12 O
therapy NN 0 1 6 O
with IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
are VBP 1 0 12 O
used VBN 1 1 12 O
: : 0 0 2 O
physiological JJ 0 1 13 O
oral JJ 0 1 6 O
magnesium NN 0 1 14 B-Drug
supplementation NN 0 1 14 O
which WDT 0 0 12 O
is VBZ 1 0 12 O
totally RB 0 0 12 O
atoxic JJ 0 0 UNK O
since IN 0 1 12 O
it PRP 0 0 12 O
palliates VBZ 1 1 UNK O
magnesium JJ 0 1 14 B-Drug
deficiencies NNS 1 1 13 O
by IN 0 0 12 O
simply RB 0 0 12 O
normalizing VBG 1 1 1 O
the DT 0 0 12 O
magnesium NN 0 1 14 B-Drug
intake NN 0 1 3 O
and CC 0 0 12 O
pharmacological JJ 0 1 14 O
magnesium NN 0 1 14 B-Drug
therapy NN 0 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
induce VB 0 1 6 O
toxicity NN 0 1 6 O
since IN 0 1 12 O
it PRP 0 0 12 O
creates VBZ 1 1 UNK O
iatrogenic JJ 0 1 13 O
magnesium NN 0 1 14 B-Drug
overload NN 0 0 1 O
. . 0 0 12 O

endocrine JJ 0 1 6 O
dysfunction NN 0 1 6 O
; : 0 0 2 O

To TO 0 0 2 O
determine VB 0 0 1 O
whether IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
has VBZ 1 0 12 O
a DT 0 0 12 O
direct JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
distribution NN 0 1 1 O
of IN 0 0 12 O
cloxacillin NN 0 1 UNK B-Drug
the DT 0 0 12 O
elimination NN 0 1 UNK O
and CC 0 0 12 O
distribution NN 0 1 1 O
of IN 0 0 12 O
cloxacillin NN 0 1 UNK B-Drug
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
six CD 0 1 12 O
patients NNS 1 1 6 O
five CD 0 1 12 O
lacking VBG 1 1 13 O
kidney NN 0 1 6 O
function NN 0 1 1 O
and CC 0 0 12 O
one CD 0 1 12 O
with IN 0 0 12 O
a DT 0 0 12 O
partially RB 0 0 1 O
impaired JJ 0 1 6 O
renal JJ 0 1 6 O
function NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
or CC 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
probenecid NN 0 1 13 B-Drug
. . 0 0 12 O

At IN 0 0 2 O
stable JJ 0 1 1 O
As IN 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
concentrations NNS 1 1 13 O
greater JJR 1 1 1 O
than IN 0 0 12 O
9 CD 0 0 2 O
mM JJ 0 0 UNK O
fractional JJ 0 1 1 O
mucosal NN 0 1 8 O
cell NN 0 1 1 O
accumulation NN 0 1 1 O
of IN 0 0 12 O
As NNP 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
remains VBZ 1 0 12 O
constant JJ 0 1 1 O
while IN 0 0 12 O
fractional JJ 0 1 1 O
transfer NN 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
declines VBZ 1 0 UNK O
. . 0 0 12 O

Transfer NN 0 1 2 O
from IN 0 0 12 O
the DT 0 0 12 O
intestinal JJ 0 1 13 O
lumen NNS 0 1 8 O
to TO 0 0 12 O
the DT 0 0 12 O
mucosal NN 0 1 8 O
cells NNS 1 1 6 O
at IN 0 0 12 O
low JJ 0 1 1 O
As IN 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
concentration NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
) ) 0 0 2 O
is VBZ 1 0 12 O
rapid JJ 0 1 1 O
while IN 0 0 12 O
transfer NN 0 1 1 O
from IN 0 0 12 O
the DT 0 0 12 O
mucosal NN 0 1 8 O
cells NNS 1 1 6 O
to TO 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
occurs VBZ 1 1 1 O
more RBR 0 1 12 O
slowly RB 0 1 3 O
. . 0 0 12 O

This DT 0 0 2 O
observation NN 0 1 1 O
has VBZ 1 0 12 O
important JJ 0 1 1 O
implications NNS 1 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
context NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
transplant JJ 0 1 6 O
recipients NNS 1 1 UNK O
. . 0 0 12 O

saline NN 0 1 14 O
+ NNP 0 0 2 O
saline NN 0 1 14 O
ephedrine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
+ FW 0 0 2 O
saline JJ 0 1 14 O
saline NN 0 1 14 O
+ NNP 0 0 2 O
dexmedetomidine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
and CC 0 0 12 O
ephedrine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
+ FW 0 0 2 O
dexmedetomidine NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
intraperitoneally RB 0 0 UNK O
9 CD 0 0 2 O
min NNS 0 1 16 O
before IN 0 1 12 O
hot JJ 0 1 3 O
plate NN 0 1 3 O
or CC 0 0 12 O
holed VBN 1 1 UNK O
open JJ 0 1 12 O
field NN 0 1 1 O
tests NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
evoked VBD 1 1 13 O
potentials NNS 1 1 UNK O
were VBD 1 0 12 O
recorded VBN 1 1 12 O
at IN 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
min NN 0 1 16 O
following VBG 1 1 1 O
IP NNP 0 1 2 O
injections NNS 1 1 6 O
of IN 0 0 12 O
saline NN 0 1 14 O
ethanol NN 0 1 1 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
g NN 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
physostigmine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
or CC 0 0 12 O
atropine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
on IN 0 0 12 O
separate JJ 0 1 1 O
days NNS 1 1 12 O
. . 0 0 12 O

and CC 0 0 12 O
exert VB 0 1 13 O
direct JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
mechanisms NN 1 1 UNK O
of IN 0 0 12 O
insulin NN 0 1 14 O
resistance NN 0 1 1 O
. . 0 0 12 O

Being VBG 0 0 2 O
moxifloxacin NN 0 1 16 B-Drug
and CC 0 0 12 O
lomefloxacin NN 0 1 UNK O
fluoroquinolones NNS 0 1 UNK B-Group
the DT 0 0 12 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
was VBD 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
with IN 0 0 12 O
sucralfate JJ 0 1 0 B-Drug
gelusil NNS 0 1 UNK B-Brand
erythromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
multi NN 0 1 16 B-Group
minerals NNS 1 1 16 I-Group
. . 0 0 12 O

Considering VBG 0 1 UNK O
the DT 0 0 12 O
variability NN 0 1 UNK O
in IN 0 0 12 O
exposure NN 0 1 1 O
following VBG 1 1 1 O
enzyme JJ 0 1 14 O
inhibition NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
fact NN 0 0 12 O
that IN 0 0 12 O
chronic JJ 0 1 6 O
dosing NN 0 0 14 O
of IN 0 0 12 O
panobinostat NN 0 1 UNK B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
studied VBN 1 0 1 O
with IN 0 0 12 O
CYP9A NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
close RB 0 1 12 O
monitoring NN 0 1 1 O
of IN 0 0 12 O
panobinostat JJ 0 1 UNK B-Drug
- : 0 0 2 O
related JJ 0 1 1 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
is VBZ 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

to TO 0 0 12 O
contend VB 0 0 UNK O
with IN 0 0 12 O
. . 0 0 12 O

Consequently RB 0 0 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
iron NN 0 1 3 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
retention NN 0 1 1 O
of IN 0 0 12 O
cobalt NN 0 1 UNK B-Drug
was VBD 1 0 12 O
lower JJR 1 1 1 O
than IN 0 0 12 O
on IN 0 0 12 O
absorption NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
demonstrate VBP 0 0 1 O
a DT 0 0 12 O
high JJ 0 1 1 O
degree NN 0 1 1 O
of IN 0 0 12 O
stereoselectivity NN 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
NANM NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

Compromised VBN 0 0 UNK O
norepinephrine JJ 0 1 14 B-Drug
uptake JJ 0 1 14 O
- : 0 0 2 O
9 CD 0 0 2 O
in IN 0 0 12 O
functional JJ 0 1 1 O
class NN 0 1 12 O
IV NNP 0 1 2 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
further RBR 1 1 1 O
increased VBN 1 1 1 O
by IN 0 0 12 O
cocaine NN 0 1 6 B-Drug
and CC 0 0 12 O
desipramine NN 0 1 16 B-Drug
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
evaluated VBD 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
potent JJ 0 1 UNK O
CYP9A NNP 0 0 UNK O
inhibitor NN 0 1 14 O
ketoconazole NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
safety NN 0 1 1 O
of IN 0 0 12 O
panobinostat NN 0 1 UNK B-Drug
. . 0 0 12 O

Western JJ 0 1 2 O
- : 0 0 2 O
blot NN 0 0 UNK O
analysis NN 0 1 1 O
indicated VBD 1 1 1 O
ALOX9 NNP 0 0 UNK O
was VBD 1 0 12 O
highly RB 0 1 1 O
expressed VBN 1 0 1 O
only RB 0 1 12 O
in IN 0 0 12 O
sensitive JJ 0 1 1 O
cell NN 0 1 1 O
line NN 0 1 12 O
H9 NNP 0 0 UNK O
and CC 0 0 12 O
greatly RB 0 1 1 O
decreased VBN 1 1 1 O
upon IN 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
treatment NN 0 1 6 O
. . 0 0 12 O

Median JJ 0 1 18 O
gastric NN 0 1 6 O
pH NN 0 1 14 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
when WRB 0 0 12 O
indinavir NN 0 1 16 B-Drug
was VBD 1 0 12 O
taken VBN 1 1 12 O
after IN 0 0 12 O
didanosine JJ 0 1 16 B-Drug
administration NN 0 1 1 O
; : 0 0 2 O

METHODS NNS 0 1 UNK O
: : 0 0 2 O
From IN 0 0 2 O
the DT 0 0 12 O
beginning NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
experiment NN 0 1 UNK O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
given VBN 1 1 12 O
9 CD 0 0 2 O
weekly JJ 0 1 12 O
subcutaneous JJ 0 1 14 O
injections NNS 1 1 6 O
of IN 0 0 12 O
AOM NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
and CC 0 0 12 O
subcutaneous JJ 0 1 14 O
injections NNS 1 1 6 O
of IN 0 0 12 O
bombesin NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
/ NNP 0 0 2 O
kg VBZ 0 1 18 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
every DT 0 0 12 O
other JJ 0 0 12 O
day NN 0 1 12 O
and CC 0 0 12 O
from IN 0 0 12 O
week NN 0 1 12 O
9 CD 0 0 2 O
intraperitoneal JJ 0 1 14 O
injections NNS 1 1 6 O
of IN 0 0 12 O
verapamil NN 0 1 0 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
kg FW 0 1 18 O
body NN 0 1 3 O
weight NN 0 1 3 O
) ) 0 0 2 O
every DT 0 0 12 O
other JJ 0 0 12 O
day NN 0 1 12 O
until IN 0 0 12 O
the DT 0 0 12 O
end NN 0 1 12 O
fo VBZ 0 0 UNK O
the DT 0 0 12 O
experiment NN 0 1 UNK O
in IN 0 0 12 O
week NN 0 1 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Much RB 0 0 2 O
less JJR 0 1 12 O
caspase JJ 0 1 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
activity NN 0 1 1 O
was VBD 1 0 12 O
noted VBN 1 0 1 O
in IN 0 0 12 O
the DT 0 0 12 O
lysate NN 0 1 UNK O
derived VBN 1 1 UNK O
from IN 0 0 12 O
serum NN 0 1 14 O
- : 0 0 2 O
deprived VBN 1 0 UNK O
RAS NNP 0 1 UNK O
- : 0 0 2 O
9T9 CD 0 0 UNK O
cells NNS 1 1 6 O
compared VBN 1 1 1 O
with IN 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
lysate NN 0 1 UNK O
of IN 0 0 12 O
serum NN 0 1 14 O
- : 0 0 2 O
deprived VBN 1 0 UNK O
NIH NNP 0 1 1 O
- : 0 0 2 O
9T9 CD 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

Misonidazole NNP 0 1 UNK B-Drug_n
reduced VBD 1 1 1 O
the DT 0 0 12 O
antitumour JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
CCNU NNP 0 1 UNK B-Drug
by IN 0 0 12 O
dose JJ 0 1 6 O
modifying VBG 1 1 UNK O
factors NNS 1 1 1 O
( ( 0 0 2 O
DMF NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
combinational JJ 0 1 UNK O
action NN 0 1 13 O
in IN 0 0 12 O
reversing VBG 1 1 UNK O
vancomycin JJ 0 1 14 O
resistance NN 0 1 1 O
of IN 0 0 12 O
enterococci JJ 0 1 UNK O
highlights NNS 1 0 UNK O
novel JJ 0 1 13 O
drug NN 0 1 1 O
targets NNS 1 1 UNK O
and CC 0 0 12 O
has VBZ 1 0 12 O
importance NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
design NN 0 1 UNK O
of IN 0 0 12 O
new JJ 0 1 12 O
therapeutic JJ 0 1 6 O
regimes NNS 1 0 UNK O
against IN 0 0 12 O
resistant JJ 0 1 3 O
pathogens NNS 1 1 6 O
. . 0 0 12 O

Our PRP$ 0 0 2 O
objective NN 0 1 13 O
was VBD 1 0 12 O
to TO 0 0 12 O
establish VB 0 1 UNK O
potential JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
on IN 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
nonheme NN 0 0 UNK B-Drug
and CC 0 0 12 O
heme NN 0 1 14 B-Drug
iron NN 0 1 3 I-Drug
and CC 0 0 12 O
the DT 0 0 12 O
dose JJ 0 1 6 O
response NN 0 1 1 O
for IN 0 0 12 O
this DT 0 0 12 O
effect NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
meal NN 0 1 12 O
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
is VBZ 1 0 12 O
the DT 0 0 12 O
only JJ 0 1 12 O
known JJ 0 1 12 O
component NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
diet NN 0 1 6 O
that WDT 0 0 12 O
may MD 0 0 1 O
affect VB 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
nonheme JJ 0 0 UNK B-Drug
and CC 0 0 12 O
heme JJ 0 1 14 B-Drug
iron NN 0 1 3 I-Drug
. . 0 0 12 O

In IN 0 0 2 O
experiment JJ 0 1 UNK O
9 CD 0 0 2 O
the DT 0 0 12 O
same JJ 0 1 12 O
regimen NN 0 1 6 O
of IN 0 0 12 O
GSLS NNP 0 1 UNK B-Drug_n
was VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
chickens NNS 1 1 UNK O
inoculated VBN 1 1 UNK O
with IN 0 0 12 O
inactivated JJ 0 0 UNK B-Drug
AI NNP 0 1 13 I-Drug
vaccines NNS 1 1 6 I-Drug
and CC 0 0 12 O
an DT 0 0 12 O
enhanced JJ 0 1 1 O
serum NN 0 1 14 O
antibody NN 0 1 14 O
response NN 0 1 1 O
to TO 0 0 12 O
AI NNP 0 1 13 O
vaccination NN 0 1 6 O
was VBD 1 0 12 O
also RB 0 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
behavioural JJ 0 1 UNK O
observations NNS 1 1 1 O
were VBD 1 0 12 O
consistent JJ 0 1 1 O
with IN 0 0 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
positron NN 0 1 UNK O
emission NN 0 1 UNK O
tomography NN 0 1 8 O
dopamine NN 0 1 14 O
transporter NN 0 1 UNK O
imaging VBG 1 1 1 O
data NNS 0 1 1 O
and CC 0 0 12 O
with IN 0 0 12 O
post NN 0 1 12 O
- : 0 0 2 O
mortem NN 0 0 UNK O
stereological JJ 0 0 UNK O
counts NNS 1 1 1 O
of IN 0 0 12 O
midbrain NN 0 1 13 O
dopaminergic JJ 0 1 UNK O
neurons NNS 1 1 UNK O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
striatal JJ 0 1 UNK O
intensity NN 0 1 1 O
measurements NNS 1 1 1 O
of IN 0 0 12 O
dopamine NN 0 1 14 O
transporter NN 0 1 UNK O
and CC 0 0 12 O
tyrosine JJ 0 1 13 O
hydroxylase NN 0 1 UNK O
immunoreactivity NN 0 1 UNK O
which WDT 0 0 12 O
were VBD 1 0 12 O
all DT 0 0 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ VBZ 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
[ NN 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
thiazol NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
yl NN 0 0 UNK I-Drug_n
) ) 0 0 2 O
ethynyl NN 0 0 UNK I-Drug_n
] FW 0 0 2 O
pyridine NN 0 1 UNK I-Drug_n
- : 0 0 2 O
treated VBN 1 1 1 O
animals NNS 1 1 12 O
than IN 0 0 12 O
in IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
methyl NN 0 0 13 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
phenyl NN 0 1 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
tetrahydropyridine NN 0 0 UNK I-Drug_n
/ NN 0 0 2 O
vehicle NN 0 1 1 O
- : 0 0 2 O
treated VBN 1 1 1 O
monkeys NNS 1 1 UNK O
. . 0 0 12 O

Combinations NNS 0 1 UNK O
of IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
and CC 0 0 12 O
gentamicin NN 0 1 14 B-Drug
were VBD 1 0 12 O
indifferent JJ 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
strains NNS 1 1 6 O
and CC 0 0 12 O
synergistic JJ 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
strains NNS 1 1 6 O
. . 0 0 12 O

During IN 0 0 2 O
the DT 0 0 12 O
above JJ 0 1 12 O
experiments NNS 1 1 UNK O
we PRP 0 0 12 O
noted VBD 1 0 1 O
a DT 0 0 12 O
massive JJ 0 1 12 O
precipitation NN 0 1 1 O
in IN 0 0 12 O
cell NN 0 1 1 O
cultures NNS 1 1 1 O
stimulated VBN 1 1 13 O
with IN 0 0 12 O
greater JJR 1 1 1 O
than IN 0 0 12 O
or CC 0 0 12 O
equal JJ 0 1 1 O
to TO 0 0 12 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
of IN 0 0 12 O
lectin NN 0 1 UNK O
. . 0 0 12 O

Although IN 0 0 12 O
single JJ 0 1 12 O
or CC 0 0 12 O
concurrent JJ 0 1 1 O
use NN 0 1 1 O
of IN 0 0 12 O
sunitinib NN 0 1 13 B-Drug
and CC 0 0 12 O
docetaxel NN 0 1 13 B-Drug
has VBZ 1 0 12 O
some DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
proliferative JJ 0 1 13 O
effects NNS 1 1 1 O
the DT 0 0 12 O
sequential JJ 0 1 1 O
administrations NNS 1 1 UNK O
of IN 0 0 12 O
both DT 0 0 12 O
drugs NNS 1 1 6 O
remarkably RB 0 0 UNK O
enhanced VBD 1 1 1 O
anti JJ 0 0 3 O
- : 0 0 2 O
tumor NN 0 1 6 O
activity NN 0 1 1 O
. . 0 0 12 O

RESULTS NN 0 1 11 O
: : 0 0 2 O
Insulin NNP 0 1 7 B-Drug
increased VBD 1 1 1 O
renal JJ 0 1 6 O
plasma NN 0 1 14 O
flow NN 0 1 1 O
and CC 0 0 12 O
fundus JJ 0 1 8 O
pulsation NN 0 0 13 O
amplitude NN 0 1 1 O
but CC 0 0 12 O
not RB 0 1 12 O
the DT 0 0 12 O
glomerular JJ 0 1 UNK O
filtration NN 0 1 3 O
rate NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
minimal JJ 0 1 1 O
inhibitory JJ 0 1 UNK O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
and CC 0 0 12 O
gentamicin VB 0 1 14 B-Drug
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
combinations NNS 1 1 1 O
were VBD 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
microdilution NN 0 0 UNK O
method NN 0 1 13 O
for IN 0 0 12 O
9 CD 0 0 2 O
aerobic JJ 0 1 6 O
facultative JJ 0 0 UNK O
and CC 0 0 12 O
anaerobic JJ 0 1 14 O
clinical JJ 0 1 6 O
isolates NNS 0 1 14 O
. . 0 0 12 O

there EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
change NN 0 1 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
test NN 0 1 1 O
results NNS 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
trials NNS 1 1 1 O
of IN 0 0 12 O
chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
and CC 0 0 12 O
methaqualone NN 0 1 13 B-Drug
. . 0 0 12 O

9 CD 0 0 2 O
PI NNP 0 1 UNK O
affecting VBG 1 1 1 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
+ NNP 0 0 2 O
/ NNP 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
identified VBN 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
LST NNP 0 1 UNK O
mice NN 1 1 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
show VB 0 1 12 O
any DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
Kd NNP 0 1 UNK O
and CC 0 0 12 O
Bmax NNP 0 0 UNK O
in IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
STR NNP 0 0 UNK O
or CC 0 0 12 O
the DT 0 0 12 O
NAC NNP 0 1 UNK O
. . 0 0 12 O

washout NN 0 1 3 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
; : 0 0 2 O

9 CD 0 0 2 O
. . 0 0 12 O

Bleeding NNP 0 1 7 O
is VBZ 1 0 12 O
the DT 0 0 12 O
most RBS 0 0 12 O
common JJ 0 1 1 O
and CC 0 0 12 O
worrisome JJ 0 0 1 O
adverse JJ 0 0 1 O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
therapy NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
roles NNS 1 1 UNK O
of IN 0 0 12 O
p9 NN 0 1 UNK O
( ( 0 0 2 O
Kip9 NNP 0 0 UNK O
) ) 0 0 2 O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Cdk9 NNP 0 1 UNK O
in IN 0 0 12 O
apoptosis NN 0 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
dasatinib NN 0 1 13 B-Drug
and CC 0 0 12 O
paclitaxel NN 0 1 13 B-Drug
were VBD 1 0 12 O
assessed VBN 1 1 1 O
using VBG 1 1 1 O
a DT 0 0 12 O
terminal JJ 0 1 1 O
deoxynucleotidyl NN 0 0 UNK O
transferase NN 0 1 14 O
- : 0 0 2 O
mediated VBN 1 1 13 O
dUTP NN 0 1 UNK O
nick SYM 0 0 UNK O
- : 0 0 2 O
end NN 0 1 12 O
labeling NN 0 1 UNK O
( ( 0 0 2 O
TUNEL NNP 0 1 UNK O
) ) 0 0 2 O
assay VBP 0 1 14 O
siRNA JJ 0 1 UNK O
knockdown NN 0 0 UNK O
of IN 0 0 12 O
gene NN 0 1 13 O
expression NN 0 1 1 O
transfection NN 0 1 UNK O
with IN 0 0 12 O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Cdk9 NNP 0 1 UNK O
expression NN 0 1 1 O
vectors NNS 1 1 UNK O
and CC 0 0 12 O
flow JJ 0 1 1 O
cytometry NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
zidovudine NN 0 1 13 B-Drug
study NN 0 1 1 O
dosed VBD 1 1 14 O
subjects NNS 1 1 UNK O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
( ( 0 0 2 O
n JJ 0 1 12 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
( ( 0 0 2 O
later RB 0 1 12 O
changed VBN 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
[ NNP 0 0 2 O
n RB 0 1 12 O
= VBD 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
) ) 0 0 2 O
for IN 0 0 12 O
Days $ 0 1 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
five CD 0 1 12 O
times NNS 1 1 12 O
/ JJ 0 0 2 O
day NN 0 1 12 O
of IN 0 0 12 O
zidovudine NN 0 1 13 B-Drug
. . 0 0 12 O

Decreasing VBG 0 1 UNK O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
CMC NNP 0 1 13 B-Drug_n
- : 0 0 2 O
Cys NNP 0 1 UNK I-Drug_n
exhibiting VBG 1 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
m JJ 0 1 2 O
/ NNP 0 0 2 O
m NN 0 1 2 O
) ) 0 0 2 O
of IN 0 0 12 O
immobilised JJ 0 0 UNK O
cysteine NN 0 1 13 B-Drug
( ( 0 0 2 O
CMC NNP 0 1 13 O
- : 0 0 2 O
Cys9 NN 0 0 UNK O
) ) 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
m JJ 0 1 2 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
m JJ 0 1 2 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
R NNP 0 1 2 O
- : 0 0 2 O
value NN 0 1 1 O
of IN 0 0 12 O
NaFlu NNP 0 0 UNK B-Drug
from IN 0 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Ethanol NNP 0 1 13 B-Drug
depressed VBD 1 1 12 O
the DT 0 0 12 O
amplitudes NNS 1 1 UNK O
of IN 0 0 12 O
most JJS 0 0 12 O
evoked JJ 0 1 13 O
potential JJ 0 1 1 O
components NNS 1 1 1 O
in IN 0 0 12 O
comparison NN 0 1 1 O
to TO 0 0 12 O
saline VB 0 1 14 O
administration NN 0 1 1 O
. . 0 0 12 O

9 CD 0 0 2 O
microg NN 0 0 UNK O
mL NN 0 1 14 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
galangin NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
mL NN 0 1 14 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
or CC 0 0 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
dihydroxyflavone NN 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
mL NN 0 1 14 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

This DT 0 0 2 O
was VBD 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
reductions NNS 1 1 1 O
in IN 0 0 12 O
both DT 0 0 12 O
renal JJ 0 1 6 O
clearance NN 0 1 16 O
( ( 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
ml NN 0 1 16 O
/ NNP 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
( ( 0 0 2 O
p NN 0 1 2 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
nonrenal JJ 0 0 13 O
clearance NN 0 1 16 O
( ( 0 0 2 O
from IN 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
+ NNS 0 0 2 O
/ SYM 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
ml NN 0 1 16 O
/ NNP 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
( ( 0 0 2 O
p NN 0 1 2 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
together RB 0 1 12 O
with IN 0 0 12 O
the DT 0 0 12 O
known VBN 1 1 12 O
relationships NNS 1 1 13 O
between IN 0 0 12 O
estrogen NN 0 1 6 B-Group
and CC 0 0 12 O
the DT 0 0 12 O
immune JJ 0 1 6 O
response NN 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
estrogens VBZ 0 1 16 B-Group
affect VBP 0 1 1 O
the DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
septic JJ 0 1 6 O
shock NN 0 1 3 O
in IN 0 0 12 O
a DT 0 0 12 O
complex JJ 0 1 1 O
fashion NN 0 0 12 O
and CC 0 0 12 O
may MD 0 0 1 O
have VB 0 0 12 O
either CC 0 1 12 O
protective VB 0 0 3 O
or CC 0 0 12 O
deleterious JJ 0 0 6 O
effect NN 0 1 1 O
. . 0 0 12 O

Resting VBG 0 1 7 O
membrane NN 0 1 3 O
potential NN 0 1 1 O
input NN 0 1 13 O
impedance NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
proportion NN 0 1 UNK O
of IN 0 0 12 O
neurons NNS 1 1 UNK O
displaying VBG 1 1 UNK O
transient JJ 0 1 1 O
outward JJ 0 1 UNK O
rectification NN 0 1 UNK O
were VBD 1 0 12 O
each DT 0 0 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
for IN 0 0 12 O
neurons NNS 1 1 UNK O
recorded VBN 1 1 12 O
with IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
but CC 0 0 12 O
not RB 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
biocytin NN 0 1 UNK O
. . 0 0 12 O

Fluvoxamine NNP 0 1 UNK B-Drug
inhibits VBZ 1 1 UNK O
the DT 0 0 12 O
CYP9C9 NNP 0 0 UNK O
catalyzed VBD 1 0 UNK O
biotransformation NN 0 1 UNK O
of IN 0 0 12 O
tolbutamide NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
benzodiazepines NNS 1 1 14 B-Group
are VBP 1 0 12 O
a DT 0 0 12 O
family NN 0 1 12 O
of IN 0 0 12 O
anxiolytic JJ 0 1 13 B-Group
and CC 0 0 12 O
hypnotic JJ 0 1 13 B-Group
drugs NNS 1 1 6 I-Group
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
we PRP 0 0 12 O
evaluated VBD 1 1 1 O
the DT 0 0 12 O
interference NN 0 1 13 O
of IN 0 0 12 O
antidepressants NNS 1 1 13 B-Group
with IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
of IN 0 0 12 O
diabetic JJ 0 1 6 O
and CC 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
diabetic JJ 0 1 6 O
rats NNS 1 1 UNK O
. . 0 0 12 O

ocular JJ 0 1 6 O
effects NNS 1 1 1 O
; : 0 0 2 O

Distinct NNP 0 0 UNK O
and CC 0 0 12 O
statistically RB 0 1 1 O
significant JJ 0 1 1 O
synergism NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
between IN 0 0 12 O
methylglyoxal NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
piperacillin NN 0 1 16 B-Drug
by IN 0 0 12 O
disc JJ 0 1 3 O
diffusion NN 0 1 1 O
tests NNS 1 1 1 O
when WRB 0 0 12 O
compared VBN 1 1 1 O
with IN 0 0 12 O
their PRP$ 0 0 12 O
individual JJ 0 1 1 O
effects NNS 1 1 1 O
. . 0 0 12 O

Acute NNP 0 1 7 O
effect NN 0 1 1 O
of IN 0 0 12 O
different JJ 0 1 1 O
antidepressants NNS 1 1 13 B-Group
on IN 0 0 12 O
glycemia NN 0 1 UNK O
in IN 0 0 12 O
diabetic JJ 0 1 6 O
and CC 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
diabetic JJ 0 1 6 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Glycosidic NNP 0 1 UNK O
enzymes VBZ 0 1 14 O
enhance JJ 0 1 UNK O
retinal JJ 0 1 6 O
transduction NN 0 1 UNK O
following VBG 1 1 1 O
intravitreal JJ 0 0 UNK O
delivery NN 0 1 1 O
of IN 0 0 12 O
AAV9 NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

Medical JJ 0 1 2 O
treatment NN 0 1 6 O
with IN 0 0 12 O
cinacalcet NN 0 1 16 B-Drug
is VBZ 1 0 12 O
effective JJ 0 1 1 O
in IN 0 0 12 O
reducing VBG 1 1 1 O
plasma JJ 0 1 14 O
parathyroid NN 0 1 14 O
hormone NN 0 1 6 O
( ( 0 0 2 O
PTH NNP 0 0 14 O
) ) 0 0 2 O
levels NNS 1 1 1 O
but CC 0 0 12 O
its PRP$ 1 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
darbepoetin NN 0 0 13 B-Drug
dosing NN 0 0 14 O
is VBZ 1 0 12 O
unknown JJ 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
development NN 0 1 1 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
vancomycin NN 0 1 14 O
- : 0 0 2 O
resistant JJ 0 1 3 O
strains NNS 1 1 6 O
of IN 0 0 12 O
enterococci NN 0 1 UNK O
( ( 0 0 2 O
VRE NNP 0 1 15 O
) ) 0 0 2 O
is VBZ 1 0 12 O
a DT 0 0 12 O
major JJ 0 1 1 O
cause NN 0 1 12 O
for IN 0 0 12 O
concern NN 0 1 1 O
. . 0 0 12 O

PTX NNP 0 1 15 B-Drug_n
caused VBD 1 1 1 O
the DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 O
from IN 0 0 12 O
the DT 0 0 12 O
muscle NN 0 1 6 O
. . 0 0 12 O

Data NNS 0 1 2 O
from IN 0 0 12 O
studies NNS 1 1 1 O
to TO 0 0 12 O
date NN 0 1 12 O
show NN 0 1 12 O
that IN 0 0 12 O
disease NN 0 1 6 O
states NNS 1 1 1 O
underlying JJ 0 0 1 O
conditions NNS 1 1 1 O
and CC 0 0 12 O
concomitantly RB 0 0 14 O
administered VBN 1 1 1 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
essentially RB 0 0 1 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
etodolac NN 0 1 13 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
eight CD 0 1 12 O
experiments NNS 1 1 UNK O
the DT 0 0 12 O
perfusion NN 0 1 8 O
medium NN 0 1 3 O
contained VBD 1 1 1 O
oxytocin UH 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
addition NN 0 1 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
herbal JJ 0 1 6 O
remedies NNS 1 0 6 O
may MD 0 0 1 O
be VB 0 0 12 O
detrimental JJ 0 0 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
patient NN 0 1 6 O
with IN 0 0 12 O
compromised JJ 0 0 1 O
renal JJ 0 1 6 O
function NN 0 1 1 O
. . 0 0 12 O

Restoration NN 0 1 UNK O
of IN 0 0 12 O
vancomycin JJ 0 1 14 B-Drug
susceptibility NN 0 1 6 O
in IN 0 0 12 O
Enterococcus NNP 0 1 14 O
faecalis NN 0 0 16 O
by IN 0 0 12 O
antiresistance NN 0 0 UNK O
determinant JJ 0 1 UNK O
gene NN 0 1 13 O
transfer NN 0 1 1 O
. . 0 0 12 O

Pharmacokinetic JJ 0 1 UNK O
evaluation NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
digoxin NN 0 1 14 B-Drug
- : 0 0 2 O
amiodarone NN 0 1 0 B-Drug
interaction NN 0 1 UNK O
. . 0 0 12 O

Toxicity NN 0 1 UNK O
of IN 0 0 12 O
cadmium NN 0 1 13 O
and CC 0 0 12 O
zinc NN 0 1 14 B-Drug
to TO 0 0 12 O
miracidia VB 0 0 UNK O
of IN 0 0 12 O
Schistosoma NNP 0 1 UNK O
mansoni NN 0 0 13 O
. . 0 0 12 O

In IN 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
two CD 0 1 12 O
outbreaks NNS 1 1 UNK O
of IN 0 0 12 O
arsenical JJ 0 1 13 O
reactive NN 0 1 1 O
encephalopathy NN 0 1 6 O
( ( 0 0 2 O
ARE NNP 0 0 UNK O
) ) 0 0 2 O
occurred VBD 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
sleeping NN 0 1 12 O
sickness NN 0 1 13 O
center NN 0 1 12 O
of IN 0 0 12 O
Adjumani NNP 0 0 UNK O
. . 0 0 12 O

[ JJ 0 0 2 O
Pharmacologic NNP 0 1 UNK O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
chronic JJ 0 1 6 O
treatments NNS 1 1 6 O
: : 0 0 2 O
corrective JJ 0 1 13 O
measures NNS 1 1 1 O
for IN 0 0 12 O
its PRP$ 1 0 12 O
prevention NN 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
basic JJ 0 1 1 O
area NN 0 1 12 O
of IN 0 0 12 O
rural JJ 0 1 UNK O
health NN 0 1 1 O
] NN 0 0 2 O
OBJECTIVES NNP 0 1 UNK O
: : 0 0 2 O
To TO 0 0 2 O
identify VB 0 0 1 O
the DT 0 0 12 O
pharmacological JJ 0 1 14 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
clinical JJ 0 1 6 O
relevance NN 0 1 UNK O
( ( 0 0 2 O
PICR NNP 0 0 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
medication NN 0 1 6 O
authorization NN 0 1 1 O
cards NNS 1 1 12 O
( ( 0 0 2 O
MAC NNP 0 1 UNK O
) ) 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
chronically NN 0 0 6 O
ill NN 0 1 12 O
and CC 0 0 12 O
to TO 0 0 12 O
establish VB 0 1 UNK O
strategies NNS 1 1 UNK O
to TO 0 0 12 O
minimise VB 0 0 UNK O
their PRP$ 0 0 12 O
appearance NN 0 1 12 O
. . 0 0 12 O

[ JJ 0 0 2 O
Influence NNP 0 0 UNK O
of IN 0 0 12 O
hemantane NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
doxycycline NN 0 1 0 B-Drug
on IN 0 0 12 O
MPTP NNP 0 1 UNK O
- : 0 0 2 O
evoked VBD 1 1 13 O
behavior JJ 0 1 1 O
violations NNS 1 0 UNK O
in IN 0 0 12 O
C9BL NNP 0 0 UNK O
/ NNP 0 0 2 O
9 CD 0 0 2 O
mice NN 1 1 UNK O
] NN 0 0 2 O
. . 0 0 12 O

Castor NNP 0 1 UNK B-Drug
oil NN 0 1 3 I-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
ml NN 0 1 16 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
p.o NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O

High JJ 0 1 2 O
- : 0 0 2 O
dose NN 0 1 6 O
cisplatin NN 0 1 14 B-Drug
with IN 0 0 12 O
sodium NN 0 1 14 B-Drug
thiosulfate NN 0 1 16 I-Drug
protection NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
DCG NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
IV NN 0 1 2 I-Drug_n
were VBD 1 0 12 O
very RB 0 1 12 O
strong JJ 0 1 12 O
and CC 0 0 12 O
completely RB 0 1 12 O
depressed VBD 1 1 12 O
the DT 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
hyperlocomotion NN 0 0 UNK O
. . 0 0 12 O

Haloperidol NNP 0 1 0 B-Drug
reduced VBD 1 1 1 O
or CC 0 0 12 O
eliminated VBD 1 1 UNK O
the DT 0 0 12 O
increases NNS 1 1 1 O
in IN 0 0 12 O
FI NNP 0 1 UNK O
responding VBG 1 0 1 O
produced VBN 1 0 1 O
by IN 0 0 12 O
intermediate JJ 0 1 13 O
doses NNS 1 1 6 O
of IN 0 0 12 O
either DT 0 1 12 O
( ( 0 0 2 O
+ NN 0 0 2 B-Drug_n
) ) 0 0 2 O
- : 0 0 2 O
NANM NN 0 0 UNK I-Drug_n
or CC 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
in IN 0 0 12 O
pigeons NNS 1 1 UNK O
but CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
antagonize VB 0 0 UNK O
the DT 0 0 12 O
decreases NNS 1 1 UNK O
in IN 0 0 12 O
FI NNP 0 1 UNK O
or CC 0 0 12 O
FR NNP 0 1 UNK O
responding VBG 1 0 1 O
produced VBN 1 0 1 O
by IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
PCP NNP 0 1 13 O
or CC 0 0 12 O
either CC 0 1 12 O
stereoisomer JJR 0 1 UNK O
of IN 0 0 12 O
NANM NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

Fifty NNP 0 1 2 O
- : 0 0 2 O
four CD 0 1 12 O
healthy JJ 0 1 12 O
nonpregnant JJ 0 0 UNK O
women NNS 1 1 UNK O
were VBD 1 0 12 O
selected VBN 1 1 UNK O
to TO 0 0 12 O
participate VB 0 0 12 O
in IN 0 0 12 O
9 CD 0 0 2 O
iron NN 0 1 3 B-Drug
absorption NN 0 1 1 O
studies NNS 1 1 1 O
using VBG 1 1 1 O
iron NN 0 1 3 O
radioactive JJ 0 1 1 O
tracers NNS 1 1 UNK O
. . 0 0 12 O

Arginine NN 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
glucose NN 0 1 14 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
caused VBN 1 1 1 O
excessive JJ 0 1 1 O
glucagon NN 0 1 14 O
release NN 0 1 12 O
but CC 0 0 12 O
nearly RB 0 1 12 O
normal JJ 0 1 1 O
insulin NN 0 1 14 O
release NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
diabetics NNS 1 1 UNK O
. . 0 0 12 O

Four CD 0 1 2 O
educational JJ 0 1 13 O
messages NNS 1 1 UNK O
advise VBP 0 0 UNK O
on IN 0 0 12 O
over IN 0 1 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
the DT 0 0 12 O
PICR NNP 0 0 UNK O
detected VBD 1 1 1 O
. . 0 0 12 O

Antagonism NN 0 1 UNK O
was VBD 1 0 12 O
never RB 0 1 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Dexamethasone NN 0 1 0 B-Drug
at IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
or CC 0 0 12 O
retinyl VB 0 0 UNK B-Drug
acetate NN 0 1 14 I-Drug
at IN 0 0 12 O
about IN 0 1 12 O
9 CD 0 0 2 O
X NNS 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
M NNP 0 1 2 O
inhibits VBZ 1 1 UNK O
proliferation NN 0 1 1 O
stimulated VBN 1 1 13 O
by IN 0 0 12 O
EGF NNP 0 0 UNK B-Drug_n
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
the DT 0 0 12 O
atypical JJ 0 1 6 B-Group
antipsychotic JJ 0 1 UNK I-Group
clozapine NN 0 1 13 B-Drug
was VBD 1 0 12 O
tested VBN 1 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
an DT 0 0 12 O
active JJ 0 1 1 O
dose NN 0 1 6 O
of IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
in IN 0 0 12 O
two CD 0 1 12 O
- : 0 0 2 O
lever RB 0 0 UNK O
drug NN 0 1 1 O
discrimination NN 0 1 13 O
and CC 0 0 12 O
mixed JJ 0 1 3 O
signalled VBD 1 1 UNK O
- : 0 0 2 O
unsignalled JJ 0 0 UNK O
differential JJ 0 1 1 O
- : 0 0 2 O
reinforcement NN 0 1 13 O
- : 0 0 2 O
of IN 0 0 12 O
- : 0 0 2 O
low JJ 0 1 1 O
- : 0 0 2 O
rates NNS 1 1 1 O
( ( 0 0 2 O
DRL NNP 0 0 UNK O
) ) 0 0 2 O
procedures NNS 1 1 1 O
. . 0 0 12 O

To TO 0 0 2 O
determine VB 0 0 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
injection NN 0 1 3 O
of IN 0 0 12 O
extracellular JJ 0 1 14 O
matrix NN 0 1 1 O
degrading VBG 1 0 UNK O
enzymes NNS 1 1 14 O
improves VBZ 1 1 1 O
retinal JJ 0 1 6 O
transduction NN 0 1 UNK O
following VBG 1 1 1 O
intravitreal JJ 0 0 UNK O
delivery NN 0 1 1 O
of IN 0 0 12 O
adeno JJ 0 0 8 B-Drug_n
- : 0 0 2 O
associated VBN 1 1 1 I-Drug_n
virus NN 0 1 6 I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
( ( 0 0 2 O
AAV9 NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
. . 0 0 12 O

In IN 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
- : 0 0 2 O
old JJ 0 1 12 O
embryos JJ 0 1 UNK O
glycine NN 0 1 UNK B-Drug
was VBD 1 0 12 O
ineffective JJ 0 1 UNK O
in IN 0 0 12 O
both DT 0 0 12 O
doses NNS 1 1 6 O
. . 0 0 12 O

Future JJ 0 1 2 O
trends NNS 1 1 UNK O
are VBP 1 0 12 O
also RB 0 0 12 O
predicted VBN 1 1 1 O
. . 0 0 12 O

Behavioral JJ 0 1 2 O
responses NNS 1 1 1 O
to TO 0 0 12 O
repeated VB 1 1 1 O
cocaine NN 0 1 6 B-Drug
exposure NN 0 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
selectively RB 0 0 UNK O
bred VBD 1 1 UNK O
for IN 0 0 12 O
differential JJ 0 1 1 O
sensitivity NN 0 1 1 O
to TO 0 0 12 O
pentobarbital VB 0 1 16 B-Drug
. . 0 0 12 O

Diethyl NNP 0 0 UNK B-Drug_n
pyrocarbonate NN 0 1 UNK I-Drug_n
at IN 0 0 12 O
pH NN 0 1 14 O
9 CD 0 0 2 O
was VBD 1 0 12 O
used VBN 1 1 12 O
to TO 0 0 12 O
chemically RB 0 1 UNK O
modify VB 0 1 UNK O
exposed JJ 0 1 3 O
histidine NN 0 1 13 O
residues NNS 1 1 UNK O
on IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
. . 0 0 12 O

Both DT 0 0 2 O
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
ibogaine NN 0 1 UNK B-Drug_n
are VBP 1 0 12 O
sequestered VBN 1 1 UNK O
in IN 0 0 12 O
fat JJ 0 1 3 O
and CC 0 0 12 O
like JJ 0 0 12 O
ibogaine NN 0 1 UNK B-Drug_n
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
probably RB 0 1 12 O
has VBZ 1 0 12 O
an DT 0 0 12 O
active JJ 0 1 1 O
metabolite NN 0 1 UNK O
. . 0 0 12 O

Amiodarone NN 0 1 0 B-Drug
caused VBD 1 1 1 O
a DT 0 0 12 O
three CD 0 1 12 O
- : 0 0 2 O
to TO 0 0 12 O
fivefold VB 0 0 UNK O
increase NN 0 1 1 O
in IN 0 0 12 O
serum JJ 0 1 14 O
reverse NN 0 1 1 O
triiodothyronine NN 0 1 13 O
levels NNS 1 1 1 O
but CC 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
thyroid JJ 0 1 6 O
function NN 0 1 1 O
were VBD 1 0 12 O
not RB 0 1 12 O
quantitatively RB 0 0 UNK O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
pharmacokinetics NNS 0 1 UNK O
. . 0 0 12 O

Antimicrobial JJ 0 1 7 O
activity NN 0 1 1 O
of IN 0 0 12 O
GL NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
the DT 0 0 12 O
aqueous JJ 0 1 16 O
extract NN 0 1 13 O
from IN 0 0 12 O
the DT 0 0 12 O
carpophores NNS 1 0 UNK O
of IN 0 0 12 O
Ganoderma NNP 0 1 UNK O
lucidum NN 0 1 UNK O
( ( 0 0 2 O
FR NNP 0 1 UNK O
) ) 0 0 2 O
KARST NNP 0 0 UNK O
) ) 0 0 2 O
was VBD 1 0 12 O
tested VBN 1 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
against IN 0 0 12 O
Gram NNP 0 1 13 O
positive JJ 0 1 1 O
and CC 0 0 12 O
Gram NNP 0 1 13 O
negative JJ 0 1 1 O
bacteria NNS 0 1 6 O
by IN 0 0 12 O
serial JJ 0 1 1 O
broth DT 0 0 UNK O
dilution NN 0 1 14 O
method NN 0 1 13 O
and CC 0 0 12 O
the DT 0 0 12 O
antimicrobial JJ 0 1 14 O
activity NN 0 1 1 O
was VBD 1 0 12 O
expressed VBN 1 0 1 O
by IN 0 0 12 O
minimal JJ 0 1 1 O
inhibitory JJ 0 1 UNK O
concentration NN 0 1 1 O
( ( 0 0 2 O
MIC NNP 0 1 13 O
) ) 0 0 2 O
. . 0 0 12 O

Studies NNS 0 1 2 O
with IN 0 0 12 O
forced JJ 0 1 13 O
expression NN 0 1 1 O
and CC 0 0 12 O
siRNA JJ 0 1 UNK O
knockdown NN 0 0 UNK O
of IN 0 0 12 O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Cdk9 NNP 0 1 UNK O
suggest VBP 0 1 1 O
that IN 0 0 12 O
dasatinib SYM 0 1 13 B-Drug
- : 0 0 2 O
mediated VBN 1 1 13 O
induction NN 0 1 1 O
of IN 0 0 12 O
p9 NN 0 1 UNK O
( ( 0 0 2 O
Kip9 NNP 0 0 UNK O
) ) 0 0 2 O
enhanced VBD 1 1 1 O
paclitaxel JJ 0 1 13 B-Drug
- : 0 0 2 O
induced VBN 1 1 6 O
apoptosis NN 0 1 UNK O
by IN 0 0 12 O
negatively RB 0 0 1 O
regulating VBG 1 0 UNK O
Bcl NNP 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
Cdk9 NNP 0 1 UNK O
expression NN 0 1 1 O
. . 0 0 12 O

Influence NN 0 0 UNK O
of IN 0 0 12 O
calcium NN 0 1 14 B-Group
- : 0 0 2 O
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
on IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
and CC 0 0 12 O
arachidonic JJ 0 0 UNK O
acid NN 0 1 14 O
metabolism NN 0 1 16 O
. . 0 0 12 O

The DT 0 0 2 O
reduced VBN 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
events NNS 1 1 12 O
and CC 0 0 12 O
therapeutic JJ 0 1 6 O
superiority NN 0 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
haloperidol NN 0 1 16 B-Drug
and CC 0 0 12 O
risperidone NN 0 1 0 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
negative JJ 0 1 1 O
and CC 0 0 12 O
depressive JJ 0 0 13 O
symptoms NNS 1 1 6 O
support VBP 0 1 1 O
the DT 0 0 12 O
choice NN 0 1 12 O
of IN 0 0 12 O
olanzapine NN 0 1 16 B-Drug
as IN 1 0 12 O
a DT 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
line NN 0 1 12 O
option NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
acute JJ 0 1 6 O
phase NN 0 1 1 O
and CC 0 0 12 O
for IN 0 0 12 O
the DT 0 0 12 O
maintenance NN 0 1 1 O
of IN 0 0 12 O
treatment NN 0 1 6 O
response NN 0 1 1 O
. . 0 0 12 O

Following VBG 0 1 2 O
multiple JJ 0 1 1 O
experimentations NNS 1 1 UNK O
it PRP 0 0 12 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
that IN 0 0 12 O
methylglyoxal NN 0 1 UNK B-Drug_n
was VBD 1 0 12 O
also RB 0 0 12 O
antimicrobic JJ 0 0 UNK O
against IN 0 0 12 O
all PDT 0 0 12 O
the DT 0 0 12 O
strains NNS 1 1 6 O
at IN 0 0 12 O
comparable JJ 0 0 1 O
levels NNS 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
calcium NN 0 1 14 B-Drug
dose NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
diminished JJ 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
heme JJ 0 1 14 B-Drug
iron NN 0 1 3 I-Drug
by IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
. . 0 0 12 O

The DT 0 0 2 O
incidence NN 0 1 6 O
rate NN 0 1 1 O
of IN 0 0 12 O
hospitalization NN 0 1 6 O
for IN 0 0 12 O
GI NNP 0 1 6 O
bleeding NN 0 1 6 O
among IN 0 0 12 O
warfarin JJ 0 1 14 B-Drug
users NNS 1 1 UNK O
was VBD 1 0 12 O
9 CD 0 0 2 O
per IN 0 0 1 O
9 CD 0 0 2 O
person NN 0 1 12 O
- : 0 0 2 O
years NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
prostaglandin NN 0 1 13 B-Drug
F9alpha NNP 0 0 UNK I-Drug
and CC 0 0 12 O
synthetic JJ 0 1 3 O
oxytocin NN 0 1 13 B-Drug
on IN 0 0 12 O
placental JJ 0 1 13 O
vessels NNS 1 1 1 O
was VBD 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Ticagrelor NNP 0 1 UNK B-Drug
( ( 0 0 2 O
Brilinta NNP 0 1 UNK B-Brand
) ) 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
better JJR 1 1 12 O
than IN 0 0 12 O
clopidogrel NN 0 1 16 B-Drug
( ( 0 0 2 O
Plavix NNP 0 1 0 B-Brand
) ) 0 0 2 O

Results NNS 0 1 2 O
. . 0 0 12 O

An DT 0 0 2 O
altered JJ 0 1 1 O
biodistribution NN 0 0 UNK O
may MD 0 0 1 O
provide VB 0 1 1 O
misleading VBG 1 0 UNK O
information NN 0 1 1 O
that WDT 0 0 12 O
can MD 0 0 12 O
either VB 0 1 12 O
mask NN 0 1 3 O
or CC 0 0 12 O
mimic JJ 0 0 UNK O
certain JJ 0 1 1 O
disease NN 0 1 6 O
symptoms NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
conference NN 0 1 UNK O
reviews VBZ 1 1 UNK O
recent JJ 0 1 12 O
developments NNS 1 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
areas NNS 1 1 1 O
examines VBP 1 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
use NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elderly JJ 0 1 12 O
and CC 0 0 12 O
implications NNS 1 0 UNK O
for IN 0 0 12 O
management NN 0 1 1 O
and CC 0 0 12 O
discusses VBZ 1 1 UNK O
current JJ 0 1 1 O
information NN 0 1 1 O
on IN 0 0 12 O
how WRB 0 0 12 O
age NN 0 1 12 O
may MD 0 0 1 O
influence VB 0 0 UNK O
the DT 0 0 12 O
response NN 0 1 1 O
of IN 0 0 12 O
cancer NN 0 1 6 O
to TO 0 0 12 O
therapy VB 0 1 6 O
. . 0 0 12 O

These DT 0 0 1 O
models NNS 1 1 UNK O
are VBP 1 0 12 O
typically RB 0 0 UNK O
nonlinear JJ 0 0 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
parameters NNS 1 1 1 O
and CC 0 0 12 O
as IN 1 0 12 O
such JJ 0 0 1 O
a DT 0 0 12 O
nonlinear JJ 0 0 UNK O
weighted VBN 1 1 1 O
least JJS 0 1 12 O
squares NNS 1 1 UNK O
approach VBP 0 1 1 O
can MD 0 0 12 O
be VB 0 0 12 O
employed VBN 1 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
purpose NN 0 1 1 O
of IN 0 0 12 O
designing VBG 1 0 UNK O
experiments NNS 1 1 UNK O
. . 0 0 12 O

Clinical JJ 0 1 7 O
trials NNS 1 1 1 O
of IN 0 0 12 O
such JJ 0 0 1 O
combinations NNS 1 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
accompanied VBN 1 0 12 O
by IN 0 0 12 O
detailed JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
evaluation NN 0 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
defect NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
failing JJ 0 1 13 O
heart NN 0 1 12 O
can MD 0 0 12 O
be VB 0 0 12 O
mimicked VBN 1 0 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
uptake JJ 0 1 14 O
blocking VBG 1 1 UNK O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
cocaine NN 0 1 6 B-Drug
and CC 0 0 12 O
desipramine NN 0 1 16 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
nonfailing JJ 0 0 UNK O
heart NN 0 1 12 O
only RB 0 1 12 O
. . 0 0 12 O

[ RB 0 0 2 O
9 CD 0 0 2 O
epidemics NNS 1 1 UNK O
of IN 0 0 12 O
arsenical JJ 0 1 13 O
encephalopathy NN 0 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
trypanosomiasis NN 0 1 13 O
Uganda NNP 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
Since IN 0 1 2 O
9 CD 0 0 2 O
the DT 0 0 12 O
french JJ 0 1 UNK O
non NN 0 1 1 O
- : 0 0 2 O
governmental JJ 0 1 UNK O
organisation NN 0 1 UNK O
M NNP 0 1 2 O
decins VBZ 0 0 UNK O
Sans NNPS 0 1 UNK O
Fronti NNP 0 0 UNK O
res VBZ 0 1 13 O
is VBZ 1 0 12 O
running VBG 1 1 12 O
a DT 0 0 12 O
control NN 0 1 1 O
program NN 0 1 1 O
of IN 0 0 12 O
human JJ 0 1 1 O
african JJ 0 1 16 O
trypanosomiasis NN 0 1 13 O
in IN 0 0 12 O
the DT 0 0 12 O
district NN 0 0 UNK O
of IN 0 0 12 O
Moyo NNP 0 0 UNK O
North NNP 0 1 2 O
- : 0 0 2 O
Uganda NN 0 1 UNK O
. . 0 0 12 O

Because IN 0 0 12 O
the DT 0 0 12 O
nitrosourea JJ 0 1 UNK B-Group
CCNU NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
exclusively RB 0 0 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
oral JJ 0 1 6 O
route NN 0 1 12 O
in IN 0 0 12 O
man NN 0 1 12 O
we PRP 0 0 12 O
have VBP 0 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
studies NNS 1 1 1 O
in IN 0 0 12 O
mice NN 1 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
antitumour NN 0 1 UNK O
activity NN 0 1 1 O
acute VBP 0 1 6 O
toxicity NN 0 1 6 O
and CC 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
oral JJ 0 1 6 O
CCNU NNP 0 1 UNK B-Drug
either CC 0 1 12 O
alone RB 0 1 12 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
the DT 0 0 12 O
chemosensitizer NN 0 1 UNK O
misonidazole NN 0 1 UNK B-Drug_n
. . 0 0 12 O

Synergistic JJ 0 1 UNK O
interaction NN 0 1 UNK O
between IN 0 0 12 O
sunitinib NN 0 1 13 B-Drug
and CC 0 0 12 O
docetaxel NN 0 1 13 B-Drug
is VBZ 1 0 12 O
sequence JJ 0 1 UNK O
dependent NN 0 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
non SYM 0 1 1 O
- : 0 0 2 O
small JJ 0 1 12 O
lung NN 0 1 6 O
cancer NN 0 1 6 O
with IN 0 0 12 O
EGFR NNP 0 1 UNK O
TKIs NNP 0 0 UNK O
- : 0 0 2 O
resistant JJ 0 1 3 O
mutation NN 0 1 13 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
structurally RB 0 0 1 O
distinct JJ 0 0 1 O
from IN 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
currently RB 0 1 12 O
available JJ 0 1 1 O
HMGCoA NNP 0 1 UNK B-Group
reductase NN 0 1 UNK I-Group
inhibitors NNS 1 1 14 I-Group
( ( 0 0 2 O
lovastatin JJ 0 1 13 B-Drug
simvastatin NN 0 1 0 B-Drug
and CC 0 0 12 O
pravastatin NN 0 1 16 B-Drug
) ) 0 0 2 O
leading VBG 1 1 1 O
to TO 0 0 12 O
unique JJ 0 1 UNK O
biopharmaceutical JJ 0 1 UNK O
properties NNS 1 1 UNK O
relative VBP 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
other JJ 0 0 12 O
agents NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
class NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
tolerability NN 0 1 UNK O
of IN 0 0 12 O
NNRTIs NNP 0 1 UNK B-Group
appears VBZ 1 1 12 O
generally RB 0 0 1 O
good JJ 0 1 12 O
with IN 0 0 12 O
few JJ 0 1 12 O
individuals NNS 1 1 1 O
discontinuing VBG 1 1 6 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
as IN 1 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
adverse JJ 0 0 1 O
drug NN 0 1 1 O
events NNS 1 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
was VBD 1 0 12 O
a DT 0 0 12 O
> JJ 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
reduction NN 0 1 1 O
in IN 0 0 12 O
cellular JJ 0 1 13 O
glutathione NN 0 1 13 O
and CC 0 0 12 O
cysteine NN 0 1 13 O
with IN 0 0 12 O
imexon NNS 0 1 UNK B-Drug
but CC 0 0 12 O
not RB 0 1 12 O
DTIC NNP 0 1 15 B-Drug
. . 0 0 12 O

Our PRP$ 0 0 2 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
TAM NNP 0 1 UNK B-Drug_n
significantly RB 0 0 1 O
potentiates VBZ 1 0 UNK O
the DT 0 0 12 O
reduction NN 0 1 1 O
in IN 0 0 12 O
cell NN 0 1 1 O
number NN 0 1 1 O
induced VBN 1 1 6 O
by IN 0 0 12 O
9 CD 0 0 2 B-Drug
9 CD 0 0 2 I-Drug
( ( 0 0 2 O
OH NNP 0 1 UNK I-Drug
) ) 0 0 2 O
9D9 CD 0 0 UNK I-Drug
alone RB 0 1 12 O
. . 0 0 12 O

Numerous JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
possible JJ 0 1 1 O
with IN 0 0 12 O
some DT 0 0 12 O
anticonvulsant JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
phenobarbitone NN 0 1 UNK B-Drug
and CC 0 0 12 O
phenytoin NN 0 1 16 B-Drug
which WDT 0 0 12 O
affect VBP 0 1 1 O
hepatic JJ 0 1 14 O
microsomal JJ 0 1 UNK O
enzyme NN 0 1 14 O
systems NNS 1 1 1 O
. . 0 0 12 O

This DT 0 0 2 O
implies VBZ 1 0 1 O
that IN 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
hepatic NN 0 1 14 O
and CC 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
CYP9A NNP 0 0 UNK O
activities NNS 1 1 1 O
are VBP 1 0 12 O
significantly RB 0 0 1 O
lower JJR 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
cyclosporine NN 0 1 14 B-Drug
than IN 0 0 12 O
in IN 0 0 12 O
those DT 0 0 12 O
receiving VBG 1 1 1 O
tacrolimus JJ 0 1 16 B-Drug
indicating NN 0 0 1 O
that WDT 0 0 12 O
at IN 0 0 12 O
the DT 0 0 12 O
doses NNS 1 1 6 O
generally RB 0 0 1 O
used VBN 1 1 12 O
in IN 0 0 12 O
clinical JJ 0 1 6 O
practice NN 0 1 UNK O
cyclosporine NN 0 1 14 B-Drug
is VBZ 1 0 12 O
the DT 0 0 12 O
stronger JJR 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
with IN 0 0 12 O
respect NN 0 1 1 O
to TO 0 0 12 O
CYP9A NNP 0 0 UNK O
inhibition NN 0 1 13 O
. . 0 0 12 O

Excretion NN 0 1 UNK O
of IN 0 0 12 O
thioethers NNS 0 1 UNK O
in IN 0 0 12 O
urine NN 0 1 6 O
after IN 0 0 12 O
exposure NN 0 1 1 O
to TO 0 0 12 O
electrophilic JJ 0 0 UNK O
chemicals NNS 1 1 13 O
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
Single NNP 0 1 2 O
- : 0 0 2 O
dose NN 0 1 6 O
diltiazem JJ 0 1 0 B-Drug
coadministration NN 0 1 UNK O
leads VBZ 1 1 12 O
to TO 0 0 12 O
higher JJR 1 1 1 O
sirolimus NN 0 1 16 B-Drug
exposure NN 0 1 1 O
presumably RB 0 0 12 O
by IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
metabolism NN 0 1 16 O
of IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
. . 0 0 12 O

OBJECTIVES NN 0 1 UNK O
: : 0 0 2 O
To TO 0 0 2 O
examine VB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
acute JJ 0 1 6 O
hydrocortisone NN 0 1 14 B-Drug
pretreatment NN 0 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
subjective JJ 0 1 1 O
and CC 0 0 12 O
behavioral JJ 0 1 13 O
effects NNS 1 1 1 O
of IN 0 0 12 O
d JJ 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
. . 0 0 12 O

Optimal NNP 0 1 UNK O
designs NNS 1 1 UNK O
for IN 0 0 12 O
the DT 0 0 12 O
individual NN 0 1 1 O
and CC 0 0 12 O
joint JJ 0 1 1 O
exposure NN 0 1 1 O
general JJ 0 1 1 O
logistic JJ 0 1 UNK O
regression NN 0 1 UNK O
models NNS 1 1 UNK O
. . 0 0 12 O

Protective JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
acetyl NN 0 0 UNK B-Drug
- : 0 0 2 O
l NN 0 1 2 I-Drug
- : 0 0 2 O
carnitine NN 0 1 13 I-Drug
and CC 0 0 12 O
alpha JJ 0 1 1 B-Drug_n
lipoic NN 0 0 UNK I-Drug_n
acid NN 0 1 14 I-Drug_n
against IN 0 0 12 O
the DT 0 0 12 O
acute JJ 0 1 6 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
diepoxybutane NN 0 1 UNK O
to TO 0 0 12 O
human JJ 0 1 1 O
lymphocytes NNS 1 1 14 O
. . 0 0 12 O

No DT 0 0 2 O
antagonistic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
( ( 0 0 2 O
FICI NNP 0 0 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

alone RB 0 1 12 O
. . 0 0 12 O

Furafylline NNP 0 1 UNK B-Drug_n
and CC 0 0 12 O
sulfaphenazole NN 0 1 UNK B-Drug_n
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
while IN 0 0 12 O
quinidine NN 0 1 16 B-Drug
appeared VBD 1 1 12 O
to TO 0 0 12 O
augment VB 0 1 13 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
toxicity NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
anti SYM 0 0 3 O
- : 0 0 2 O
cryptosporidial JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
buforin NN 0 0 UNK B-Drug_n
II NNP 0 0 2 I-Drug_n
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
azithromycin NN 0 1 0 B-Drug
and CC 0 0 12 O
minocycline NN 0 1 13 B-Drug
was VBD 1 0 12 O
investigated VBN 1 1 1 O
. . 0 0 12 O

Relative JJ 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
general JJ 0 1 1 O
population NN 0 1 13 O
plasma NN 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
fluvastatin NNS 0 1 13 B-Drug
do VBP 0 0 12 O
not RB 0 1 12 O
vary VB 0 0 1 O
as IN 1 0 12 O
a DT 0 0 12 O
function NN 0 1 1 O
of IN 0 0 12 O
either DT 0 1 12 O
age NN 0 1 12 O
or CC 0 0 12 O
gender NN 0 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
caffeine NN 0 1 6 B-Drug
is VBZ 1 0 12 O
frequently RB 0 1 1 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
it PRP 0 0 12 O
is VBZ 1 0 12 O
of IN 0 0 12 O
clinical JJ 0 1 6 O
interest NN 0 1 1 O
to TO 0 0 12 O
study VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
hepatotoxicity NN 0 1 13 O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
. . 0 0 12 O

Since IN 0 1 2 O
photic JJ 0 1 UNK O
evoked VBD 1 1 13 O
potential JJ 0 1 1 O
components NNS 1 1 1 O
are VBP 1 0 12 O
representations NNS 1 1 UNK O
of IN 0 0 12 O
neural JJ 0 1 6 O
pathways NNS 1 1 13 O
which WDT 0 0 12 O
are VBP 1 0 12 O
activated VBN 1 1 1 O
during IN 0 0 12 O
photic JJ 0 1 UNK O
stimulation NN 0 1 6 O
study NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
on IN 0 0 12 O
these DT 0 0 12 O
components NNS 1 1 1 O
may MD 0 0 1 O
help VB 0 1 12 O
to TO 0 0 12 O
trace VB 0 1 1 O
pathways NNS 1 1 13 O
which WDT 0 0 12 O
are VBP 1 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
Sildenafil NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
an DT 0 0 12 O
effective JJ 0 1 1 O
first JJ 0 1 12 O
- : 0 0 2 O
line NN 0 1 12 O
therapy NN 0 1 6 O
for IN 0 0 12 O
erectile JJ 0 1 13 O
dysfunction NN 0 1 6 O
in IN 0 0 12 O
men NNS 0 1 13 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
paper NN 0 1 13 O
we PRP 0 0 12 O
show VBP 0 1 12 O
that IN 0 0 12 O
the DT 0 0 12 O
precipitate NN 0 1 13 O
is VBZ 1 0 12 O
formed VBN 1 1 UNK O
after IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
jacalin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
the DT 0 0 12 O
serum NN 0 1 14 O
protein NN 0 1 14 O
added VBD 1 1 12 O
to TO 0 0 12 O
the DT 0 0 12 O
culture NN 0 1 1 O
medium NN 0 1 3 O
. . 0 0 12 O

Inhibition NN 0 1 UNK O
and CC 0 0 12 O
stimulation NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
oxytocin NN 0 1 13 B-Drug
on IN 0 0 12 O
milk NN 0 1 3 O
ejection NN 0 1 3 O
by IN 0 0 12 O
vasopressin NN 0 1 13 O
was VBD 1 0 12 O
demonstrated VBN 1 0 1 O
. . 0 0 12 O

Analysis NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
concentration NN 0 1 1 O
of IN 0 0 12 O
budesonide NN 0 1 16 B-Drug
following VBG 1 1 1 O
ultracentrifugation NN 0 1 UNK O
indicated VBD 1 1 1 O
that IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
rapid JJ 0 1 1 O
equilibration NN 0 0 UNK O
of IN 0 0 12 O
budesonide NN 0 1 16 B-Drug
between IN 0 0 12 O
the DT 0 0 12 O
Survanta NNP 0 1 0 B-Brand
and CC 0 0 12 O
aqueous JJ 0 1 16 O
phase NN 0 1 1 O
. . 0 0 12 O

9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
a DT 0 0 12 O
novel JJ 0 1 13 O
iboga NN 0 1 UNK O
alkaloid NN 0 1 UNK O
congener NN 0 1 UNK O
is VBZ 1 0 12 O
being VBG 1 0 12 O
developed VBN 1 0 1 O
as IN 1 0 12 O
a DT 0 0 12 O
potential JJ 0 1 1 O
treatment NN 0 1 6 O
for IN 0 0 12 O
multiple JJ 0 1 1 O
forms NNS 1 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
abuse NN 0 1 12 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
suppress VBP 0 1 1 O
the DT 0 0 12 O
immune NN 0 1 6 O
system NN 0 1 1 O
are VBP 1 0 12 O
widely RB 0 0 1 O
used VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
siRNA JJ 0 1 UNK O
knockdown NN 0 0 UNK O
of IN 0 0 12 O
p9 NN 0 1 UNK O
( ( 0 0 2 O
Kip9 NNP 0 0 UNK O
) ) 0 0 2 O
decreased VBD 1 1 1 O
dasatinib JJ 0 1 13 B-Drug
- : 0 0 2 O
and CC 0 0 12 O
paclitaxel VB 0 1 13 B-Drug
- : 0 0 2 O
induced JJ 0 1 6 O
apoptosis NN 0 1 UNK O
compared VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
negative JJ 0 1 1 O
control NN 0 1 1 O
siRNA NN 0 1 UNK O
( ( 0 0 2 O
sub JJ 0 1 1 O
- : 0 0 2 O
G9 NNP 0 0 13 O
fraction NN 0 1 1 O
control NN 0 1 1 O
siRNA NN 0 1 UNK O
vs. FW 0 1 2 O
p9 NN 0 1 UNK O
( ( 0 0 2 O
Kip9 NNP 0 0 UNK O
) ) 0 0 2 O
siRNA NN 0 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
vs. FW 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
difference NN 0 1 UNK O
= CD 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
9 CD 0 0 2 O
% NN 0 0 18 O
CI NNP 0 1 UNK O
= NNP 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
combination NN 0 1 1 O
of IN 0 0 12 O
minocycline NN 0 1 13 B-Drug
and CC 0 0 12 O
fosfomycin NN 0 1 13 B-Drug
can MD 0 0 12 O
be VB 0 0 12 O
synergistic JJ 0 1 UNK O
against IN 0 0 12 O
MRSA NNP 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
ticlopidine NN 0 1 16 B-Drug
and CC 0 0 12 O
itraconazole JJ 0 1 0 B-Drug
phases VBZ 1 1 UNK O
the DT 0 0 12 O
areas NNS 1 1 1 O
under IN 0 0 12 O
the DT 0 0 12 O
effect NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curves NNS 1 1 UNK O
( ( 0 0 2 O
self PRP 0 1 12 O
- : 0 0 2 O
reported VBD 1 1 1 O
drowsiness JJ 0 1 13 O
and CC 0 0 12 O
performance NN 0 1 13 O
) ) 0 0 2 O
were VBD 1 0 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
than IN 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
placebo NN 0 1 13 O
phase NN 0 1 1 O
( ( 0 0 2 O
P NNP 0 1 2 O
< NNP 0 0 16 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

However RB 0 0 1 O
hydrocortisone JJ 0 1 14 B-Drug
pretreatment NN 0 1 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
physiological JJ 0 1 13 O
behavioral NN 0 1 13 O
or CC 0 0 12 O
subjective JJ 0 1 1 O
effects NNS 1 1 1 O
of IN 0 0 12 O
d JJ 0 1 16 B-Drug
- : 0 0 2 O
amphetamine NN 0 1 13 I-Drug
. . 0 0 12 O

Fluvastatin NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
synthetic JJ 0 1 3 B-Group
9 CD 0 0 2 I-Group
- : 0 0 2 O
hydroxy NN 0 1 14 I-Group
- : 0 0 2 O
9 CD 0 0 2 I-Group
- : 0 0 2 O
methylglutaryl NN 0 0 UNK I-Group
coenzyme VBZ 0 1 16 I-Group
A NNP 0 0 2 I-Group
( ( 0 0 2 O
HMGCoA NNP 0 1 UNK I-Group
) ) 0 0 2 O
reductase NN 0 1 UNK I-Group
inhibitor NN 0 1 14 I-Group
to TO 0 0 12 O
be VB 0 0 12 O
approved VBN 1 1 1 O
for IN 0 0 12 O
clinical JJ 0 1 6 O
use NN 0 1 1 O
and CC 0 0 12 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
extensively RB 0 0 1 O
in IN 0 0 12 O
humans NNS 1 1 UNK O
since IN 0 1 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Panobinostat NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
partly RB 0 0 UNK O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Arginine NN 0 1 UNK B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
absence NN 0 1 1 O
of IN 0 0 12 O
glucose NN 0 1 14 B-Drug
or CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
caused VBN 1 1 1 O
excessive JJ 0 1 1 O
glucagon NN 0 1 14 O
release NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
diabetics NNS 1 1 UNK O
and CC 0 0 12 O
undetectable JJ 0 1 6 O
insulin NN 0 1 14 O
release NN 0 1 12 O
in IN 0 0 12 O
either CC 0 1 12 O
diabetics NNS 1 1 UNK O
or CC 0 0 12 O
normals NNS 1 1 UNK O
. . 0 0 12 O

Aerosol NNP 0 1 7 O
particles NNS 1 1 UNK O
of IN 0 0 12 O
budesonide NN 0 1 16 B-Drug
were VBD 1 0 12 O
generated VBN 1 1 1 O
from IN 0 0 12 O
an DT 0 0 12 O
ethanol JJ 0 1 1 B-Drug
solution NN 0 1 1 O
dried VBD 1 1 3 O
and CC 0 0 12 O
collected VBN 1 1 1 O
by IN 0 0 12 O
a DT 0 0 12 O
cascade NN 0 1 UNK O
impactor NN 0 1 UNK O
for IN 0 0 12 O
characterization NN 0 1 UNK O
or CC 0 0 12 O
by IN 0 0 12 O
a DT 0 0 12 O
liquid JJ 0 1 3 O
impinger NN 0 0 UNK O
for IN 0 0 12 O
dissolution NN 0 0 UNK O
experiments NNS 1 1 UNK O
. . 0 0 12 O

Systemic JJ 0 1 7 O
exposure NN 0 1 1 O
is VBZ 1 0 12 O
limited VBN 1 1 1 O
as IN 1 0 12 O
fluvastatin NN 0 1 13 B-Drug
is VBZ 1 0 12 O
subject JJ 0 1 UNK O
to TO 0 0 12 O
first JJ 0 1 12 O
- : 0 0 2 O
pass NN 1 1 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
half NN 0 1 12 O
- : 0 0 2 O
life NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
is VBZ 1 0 12 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
minutes NNS 1 1 12 O
. . 0 0 12 O

Both DT 0 0 2 O
studies NNS 1 1 1 O
used VBD 1 1 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
. . 0 0 12 O

OBJECTIVE NN 0 1 UNK O
: : 0 0 2 O
To TO 0 0 2 O
report VB 0 1 1 O
a DT 0 0 12 O
case NN 0 1 12 O
of IN 0 0 12 O
rhabdomyolysis NN 0 1 8 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
clarithromycin NN 0 1 13 B-Drug
and CC 0 0 12 O
simvastatin NN 0 1 0 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
objective NN 0 1 13 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
if IN 0 0 12 O
there EX 0 0 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
when WRB 0 0 12 O
amprenavir NN 0 1 13 B-Drug
is VBZ 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
rifabutin NN 0 1 13 B-Drug
or CC 0 0 12 O
rifampin NN 0 1 16 B-Drug
and CC 0 0 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
on IN 0 0 12 O
the DT 0 0 12 O
erythromycin JJ 0 1 0 O
breath NN 0 1 3 O
test NN 0 1 1 O
( ( 0 0 2 O
ERMBT NNP 0 0 UNK O
) ) 0 0 2 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
rat NN 0 1 13 O
liver NN 0 1 6 O
slices NNS 1 1 UNK O
do VBP 0 0 12 O
not RB 0 1 12 O
reproduce VB 0 0 1 O
the DT 0 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
biotransformation NN 0 1 UNK O
of IN 0 0 12 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
and CC 0 0 12 O
therefore RB 0 0 1 O
may MD 0 0 1 O
not RB 0 1 12 O
be VB 0 0 12 O
an DT 0 0 12 O
appropriate JJ 0 1 1 O
model NN 0 1 UNK O
for IN 0 0 12 O
precocene NN 0 0 UNK B-Drug_n
I PRP 0 1 12 I-Drug_n
metabolism VBP 0 1 16 O
. . 0 0 12 O

Effects NNS 0 1 UNK O
on IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
excystment NN 0 0 UNK O
rates NNS 1 1 1 O
over IN 0 1 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
period NN 0 1 1 O
demonstrated VBD 1 0 1 O
widespread JJ 0 1 1 O
effects NNS 1 1 1 O
for IN 0 0 12 O
cercariae NN 1 1 UNK O
- : 0 0 2 O
exposed VBN 1 1 3 O
P NNP 0 1 2 O
. . 0 0 12 O

Influence NN 0 0 UNK O
of IN 0 0 12 O
estradiol NN 0 1 13 B-Drug
and CC 0 0 12 O
progesterone NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
sensitivity NN 0 1 1 O
of IN 0 0 12 O
rat NN 0 1 13 O
thoracic NN 0 0 8 O
aorta NN 0 1 8 O
to TO 0 0 12 O
noradrenaline VB 0 1 UNK B-Drug
. . 0 0 12 O

Evoked VBN 0 1 UNK O
hind NN 0 1 13 O
limb NN 0 1 6 O
digital JJ 0 1 1 O
extensor NN 0 1 8 O
tension NN 0 1 13 O
( ( 0 0 2 O
hoof JJ 0 1 UNK O
twitch NN 0 1 3 O
) ) 0 0 2 O
was VBD 1 0 12 O
maintained VBN 1 1 1 O
at IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
baseline NN 0 1 1 O
for IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
by IN 0 0 12 O
atracurium NN 0 1 13 B-Drug
infusion NN 0 1 14 O
in IN 0 0 12 O
9 CD 0 0 2 O
horses NNS 1 1 UNK O
anaesthetised VBN 1 1 UNK O
with IN 0 0 12 O
halothane NN 0 1 13 B-Drug
. . 0 0 12 O

Acute NNP 0 1 7 O
administration NN 0 1 1 O
of IN 0 0 12 O
hemantane NN 0 1 UNK B-Drug_n
or CC 0 0 12 O
doxycycline NN 0 1 0 B-Drug
failed VBN 1 1 12 O
to TO 0 0 12 O
influence VB 0 0 UNK O
locomotion NN 0 1 UNK O
in IN 0 0 12 O
mice NNS 1 1 UNK O
while IN 0 0 12 O
their PRP$ 0 0 12 O
combination NN 0 1 1 O
normalized VBN 1 1 1 O
motor NN 0 1 3 O
activity NN 0 1 1 O
. . 0 0 12 O

Improvements NNS 0 1 UNK O
in IN 0 0 12 O
general JJ 0 1 1 O
cognitive JJ 0 1 1 O
function NN 0 1 1 O
seen VBN 1 1 12 O
with IN 0 0 12 O
olanzapine JJ 0 1 16 B-Drug
treatment NN 0 1 6 O
in IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
year NN 0 1 12 O
controlled VBD 1 1 1 O
study NN 0 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
early JJ 0 1 12 O
- : 0 0 2 O
phase NN 0 1 1 O
schizophrenia NN 0 1 13 O
were VBD 1 0 12 O
significantly RB 0 0 1 O
greater JJR 1 1 1 O
than IN 0 0 12 O
changes NNS 1 1 1 O
seen VBN 1 1 12 O
with IN 0 0 12 O
either DT 0 1 12 O
risperidone NN 0 1 0 B-Drug
or CC 0 0 12 O
haloperidol NN 0 1 16 B-Drug
. . 0 0 12 O

Induction NN 0 1 UNK O
of IN 0 0 12 O
apoptosis NN 0 1 UNK O
in IN 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
cells NNS 1 1 6 O
in IN 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
vitamin VB 0 1 6 B-Group
D NNP 0 1 2 I-Group
and CC 0 0 12 O
antiestrogens NNS 0 1 UNK B-Group
. . 0 0 12 O

While IN 0 0 12 O
additional JJ 0 1 1 O
research NN 0 1 13 O
is VBZ 1 0 12 O
needed VBN 1 1 12 O
the DT 0 0 12 O
initial JJ 0 1 1 O
clinical JJ 0 1 6 O
data NNS 0 1 1 O
in IN 0 0 12 O
kidney NN 0 1 6 O
recipients NNS 1 1 UNK O
suggest VBP 0 1 1 O
that IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
or CC 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
might MD 0 0 12 O
have VB 0 0 12 O
the DT 0 0 12 O
potential JJ 0 1 1 O
to TO 0 0 12 O
reduce VB 0 0 1 O
the DT 0 0 12 O
frequency NN 0 1 1 O
of IN 0 0 12 O
rejection NN 0 1 1 O
episodes NNS 1 1 12 O
permit VBP 0 1 UNK O
reductions NNS 1 1 1 O
in IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
or CC 0 0 12 O
tacrolimus JJ 0 1 16 B-Drug
dosage NN 0 1 0 O
and CC 0 0 12 O
permit NN 0 1 UNK O
steroid NN 0 1 6 O
withdrawal NN 0 1 1 O
( ( 0 0 2 O
Kelly NNP 0 0 19 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

At IN 0 0 2 O
a DT 0 0 12 O
higher JJR 1 1 1 O
dose NN 0 1 6 O
and CC 0 0 12 O
a DT 0 0 12 O
shorter JJR 1 1 UNK O
withdrawal NN 0 1 1 O
period NN 0 1 1 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg VBD 0 1 18 O
daily RB 0 1 12 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
followed VBN 1 1 12 O
by IN 0 0 12 O
a DT 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
day NN 0 1 12 O
withdrawal NN 0 1 1 O
) ) 0 0 2 O
the DT 0 0 12 O
SST NNP 0 1 UNK O
mice NN 1 1 UNK O
showed VBD 1 1 12 O
behavioral JJ 0 1 13 O
sensitization NN 0 1 13 O
similar JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
RBC NNP 0 1 13 O
mice NN 1 1 UNK O
but CC 0 0 12 O
the DT 0 0 12 O
LST NNP 0 1 UNK O
mice NN 1 1 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
develop VB 0 0 1 O
sensitization NN 0 1 13 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
extensively RB 0 0 1 O
transformed VBN 1 1 UNK O
into IN 0 0 12 O
its PRP$ 1 0 12 O
active JJ 0 1 1 O
metabolites NNS 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
enzyme NN 0 1 14 O
system NN 0 1 1 O
especially RB 0 0 12 O
into IN 0 0 12 O
endoxifen VBN 0 1 UNK B-Drug_n
by IN 0 0 12 O
isoenzyme JJ 0 1 13 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
. . 0 0 12 O

gestational JJ 0 1 6 O
trophoblastic JJ 0 1 13 O
disease NN 0 1 6 O
; : 0 0 2 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
concluded VBN 1 1 1 O
that IN 0 0 12 O
neurotensin NN 0 1 UNK B-Drug_n
modulates NNS 0 1 UNK O
in IN 0 0 12 O
an DT 0 0 12 O
opposite JJ 0 1 UNK O
way NN 0 0 12 O
the DT 0 0 12 O
function NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
enkephalinergic JJ 0 0 UNK O
neurons NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
central JJ 0 1 1 O
action NN 0 1 13 O
of IN 0 0 12 O
tuftsin NN 0 1 UNK B-Drug_n
. . 0 0 12 O

In IN 0 0 2 O
a DT 0 0 12 O
first JJ 0 1 12 O
experiment NN 0 1 UNK O
male NN 0 1 12 O
adult NN 0 1 12 O
Wistar NNP 0 1 UNK O
rats NNS 1 1 UNK O
were VBD 1 0 12 O
fasted VBN 1 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
. . 0 0 12 O

It PRP 0 0 12 O
reduced VBD 1 1 1 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
deaths NNS 1 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
nonlethal NN 0 0 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
dose NN 0 1 6 O
of IN 0 0 12 O
endotoxin NN 0 1 UNK B-Drug_n
but CC 0 0 12 O
increased VBD 1 1 1 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
deaths NNS 1 1 UNK O
induced VBN 1 1 6 O
by IN 0 0 12 O
a DT 0 0 12 O
highly RB 0 1 1 O
lethal JJ 0 1 13 O
dose NN 0 1 6 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
concluded VBN 1 1 1 O
that IN 0 0 12 O
chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
and CC 0 0 12 O
methaqualone NN 0 1 13 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
administered VBN 1 1 1 O
safely RB 0 0 UNK O
without IN 0 0 12 O
additional JJ 0 1 1 O
caution NN 0 0 1 O
in IN 0 0 12 O
prothrombin JJ 0 1 14 O
test NN 0 1 1 O
monitoring NN 0 1 1 O
during IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulant JJ 0 1 13 B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

For IN 0 0 2 O
example NN 0 1 1 O
the DT 0 0 12 O
plasma NN 0 1 14 O
nitrosourea JJ 0 1 UNK B-Group
AUC NNP 0 1 UNK O
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
factors NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
for IN 0 0 12 O
MEC NNP 0 0 UNK O
values NNS 1 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
micrograms NNS 1 1 14 O
ml VBD 0 1 16 O
- : 0 0 2 O
9 CD 0 0 2 O
respectively RB 0 0 1 O
. . 0 0 12 O

Lastly RB 0 0 UNK O
local JJ 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
mucocutaneous JJ 0 0 8 O
and CC 0 0 12 O
cytoprotective JJ 0 0 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
is VBZ 1 0 12 O
still RB 0 0 12 O
valid JJ 0 1 UNK O
in IN 0 0 12 O
cardioplegic JJ 0 1 UNK B-Drug
solutions NNS 1 1 UNK I-Drug
and CC 0 0 12 O
for IN 0 0 12 O
preservation NN 0 1 1 O
of IN 0 0 12 O
transplants NNS 1 1 13 O
particularly RB 0 0 1 O
. . 0 0 12 O

Twitch NNP 0 1 UNK O
gradually RB 0 0 1 O
returned VBD 1 1 12 O
to TO 0 0 12 O
pre VB 0 1 1 O
- : 0 0 2 O
gentamycin NN 0 1 14 B-Drug
strength NN 0 1 1 O
over IN 0 1 12 O
the DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
next JJ 0 1 12 O
hour NN 0 1 12 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
plus CC 0 1 16 O
rifabutin NN 0 1 13 B-Drug
was VBD 1 0 12 O
poorly RB 0 1 1 O
tolerated VBN 1 0 1 O
and CC 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
9 CD 0 0 2 O
subjects NNS 1 1 UNK O
discontinued VBN 1 1 1 O
therapy NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
biochemical JJ 0 1 UNK O
toxicology NN 0 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoroacetone NN 0 0 UNK I-Drug_n
a DT 0 0 12 O
known VBN 1 1 12 O
metabolite NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
major JJ 0 1 1 O
ingredient NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
pesticide NN 0 1 UNK O
Gliftor NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 B-Drug_n
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
difluoro NN 0 0 UNK I-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
- : 0 0 2 O
propanol NN 0 1 UNK I-Drug_n
) ) 0 0 2 O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
and CC 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
paper NN 0 1 13 O
lists VBZ 1 1 UNK O
of IN 0 0 12 O
multiple JJ 0 1 1 O
exposure NN 0 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
the DT 0 0 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
substances NNS 1 1 1 O
the DT 0 0 12 O
types NNS 1 1 1 O
of IN 0 0 12 O
interferences NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
behaviour NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
biological JJ 0 1 13 O
levels NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
drawn VBN 1 0 12 O
up RP 0 0 12 O
and CC 0 0 12 O
proposed VBN 1 1 UNK O
as IN 1 0 12 O
a DT 0 0 12 O
tool NN 0 1 13 O
for IN 0 0 12 O
easy JJ 0 1 12 O
consultation NN 0 1 1 O
. . 0 0 12 O

Hyaluronan NNP 0 1 UNK B-Drug_n
lyase NN 0 1 UNK I-Drug_n
had VBD 1 0 12 O
a DT 0 0 12 O
limited JJ 0 1 1 O
effect NN 0 1 1 O
and CC 0 0 12 O
collagenase NN 0 1 16 B-Drug_n
was VBD 1 0 12 O
ineffective JJ 0 1 UNK O
. . 0 0 12 O

Formulation NN 0 1 UNK O
of IN 0 0 12 O
fluorescence NN 0 1 13 O
labelled VBN 1 1 UNK O
bacitracin NN 0 1 16 B-Drug
and CC 0 0 12 O
insulin NN 0 1 14 B-Drug
in IN 0 0 12 O
unconjugated JJ 0 1 UNK O
NaCMC NNP 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
m NN 0 1 2 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
improve VB 0 0 1 O
the DT 0 0 12 O
permeation NN 0 1 UNK O
however RB 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
m JJ 0 1 2 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
CMC NNP 0 1 13 B-Drug_n
- : 0 0 2 O
Cys NNP 0 1 UNK I-Drug_n
9 CD 0 0 2 O
a DT 0 0 12 O
significantly RB 0 0 1 O
improved VBN 1 1 1 O
permeation NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
( ( 0 0 2 O
R= NNP 0 1 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

DESIGN NN 0 1 UNK O
: : 0 0 2 O
Cross NNP 0 1 UNK O
- : 0 0 2 O
sectional JJ 0 1 UNK O
descriptive NN 0 1 UNK O
study NN 0 1 1 O
. . 0 0 12 O

Self NNP 0 1 2 O
- : 0 0 2 O
control NN 0 1 1 O
of IN 0 0 12 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
( ( 0 0 2 O
BP NNP 0 1 13 O
) ) 0 0 2 O
was VBD 1 0 12 O
performed VBN 1 1 1 O
by IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
UA9PC NNP 0 0 UNK O
apparatus NN 0 1 13 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
show VBP 0 1 12 O
that IN 0 0 12 O
lung NN 0 1 6 B-Group
surfactant NN 0 1 14 I-Group
has VBZ 1 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
of IN 0 0 12 O
enhancing VBG 1 1 1 O
the DT 0 0 12 O
rate NN 0 1 1 O
and CC 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
dissolution NN 0 0 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
administered VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
lung NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
article NN 0 1 UNK O
will MD 0 0 12 O
describe VB 0 0 1 O
the DT 0 0 12 O
escalating NN 0 0 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
herbal JJ 0 1 6 O
therapy NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
hazards NNS 1 1 13 O
of IN 0 0 12 O
herbal JJ 0 1 6 O
remedy NN 0 0 UNK O
use NN 0 1 1 O
among IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
strong JJ 0 1 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
insulin NN 0 1 14 O
resistance NN 0 1 1 O
is VBZ 1 0 12 O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
not RB 0 1 12 O
only RB 0 1 12 O
hyperglycemia NN 0 1 14 O
but CC 0 0 12 O
also RB 0 0 12 O
dyslipidemia JJ 0 1 UNK O
hypertension NN 0 1 6 O
hypercoagulation NN 0 1 UNK O
vasculopathy NN 0 1 8 O
and CC 0 0 12 O
ultimately RB 0 0 1 O
atherosclerotic JJ 0 1 8 O
cardiovascular JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Olanzapine VB 0 1 0 B-Drug
a DT 0 0 12 O
thienobenzodiazepine NN 0 0 UNK B-Group
derivative NN 0 1 13 I-Group
is VBZ 1 0 12 O
a DT 0 0 12 O
second JJ 0 1 12 B-Group
generation NN 0 1 UNK I-Group
atypical JJ 0 1 6 I-Group
antipsychotic JJ 0 1 UNK I-Group
agent NN 0 1 1 I-Group
which WDT 0 0 12 O
has VBZ 1 0 12 O
proven VBN 1 1 1 O
efficacy NN 0 1 UNK O
against IN 0 0 12 O
the DT 0 0 12 O
positive JJ 0 1 1 O
and CC 0 0 12 O
negative JJ 0 1 1 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
schizophrenia NN 0 1 13 O
. . 0 0 12 O

Although IN 0 0 12 O
activation NN 0 1 13 O
of IN 0 0 12 O
several JJ 0 1 12 O
transcription NN 0 1 UNK O
factor NN 0 1 1 O
IEGs NNP 0 0 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
described VBN 1 1 1 O
little JJ 0 1 12 O
is VBZ 1 0 12 O
known VBN 1 1 12 O
about IN 0 1 12 O
effector NN 0 0 UNK O
IEGs NNP 0 0 UNK O
. . 0 0 12 O

On IN 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
ketoconazole NN 0 1 16 B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
. . 0 0 12 O

Both DT 0 0 2 O
steady JJ 0 1 1 O
- : 0 0 2 O
state NN 0 1 1 O
maximum JJ 0 1 1 O
concentration NN 0 1 1 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
were VBD 1 0 12 O
dose JJ 0 1 6 O
proportional JJ 0 1 UNK O
over IN 0 1 12 O
the DT 0 0 12 O
full JJ 0 1 12 O
dose NN 0 1 6 O
range NN 0 1 1 O
when WRB 0 0 12 O
assessed VBN 1 1 1 O
on IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
for IN 0 0 12 O
the DT 0 0 12 O
full JJ 0 1 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
at IN 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
. . 0 0 12 O

Mechanistic JJ 0 1 UNK O
investigations NNS 1 1 1 O
revealed VBD 1 1 12 O
that IN 0 0 12 O
celecoxib NN 0 1 16 B-Drug
exerts NNS 0 1 UNK O
different JJ 0 1 1 O
molecular JJ 0 1 1 O
effects NNS 1 1 1 O
in IN 0 0 12 O
different JJ 0 1 1 O
cells NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
agent NN 0 1 1 O
was VBD 1 0 12 O
found VBN 1 1 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
some DT 0 0 12 O
inhibiting NN 0 1 UNK O
activity NN 0 1 1 O
against IN 0 0 12 O
hepatic JJ 0 1 14 O
microsomal JJ 0 1 UNK O
9 CD 0 0 2 O
- : 0 0 2 O
ethoxycoumarine NN 0 0 UNK O
deethylase NN 0 0 UNK O
in IN 0 0 12 O
male JJ 0 1 12 O
Wistar NNP 0 1 UNK O
rats NNS 1 1 UNK O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
experiments NNS 1 1 UNK O
. . 0 0 12 O

Before IN 0 1 2 O
prescribing VBG 1 1 UNK O
a DT 0 0 12 O
symptomatic JJ 0 1 6 O
( ( 0 0 2 O
pharmaceutical JJ 0 1 13 O
) ) 0 0 2 O
treatment NN 0 1 6 O
for IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
an DT 0 0 12 O
erection NN 0 1 UNK O
disorder NN 0 1 6 O
attention NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
given VBN 1 1 12 O
tot RP 0 0 13 O
the DT 0 0 12 O
sexological JJ 0 1 UNK O
psychological NN 0 1 1 O
and CC 0 0 12 O
medical JJ 0 1 1 O
backgrounds NNS 1 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
disorder NN 0 1 6 O
. . 0 0 12 O

phase NN 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
: : 0 0 2 O
cisapride NN 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
9 CD 0 0 2 O
times NNS 1 1 12 O
/ JJ 0 0 2 O
day NN 0 1 12 O
; : 0 0 2 O

With IN 0 0 2 O
respect NN 0 1 1 O
to TO 0 0 12 O
toxicity VB 0 1 6 O
the DT 0 0 12 O
order NN 0 1 1 O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
inhibitor NN 0 1 14 O
effectiveness NN 0 1 UNK O
was VBD 1 0 12 O
ABT NNP 0 1 UNK B-Drug_n
> NNP 0 0 2 O
diethyldithiocarbamate NN 0 1 UNK B-Drug_n
~ NNP 0 0 2 O
tranylcypromine NN 0 1 13 B-Drug
> NNP 0 0 2 O
ketoconazole NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
aim NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
investigate VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
low JJ 0 1 1 O
and CC 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
of IN 0 0 12 O
estradiol NN 0 1 13 B-Drug
and CC 0 0 12 O
of IN 0 0 12 O
progesterone NN 0 1 13 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
noradrenaline VB 0 1 UNK B-Drug
in IN 0 0 12 O
rat NN 0 1 13 O
thoracic NN 0 0 8 O
aorta NN 0 1 8 O
. . 0 0 12 O

Vitamin NNP 0 1 2 B-Drug
D9 NNP 0 1 UNK I-Drug
administration NN 0 1 1 O
to TO 0 0 12 O
rachitic JJ 0 1 UNK O
chicks NNS 1 1 UNK O
was VBD 1 0 12 O
effective JJ 0 1 1 O
in IN 0 0 12 O
significantly RB 0 0 1 O
elevating VBG 1 1 UNK O
duodenal JJ 0 1 8 O
arsenate NN 0 1 UNK B-Drug_n
absorption NN 0 1 1 O
acting VBG 1 1 12 O
primarily RB 0 0 1 O
to TO 0 0 12 O
enhance VB 0 1 UNK O
serosal JJ 0 1 8 O
transport NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
intestinal JJ 0 1 13 O
absorption NN 0 1 1 O
of IN 0 0 12 O
arsenate NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
As IN 0 0 2 B-Drug_n
( ( 0 0 2 O
V NNP 0 0 2 I-Drug_n
) ) 0 0 2 O
) ) 0 0 2 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
chick NN 0 1 UNK O
by IN 0 0 12 O
means NNS 1 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
in IN 0 0 12 O
situ NN 0 0 1 O
ligated VBD 1 0 8 O
duodenal JJ 0 1 8 O
loop NN 0 1 3 O
technique NN 0 1 1 O
. . 0 0 12 O

Ways NNS 0 0 UNK O
of IN 0 0 12 O
improving VBG 1 1 1 O
the DT 0 0 12 O
adequacy NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
psychotic JJ 0 1 6 O
patients NNS 1 1 6 O
with IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
are VBP 1 0 12 O
discussed VBN 1 1 1 O
. . 0 0 12 O

Ephedrine NNP 0 1 UNK B-Drug
enhances VBZ 1 1 UNK O
the DT 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
dexmedetomidine NN 0 1 16 B-Drug
in IN 0 0 12 O
mice NN 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
have VBP 0 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
assessed VBN 1 1 1 O
in IN 0 0 12 O
various JJ 0 1 1 O
demographic JJ 0 1 UNK O
groups NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
second JJ 0 1 12 O
response NN 0 1 1 O
is VBZ 1 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
release NN 0 1 12 O
of IN 0 0 12 O
norepinephrine NN 0 1 14 O
from IN 0 0 12 O
nerves NNS 1 1 6 O
and CC 0 0 12 O
was VBD 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
ouabain NN 0 1 UNK B-Drug
through IN 0 0 12 O
the DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
norepinephrine JJ 0 1 14 O
release NN 0 1 12 O
whereas IN 0 0 UNK O
the DT 0 0 12 O
first JJ 0 1 12 O
response NN 0 1 1 O
was VBD 1 0 12 O
not RB 0 1 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
norepinephrine JJ 0 1 14 O
release NN 0 1 12 O
but CC 0 0 12 O
presumably RB 0 0 12 O
to TO 0 0 12 O
a DT 0 0 12 O
direct JJ 0 1 1 O
action NN 0 1 13 O
on IN 0 0 12 O
smooth JJ 0 1 3 O
muscle NN 0 1 6 O
cell NN 0 1 1 O
and CC 0 0 12 O
was VBD 1 0 12 O
inhibited VBN 1 1 13 O
by IN 0 0 12 O
ouabain NN 0 1 UNK B-Drug
. . 0 0 12 O

Pharmacokinetic NNP 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
etodolac NN 0 1 13 B-Drug
in IN 0 0 12 O
special JJ 0 1 12 O
populations NNS 1 1 UNK O
. . 0 0 12 O

Palytoxin NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
PTX NNP 0 1 15 B-Drug_n
) ) 0 0 2 O
C9H9N9O9 NNP 0 0 UNK O
isolated VBN 1 1 1 O
from IN 0 0 12 O
marine JJ 0 1 13 O
coelenterates NNS 1 1 UNK O
of IN 0 0 12 O
Palythoa NNP 0 1 UNK O
tuberculosa NN 0 0 UNK O
caused VBD 1 1 1 O
a DT 0 0 12 O
first JJ 0 1 12 O
rapid JJ 0 1 1 O
contraction NN 0 1 6 O
followed VBN 1 1 12 O
by IN 0 0 12 O
the DT 0 0 12 O
slow JJ 0 1 12 O
phasic JJ 0 1 8 O
contraction NN 0 1 6 O
of IN 0 0 12 O
guinea NN 0 1 UNK O
- : 0 0 2 O
pig NN 0 1 UNK O
vas NN 1 1 13 O
deferens NNS 0 0 13 O
. . 0 0 12 O

There EX 0 0 12 O
is VBZ 1 0 12 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
convulsions NNS 1 1 13 O
occurring VBG 1 1 1 O
in IN 0 0 12 O
susceptible JJ 0 1 1 O
patients NNS 1 1 6 O
following VBG 1 1 1 O
the DT 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
new JJ 0 1 12 O
anaesthetic JJ 0 1 UNK B-Group
agents NNS 1 1 1 I-Group
which WDT 0 0 12 O
are VBP 1 0 12 O
capable JJ 0 1 UNK O
of IN 0 0 12 O
inducing VBG 1 1 6 O
CNS NNP 0 1 6 O
excitability NN 0 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
histology NN 0 1 6 O
of IN 0 0 12 O
the DT 0 0 12 O
liver NN 0 1 6 O
was VBD 1 0 12 O
altered VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
three CD 0 1 12 O
groups NNS 1 1 1 O
which WDT 0 0 12 O
were VBD 1 0 12 O
submitted VBN 1 1 UNK O
to TO 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
hydroalcoholic JJ 0 0 UNK O
solutions NNS 1 1 UNK O
with IN 0 0 12 O
quantitative JJ 0 1 1 O
and CC 0 0 12 O
qualitative JJ 0 1 13 O
differences NNS 1 1 UNK O
between IN 0 0 12 O
the DT 0 0 12 O
groups NNS 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
variety NN 0 1 1 O
of IN 0 0 12 O
parametric JJ 0 1 UNK O
dose JJ 0 1 6 O
- : 0 0 2 O
response NN 0 1 1 O
models NNS 1 1 UNK O
based VBN 1 1 1 O
on IN 0 0 12 O
either CC 0 1 12 O
the DT 0 0 12 O
normal JJ 0 1 1 O
or CC 0 0 12 O
logistic JJ 0 1 UNK O
probability NN 0 1 1 O
distribution NN 0 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
proposed VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
literature NN 0 1 UNK O
. . 0 0 12 O

ADL $ 0 1 UNK B-Drug
9 CD 0 0 2 I-Drug
- : 0 0 2 O
9 CD 0 0 2 I-Drug
a DT 0 0 12 O
trans NNS 0 1 3 O
- : 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
dimethyl NN 0 0 UNK O
- : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
hydroxyphenyl NN 0 0 UNK O
) ) 0 0 2 O
piperidine NN 0 1 UNK O
prevents NNS 0 1 UNK O
gastrointestinal JJ 0 1 6 O
effects NNS 1 1 1 O
of IN 0 0 12 O
intravenous JJ 0 1 14 O
morphine NN 0 1 14 B-Drug
without IN 0 0 12 O
affecting VBG 1 1 1 O
analgesia NN 0 1 6 O
. . 0 0 12 O

For IN 0 0 2 O
the DT 0 0 12 O
identification NN 0 1 1 O
of IN 0 0 12 O
`` `` 0 0 13 O
limit NN 0 1 1 O
values NNS 1 1 1 O
'' '' 0 0 13 O
it PRP 0 0 12 O
has VBZ 1 0 12 O
generally RB 0 0 1 O
been VBN 1 0 12 O
suggested VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
literature NN 0 1 UNK O
that IN 0 0 12 O
the DT 0 0 12 O
possible JJ 0 1 1 O
effects NNS 1 1 1 O
deriving VBG 1 1 UNK O
from IN 0 0 12 O
multiple JJ 0 1 1 O
exposure NN 0 1 1 O
be VB 0 0 12 O
considered VBN 1 1 1 O
as IN 1 0 12 O
additive JJ 0 1 16 O
. . 0 0 12 O

It PRP 0 0 12 O
has VBZ 1 0 12 O
recently RB 0 1 12 O
been VBN 1 0 12 O
demonstrated VBN 1 0 1 O
that IN 0 0 12 O
toxin NN 0 1 14 B-Drug_n
A NNP 0 0 2 I-Drug_n
exerts VBZ 1 1 UNK O
its PRP$ 1 0 12 O
cytotoxic JJ 0 1 UNK O
effect NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
glucosylation NN 0 0 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
small JJ 0 1 12 O
GTP NNP 0 1 UNK O
- : 0 0 2 O
binding NN 0 1 1 O
proteins NNS 1 1 14 O
of IN 0 0 12 O
the DT 0 0 12 O
Rho NNP 0 0 UNK O
family NN 0 1 12 O
. . 0 0 12 O

faecalis NNS 0 0 16 O
ATCC VBP 0 1 UNK O
99 CD 0 0 10 O
showed VBD 1 1 12 O
the DT 0 0 12 O
flavonoids NNS 1 1 UNK O
alone RB 0 1 12 O
significantly RB 0 0 1 O
lowered JJ 0 1 3 O
numbers NNS 1 1 1 O
of IN 0 0 12 O
colony NN 0 1 12 O
forming VBG 1 1 3 O
units NNS 1 1 1 O
( ( 0 0 2 O
CFUs NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
active JJ 0 1 1 O
ingredient NN 0 1 UNK O
is VBZ 1 0 12 O
simeticone RB 0 1 UNK B-Drug
. . 0 0 12 O

AIMS NNP 0 1 UNK O
/ NNP 0 0 2 O
HYPOTHESIS NNP 0 1 UNK O
: : 0 0 2 O
There EX 0 0 12 O
is VBZ 1 0 12 O
evidence NN 0 1 1 O
that IN 0 0 12 O
insulin NN 0 1 14 B-Drug
and CC 0 0 12 O
glucose NN 0 1 14 B-Drug
cause VBP 0 1 12 O
renal JJ 0 1 6 O
and CC 0 0 12 O
ocular JJ 0 1 6 O
vasodilation NN 0 1 14 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NN 0 0 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
promising JJ 0 1 UNK O
therapeutic JJ 0 1 6 O
target NN 0 1 1 O
for IN 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
ALL DT 0 1 11 O
. . 0 0 12 O

In IN 0 0 2 O
an DT 0 0 12 O
effort NN 0 1 12 O
to TO 0 0 12 O
screen VB 0 1 3 O
compounds NNS 1 1 13 O
for IN 0 0 12 O
antipsychotic JJ 0 1 UNK O
activity NN 0 1 1 O
preclinical JJ 0 1 UNK O
researchers NNS 1 1 UNK O
have VBP 0 0 12 O
investigated VBN 1 1 1 O
whether IN 0 0 12 O
these DT 0 0 12 O
compounds NNS 1 1 13 O
block VBP 0 1 3 O
PCP NNP 0 1 13 B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
behaviors NNS 1 1 1 O
in IN 0 0 12 O
animals NNS 1 1 12 O
. . 0 0 12 O

Both DT 0 0 2 O
efavirenz FW 0 1 13 B-Drug
and CC 0 0 12 O
nevirapine NNS 0 1 13 B-Drug
have VBP 0 0 12 O
been VBN 1 0 12 O
compared VBN 1 1 1 O
to TO 0 0 12 O
triple VB 0 1 3 O
therapy NN 0 1 6 O
with IN 0 0 12 O
the DT 0 0 12 O
PI NNP 0 1 UNK B-Group
indinavir NN 0 1 16 B-Drug
over IN 0 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
as IN 1 0 12 O
initial JJ 0 1 1 O
therapy NN 0 1 6 O
with IN 0 0 12 O
similar JJ 0 1 1 O
responses NNS 1 1 1 O
being VBG 1 0 12 O
observed VBN 1 1 1 O
with IN 0 0 12 O
nevirapine JJ 0 1 13 B-Drug
regimens NNS 1 1 UNK O
and CC 0 0 12 O
superiority NN 0 1 UNK O
observed VBN 1 1 1 O
with IN 0 0 12 O
efavirenz NN 0 1 13 B-Drug
. . 0 0 12 O

Despite IN 0 0 12 O
adequate JJ 0 1 1 O
levothyroxine NN 0 1 0 B-Drug
dosage NN 0 1 0 O
thyroid NN 0 1 6 O
stimulating VBG 1 1 1 O
hormone NN 0 1 6 O
( ( 0 0 2 O
TSH NNP 0 0 14 O
) ) 0 0 2 O
was VBD 1 0 12 O
high JJ 0 1 1 O
suggesting VBG 1 1 1 O
undertreatment NN 0 0 UNK O
. . 0 0 12 O

Buforin NNP 0 0 UNK B-Drug_n
II NNP 0 0 2 I-Drug_n
may MD 0 0 1 O
be VB 0 0 12 O
active JJ 0 1 1 O
in IN 0 0 12 O
inhibiting VBG 1 1 UNK O
Cryptosporidium NNP 0 1 UNK O
parvum NN 0 1 13 O
growth NN 0 1 1 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
upon IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
either DT 0 1 12 O
azithromycin NN 0 1 0 B-Drug
or CC 0 0 12 O
minocycline NN 0 1 13 B-Drug
. . 0 0 12 O

RNA NN 0 1 UNK O
from IN 0 0 12 O
un JJ 0 1 13 O
- : 0 0 2 O
treated VBN 1 1 1 O
and CC 0 0 12 O
DZNep NNP 0 0 UNK B-Drug_n
treated VBD 1 1 1 O
cells NNS 1 1 6 O
was VBD 1 0 12 O
profiled VBN 1 1 UNK O
by IN 0 0 12 O
Affymetrix NNP 0 0 UNK O
HG NNP 0 1 UNK O
- : 0 0 2 O
U9 NNP 0 0 UNK O
Plus CC 0 1 2 O
9 CD 0 0 2 O
microarray NN 0 1 UNK O
and CC 0 0 12 O
genes NNS 1 1 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
significant JJ 0 1 1 O
change NN 0 1 1 O
in IN 0 0 12 O
gene NN 0 1 13 O
expression NN 0 1 1 O
were VBD 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
significance NN 0 1 13 O
analysis NN 0 1 1 O
of IN 0 0 12 O
microarray NN 0 1 UNK O
( ( 0 0 2 O
SAM NNP 0 1 UNK O
) ) 0 0 2 O
testing NN 0 1 1 O
. . 0 0 12 O

however RB 0 0 12 O
the DT 0 0 12 O
second JJ 0 1 12 O
contraction NN 0 1 6 O
was VBD 1 0 12 O
potentiated VBN 1 0 UNK O
. . 0 0 12 O

The DT 0 0 2 O
response NN 0 1 1 O
rates NNS 1 1 1 O
were VBD 1 0 12 O
similar JJ 0 1 1 O
between IN 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
groups NNS 1 1 1 O
. . 0 0 12 O

Among IN 0 0 UNK O
the DT 0 0 12 O
risk NN 0 1 1 O
factors NNS 1 1 1 O
studied VBD 1 0 1 O
two CD 0 1 12 O
appear VBP 0 1 12 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
risk NN 0 1 1 O
of IN 0 0 12 O
ARE NNP 0 0 UNK O
: : 0 0 2 O
the DT 0 0 12 O
prescription NN 0 1 0 O
of IN 0 0 12 O
thiabendazole NN 0 1 UNK B-Drug
to TO 0 0 12 O
treat VB 0 1 12 O
strongyloidiasis NN 0 1 13 O
during IN 0 0 12 O
the DT 0 0 12 O
melarsoprol NN 0 1 UNK B-Drug
cure NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
bad JJ 0 1 12 O
general JJ 0 1 1 O
clinical JJ 0 1 6 O
conditions NNS 1 1 1 O
of IN 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

Cyclosporine NNP 0 1 UNK B-Drug
doses VBZ 1 1 6 O
trough JJ 0 1 3 O
concentrations NNS 1 1 13 O
and CC 0 0 12 O
AUC NNP 0 1 UNK O
exhibited VBD 1 1 1 O
similar JJ 0 1 1 O
temporal JJ 0 1 1 O
patterns NNS 1 1 1 O
during IN 0 0 12 O
the DT 0 0 12 O
course NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
study NN 0 1 1 O
regardless NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
everolimus VBP 0 1 13 B-Drug
dose JJ 0 1 6 O
level NN 0 1 1 O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
.9 NNP 0 0 18 O
.9 NNP 0 0 18 O
and CC 0 0 12 O
.9 NNP 0 0 18 O
respectively RB 0 0 1 O
) ) 0 0 2 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
concluded VBN 1 1 1 O
from IN 0 0 12 O
these DT 0 0 12 O
results NNS 1 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
modulatory JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
glycine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
evidently RB 0 0 12 O
a DT 0 0 12 O
later JJ 1 1 12 O
developmental JJ 0 1 1 O
acquisition NN 0 1 UNK O
( ( 0 0 2 O
after IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
incubation NN 0 0 UNK O
) ) 0 0 2 O
in IN 0 0 12 O
the DT 0 0 12 O
embryogenesis NN 0 1 UNK O
of IN 0 0 12 O
NMDA NNP 0 1 UNK O
- : 0 0 2 O
ergic JJ 0 1 UNK O
activation NN 0 1 13 O
of IN 0 0 12 O
spontaneous JJ 0 1 1 O
motility NN 0 1 6 O
in IN 0 0 12 O
chick JJ 0 1 UNK O
embryos NN 1 1 UNK O
similarly RB 0 0 1 O
as IN 1 0 12 O
glycinergic JJ 0 0 UNK O
inhibition NN 0 1 13 O
. . 0 0 12 O

HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NN 0 0 UNK O
was VBD 1 0 12 O
strongly RB 0 0 1 O
expressed VBN 1 0 1 O
by IN 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
ALL DT 0 1 11 O
cell NN 0 1 1 O
lines NNS 1 1 3 O
and CC 0 0 12 O
the DT 0 0 12 O
expression NN 0 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NN 0 0 UNK O
and CC 0 0 12 O
EGFR NNP 0 1 UNK O
was VBD 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
doxorubicin NN 0 1 13 B-Drug
. . 0 0 12 O

Blood NNP 0 1 2 O
sampling VBG 1 1 13 O
for IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
everolimus NN 0 1 13 B-Drug
and CC 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
was VBD 1 0 12 O
performed VBN 1 1 1 O
on IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
on IN 0 0 12 O
weeks NNS 1 1 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
on IN 0 0 12 O
months NNS 1 1 12 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
. . 0 0 12 O

Both DT 0 0 2 O
of IN 0 0 12 O
these DT 0 0 12 O
strategies NNS 1 1 UNK O
will MD 0 0 12 O
become VB 0 0 12 O
more RBR 0 1 12 O
feasible JJ 0 0 1 O
as IN 1 0 12 O
specific JJ 0 1 1 O
molecular JJ 0 1 1 O
differences NNS 1 1 UNK O
between IN 0 0 12 O
tumor NN 0 1 6 O
and CC 0 0 12 O
normal JJ 0 1 1 O
cells NNS 1 1 6 O
are VBP 1 0 12 O
being VBG 1 0 12 O
rapidly RB 0 1 1 O
identified VBN 1 1 1 O
and CC 0 0 12 O
new JJ 0 1 12 O
combination NN 0 1 1 O
therapies NNS 1 1 6 O
that WDT 0 0 12 O
take VBP 0 1 12 O
advantage NN 0 0 UNK O
of IN 0 0 12 O
these DT 0 0 12 O
differences NNS 1 1 UNK O
are VBP 1 0 12 O
being VBG 1 0 12 O
designed VBN 1 1 UNK O
and CC 0 0 12 O
tested VBN 1 1 1 O
. . 0 0 12 O

Since IN 0 1 2 O
etodolac NN 0 1 13 B-Drug
has VBZ 1 0 12 O
a DT 0 0 12 O
well RB 0 1 12 O
- : 0 0 2 O
defined VBN 1 1 1 O
pharmacokinetic JJ 0 1 UNK O
- : 0 0 2 O
pharmacodynamic JJ 0 1 UNK O
relationship NN 0 1 12 O
measurement NN 0 1 1 O
of IN 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
parameters NNS 1 1 1 O
is VBZ 1 0 12 O
clinically RB 0 0 6 O
relevant JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
result NN 0 1 1 O
of IN 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
both DT 0 0 12 O
CYP9C9 NNP 0 0 UNK B-Drug
and CC 0 0 12 O
9C9 CD 0 0 UNK O
by IN 0 0 12 O
fluvoxamine NN 0 1 16 B-Drug
. . 0 0 12 O

Other JJ 0 0 2 O
factors NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
tolerance NN 0 1 1 O
and CC 0 0 12 O
sensitization NN 0 1 13 O
to TO 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
' POS 0 0 2 O
actions NNS 1 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
withdrawal NN 0 1 1 O
symptoms NNS 1 1 6 O
may MD 0 0 1 O
also RB 0 0 12 O
contribute VB 0 1 UNK O
to TO 0 0 12 O
dependence VB 0 1 1 O
. . 0 0 12 O

Fluoroquinolones NNS 0 1 7 B-Group
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
have VB 0 0 12 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
active JJ 0 1 1 O
in IN 0 0 12 O
gastro JJ 0 1 13 O
intestinal JJ 0 1 13 O
tract NN 0 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
report NN 0 1 1 O
describes VBZ 1 0 1 O
two CD 0 1 12 O
cases NNS 1 1 UNK O
in IN 0 0 12 O
which WDT 0 0 12 O
theophylline JJ 0 1 16 B-Drug
clearance NN 0 1 16 O
accelerated VBD 1 1 1 O
markedly RB 0 1 1 O
with IN 0 0 12 O
concomitant JJ 0 1 6 O
phenytoin NN 0 1 16 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Several JJ 0 1 2 O
classes NNS 1 1 UNK O
of IN 0 0 12 O
cardiovascular JJ 0 1 6 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
also RB 0 0 12 O
discussed VBN 1 1 1 O
in IN 0 0 12 O
relationship NN 0 1 12 O
to TO 0 0 12 O
their PRP$ 0 0 12 O
differential JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
and CC 0 0 12 O
progression NN 0 1 1 O
of IN 0 0 12 O
renal JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
EC9 NNP 0 0 UNK O
values NNS 1 1 1 O
for IN 0 0 12 O
isoproterenol NN 0 1 13 B-Drug
which WDT 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
a DT 0 0 12 O
substrate NN 0 1 UNK O
for IN 0 0 12 O
norepinephrine JJ 0 1 14 B-Drug
uptake JJ 0 1 14 O
- : 0 0 2 O
9 CD 0 0 2 O
were VBD 1 0 12 O
reduced VBN 1 1 1 O
in IN 0 0 12 O
myocardium NN 0 1 8 O
in IN 0 0 12 O
functional JJ 0 1 1 O
classes NNS 1 1 UNK O
II NNP 0 0 2 O
to TO 0 0 12 O
III NNP 0 1 2 O
and CC 0 0 12 O
IV NNP 0 1 2 O
compared VBN 1 1 1 O
with IN 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
nonfailing VBG 0 0 UNK O
myocardium NN 0 1 8 O
. . 0 0 12 O

Organometals NNS 0 0 UNK O
also RB 0 0 12 O
compromise VBP 0 1 1 O
the DT 0 0 12 O
limbic JJ 0 0 UNK O
system NN 0 1 1 O
and CC 0 0 12 O
result NN 0 1 1 O
in IN 0 0 12 O
deficits NNS 1 1 1 O
in IN 0 0 12 O
learning NN 0 1 13 O
and CC 0 0 12 O
memory NN 0 1 1 O
. . 0 0 12 O

Survival NN 0 1 UNK O
of IN 0 0 12 O
miracidia NN 0 0 UNK O
was VBD 1 0 12 O
reduced VBN 1 1 1 O
by IN 0 0 12 O
increasing VBG 1 1 1 O
metal JJ 0 1 3 O
concentration NN 0 1 1 O
except IN 0 0 12 O
at IN 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
9 CD 0 0 2 O
microg NNS 0 0 UNK O
/ JJ 0 0 2 O
l NN 0 1 2 O
for IN 0 0 12 O
single JJ 0 1 12 O
metal NN 0 1 3 O
toxicity NN 0 1 6 O
where WRB 0 0 12 O
survival NN 0 1 1 O
was VBD 1 0 12 O
increased VBN 1 1 1 O
above IN 0 1 12 O
the DT 0 0 12 O
control NN 0 1 1 O
. . 0 0 12 O

Calcium NN 0 1 7 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
absorption NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
milligrams NNS 1 1 14 O
of IN 0 0 12 O
nonheme NN 0 0 UNK B-Drug
or CC 0 0 12 O
heme NN 0 1 14 B-Drug
iron NN 0 1 3 I-Drug
at IN 0 0 12 O
doses NNS 1 1 6 O
less JJR 0 1 12 O
than IN 0 0 12 O
9 CD 0 0 2 O
milligrams NNS 1 1 14 O
in IN 0 0 12 O
nonpregnant JJ 0 0 UNK O
women NNS 1 1 UNK O
. . 0 0 12 O

Gene NNP 0 1 19 O
expression NN 0 1 1 O
analysis NN 0 1 1 O
on IN 0 0 12 O
MM NNP 0 0 13 O
patient JJ 0 1 6 O
dataset NN 0 1 UNK O
indicated VBD 1 1 1 O
ALOX9 NNP 0 0 UNK O
expression NN 0 1 1 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
higher JJR 1 1 1 O
in IN 0 0 12 O
MM NNP 0 0 13 O
patients NNS 1 1 6 O
compared VBN 1 1 1 O
to TO 0 0 12 O
normal JJ 0 1 1 O
plasma JJ 0 1 14 O
cells NNS 1 1 6 O
. . 0 0 12 O

Taken VBN 0 1 UNK O
together RB 0 1 12 O
these DT 0 0 12 O
findings NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
Kd NNP 0 1 UNK O
of IN 0 0 12 O
D9 NNP 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
NAC NNP 0 1 UNK O
and CC 0 0 12 O
the DT 0 0 12 O
Bmax NNP 0 0 UNK O
of IN 0 0 12 O
D9 NNP 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
STR NNP 0 0 UNK O
may MD 0 0 1 O
contribute VB 0 1 UNK O
to TO 0 0 12 O
the DT 0 0 12 O
differences NNS 1 1 UNK O
in IN 0 0 12 O
locomotor NN 0 0 UNK O
responses NNS 1 1 1 O
to TO 0 0 12 O
cocaine VB 0 1 6 B-Drug
exposure NN 0 1 1 O
in IN 0 0 12 O
these DT 0 0 12 O
mouse NN 0 1 UNK O
lines NNS 1 1 3 O
. . 0 0 12 O

Loperamide NNP 0 1 UNK B-Drug
and CC 0 0 12 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
s.c. NN 0 1 UNK O
) ) 0 0 2 O
inhibited VBD 1 1 13 O
the DT 0 0 12 O
dmPGE9 NN 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
p.o NN 0 1 UNK O
. . 0 0 12 O
) ) 0 0 2 O
- : 0 0 2 O
induced VBN 1 1 6 O
diarrhea NN 0 1 6 O
in IN 0 0 12 O
cecectomized JJ 0 0 UNK O
rats NNS 1 1 UNK O
. . 0 0 12 O

These DT 0 0 1 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
relatively RB 0 0 1 O
specific JJ 0 1 1 O
blockade NN 0 1 1 O
of IN 0 0 12 O
diverse JJ 0 1 UNK O
potassium NN 0 1 14 O
channel NN 0 1 1 O
types NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
this DT 0 0 12 O
study NN 0 1 1 O
we PRP 0 0 12 O
investigated VBD 1 1 1 O
the DT 0 0 12 O
mechanism NN 0 1 13 O
( ( 0 0 2 O
) ) 0 0 2 O
of IN 0 0 12 O
resveratrol NN 0 1 UNK B-Drug_n
- : 0 0 2 O
induced JJ 0 1 6 O
vasorelaxation NN 0 1 UNK O
in IN 0 0 12 O
resistance NN 0 1 1 O
mesenteric JJ 0 1 8 O
arteries NNS 1 1 6 O
from IN 0 0 12 O
male JJ 0 1 12 O
lean JJ 0 0 13 O
and CC 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
induced JJ 0 1 6 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Moreover RB 0 0 1 O
the DT 0 0 12 O
mechanisms NNS 1 1 UNK O
underlying VBG 1 0 1 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
dependence NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
similar JJ 0 1 1 O
for IN 0 0 12 O
alcohol NN 0 1 1 B-Drug
and CC 0 0 12 O
nicotine NN 0 1 6 B-Drug
. . 0 0 12 O

When WRB 0 0 12 O
prescribing VBG 1 1 UNK O
for IN 0 0 12 O
older JJR 1 1 12 O
patients NNS 1 1 6 O
some DT 0 0 12 O
physicians NNS 1 1 6 O
are VBP 1 0 12 O
overly RB 0 0 UNK O
cautious JJ 0 0 UNK O
and CC 0 0 12 O
this DT 0 0 12 O
strategy NN 0 1 1 O
can MD 0 0 12 O
result VB 0 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
less JJR 0 1 12 O
than IN 0 0 12 O
optimal JJ 0 1 1 O
treatment NN 0 1 6 O
outcome NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
levorotatory JJ 0 1 UNK O
isomer NN 0 1 UNK O
had VBD 1 0 12 O
opioid VBN 0 1 13 O
- : 0 0 2 O
antagonist NN 0 1 13 O
and CC 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
opioid JJ 0 1 13 O
agonist NN 0 1 14 O
effects NNS 1 1 1 O
in IN 0 0 12 O
pigeons NNS 1 1 UNK O
and CC 0 0 12 O
mixed JJ 0 1 3 O
opioid JJ 0 1 13 O
agonist NN 0 1 14 O
- : 0 0 2 O
antagonist NN 0 1 13 O
effects NNS 1 1 1 O
in IN 0 0 12 O
monkeys NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
key NN 0 0 13 O
to TO 0 0 12 O
maximizing VBG 1 0 1 O
therapy NN 0 1 6 O
lies VBZ 1 0 UNK O
in IN 0 0 12 O
individualizing VBG 1 0 UNK O
it PRP 0 0 12 O
as RB 0 0 12 O
much RB 0 0 12 O
as IN 1 0 12 O
possible JJ 0 1 1 O
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
KRM NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
has VBZ 1 0 12 O
a DT 0 0 12 O
great JJ 0 1 12 O
potential NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
M NNP 0 1 2 O
. . 0 0 12 O

Both DT 0 0 2 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
filipin NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
value NN 0 1 1 O
of IN 0 0 12 O
amphotericin NN 0 1 14 B-Drug
B NNP 0 0 2 I-Drug
can MD 0 0 12 O
be VB 0 0 12 O
rationalized VBN 1 0 UNK O
at IN 0 0 12 O
the DT 0 0 12 O
cellular JJ 0 1 13 O
and CC 0 0 12 O
molecular JJ 0 1 1 O
level NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
observations NNS 1 1 1 O
: : 0 0 2 O
( ( 0 0 2 O
i NN 0 1 12 O
) ) 0 0 2 O
these DT 0 0 12 O
polyene NN 0 1 UNK B-Group
antibiotics NNS 1 1 6 I-Group
showed VBD 1 1 12 O
differential JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
cells NNS 1 1 6 O
; : 0 0 2 O

METHODS NNS 0 1 UNK O
: : 0 0 2 O
We PRP 0 0 12 O
carried VBD 1 1 12 O
out RP 0 1 12 O
two CD 0 1 12 O
different JJ 0 1 1 O
9 CD 0 0 2 O
- : 0 0 2 O
way NN 0 0 12 O
crossover NN 0 1 UNK O
studies NNS 1 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
subjects NNS 1 1 UNK O
( ( 0 0 2 O
each DT 0 0 12 O
n NN 0 1 12 O
= VBZ 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Unmodified VBN 0 0 UNK O
NaCMC NNP 0 0 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
m NN 0 1 2 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
significantly RB 0 0 1 O
improved VBN 1 1 1 O
the DT 0 0 12 O
transport NN 0 1 1 O
ratio NN 0 1 1 O
( ( 0 0 2 O
R= NNP 0 1 UNK O
P NNP 0 1 2 O
( ( 0 0 2 O
app NN 0 0 13 O
) ) 0 0 2 O
polymer NN 0 1 UNK O
/ NN 0 0 2 O
P NNP 0 1 2 O
( ( 0 0 2 O
app NN 0 0 13 O
) ) 0 0 2 O
control NN 0 1 1 O
) ) 0 0 2 O
of IN 0 0 12 O
NaFlu NNP 0 0 UNK B-Drug
to TO 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
( ( 0 0 2 O
m JJ 0 1 2 O
/ NNP 0 0 2 O
v NN 0 0 16 O
) ) 0 0 2 O
NaCMC NNP 0 0 UNK B-Drug_n
conjugated VBN 1 1 14 O
with IN 0 0 12 O
cysteine NN 0 1 13 B-Drug
further RBR 1 1 1 O
enhanced VBD 1 1 1 O
the DT 0 0 12 O
permeation NN 0 1 UNK O
. . 0 0 12 O

On IN 0 0 2 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
estimated JJ 0 1 1 O
number NN 0 1 1 O
of IN 0 0 12 O
regular JJ 0 1 12 O
users NNS 1 1 UNK O
of IN 0 0 12 O
intravenous JJ 0 1 14 O
amphetamine NN 0 1 13 B-Drug
in IN 0 0 12 O
Ontario NNP 0 1 UNK O
the DT 0 0 12 O
mortality NN 0 1 13 O
rate NN 0 1 1 O
in IN 0 0 12 O
such JJ 0 0 1 O
users NNS 1 1 UNK O
is VBZ 1 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
four CD 0 1 12 O
times NNS 1 1 12 O
as RB 0 0 12 O
high JJ 0 1 1 O
as IN 1 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
general JJ 0 1 1 O
population NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
age NN 0 1 12 O
and CC 0 0 12 O
is VBZ 1 0 12 O
comparable JJ 0 0 1 O
to TO 0 0 12 O
that DT 0 0 12 O
in IN 0 0 12 O
alcoholics NNS 1 1 UNK O
and CC 0 0 12 O
heroin NN 0 1 13 B-Drug_n
addicts NNS 1 1 UNK O
. . 0 0 12 O

Toxicity NN 0 1 UNK O
of IN 0 0 12 O
cadmium NN 0 1 13 O
and CC 0 0 12 O
zinc NN 0 1 14 B-Drug
to TO 0 0 12 O
encystment VB 0 0 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
excystment NN 0 0 UNK O
of IN 0 0 12 O
Parorchis NNP 0 1 UNK O
acanthus NN 0 1 UNK O
( ( 0 0 2 O
Digenea NNP 0 1 UNK O
: : 0 0 2 O
Philophthalmidae NN 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
general JJ 0 1 1 O
public JJ 0 0 12 O
feels NNS 1 1 12 O
that IN 0 0 12 O
cocaine NN 0 1 6 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
particularly RB 0 0 1 O
dangerous JJ 0 1 UNK O
because IN 0 0 12 O
it PRP 0 0 12 O
does VBZ 1 0 12 O
not RB 0 1 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
well NN 0 1 12 O
defined VBN 1 1 1 O
physical JJ 0 1 1 O
dependency NN 0 1 UNK O
and CC 0 0 12 O
abstinence NN 0 1 UNK O
syndrome NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
patient NN 0 1 6 O
had VBD 1 0 12 O
been VBN 1 0 12 O
receiving VBG 1 1 1 O
simvastatin NN 0 1 0 B-Drug
for IN 0 0 12 O
approximately RB 0 1 1 O
six CD 0 1 12 O
months NNS 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
influence NN 0 0 UNK O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
and CC 0 0 12 O
diazepam NN 0 1 0 B-Drug
on IN 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
morphine NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
metamizol NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
and CC 0 0 12 O
indomethacin NN 0 1 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
was VBD 1 0 12 O
investigated VBN 1 1 1 O
in IN 0 0 12 O
a DT 0 0 12 O
mouse NN 0 1 UNK O
model NN 0 1 UNK O
using VBG 1 1 1 O
the DT 0 0 12 O
tail NN 0 1 3 O
- : 0 0 2 O
flick NN 0 0 UNK O
and CC 0 0 12 O
hot JJ 0 1 3 O
- : 0 0 2 O
plate NN 0 1 3 O
tests NNS 1 1 1 O
. . 0 0 12 O

On IN 0 0 2 O
second JJ 0 1 12 O
day NN 0 1 12 O
after IN 0 0 12 O
injection NN 0 1 3 O
MPTP NNP 0 1 UNK B-Drug_n
decreased VBD 1 1 1 O
the DT 0 0 12 O
locomot NN 0 0 UNK O
or CC 0 0 12 O
activity NN 0 1 1 O
in IN 0 0 12 O
comparison NN 0 1 1 O
to TO 0 0 12 O
saline VB 0 1 14 O
. . 0 0 12 O

However RB 0 0 1 O
the DT 0 0 12 O
evidence NN 0 1 1 O
for IN 0 0 12 O
a DT 0 0 12 O
calcium NN 0 1 14 B-Drug
effect NN 0 1 1 O
on IN 0 0 12 O
iron NN 0 1 3 B-Drug
absorption NN 0 1 1 O
mainly RB 0 0 1 O
comes VBZ 1 0 12 O
from IN 0 0 12 O
studies NNS 1 1 1 O
that WDT 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
isolate VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
calcium NN 0 1 14 B-Drug
from IN 0 0 12 O
that DT 0 0 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
dietary JJ 0 1 6 O
components NNS 1 1 1 O
because IN 0 0 12 O
it PRP 0 0 12 O
was VBD 1 0 12 O
detected VBN 1 1 1 O
in IN 0 0 12 O
single JJ 0 1 12 O
- : 0 0 2 O
meal NN 0 1 12 O
studies NNS 1 1 1 O
. . 0 0 12 O

EA NNP 0 1 UNK O
signs NNS 1 1 12 O
were VBD 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
all DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
propofol JJ 0 1 14 B-Drug
TIVA NNP 0 0 UNK O
but CC 0 0 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
recur VB 0 1 13 O
in IN 0 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
9 CD 0 0 2 O
subsequent JJ 0 1 1 O
anesthetics NNS 1 1 13 O
sessions NNS 1 1 UNK O
during IN 0 0 12 O
which WDT 0 0 12 O
low JJ 0 1 1 O
- : 0 0 2 O
dose NN 0 1 6 O
ketamine NN 0 1 13 B-Drug
was VBD 1 0 12 O
added VBN 1 1 12 O
to TO 0 0 12 O
propofol VB 0 1 14 B-Drug
. . 0 0 12 O

We PRP 0 0 12 O
propose VBP 0 0 UNK O
these DT 0 0 12 O
pharmacokinetic JJ 0 1 UNK O
changes NNS 1 1 1 O
to TO 0 0 12 O
be VB 0 0 12 O
the DT 0 0 12 O
underlying JJ 0 0 1 O
mechanism NN 0 1 13 O
for IN 0 0 12 O
the DT 0 0 12 O
reduction NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
CCNU NNP 0 1 UNK B-Drug
cytotoxicity NN 0 1 UNK O
by IN 0 0 12 O
misonidazole NN 0 1 UNK B-Drug_n
. . 0 0 12 O

The DT 0 0 2 O
thiazolidinediones NNS 0 1 UNK B-Group
( ( 0 0 2 O
rosiglitazone NN 0 1 16 B-Drug
and CC 0 0 12 O
pioglitazone NN 0 1 16 B-Drug
) ) 0 0 2 O
a DT 0 0 12 O
new JJ 0 1 12 O
class NN 0 1 12 O
of IN 0 0 12 O
oral JJ 0 1 6 O
antidiabetic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
are VBP 1 0 12 O
`` `` 0 0 13 O
insulin JJ 0 1 14 O
sensitizers NNS 1 0 UNK O
'' '' 0 0 13 O

The DT 0 0 2 O
serum NN 0 1 14 O
androgen NN 0 1 13 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
estradiol JJ 0 1 13 B-Drug
+ NNP 0 0 2 O
endotoxin NN 0 1 UNK B-Drug_n
- : 0 0 2 O
treated JJ 0 1 1 O
rats NNS 1 1 UNK O
did VBD 1 0 12 O
not RB 0 1 12 O
change VB 0 1 1 O
significantly RB 0 0 1 O
while IN 0 0 12 O
those DT 0 0 12 O
of IN 0 0 12 O
endotoxin JJ 0 1 UNK B-Drug_n
- : 0 0 2 O
treated JJ 0 1 1 O
rats NNS 1 1 UNK O
dropped VBD 1 1 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O

In IN 0 0 2 O
this DT 0 0 12 O
study NN 0 1 1 O
we PRP 0 0 12 O
investigated VBD 1 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
ginsenosides NNS 0 1 UNK B-Drug_n
on IN 0 0 12 O
high JJ 0 1 1 O
threshold NN 0 1 1 O
voltage NN 0 1 1 O
- : 0 0 2 O
dependent NN 0 1 1 O
Ca NNP 0 1 2 O
( ( 0 0 2 O
9+ CD 0 0 16 O
) ) 0 0 2 O
channel NN 0 1 1 O
subtypes NNS 0 1 UNK O
using VBG 1 1 1 O
their PRP$ 0 0 12 O
selective JJ 0 1 13 B-Group
Ca NNP 0 1 2 I-Group
( ( 0 0 2 O
9+ CD 0 0 16 I-Group
) ) 0 0 2 O
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
nimodipine VBP 0 1 16 B-Drug
( ( 0 0 2 O
L NNP 0 1 2 O
- : 0 0 2 O
type NN 0 1 1 O
) ) 0 0 2 O
omega SYM 0 1 16 B-Drug_n
- : 0 0 2 O
conotoxin NN 0 1 UNK I-Drug_n
GVIA NNP 0 0 UNK I-Drug_n
( ( 0 0 2 O
N NNP 0 1 2 O
- : 0 0 2 O
type NN 0 1 1 O
) ) 0 0 2 O
or CC 0 0 12 O
omega JJ 0 1 16 B-Drug_n
- : 0 0 2 O
agatoxin NN 0 0 UNK I-Drug_n
IVA NNP 0 1 UNK I-Drug_n
( ( 0 0 2 O
P NNP 0 1 2 O
- : 0 0 2 O
type NN 0 1 1 O
) ) 0 0 2 O
in IN 0 0 12 O
bovine NN 0 1 13 O
chromaffin NN 0 0 UNK O
cells NNS 1 1 6 O
. . 0 0 12 O

Overall JJ 0 1 2 O
PTH NNP 0 0 14 O
levels NNS 1 1 1 O
decreased VBN 1 1 1 O
from IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
; : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
; : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
( ( 0 0 2 O
median JJ 0 1 1 O
( ( 0 0 2 O
9th CD 0 0 13 O
; : 0 0 2 O
9th CD 0 0 13 O
percentile NN 0 1 1 O
) ) 0 0 2 O
) ) 0 0 2 O
pmol NN 0 1 UNK O
/ NNP 0 0 2 O
l NN 0 1 2 O
; : 0 0 2 O

The DT 0 0 2 O
unrestricted JJ 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
ascorbic JJ 0 0 16 B-Drug
acid NN 0 1 14 I-Drug
for IN 0 0 12 O
these DT 0 0 12 O
purposes NNS 1 1 13 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
advocated VBN 1 1 UNK O
on IN 0 0 12 O
the DT 0 0 12 O
basis NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
evidence NN 0 1 1 O
currently RB 0 1 12 O
available JJ 0 1 1 O
. . 0 0 12 O

Physiological JJ 0 1 UNK O
oral JJ 0 1 6 O
magnesium NN 0 1 14 B-Drug
load NN 0 1 3 O
constitutes VBZ 1 0 UNK O
the DT 0 0 12 O
best JJS 0 1 12 O
tool NN 0 1 13 O
for IN 0 0 12 O
diagnosis NN 0 1 6 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
deficiency NN 0 1 6 O
and CC 0 0 12 O
the DT 0 0 12 O
first JJ 0 1 12 O
step NN 0 1 12 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

Cercarial JJ 0 1 UNK O
encystment NN 0 0 UNK O
at IN 0 0 12 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
99 CD 0 0 10 O
microg NNS 0 0 UNK O
/ JJ 0 0 2 O
l NN 0 1 2 O
or CC 0 0 12 O
higher JJR 1 1 1 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
impaired VBN 1 1 6 O
by IN 0 0 12 O
all DT 0 0 12 O
test NN 0 1 1 O
metals NNS 1 1 13 O
; : 0 0 2 O

While IN 0 0 12 O
the DT 0 0 12 O
recognition NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
toxicity NN 0 1 6 O
resulting VBG 1 1 1 O
from IN 0 0 12 O
interactions NNS 1 1 UNK O
is VBZ 1 0 12 O
of IN 0 0 12 O
importance NN 0 1 1 O
to TO 0 0 12 O
all DT 0 0 12 O
physciains NNS 0 0 UNK O
it PRP 0 0 12 O
is VBZ 1 0 12 O
especially RB 0 0 12 O
so RB 0 1 12 O
for IN 0 0 12 O
the DT 0 0 12 O
clinician JJ 0 1 13 O
responsible JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
welfare NN 0 1 13 O
of IN 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
the DT 0 0 12 O
aerospace NN 0 0 UNK O
environment NN 0 1 1 O
. . 0 0 12 O

dasatinib NN 0 1 13 B-Drug
+ NNP 0 0 2 O
paclitaxel NN 0 1 13 B-Drug
vs NN 1 0 2 O
. . 0 0 12 O

CONCLUSIONS NN 0 1 UNK O
: : 0 0 2 O
It PRP 0 0 12 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
to TO 0 0 12 O
identify VB 0 0 1 O
the DT 0 0 12 O
medications NNS 1 1 6 O
most RBS 0 0 12 O
commonly RB 0 0 UNK O
involved VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
PICR NNP 0 0 UNK O
so RB 0 1 12 O
as IN 1 0 12 O
to TO 0 0 12 O
establish VB 0 1 UNK O
corrective JJ 0 1 13 O
measures NNS 1 1 1 O
to TO 0 0 12 O
minimise VB 0 0 UNK O
the DT 0 0 12 O
risks NNS 1 1 1 O
arising VBG 1 1 1 O
from IN 0 0 12 O
multiple JJ 0 1 1 O
medication NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
intensity NN 0 1 1 O
uniformity NN 0 1 UNK O
and CC 0 0 12 O
time NN 0 1 12 O
course NN 0 1 12 O
of IN 0 0 12 O
anticoagulant JJ 0 1 13 B-Group
interference NN 0 1 13 O
by IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
secobarbital JJ 0 1 UNK B-Drug
glutethimide JJ 0 1 13 B-Drug
chloral JJ 0 1 16 B-Drug
hydrate NN 0 1 16 I-Drug
and CC 0 0 12 O
methaqualone NN 0 1 13 B-Drug
were VBD 1 0 12 O
systematically RB 0 0 UNK O
investigated VBN 1 1 1 O
in IN 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
coumarin JJ 0 1 UNK B-Group
therapy NN 0 1 6 O
. . 0 0 12 O

Antimicrobial JJ 0 1 7 O
activity NN 0 1 1 O
of IN 0 0 12 O
Ganoderma NNP 0 1 UNK B-Drug_n
lucidum FW 0 1 UNK I-Drug_n
extract VB 0 1 13 I-Drug_n
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
some DT 0 0 12 O
antibiotics NNS 1 1 6 B-Group
. . 0 0 12 O

sickle NN 0 0 6 O
cell NN 0 1 1 O
disease NN 0 1 6 O
; : 0 0 2 O

We PRP 0 0 12 O
compared VBN 1 1 1 O
indinavir JJ 0 1 16 B-Drug
pharmacokinetics NNS 0 1 UNK O
and CC 0 0 12 O
gastric JJ 0 1 6 O
pH NN 0 1 14 O
in IN 0 0 12 O
9 CD 0 0 2 O
human JJ 0 1 1 O
immunodeficiency NN 0 1 14 O
virus NN 0 1 6 O
- : 0 0 2 O
positive JJ 0 1 1 O
patients NNS 1 1 6 O
by IN 0 0 12 O
use NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
alone RB 0 1 12 O
versus VBD 0 0 1 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
indinavir NN 0 1 16 B-Drug
administered VBD 1 1 1 O
9 CD 0 0 2 O
h NN 0 1 16 O
after IN 0 0 12 O
didanosine JJ 0 1 16 B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Genetic JJ 0 1 UNK O
variation NN 0 1 1 O
also RB 0 0 12 O
occurs VBZ 1 1 1 O
in IN 0 0 12 O
proteins NNS 1 1 14 O
interacting VBG 1 0 1 O
with IN 0 0 12 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
change VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
e.g NN 0 0 UNK O
. . 0 0 12 O

Verapamil NNP 0 1 0 B-Drug
also RB 0 0 12 O
significantly RB 0 0 1 O
decreased VBD 1 1 1 O
the DT 0 0 12 O
incidence NN 0 1 6 O
of IN 0 0 12 O
lymphatic JJ 0 1 6 O
invasion NN 0 1 12 O
of IN 0 0 12 O
adenocarcinomas NN 1 1 UNK O
which WDT 0 0 12 O
was VBD 1 0 12 O
enhanced VBN 1 1 1 O
by IN 0 0 12 O
bombesin NN 0 1 UNK B-Drug_n
. . 0 0 12 O

These DT 0 0 1 O
results NNS 1 1 1 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
acute JJ 0 1 6 O
dosing VBG 1 0 14 O
with IN 0 0 12 O
clozapine NN 0 1 13 B-Drug
would MD 0 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
behaviors NNS 1 1 1 O
most RBS 0 0 12 O
closely RB 0 0 1 O
associated VBN 1 1 1 O
with IN 0 0 12 O
PCP NNP 0 1 13 B-Drug_n
intoxication NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
ewes JJ 0 1 UNK O
given VBN 1 1 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
phenobarbital JJ 0 1 16 B-Drug
sodium NN 0 1 14 I-Drug
/ NNP 0 0 2 O
kg NN 0 1 18 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
intraperitoneally RB 0 0 UNK O
( ( 0 0 2 O
IP NNP 0 1 2 O
) ) 0 0 2 O
the DT 0 0 12 O
anticholinesterase JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
coumaphos NN 0 1 UNK B-Drug_n
/ NNP 0 0 2 O
kg NN 0 1 18 O
was VBD 1 0 12 O
significantly RB 0 0 1 O
reduced VBN 1 1 1 O
and CC 0 0 12 O
signs NNS 1 1 12 O
of IN 0 0 12 O
toxicity NN 0 1 6 O
were VBD 1 0 12 O
not RB 0 1 12 O
present JJ 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
aim NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
present JJ 0 1 1 O
study NN 0 1 1 O
was VBD 1 0 12 O
to TO 0 0 12 O
investigate VB 0 1 1 O
whether IN 0 0 12 O
HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NN 0 0 UNK O
is VBZ 1 0 12 O
a DT 0 0 12 O
therapeutic JJ 0 1 6 O
target NN 0 1 1 O
for IN 0 0 12 O
T NNP 0 1 2 O
- : 0 0 2 O
ALL DT 0 1 11 O
and CC 0 0 12 O
to TO 0 0 12 O
further RBR 1 1 1 O
elucidate VB 0 0 UNK O
the DT 0 0 12 O
antitumor NN 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
specific JJ 0 1 1 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NNP 0 0 UNK O
cross SYM 0 1 12 B-Drug_n
- : 0 0 2 O
reacting VBG 1 0 1 I-Drug_n
material NN 0 1 1 I-Drug_n
9 CD 0 0 2 I-Drug_n
( ( 0 0 2 O
CRM9 NNP 0 0 UNK B-Drug_n
) ) 0 0 2 O
. . 0 0 12 O

To TO 0 0 2 O
find VB 0 1 12 O
out RP 0 1 12 O
whether IN 0 0 12 O
this DT 0 0 12 O
observation NN 0 1 1 O
is VBZ 1 0 12 O
related VBN 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
increased VBN 1 1 1 O
regional JJ 0 1 1 O
perfusion NN 0 1 8 O
in IN 0 0 12 O
diabetes NNS 0 1 6 O
longitudinal JJ 0 1 13 O
studies NNS 1 1 1 O
on IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
Type NNP 0 1 2 O
I PRP 0 1 12 O
( ( 0 0 2 O
insulin JJ 0 1 14 O
- : 0 0 2 O
dependent NN 0 1 1 O
) ) 0 0 2 O
diabetes VBZ 0 1 6 O
mellitus NNS 0 0 6 O
are VBP 1 0 12 O
needed VBN 1 1 12 O
. . 0 0 12 O

unlike IN 0 0 12 O
ibogaine NN 0 1 UNK B-Drug_n
9 CD 0 0 2 B-Drug_n
- : 0 0 2 O
MC NN 0 1 UNK I-Drug_n
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
responding VBG 1 0 1 O
for IN 0 0 12 O
a DT 0 0 12 O
nondrug JJ 0 0 13 O
reinforcer NN 0 1 UNK O
( ( 0 0 2 O
water NN 0 1 3 O
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
may MD 0 0 1 O
remain VB 0 0 12 O
some DT 0 0 12 O
indications NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
laxative NN 0 1 6 O
and CC 0 0 12 O
antacid JJ 0 1 UNK O
properties NNS 1 1 UNK O
of IN 0 0 12 O
non NN 0 1 1 O
soluble JJ 0 1 16 O
magnesium NN 0 1 14 B-Drug
particularly RB 0 0 1 O
during IN 0 0 12 O
intermittent JJ 0 1 1 O
haemodialysis NN 0 1 UNK O
. . 0 0 12 O

Comparison NNP 0 1 2 O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
pharmacokinetics NNS 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
m9 JJ 0 1 UNK O
plus CC 0 1 16 O
thiosulfate JJ 0 1 16 B-Drug
to TO 0 0 12 O
those DT 0 0 12 O
in IN 0 0 12 O
patients NNS 1 1 6 O
treated VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
mg NNS 0 1 0 O
/ JJ 0 0 2 O
m9 NN 0 1 UNK O
without IN 0 0 12 O
thiosulfate NN 0 1 16 B-Drug
indicated VBD 1 1 1 O
that IN 0 0 12 O
there EX 0 0 12 O
were VBD 1 0 12 O
no DT 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
elimination NN 0 1 UNK O
rate NN 0 1 1 O
constant JJ 0 1 1 O
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
or CC 0 0 12 O
total JJ 0 1 1 O
body NN 0 1 3 O
clearance NN 0 1 16 O
of IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
contrast NN 0 1 1 O
the DT 0 0 12 O
reverse NN 0 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
sequential JJ 0 1 1 O
administration NN 0 1 1 O
resulted VBD 1 1 1 O
in IN 0 0 12 O
antagonism NN 0 1 UNK O
which WDT 0 0 12 O
may MD 0 0 1 O
be VB 0 0 12 O
due JJ 0 1 1 O
to TO 0 0 12 O
differential JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
cell NN 0 1 1 O
cycle NN 0 1 1 O
arrest NN 0 1 12 O
. . 0 0 12 O

Many JJ 0 0 UNK O
drugs NNS 1 1 6 O
used VBN 1 1 12 O
in IN 0 0 12 O
dentistry NN 0 1 UNK O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
these DT 0 0 12 O
medications NNS 1 1 6 O
. . 0 0 12 O

Moreover RB 0 0 1 O
additional JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
niacin JJ 0 1 14 B-Drug
and CC 0 0 12 O
propranolol NNS 0 1 16 B-Drug
have VBP 0 0 12 O
not RB 0 1 12 O
demonstrated VBN 1 0 1 O
any DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
fluvastatin NN 0 1 13 B-Drug
plasma NN 0 1 14 O
levels NNS 1 1 1 O
and CC 0 0 12 O
administration NN 0 1 1 O
to TO 0 0 12 O
a DT 0 0 12 O
patient JJ 0 1 6 O
population NN 0 1 13 O
chronically RB 0 0 6 O
receiving VBG 1 1 1 O
digoxin NN 0 1 14 B-Drug
resulted VBD 1 1 1 O
in IN 0 0 12 O
no DT 0 0 12 O
difference NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
extent NN 0 1 1 O
of IN 0 0 12 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
relative JJ 0 1 1 O
to TO 0 0 12 O
control VB 0 1 1 O
data NNS 0 1 1 O
. . 0 0 12 O

Treatment NN 0 1 7 O
with IN 0 0 12 O
antidepressant JJ 0 1 6 B-Group
drugs NNS 1 1 6 I-Group
can MD 0 0 12 O
directly RB 0 1 1 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
blood NN 0 1 6 O
glucose NN 0 1 14 O
levels NNS 1 1 1 O
or CC 0 0 12 O
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
hypoglycemic JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

The DT 0 0 2 O
dicarbonyl NN 0 0 UNK O
compound NN 0 1 13 O
methylglyoxal NN 0 1 UNK B-Drug_n
is VBZ 1 0 12 O
a DT 0 0 12 O
natural JJ 0 1 13 O
constituent NN 0 1 UNK O
of IN 0 0 12 O
Manuka NNP 0 0 UNK O
honey NN 0 1 UNK O
produced VBN 1 0 1 O
from IN 0 0 12 O
Manuka NNP 0 0 UNK O
flowers NNS 1 1 UNK O
in IN 0 0 12 O
New NNP 0 1 2 O
Zealand NNP 0 0 UNK O
. . 0 0 12 O

Seventeen JJ 0 1 UNK O
percent NN 0 1 1 O
of IN 0 0 12 O
CHOP NNP 0 1 UNK O
- : 0 0 2 O
HAART NN 0 1 14 O
patients NNS 1 1 6 O
developed VBD 1 0 1 O
severe JJ 0 1 6 O
autonomic JJ 0 1 6 O
neurotoxicity NN 0 1 UNK O
whereas IN 0 0 UNK O
none NN 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
CHOP NNP 0 1 UNK O
patients NNS 1 1 6 O
developed VBD 1 0 1 O
neurotoxicity NN 0 1 UNK O
( ( 0 0 2 O
P NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

Clonazepam NNP 0 1 0 B-Drug
would MD 0 0 12 O
be VB 0 0 12 O
useful JJ 0 1 UNK O
in IN 0 0 12 O
cases NNS 1 1 UNK O
with IN 0 0 12 O
potential JJ 0 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
hypoglycemia NN 0 1 6 O
. . 0 0 12 O

Reduced VBN 0 1 UNK O
levels NNS 1 1 1 O
( ( 0 0 2 O
up IN 0 0 12 O
to TO 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
of IN 0 0 12 O
total JJ 0 1 1 O
glutathione NN 0 1 13 O
( ( 0 0 2 O
total JJ 0 1 1 O
GSH NNP 0 1 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
elevation NN 0 1 1 O
of IN 0 0 12 O
conjugated VBN 1 1 14 O
dienes NNS 0 1 UNK O
( ( 0 0 2 O
approximately RB 0 1 1 O
9 CD 0 0 2 O
% NN 0 0 18 O
in IN 0 0 12 O
liver NN 0 1 6 O
by IN 0 0 12 O
single JJ 0 1 12 O
dose NN 0 1 6 O
at IN 0 0 12 O
9 CD 0 0 2 O
h NN 0 1 16 O
) ) 0 0 2 O
also RB 0 0 12 O
indicated VBD 1 1 1 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
an DT 0 0 12 O
oxidative JJ 0 1 UNK O
insult NN 0 0 UNK O
. . 0 0 12 O

Thus RB 0 0 1 O
the DT 0 0 12 O
identification NN 0 1 1 O
of IN 0 0 12 O
putative JJ 0 0 UNK O
inhibitors NNS 1 1 14 O
of IN 0 0 12 O
bioactivation NN 0 0 UNK O
as RB 0 0 12 O
well RB 0 1 12 O
as IN 1 0 12 O
the DT 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
protective JJ 0 0 3 O
role NN 0 1 1 O
of IN 0 0 12 O
oxidant JJ 0 1 UNK O
defenses NNS 1 1 UNK O
on IN 0 0 12 O
DEB NNP 0 1 UNK O
- : 0 0 2 O
induced JJ 0 1 6 O
toxicity NN 0 1 6 O
can MD 0 0 12 O
help VB 0 1 12 O
to TO 0 0 12 O
understand VB 0 1 12 O
what WP 0 0 12 O
is VBZ 1 0 12 O
failing VBG 1 1 13 O
in IN 0 0 12 O
FA NNP 0 0 13 O
cells NNS 1 1 6 O
. . 0 0 12 O

Sirolimus NNP 0 1 UNK B-Drug
works VBZ 1 1 12 O
differently RB 0 0 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
immunosuppressants NNS 1 1 UNK B-Group
currently RB 0 1 12 O
available JJ 0 1 1 O
and CC 0 0 12 O
except IN 0 0 12 O
for IN 0 0 12 O
increased JJ 0 1 1 O
lipid NN 0 1 14 O
levels NNS 1 1 1 O
the DT 0 0 12 O
adverse JJ 0 0 1 O
reaction NN 0 1 1 O
profile NN 0 1 1 O
of IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
overlap VB 0 1 13 O
to TO 0 0 12 O
any DT 0 0 12 O
great JJ 0 1 12 O
extent NN 0 1 1 O
with IN 0 0 12 O
that DT 0 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
cyclosporine NN 0 1 14 B-Drug
or CC 0 0 12 O
tacrolimus NN 0 1 16 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
study NN 0 1 1 O
one CD 0 1 12 O
hyperglycaemic NN 0 0 UNK O
clamps NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
mmol NN 0 1 13 O
/ NNP 0 0 2 O
l VBZ 0 1 2 O
9 CD 0 0 2 O
mmol NN 0 1 13 O
/ VBD 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
mmol NN 0 1 13 O
/ NNP 0 0 2 O
l NN 0 1 2 O
) ) 0 0 2 O
were VBD 1 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
during IN 0 0 12 O
placebo NN 0 1 13 O
or CC 0 0 12 O
insulin NN 0 1 14 B-Drug
( ( 0 0 2 O
dose JJ 0 1 6 O
9 CD 0 0 2 O
: : 0 0 2 O
9 CD 0 0 2 O
mU NN 0 1 UNK O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
/ NNP 0 0 2 O
min NN 0 1 16 O
; : 0 0 2 O
dose JJ 0 1 6 O
9 CD 0 0 2 O
: : 0 0 2 O
9 CD 0 0 2 O
mU NN 0 1 UNK O
/ NNP 0 0 2 O
kg NNP 0 1 18 O
/ NNP 0 0 2 O
min NN 0 1 16 O
) ) 0 0 2 O
infusion NN 0 1 14 O
. . 0 0 12 O

METHODS NNS 0 1 UNK O
: : 0 0 2 O
Healthy JJ 0 1 2 O
subjects NNS 1 1 UNK O
who WP 0 0 12 O
were VBD 1 0 12 O
9 CD 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O
years NNS 1 1 12 O
old JJ 0 1 12 O
participated VBD 1 0 12 O
in IN 0 0 12 O
an DT 0 0 12 O
open JJ 0 1 12 O
three CD 0 1 12 O
- : 0 0 2 O
period NN 0 1 1 O
randomized VBD 1 1 6 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
oral JJ 0 1 6 O
dose NN 0 1 6 O
of IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
a DT 0 0 12 O
single JJ 0 1 12 O
oral JJ 0 1 6 O
9 CD 0 0 2 O
- : 0 0 2 O
mg NN 0 1 0 O
dose NN 0 1 6 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
and CC 0 0 12 O
the DT 0 0 12 O
two CD 0 1 12 O
drugs NNS 1 1 6 O
given VBN 1 1 12 O
together RB 0 1 12 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
9 CD 0 0 2 O
types NNS 1 1 1 O
of IN 0 0 12 O
indications NNS 1 1 1 O
: : 0 0 2 O
specific NN 0 1 1 O
( ( 0 0 2 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
some DT 0 0 12 O
forms NNS 1 1 1 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
deficit NN 0 1 1 O
i.e NN 0 1 16 O
. . 0 0 12 O
acute NN 0 1 6 O
) ) 0 0 2 O
pharmacological NN 0 1 14 O
( ( 0 0 2 O
i.e NN 0 1 16 O
. . 0 0 12 O
without IN 0 0 12 O
alterations NNS 1 1 1 O
of IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
status NN 0 1 1 O
) ) 0 0 2 O
and CC 0 0 12 O
mixed JJ 0 1 3 O
- : 0 0 2 O
- : 0 0 2 O
pharmacological JJ 0 1 14 O
and CC 0 0 12 O
aetiopathogenic JJ 0 0 UNK O
- : 0 0 2 O
- : 0 0 2 O
( ( 0 0 2 O
for IN 0 0 12 O
example NN 0 1 1 O
complications NNS 1 1 6 O
of IN 0 0 12 O
chronic JJ 0 1 6 O
alcoholism NN 0 1 6 O
) ) 0 0 2 O
. . 0 0 12 O

After IN 0 0 2 O
exposure NN 0 1 1 O
the DT 0 0 12 O
cell NN 0 1 1 O
viability NN 0 1 1 O
was VBD 1 0 12 O
measured VBN 1 1 1 O
by IN 0 0 12 O
MTT NNP 0 1 UNK O
assay VBP 0 1 14 O
cell NN 0 1 1 O
cycle NN 0 1 1 O
distribution NN 0 1 1 O
was VBD 1 0 12 O
analyzed VBN 1 1 13 O
by IN 0 0 12 O
flow JJ 0 1 1 O
cytometry NN 0 1 UNK O
and CC 0 0 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
signaling VBG 1 1 UNK O
pathway NN 0 1 UNK O
were VBD 1 0 12 O
determined VBN 1 1 1 O
by IN 0 0 12 O
immunoblotting VBG 0 1 UNK O
. . 0 0 12 O

When WRB 0 0 12 O
cells NNS 1 1 6 O
were VBD 1 0 12 O
exposed VBN 1 1 3 O
to TO 0 0 12 O
docetaxel VB 0 1 13 B-Drug
followed VBN 1 1 12 O
by IN 0 0 12 O
sunitinib JJ 0 1 13 B-Drug
synergism NN 0 1 UNK O
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Each DT 0 0 2 O
healthy JJ 0 1 12 O
subject NN 0 1 UNK O
( ( 0 0 2 O
N NNP 0 1 2 O
= NNP 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
received VBN 1 1 12 O
rofecoxib NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
once RB 0 0 12 O
daily JJ 0 1 12 O
) ) 0 0 2 O
or CC 0 0 12 O
placebo NN 0 1 13 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
in IN 0 0 12 O
a DT 0 0 12 O
double JJ 0 1 3 O
- : 0 0 2 O
blind NN 0 1 12 O
randomized VBN 1 1 6 O
balanced VBD 1 1 1 O
two CD 0 1 12 O
- : 0 0 2 O
period NN 0 1 1 O
crossover NN 0 1 UNK O
study NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
general JJ 0 1 1 O
population NN 0 1 13 O
sildenafil NN 0 1 16 B-Drug
is VBZ 1 0 12 O
considered VBN 1 1 1 O
to TO 0 0 12 O
have VB 0 0 12 O
an DT 0 0 12 O
acceptable JJ 0 1 1 O
tolerability NN 0 1 UNK O
profile NN 0 1 1 O
; : 0 0 2 O

A DT 0 0 2 O
review NN 0 1 2 O
is VBZ 1 0 12 O
presented VBN 1 1 1 O
of IN 0 0 12 O
some DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
problems NNS 1 1 1 O
that WDT 0 0 12 O
may MD 0 0 1 O
arise VB 0 0 1 O
in IN 0 0 12 O
association NN 0 1 1 O
with IN 0 0 12 O
anaesthesia NN 0 1 UNK O
for IN 0 0 12 O
epileptic JJ 0 1 13 O
patients NNS 1 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
study NN 0 1 1 O
ensures VBZ 1 1 UNK O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
fluoroquinolones NNS 0 1 UNK B-Group
with IN 0 0 12 O
selected JJ 0 1 UNK O
class NN 0 1 12 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Effective JJ 0 1 UNK O
use NN 0 1 1 O
of IN 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
therapy NN 0 1 6 O
depends VBZ 1 1 UNK O
not RB 0 1 12 O
only RB 0 1 12 O
on IN 0 0 12 O
clinical JJ 0 1 6 O
acumen NNS 0 0 UNK O
but CC 0 0 12 O
also RB 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
availability NN 0 1 UNK O
of IN 0 0 12 O
relevant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
and CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
data NNS 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
decision NN 0 1 12 O
to TO 0 0 12 O
prescribe VB 0 0 UNK O
this DT 0 0 12 O
agent NN 0 1 1 O
should MD 0 0 12 O
include VB 0 1 1 O
such JJ 0 0 1 O
considerations NNS 1 1 1 O
as IN 1 0 12 O
the DT 0 0 12 O
cost NN 0 1 UNK O
- : 0 0 2 O
risk NN 0 1 1 O
- : 0 0 2 O
benefit NN 0 1 1 O
balance NN 0 1 1 O
patient JJ 0 1 6 O
access NN 0 1 1 O
drug NN 0 1 1 O
distribution NN 0 1 1 O
pathways NNS 1 1 13 O
and CC 0 0 12 O
prescription NN 0 1 0 O
drug NN 0 1 1 O
coverage NN 0 1 1 O
. . 0 0 12 O

Ibogaine NNP 0 1 UNK B-Drug_n
produces VBZ 1 0 1 O
whole JJ 0 1 12 O
body NN 0 1 3 O
tremors NNS 1 1 6 O
and CC 0 0 12 O
at IN 0 0 12 O
high JJ 0 1 1 O
doses NNS 1 1 6 O
( ( 0 0 2 O
> CD 0 0 2 O
or CC 0 0 12 O
= VB 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
cerebellar JJ 0 1 8 O
damage NN 0 1 1 O
; : 0 0 2 O

Panobinostat NNP 0 1 UNK B-Drug
was VBD 1 0 12 O
administered VBN 1 1 1 O
as IN 1 0 12 O
single JJ 0 1 12 O
agent NN 0 1 1 O
three CD 0 1 12 O
times NNS 1 1 12 O
a DT 0 0 12 O
week NN 0 1 12 O
on IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
onward RB 0 0 UNK O
. . 0 0 12 O

Apparent JJ 0 1 UNK O
oral JJ 0 1 6 O
clearance NN 0 1 16 O
and CC 0 0 12 O
volume NN 0 1 1 O
of IN 0 0 12 O
distribution NN 0 1 1 O
of IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
decreased VBN 1 1 1 O
with IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
respectively RB 0 0 1 O
when WRB 0 0 12 O
sirolimus NN 0 1 16 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
with IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
. . 0 0 12 O

Patients NNS 0 1 7 O
received VBD 1 1 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
panobinostat NN 0 1 UNK B-Drug
oral JJ 0 1 6 O
dose NN 0 1 6 O
on IN 0 0 12 O
day NN 0 1 12 O
9 CD 0 0 2 O
followed VBN 1 1 12 O
by IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
wash SYM 0 1 3 O
- : 0 0 2 O
out RP 0 1 12 O
period NN 0 1 1 O
. . 0 0 12 O

Interactions NNS 0 1 UNK O
between IN 0 0 12 O
theraputic JJ 0 0 15 O
agents NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
recognized VBN 1 0 13 O
as IN 1 0 12 O
increasingly RB 0 0 1 O
important JJ 0 1 1 O
causes NNS 1 1 6 O
of IN 0 0 12 O
drug NN 0 1 1 O
at IN 0 0 12 O
their PRP$ 0 0 12 O
usual JJ 0 1 12 O
recommended VBN 1 1 1 O
dose NN 0 1 6 O
may MD 0 0 1 O
under IN 0 0 12 O
certain JJ 0 1 1 O
conditions NNS 1 1 1 O
produce VBP 0 0 1 O
toxicity NN 0 1 6 O
of IN 0 0 12 O
life NN 0 1 12 O
- : 0 0 2 O
endangering NN 0 0 UNK O
proportions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
goal NN 0 1 12 O
of IN 0 0 12 O
enhancing VBG 1 1 1 O
selective JJ 0 1 13 O
tumor NN 0 1 6 O
cell NN 0 1 1 O
killing VBG 1 1 UNK O
relative JJ 0 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
normal JJ 0 1 1 O
cells NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
dose JJ 0 1 6 O
limiting NN 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
achieved VBN 1 0 1 O
either DT 0 1 12 O
by IN 0 0 12 O
overcoming VBG 1 1 UNK O
tumor NN 0 1 6 O
cell NN 0 1 1 O
resistance NN 0 1 1 O
or CC 0 0 12 O
by IN 0 0 12 O
protecting VBG 1 0 UNK O
normal JJ 0 1 1 O
cells NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
study NN 0 1 1 O
was VBD 1 0 12 O
aimed VBN 1 1 UNK O
to TO 0 0 12 O
investigate VB 0 1 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
single JJ 0 1 12 O
use NN 0 1 1 O
of IN 0 0 12 O
sunitinib NN 0 1 13 B-Drug
and CC 0 0 12 O
that IN 0 0 12 O
of IN 0 0 12 O
concurrent NN 0 1 1 O
or CC 0 0 12 O
sequential JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
sunitinib NN 0 1 13 B-Drug
and CC 0 0 12 O
docetaxel NN 0 1 13 B-Drug
in IN 0 0 12 O
NSCLC NNP 0 1 UNK O
cell NN 0 1 1 O
lines NNS 1 1 3 O
that WDT 0 0 12 O
are VBP 1 0 12 O
resistant JJ 0 1 3 O
to TO 0 0 12 O
EGFR NNP 0 1 UNK O
TKIs NNP 0 0 UNK O
. . 0 0 12 O

In IN 0 0 2 O
practice NN 0 1 UNK O
the DT 0 0 12 O
greatest JJS 1 1 UNK O
value NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
thioether NN 0 1 UNK O
assay NN 0 1 14 O
appears VBZ 1 1 12 O
to TO 0 0 12 O
lie VB 0 0 12 O
in IN 0 0 12 O
its PRP$ 1 0 12 O
signal JJ 0 1 1 O
function NN 0 1 1 O
. . 0 0 12 O

Physiological JJ 0 1 UNK O
oral JJ 0 1 6 O
magnesium NN 0 1 14 B-Drug
supplementation NN 0 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
/ NNP 0 0 2 O
day NN 0 1 12 O
) ) 0 0 2 O
is VBZ 1 0 12 O
easy JJ 0 1 12 O
and CC 0 0 12 O
can MD 0 0 12 O
be VB 0 0 12 O
carried VBN 1 1 12 O
out RP 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
diet NN 0 1 6 O
or CC 0 0 12 O
with IN 0 0 12 O
magnesium NN 0 1 14 B-Drug
salts NNS 1 1 13 I-Drug
with IN 0 0 12 O
practically RB 0 0 UNK O
only RB 0 1 12 O
one CD 0 1 12 O
contra JJ 0 0 UNK O
- : 0 0 2 O
indication NN 0 1 1 O
: : 0 0 2 O
overt JJ 0 0 UNK O
renal JJ 0 1 6 O
failure NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
female JJ 0 1 12 O
rats NNS 1 1 UNK O
neonatal JJ 0 1 6 O
quinpirole JJ 0 1 UNK B-Drug_n
treatment NN 0 1 6 O
enhanced VBD 1 1 1 O
amphetamine JJ 0 1 13 B-Drug
locomotor NN 0 0 UNK O
sensitization NN 0 1 13 O
compared VBN 1 1 1 O
with IN 0 0 12 O
quinpirole JJ 0 1 UNK B-Drug_n
- : 0 0 2 O
free JJ 0 1 12 O
controls NNS 1 1 UNK O
sensitized VBN 1 1 UNK O
to TO 0 0 12 O
amphetamine VB 0 1 13 B-Drug
. . 0 0 12 O

Such JJ 0 0 1 O
information NN 0 1 1 O
assists NNS 1 1 UNK O
in IN 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
safe JJ 0 0 12 O
dosing VBG 1 0 14 O
regimens JJ 0 1 UNK O
prediction NN 0 1 13 O
of IN 0 0 12 O
abnormal JJ 0 1 6 O
handling NN 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
in IN 0 0 12 O
states NNS 1 1 1 O
of IN 0 0 12 O
disease NN 0 1 6 O
and CC 0 0 12 O
disorder NN 0 1 6 O
and CC 0 0 12 O
anticipation NN 0 1 12 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

This DT 0 0 2 O
could MD 0 0 12 O
facilitate VB 0 0 1 O
the DT 0 0 12 O
action NN 0 1 13 O
of IN 0 0 12 O
fatty JJ 0 0 6 O
acids NNS 1 1 14 O
and CC 0 0 12 O
enable JJ 0 1 UNK O
cells NNS 1 1 6 O
to TO 0 0 12 O
increase VB 0 1 1 O
their PRP$ 0 0 12 O
capacity NN 0 1 1 O
for IN 0 0 12 O
triacylglycerol NN 0 1 UNK O
synthesis NN 0 1 UNK O
to TO 0 0 12 O
match VB 0 1 13 O
an DT 0 0 12 O
increased JJ 0 1 1 O
availability NN 0 1 UNK O
of IN 0 0 12 O
fatty JJ 0 0 6 O
acids NNS 1 1 14 O
. . 0 0 12 O

RATIONALE NN 0 1 UNK O
: : 0 0 2 O
Stress NN 0 1 2 O
and CC 0 0 12 O
glucocorticoids NNS 1 1 UNK B-Group
facilitate NN 0 0 1 O
and CC 0 0 12 O
reinstate NN 0 0 UNK O
psychostimulant NN 0 1 13 O
self PRP 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
in IN 0 0 12 O
rodents NNS 1 1 UNK O
. . 0 0 12 O

and CC 0 0 12 O
phase VB 0 1 1 O
9 CD 0 0 2 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
: : 0 0 2 O
cisapride NN 0 1 UNK B-Drug
9 CD 0 0 2 O
mg NN 0 1 0 O
9 CD 0 0 2 O
times NNS 1 1 12 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
plus CC 0 1 16 O
fluoxetine JJ 0 1 16 B-Drug
9 CD 0 0 2 O
mg JJ 0 1 0 O
/ JJ 0 0 2 O
day NN 0 1 12 O
( ( 0 0 2 O
days NNS 1 1 12 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

METHODS NN 0 1 UNK O
: : 0 0 2 O
Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
case NN 0 1 12 O
reports NNS 1 1 1 O
and CC 0 0 12 O
commentaries NNS 1 1 UNK O
and CC 0 0 12 O
editorials NNS 1 1 UNK O
concerning VBG 1 1 1 O
sildenafil NN 0 1 16 B-Drug
published VBN 1 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
international JJ 0 1 1 O
literature NN 0 1 UNK O
between IN 0 0 12 O
January NNP 0 1 2 O
9 CD 0 0 2 O
and CC 0 0 12 O
August NNP 0 1 2 O
9 CD 0 0 2 O
were VBD 1 0 12 O
identified VBN 1 1 1 O
through IN 0 0 12 O
searches NNS 1 1 UNK O
of IN 0 0 12 O
MEDLINE NNP 0 1 UNK O
PREMEDLINE NNP 0 0 UNK O
and CC 0 0 12 O
International NNP 0 1 UNK O
Pharmaceutical NNP 0 1 UNK O
Abstracts NNP 0 1 UNK O
using VBG 1 1 1 O
the DT 0 0 12 O
terms NNS 1 1 1 O
sildenafil VBP 0 1 16 B-Drug
Viagra NNP 0 1 0 B-Brand
and CC 0 0 12 O
erectile JJ 0 1 13 O
dysfunction NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
effects NNS 1 1 1 O
of IN 0 0 12 O
diethyl NN 0 0 UNK B-Drug_n
pyrocarbonate NN 0 1 UNK I-Drug_n
could MD 0 0 12 O
be VB 0 0 12 O
reversed VBN 1 1 1 O
by IN 0 0 12 O
hydroxylamine NN 0 1 UNK B-Drug_n
treatment NN 0 1 6 O
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
better RBR 1 1 12 O
to TO 0 0 12 O
avoid VB 0 0 12 O
prescribing VBG 1 1 UNK O
isoenzyme JJ 0 1 13 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
to TO 0 0 12 O
women NNS 1 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
tamoxifen NN 0 1 0 B-Drug
for IN 0 0 12 O
breast NN 0 1 6 O
cancer NN 0 1 6 O
especially RB 0 0 12 O
SSRI NNP 0 1 UNK B-Group
antidepressants NNS 1 1 13 I-Group
such JJ 0 0 1 O
as IN 1 0 12 O
paroxetine NN 0 1 16 B-Drug
and CC 0 0 12 O
fluoxetine NN 0 1 16 B-Drug
. . 0 0 12 O

( ( 0 0 2 O
Cancer NNP 0 1 7 O
Res. NNP 0 1 UNK O
9 CD 0 0 2 O
: : 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
have VBP 0 0 12 O
reported VBN 1 1 1 O
that IN 0 0 12 O
a DT 0 0 12 O
single JJ 0 1 12 O
small JJ 0 1 12 O
pulse NN 0 1 3 O
of IN 0 0 12 O
carcinogen NN 0 1 UNK O
can MD 0 0 12 O
induce VB 0 1 6 O
early JJ 0 1 12 O
and CC 0 0 12 O
numerous JJ 0 1 1 O
liver NN 0 1 6 O
tumors NNS 1 1 6 O
when WRB 0 0 12 O
administered VBN 1 1 1 O
neonatally RB 0 0 UNK O
to TO 0 0 12 O
mice VB 0 1 UNK O
with IN 0 0 12 O
a DT 0 0 12 O
genetic JJ 0 1 13 O
predisposition NN 0 1 UNK O
to TO 0 0 12 O
hepatotumorigenesis NN 0 0 UNK O
. . 0 0 12 O

During IN 0 0 2 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
fluvoxamine JJ 0 1 16 O
treatment NN 0 1 6 O
ataxia VBZ 0 1 6 O
a DT 0 0 12 O
typical JJ 0 1 1 O
side NN 0 1 3 O
effect NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
was VBD 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Metabotropic NNP 0 0 UNK O
glutamate NN 0 1 UNK O
receptor NN 0 1 14 O
9 CD 0 0 2 O
antagonist NN 0 1 13 O
protects NNS 0 0 UNK O
dopaminergic JJ 0 1 UNK O
and CC 0 0 12 O
noradrenergic JJ 0 1 UNK O
neurons NNS 1 1 UNK O
from IN 0 0 12 O
degeneration NN 0 1 6 O
in IN 0 0 12 O
MPTP NNP 0 1 UNK B-Drug_n
- : 0 0 2 O
treated VBD 1 1 1 O
monkeys NNS 1 1 UNK O
. . 0 0 12 O

Treatment NN 0 1 7 O
with IN 0 0 12 O
daily JJ 0 1 12 O
doses NNS 1 1 6 O
of IN 0 0 12 O
9 CD 0 0 2 O
mg NN 0 1 0 O
of IN 0 0 12 O
coumaphos NN 0 1 UNK B-Drug_n
/ NNP 0 0 2 O
kg NN 0 1 18 O
for IN 0 0 12 O
9 CD 0 0 2 O
days NNS 1 1 12 O
did VBD 1 0 12 O
not RB 0 1 12 O
modify VB 0 1 UNK O
the DT 0 0 12 O
anticholinesterase NN 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
9nd CD 0 0 UNK O
series NN 0 1 12 O
of IN 0 0 12 O
treatments NNS 1 1 6 O
given VBN 1 1 12 O
9 CD 0 0 2 O
weeks NNS 1 1 12 O
later RB 0 1 12 O
. . 0 0 12 O

Understanding VBG 0 1 UNK O
the DT 0 0 12 O
breadth NN 0 0 13 O
of IN 0 0 12 O
systemic JJ 0 1 6 O
antimicrobial JJ 0 1 14 B-Group
agents NNS 1 1 1 I-Group
available JJ 0 1 1 O
for IN 0 0 12 O
use NN 0 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
dermatologist NN 0 1 UNK O
and CC 0 0 12 O
their PRP$ 0 0 12 O
associated JJ 0 1 1 O
side NN 0 1 3 O
- : 0 0 2 O
effect NN 0 1 1 O
profiles NNS 1 1 UNK O
and CC 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
allows VBZ 1 1 UNK O
the DT 0 0 12 O
clinician NN 0 1 13 O
to TO 0 0 12 O
offer VB 0 0 12 O
patients NNS 1 1 6 O
optimal JJ 0 1 1 O
care NN 0 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
management NN 0 1 1 O
of IN 0 0 12 O
cutaneous JJ 0 1 13 O
infectious JJ 0 1 6 O
disease NN 0 1 6 O
. . 0 0 12 O

Methamphetamine NNP 0 1 UNK B-Drug
like IN 0 0 12 O
MPTP NNP 0 1 UNK B-Drug_n
produced VBD 1 0 1 O
depletions NNS 1 1 UNK O
of IN 0 0 12 O
striatal JJ 0 1 UNK O
dopamine NN 0 1 14 O
but CC 0 0 12 O
these DT 0 0 12 O
actions NNS 1 1 UNK O
were VBD 1 0 12 O
potentiated VBN 1 0 UNK O
by IN 0 0 12 O
pargyline JJ 0 1 UNK B-Drug
pretreatment NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
treatment NN 0 1 6 O
- : 0 0 2 O
experienced JJ 0 0 12 O
patients NNS 1 1 6 O
available JJ 0 1 1 O
uncontrolled JJ 0 1 6 O
data NNS 0 1 1 O
suggest VBP 0 1 1 O
these DT 0 0 12 O
agents NNS 1 1 1 O
contribute VBP 0 1 UNK O
to TO 0 0 12 O
regimen VB 0 1 6 O
efficacy NN 0 1 UNK O
in IN 0 0 12 O
NNRTI NNP 0 1 UNK B-Group
- : 0 0 2 O
na JJ 0 1 16 O
ve NN 0 1 13 O
treatment NN 0 1 6 O
- : 0 0 2 O
experienced JJ 0 0 12 O
patients NNS 1 1 6 O
. . 0 0 12 O

SUBJECTS NN 0 1 UNK O
: : 0 0 2 O
Twelve NNP 0 1 UNK O
healthy JJ 0 1 12 O
male NN 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
the DT 0 0 12 O
digitalized JJ 0 1 UNK O
patient NN 0 1 6 O
slow JJ 0 1 12 O
alterations NNS 1 1 1 O
in IN 0 0 12 O
serum NN 0 1 14 O
levels NNS 1 1 1 O
after IN 0 0 12 O
oral JJ 0 1 6 O
administration NN 0 1 1 O
appeared VBD 1 1 12 O
well RB 0 1 12 O
correlated VBN 1 1 1 O
with IN 0 0 12 O
at IN 0 0 12 O
least JJS 0 1 12 O
the DT 0 0 12 O
negative JJ 0 1 1 O
chronotropic NN 0 1 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
. . 0 0 12 O

n SYM 0 1 12 O
- : 0 0 2 O
Octyl NN 0 0 UNK O
and CC 0 0 12 O
n JJ 0 1 12 O
- : 0 0 2 O
cetyl NN 0 0 UNK O
gallate NN 0 0 UNK O
also RB 0 0 12 O
showed VBD 1 1 12 O
good JJ 0 1 12 O
inhibition NN 0 1 13 O
while IN 0 0 12 O
gallic JJ 0 0 UNK O
acid FW 0 1 14 O
itself PRP 0 0 UNK O
was VBD 1 0 12 O
not RB 0 1 12 O
so RB 0 1 12 O
active JJ 0 1 1 O
suggesting NN 0 1 1 O
that IN 0 0 12 O
the DT 0 0 12 O
presence NN 0 1 1 O
of IN 0 0 12 O
hydrophobic JJ 0 1 UNK O
side NN 0 1 3 O
chain NN 0 1 16 O
is VBZ 1 0 12 O
important JJ 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
suppressive JJ 0 1 UNK O
effect NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
authors NNS 1 1 UNK O
report VBP 0 1 1 O
the DT 0 0 12 O
case NN 0 1 12 O
of IN 0 0 12 O
an DT 0 0 12 O
infant NN 0 1 6 O
with IN 0 0 12 O
confirmed JJ 0 1 12 O
congenital JJ 0 1 6 O
hypothyroidism NN 0 1 6 O
on IN 0 0 12 O
levothyroxine NN 0 1 0 B-Drug
who WP 0 0 12 O
experienced VBD 1 0 12 O
a DT 0 0 12 O
possible JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
simeticone NN 0 1 UNK B-Drug
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
assumed VBN 1 1 1 O
that IN 0 0 12 O
increased VBD 1 1 1 O
interaction NN 0 1 UNK O
between IN 0 0 12 O
9H CD 0 0 UNK B-Drug_n
- : 0 0 2 O
spiroperidol NN 0 1 UNK I-Drug_n
and CC 0 0 12 O
high JJ 0 1 1 O
affinity NN 0 1 UNK O
binding NN 0 1 1 O
sites NNS 1 1 1 O
for IN 0 0 12 O
apomorphine NN 0 1 UNK B-Drug
on IN 0 0 12 O
dopamine9 NN 0 0 UNK O
- : 0 0 2 O
and CC 0 0 12 O
serotonin9 VB 0 0 UNK O
- : 0 0 2 O
receptors NNS 1 1 13 O
underlies VBZ 1 0 UNK O
the DT 0 0 12 O
antipsychotic JJ 0 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
neuroleptics NNS 1 1 13 B-Group
after IN 0 0 12 O
their PRP$ 0 0 12 O
prolonged JJ 0 1 6 O
administration NN 0 1 1 O
. . 0 0 12 O

Rifampin NNP 0 1 0 B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
warfarin NN 0 1 14 B-Drug
requirements NNS 1 1 1 O
in IN 0 0 12 O
human JJ 0 1 1 O
subjects NNS 1 1 UNK O
ingesting VBG 1 1 UNK O
these DT 0 0 12 O
agents NNS 1 1 1 O
simultaneously RB 0 1 13 O
. . 0 0 12 O

Adenosine $ 0 1 14 O
9':9' CD 0 0 UNK O
- : 0 0 2 O
cyclic JJ 0 1 13 O
phosphate NN 0 1 14 O
in IN 0 0 12 O
turn NN 0 1 12 O
controls NNS 1 1 UNK O
levels NNS 1 1 1 O
of IN 0 0 12 O
free JJ 0 1 12 O
calcium NN 0 1 14 O
ions NNS 1 1 UNK O
in IN 0 0 12 O
platelets NNS 1 1 14 O
and CC 0 0 12 O
regulates VBZ 1 0 UNK O
calcium JJ 0 1 14 O
- : 0 0 2 O
dependent JJ 0 1 1 O
reactions NNS 1 1 1 O
. . 0 0 12 O

Each DT 0 0 2 O
subject NN 0 1 UNK O
received VBD 1 1 12 O
an DT 0 0 12 O
individualized JJ 0 1 UNK O
fixed JJ 0 1 1 O
daily JJ 0 1 12 O
dose NN 0 1 6 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
and CC 0 0 12 O
served VBD 1 0 12 O
as IN 1 0 12 O
his PRP$ 0 0 12 O
own JJ 0 0 12 O
pre NN 0 1 1 O
- : 0 0 2 O
and CC 0 0 12 O
postsedative JJ 0 0 UNK O
treatment NN 0 1 6 O
control NN 0 1 1 O
. . 0 0 12 O

One CD 0 1 2 O
of IN 0 0 12 O
the DT 0 0 12 O
factors NNS 1 1 1 O
that WDT 0 0 12 O
might MD 0 0 12 O
increase VB 0 1 1 O
bleeding VBG 1 1 6 O
risk NN 0 1 1 O
is VBZ 1 0 12 O
initiation NN 0 1 1 O
of IN 0 0 12 O
interacting VBG 1 0 1 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
potentiate VBP 0 0 UNK O
warfarin NNS 0 1 14 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
results NNS 1 1 1 O
demonstrated VBD 1 0 1 O
the DT 0 0 12 O
following JJ 0 1 1 O
interactions NNS 1 1 UNK O
: : 0 0 2 O
9 CD 0 0 2 O
isolates NNS 0 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
showed VBD 1 1 12 O
synergistic JJ 0 1 UNK O
interactions NNS 1 1 UNK O
( ( 0 0 2 O
FICI NNP 0 0 UNK O
9 CD 0 0 2 O
) ) 0 0 2 O
and CC 0 0 12 O
9 CD 0 0 2 O
isolates NNS 0 1 14 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
showed VBD 1 1 12 O
indifferent JJ 0 1 UNK O
interactions NNS 1 1 UNK O
( ( 0 0 2 O
9 CD 0 0 2 O
& CC 0 0 2 O
lt NN 0 1 13 O
; : 0 0 2 O
FICI NNP 0 0 UNK O
& CC 0 0 2 O
lt NN 0 1 13 O
; : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
plasma NN 0 1 14 O
maximum JJ 0 1 1 O
concentration NN 0 1 1 O
and CC 0 0 12 O
area NN 0 1 12 O
under IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
concentration NN 0 1 1 O
- : 0 0 2 O
time NN 0 1 12 O
curve NN 0 1 13 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
desacetyldiltiazem NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
desmethyldiltiazem NN 0 0 UNK B-Drug_n
were VBD 1 0 12 O
unchanged JJ 0 1 1 O
after IN 0 0 12 O
coadministration NN 0 1 UNK O
of IN 0 0 12 O
sirolimus NN 0 1 16 B-Drug
and CC 0 0 12 O
no DT 0 0 12 O
potentiation NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
diltiazem NN 0 1 0 B-Drug
on IN 0 0 12 O
diastolic NN 0 1 8 O
or CC 0 0 12 O
systolic JJ 0 1 8 O
blood NN 0 1 6 O
pressure NN 0 1 1 O
or CC 0 0 12 O
on IN 0 0 12 O
the DT 0 0 12 O
electrocardiographic JJ 0 1 8 O
parameters NNS 1 1 1 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
effect NN 0 1 1 O
of IN 0 0 12 O
temperature NN 0 1 3 O
changes NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
number NN 0 1 1 O
of IN 0 0 12 O
microtubules NNS 1 1 UNK O
in IN 0 0 12 O
non JJ 0 1 1 O
- : 0 0 2 O
myelinated VBN 0 1 UNK O
axons NNS 1 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
studied VBN 1 0 1 O
in IN 0 0 12 O
cat NN 0 1 12 O
inferior JJ 0 1 1 O
mesenteric JJ 0 1 8 O
ganglion NN 0 1 8 O
/ NNP 0 0 2 O
hypogastric NN 0 1 13 O
nerve NN 0 1 6 O
preparations NNS 1 1 13 O
incubated VBN 1 1 UNK O
at IN 0 0 12 O
various JJ 0 1 1 O
temperatures NNS 1 1 3 O
in IN 0 0 12 O
Eagles NNP 0 1 UNK O
minimal JJ 0 1 1 O
essential JJ 0 1 13 O
tissue NN 0 1 6 O
culture NN 0 1 1 O
medium NN 0 1 3 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
. . 0 0 12 O

Increased VBN 0 1 7 O
hepatotoxicity NN 0 1 13 O
of IN 0 0 12 O
acetaminophen NN 0 1 16 B-Drug
by IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
caffeine NN 0 1 6 B-Drug
in IN 0 0 12 O
the DT 0 0 12 O
rat NN 0 1 13 O
. . 0 0 12 O

Recently RB 0 1 2 O
we PRP 0 0 12 O
showed VBD 1 1 12 O
that IN 0 0 12 O
heparin SYM 0 1 14 O
- : 0 0 2 O
binding VBG 1 1 1 O
epidermal JJ 0 1 13 O
growth NN 0 1 1 O
factor NN 0 1 1 O
- : 0 0 2 O
like IN 0 0 12 O
growth NN 0 1 1 O
factor NN 0 1 1 O
( ( 0 0 2 O
HB NNP 0 1 UNK O
- : 0 0 2 O
EGF NN 0 0 UNK O
) ) 0 0 2 O
a DT 0 0 12 O
member NN 0 1 12 O
of IN 0 0 12 O
the DT 0 0 12 O
EGF NNP 0 0 UNK O
family NN 0 1 12 O
is VBZ 1 0 12 O
a DT 0 0 12 O
promising JJ 0 1 UNK O
target NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
various JJ 0 1 1 O
types NNS 1 1 1 O
of IN 0 0 12 O
cancer NN 0 1 6 O
. . 0 0 12 O

The DT 0 0 2 O
present JJ 0 1 1 O
work NN 0 1 12 O
involved VBN 1 1 12 O
the DT 0 0 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
both DT 0 0 12 O
ethynyl JJ 0 0 UNK B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
levonorgestrel NN 0 1 13 B-Drug
to TO 0 0 12 O
groups NNS 1 1 1 O
of IN 0 0 12 O
rats NNS 1 1 UNK O
followed VBN 1 1 12 O
by IN 0 0 12 O
determination NN 0 1 13 O
of IN 0 0 12 O
the DT 0 0 12 O
homocysteine JJ 0 1 13 O
excretion NN 0 1 14 O
rate NN 0 1 1 O
in IN 0 0 12 O
urine NN 0 1 6 O
. . 0 0 12 O

For IN 0 0 2 O
locomotor NN 0 0 UNK O
sensitization NN 0 1 13 O
subjects NNS 1 1 UNK O
were VBD 1 0 12 O
given VBN 1 1 12 O
amphetamine NN 0 1 13 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
/ NNP 0 0 2 O
kg NN 0 1 18 O
) ) 0 0 2 O
or CC 0 0 12 O
saline JJ 0 1 14 O
every DT 0 0 12 O
second JJ 0 1 12 O
day NN 0 1 12 O
from IN 0 0 12 O
P9 NNP 0 1 UNK O
to TO 0 0 12 O
P9 NNP 0 1 UNK O
and CC 0 0 12 O
were VBD 1 0 12 O
placed VBN 1 1 12 O
into IN 0 0 12 O
a DT 0 0 12 O
locomotor NN 0 0 UNK O
arena NN 0 0 UNK O
. . 0 0 12 O

Among IN 0 0 UNK O
the DT 0 0 12 O
polyene NN 0 1 UNK B-Group
antibiotics VBD 0 1 6 I-Group
many JJ 0 0 12 O
like IN 0 0 12 O
filipin NNS 0 1 UNK B-Drug_n
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
clinically RB 0 0 6 O
because IN 0 0 12 O
they PRP 0 0 12 O
are VBP 1 0 12 O
toxic JJ 0 1 1 O
; : 0 0 2 O

Immunosuppressive JJ 0 1 UNK B-Group
drugs NNS 1 1 6 I-Group
and CC 0 0 12 O
their PRP$ 0 0 12 O
complications NNS 1 1 6 O
. . 0 0 12 O

MICs NNP 0 1 UNK O
of IN 0 0 12 O
vancomycin NN 0 1 14 B-Drug
against IN 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
of IN 0 0 12 O
resistant JJ 0 1 3 O
clinical JJ 0 1 6 O
isolates NNS 0 1 14 O
and CC 0 0 12 O
a DT 0 0 12 O
type NN 0 1 1 O
strain NN 0 1 3 O
of IN 0 0 12 O
enterococci NN 0 1 UNK O
were VBD 1 0 12 O
lowered VBN 1 1 3 O
from IN 0 0 12 O
> JJ 0 0 2 O
9 CD 0 0 2 O
microg NN 0 0 UNK O
mL NN 0 1 14 O
( ( 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
) ) 0 0 2 O
to TO 0 0 12 O
9 CD 0 0 2 O

The DT 0 0 2 O
glucocorticoid JJ 0 1 13 O
- : 0 0 2 O
induced JJ 0 1 6 O
gene NN 0 1 13 O
transcription NN 0 1 UNK O
was VBD 1 0 12 O
strongly RB 0 0 1 O
suppressed VBN 1 1 1 O
by IN 0 0 12 O
synthetic JJ 0 1 3 O
alkyl NN 0 1 UNK O
esters NNS 1 1 UNK O
; : 0 0 2 O

It PRP 0 0 12 O
was VBD 1 0 12 O
shown VBN 1 1 1 O
that IN 0 0 12 O
neurotensin NN 0 1 UNK B-Drug_n
antagonized VBN 1 0 UNK O
evidently RB 0 0 12 O
the DT 0 0 12 O
antinociceptive JJ 0 0 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
enkephalins NNS 1 1 UNK B-Drug_n
and CC 0 0 12 O
their PRP$ 0 0 12 O
analogue NN 0 1 UNK O
. . 0 0 12 O

Combinations NNS 0 1 UNK O
of IN 0 0 12 O
clindamycin NN 0 1 0 B-Drug
and CC 0 0 12 O
gentamicin NN 0 1 14 B-Drug
were VBD 1 0 12 O
indifferent JJ 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
and CC 0 0 12 O
synergistic JJ 0 1 UNK O
for IN 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
resistant JJ 0 1 3 O
strains NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
myopathy NN 0 1 8 O
and CC 0 0 12 O
rhabdomyolysis NN 0 1 8 O
particularly RB 0 0 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
renal JJ 0 1 6 O
insufficiency NN 0 1 6 O
or CC 0 0 12 O
those DT 0 0 12 O
who WP 0 0 12 O
are VBP 1 0 12 O
concurrently RB 0 0 1 O
taking VBG 1 0 12 O
medications NNS 1 1 6 O
associated VBN 1 1 1 O
with IN 0 0 12 O
myopathy NN 0 1 8 O
. . 0 0 12 O

and CC 0 0 12 O
overdose PRP 0 1 6 O
. . 0 0 12 O

Although IN 0 0 12 O
this DT 0 0 12 O
effect NN 0 1 1 O
was VBD 1 0 12 O
noted VBN 1 0 1 O
even RB 0 0 12 O
when WRB 0 0 12 O
cholestyramine NN 0 1 13 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
prior RB 0 1 1 O
to TO 0 0 12 O
fluvastatin VB 0 1 13 B-Drug
this DT 0 0 12 O
regimen NNS 0 1 6 O
did VBD 1 0 12 O
not RB 0 1 12 O
result VB 0 1 1 O
in IN 0 0 12 O
diminished JJ 0 1 1 O
efficacy NN 0 1 UNK O
. . 0 0 12 O

Permeation NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
performed VBN 1 1 1 O
on IN 0 0 12 O
guinea NN 0 1 UNK O
pig NN 0 1 UNK O
small JJ 0 1 12 O
intestinal JJ 0 1 13 O
mucosa NN 0 1 8 O
mounted VBD 1 1 UNK O
in IN 0 0 12 O
Ussing NNP 0 0 UNK O
- : 0 0 2 O
type NN 0 1 1 O
chamber NN 0 1 3 O
. . 0 0 12 O

This DT 0 0 2 O
effect NN 0 1 1 O
did VBD 1 0 12 O
not RB 0 1 12 O
depend VB 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
order NN 0 1 1 O
of IN 0 0 12 O
application NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

INTERVENTIONS NNS 0 1 UNK O
: : 0 0 2 O
Each DT 0 0 2 O
subject NN 0 1 UNK O
was VBD 1 0 12 O
treated VBN 1 1 1 O
according VBG 1 1 1 O
to TO 0 0 12 O
the DT 0 0 12 O
following JJ 0 1 1 O
sequence NN 0 1 UNK O
: : 0 0 2 O
baseline NN 0 1 1 O
; : 0 0 2 O

Reduction NN 0 1 UNK O
of IN 0 0 12 O
PTH NNP 0 0 14 O
by IN 0 0 12 O
cinacalcet NN 0 1 16 B-Drug
is VBZ 1 0 12 O
associated VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
decrease NN 0 1 1 O
in IN 0 0 12 O
darbepoetin JJ 0 0 13 B-Drug
requirement NN 0 1 1 O
. . 0 0 12 O

Resveratrol NNP 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
- : 0 0 2 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
l NN 0 1 2 O
) ) 0 0 2 O
induced VBD 1 1 6 O
concentration NN 0 1 1 O
- : 0 0 2 O
dependent JJ 0 1 1 O
relaxation NN 0 1 1 O
of IN 0 0 12 O
mesenteric JJ 0 1 8 O
arteries NNS 1 1 6 O
preconstricted VBN 0 0 UNK O
with IN 0 0 12 O
noradrenaline NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
micromol NN 0 1 UNK O
/ NNP 0 0 2 O
l NN 0 1 2 O
) ) 0 0 2 O
or CC 0 0 12 O
KCl NNP 0 0 14 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mmol NN 0 1 13 O
/ NNP 0 0 2 O
l NN 0 1 2 O
) ) 0 0 2 O
from IN 0 0 12 O
both DT 0 0 12 O
lean JJ 0 0 13 O
and CC 0 0 12 O
dietary JJ 0 1 6 O
- : 0 0 2 O
obese JJ 0 1 6 O
rats NNS 1 1 UNK O
. . 0 0 12 O

Tamoxifen NNP 0 1 0 B-Drug
and CC 0 0 12 O
CYP NNP 0 1 UNK O
9D9 CD 0 0 UNK O
inhibitors NNS 1 1 14 O
: : 0 0 2 O
caution NN 0 0 1 O
. . 0 0 12 O

Amprenavir NNP 0 1 UNK B-Drug
plus CC 0 1 16 O
rifampin NN 0 1 16 B-Drug
was VBD 1 0 12 O
well RB 0 1 12 O
tolerated VBN 1 0 1 O
. . 0 0 12 O

A DT 0 0 2 O
host NN 0 1 12 O
of IN 0 0 12 O
other JJ 0 0 12 O
medical JJ 0 1 1 O
considerations NNS 1 1 1 O
are VBP 1 0 12 O
discussed VBN 1 1 1 O
in IN 0 0 12 O
chapter NN 0 1 UNK O
9 CD 0 0 2 O
including VBG 1 1 1 O
persistent JJ 0 1 1 O
ovarian JJ 0 1 6 O
follicles NNS 1 1 13 O
; : 0 0 2 O

Concomitant NNP 0 1 UNK O
cyclophosphamide NN 0 1 14 B-Drug
doxorubicin NN 0 1 13 B-Drug
vincristine NN 0 1 16 B-Drug
and CC 0 0 12 O
prednisone NN 0 1 0 B-Drug
chemotherapy NN 0 1 6 O
plus CC 0 1 16 O
highly RB 0 1 1 B-Group
active JJ 0 1 1 I-Group
antiretroviral JJ 0 0 UNK I-Group
therapy NN 0 1 6 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
human JJ 0 1 1 O
immunodeficiency NN 0 1 14 O
virus SYM 0 1 6 O
- : 0 0 2 O
related VBN 1 1 1 O
non JJ 0 1 1 O
- : 0 0 2 O
Hodgkin NNP 0 0 7 O
lymphoma NN 0 1 6 O
. . 0 0 12 O

By IN 0 0 2 O
contrast NN 0 1 1 O
spermidine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
putrescine NN 0 1 UNK B-Drug_n
( ( 0 0 2 O
9 CD 0 0 2 O
mM NN 0 0 UNK O
) ) 0 0 2 O
had VBD 1 0 12 O
no DT 0 0 12 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
translocation NN 0 1 13 O
when WRB 0 0 12 O
added VBD 1 1 12 O
alone RB 0 1 12 O
. . 0 0 12 O

Electroretinograms NNS 0 1 UNK O
survived VBD 1 1 UNK O
with IN 0 0 12 O
higher JJR 1 1 1 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
heparinase NN 0 1 UNK B-Drug_n
III NNP 0 1 2 I-Drug_n
and CC 0 0 12 O
chondroitin VB 0 1 13 B-Drug_n
ABC NNP 0 1 UNK I-Drug_n
lyase NN 0 1 UNK I-Drug_n
than IN 0 0 12 O
were VBD 1 0 12 O
required VBN 1 1 1 O
for IN 0 0 12 O
optimal JJ 0 1 1 O
retinal JJ 0 1 6 O
transduction NN 0 1 UNK O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
KRM NNP 0 0 UNK B-Drug_n
- : 0 0 2 O
9 CD 0 0 2 I-Drug_n
either CC 0 1 12 O
singly RB 0 0 3 O
or CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
ofloxacin NN 0 1 0 B-Drug_n
against IN 0 0 12 O
Mycobacterium NNP 0 1 UNK O
ulcerans NNPS 0 0 UNK O
. . 0 0 12 O

Long NNP 0 1 2 O
- : 0 0 2 O
term NN 0 1 1 O
studies NNS 1 1 1 O
are VBP 1 0 12 O
needed VBN 1 1 12 O
to TO 0 0 12 O
determine VB 0 0 1 O
whether IN 0 0 12 O
the DT 0 0 12 O
insulin NN 0 1 14 O
- : 0 0 2 O
sensitizing VBG 1 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
glitazones NNS 0 1 UNK B-Group
can MD 0 0 12 O
prevent VB 0 1 1 O
or CC 0 0 12 O
delay VB 0 1 1 O
premature JJ 0 1 6 O
atherosclerotic JJ 0 1 8 O
cardiovascular JJ 0 1 6 O
disease NN 0 1 6 O
morbidity NN 0 1 13 O
and CC 0 0 12 O
death NN 0 1 12 O
. . 0 0 12 O

Interaction NNP 0 1 2 O
study NN 0 1 1 O
of IN 0 0 12 O
moxifloxacin NN 0 1 16 B-Drug
and CC 0 0 12 O
lomefloxacin NN 0 1 UNK B-Drug
with IN 0 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
drugs NNS 1 1 6 O
. . 0 0 12 O

We PRP 0 0 12 O
incorporate VBP 0 0 UNK O
the DT 0 0 12 O
principles NNS 1 0 UNK O
of IN 0 0 12 O
recovery NN 0 1 1 O
and CC 0 0 12 O
define VB 0 0 1 O
positive JJ 0 1 1 O
and CC 0 0 12 O
constructive JJ 0 1 UNK O
alternatives NNS 1 1 UNK O
in IN 0 0 12 O
dealing VBG 1 0 UNK O
with IN 0 0 12 O
cocaine NN 0 1 6 O
hunger NN 0 1 12 O
. . 0 0 12 O

The DT 0 0 2 O
intravenous JJ 0 1 14 O
application NN 0 1 1 O
of IN 0 0 12 O
perchlorate NN 0 1 UNK B-Drug_n
offers NNS 1 0 1 O
advantages NNS 1 0 UNK O
in IN 0 0 12 O
clinical JJ 0 1 6 O
use NN 0 1 1 O
. . 0 0 12 O

